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Abstract 
Heparin therapy involves the clinical use of heparin as an anti-coagulant, for example, 
during surgery. At the conclusion of treatment, systemic heparin levels must be 
quantified to allow accurate dosing of a heparin antidote. This thesis details work 
towards a better sensing methodology and an improved antidote.    
A synthetically-simple arginine-functionalized dye – Mallard Blue (MalB) – was 
synthesised and shown able to detect heparin across a clinically relevant concentration 
range in biological media such as human serum. The heparin binding of MalB is 
selective over structurally related glycosaminoglycans and is highly tolerant of 
electrolytic competition. Indeed, the performance of MalB is comparable with the best 
heparin sensors currently known and makes it the new best-in-class thionine dye.  
Mallard Blue was developed into a straightforward competition assay able to report on 
the relative heparin binding efficiencies of candidate molecules in competitive media, 
including human serum. Using this assay in conjunction with molecular dynamics 
modelling techniques, fundamental insights into the binding of poly(amidoamine) 
(PAMAM) dendrimers to heparin were gained. Interestingly, the medium sized (G2-G4) 
dendrimers achieved the most charge-efficient heparin binding. Comparisons against 
derivatives modified with poly(phenylenevinylene) cores revealed native PAMAMs to 
be exponents of adaptive multivalency, in contrast to the more rigid derivatives’ shape-
persistent multivalency. 
The performance of self-assembled multivalent (SAMul) heparin binder C22G1DAPMA 
was studied in different biological media and shown to be more charge-efficient than 
the currently used heparin antidote under competitive conditions. Also, C22G1DAPMA 
was able to reverse anti-coagulation in heparinized human plasma and degrade on a 
clinically interesting timescale. Structural modifications afforded two new families of 
SAMul binders, which unveiled fundamental differences in the chiral preferences of 
heparin and DNA, along with probing the effects of nanoscale morphology on heparin 
binding ability and aggregate-stability in serum.         
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1 Introduction 
1.1 From Multivalency to Self-Assembling Multivalency (SAMul) 
1.1.1 Multivalency 
1.1.1.1 Concept 
Velcro is arguably the most widely acknowledged exponent of multivalency. Through 
establishment of many individually weak interactions between hooks on one side of the 
material and loops on the other, two physically distinct materials can be reversibly 
attached to each other. Within this macroscale analogy, the individual hook-loop 
interactions can be thought of as a monovalent interaction between a binding ligand and 
a complementary receptor site. In isolation, each single, reversible, interaction would be 
unable to meaningfully adhere the materials together, but when many of these 
interactions combine together, the resulting overall binding can be rather powerful.   
1.1.1.2 Terminology and Thermodynamics 
The concept of multivalency is widely applied across a range of scientific disciplines 
although only macromolecular chemists tend to employ the term ‘multivalency.’1 
Inorganic chemists refer to the same phenomenon as the ‘chelate effect,’ often with 
respect to the binding of multidentate ligands within the coordination sphere of a metal 
centre;
2,3
 while biologists tend to discuss ‘polyvalent’ interactions such as those of a 
virus with a cell surface.
4
 For the purposes of our discussion, the term multivalency will 
be taken to mean the simultaneous interaction of multiple binding groups on one species 
with complementary species on another, often to achieve high-affinity binding.   
Defining multivalent interactions on the molecular level must be done with care. For 
example, a multivalent host – that is one with two or more binding sites – interacting 
with two or more monomeric guest molecules does not constitute a multivalent 
interaction as each individual guest only forms a single interaction with the host. As 
soon as the guest becomes divalent (or larger), the interactions can be classed as 
multivalent, so long as multiple binding groups on the guest interact with different 
receptor groups on the same host molecule. When all of the receptor and/or binding 
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sites are chemically identical, the species can be categorised as homomultivalent, while 
when the interacting groups vary, it is said to be heteromultivalent.  
As we shall see in the next section, multivalent binding can be utilised across a variety 
of biological and chemical systems. Archetypal examples can be found in the adhesion 
of a virus to the exterior of a cell wall or the interaction of a dendritic polymer with 
DNA, as represented schematically in Figure 1.1.  
 
Figure 1.1 – Schematic cartoon of (a) a virus binding to cell surface and (b) a dendritic 
polymer binding to DNA. 
1.1.1.3 Thermodynamics 
As with all host-guest interactions, binding or association constants, K, can be 
calculated for multivalent interactions, although not without some fundamental 
considerations. Firstly, association constants for monovalent systems refer exclusively 
to the formation of a single interaction between two physically distinct species, while 
for multivalent binding it is not so simple. In changing from ‘fully unbound’ to ‘fully 
bound,’ a multivalent binder will necessarily form several interactions with its host. 
Despite much explanation in the literature, the misconception that a multivalent system 
must form multiple interactions which individually should have a higher association 
constant than the monovalent system remains.
5
 In fact, the individual interactions of a 
successful multivalent system should bind to the host collectively in a superior manner 
to the monovalent system. That is to say that the overall binding constant for a 
multivalent interaction, 𝐾𝑚𝑢𝑙𝑡𝑖, referred to as the ‘avidity’ of the system, should be 
superior to the binding constant of the monovalent system, 𝐾𝑚𝑜𝑛𝑜.  
Whitesides and co-workers were the first to attempt to quantify the superiority (or 
otherwise) of multivalent systems with respect to their monovalent counterparts.
4
 To do 
this, they calculated a so-called ‘enhancement factor’, β, which was simply a ratio of the 
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avidity of the multivalent system to the association constant of the monovalent system 
when each system was interacting with a multivalent host, Equation 1.1.  This 
subsequently enabled multivalent systems to be categorized as either cooperative 
(synergistic, β > 1), non-cooperative (additive, β = 1) or negatively cooperative 
(interfering, β < 1).4 The simplicity of this calculation does however limit the 
information which can be derived from it; for example, it is not possible to deconvolute 
the effect of the number of charges on a multivalent binder – referred to as symmetry 
effects – from the associated cooperativity.6 As such, β can become a useful parameter 
for the comparison of multivalent systems where the exact valence of the binder is 




    
Equation 1.1 – Calculation of Whitesides and co-workers’ multivalency enhancement 
factor, β. 
Accurately assigning cooperativity is tricky as the binding of a second (or subsequent) 
ligand group of an already partially-bound multivalent guest to the host is 
fundamentally different to the establishment of a new interaction between the host and a 
separate guest molecule. Indeed, the first interaction serves to ‘tether’ together the host 
and guest allowing subsequent interaction to be viewed as intramolecular, rather than 
intermolecular, binding events.
7
 This tethering also positions the ligand groups of the 
partially-bound system closer to the host further increasing the statistical likelihood of a 
complementary binding interaction forming, and ultimately leading to cooperativity.
8
 
This dichotomy of the first and subsequent binding interactions must be taken into 
account for multivalent interactions and, as exemplified by Ercolani in 2011, the inter- 
and intramolecular processes should be considered independently in order to 
meaningfully assess cooperativity.
9
 Ercolani suggested that many systems had 
incorrectly being designated as cooperative or non-cooperative based solely on the 
consideration of Whitesides and co-workers enhancement factor, β.9    
There have been several attempts to formalize and delineate different cooperativity 
regimes. In 2008, Whitty defined allosteric and chelate/configurational regimes as the 
‘two faces’ of cooperativity.10 Whitty suggested that within an allosteric system, the 
binding of one ligand to a receptor site altered the affinity of a separate ligand for a 
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different binding site, while chelate or configurational cooperativity arose from the 
intramolecular nature of all but the first binding interactions within a multivalent 
system. In 2009, Hunter and Anderson
11
 reaffirmed Whitty’s observations in their 
candidly titled essay “What is cooperativity?” before Ercolani again went further and 
rigorously reasoned that a third type of cooperativity regime required defining. 
Ercolani’s formalised definitions of allosteric, chelate and interannular cooperativity are 




Figure 1.2 – Schematic representations of allosteric, chelate and interannular 
cooperativity. 
The definition of allosteric cooperativity, which is the best understood of the three 
categories, did not greatly change. Specifically, allosteric cooperativity was said to 
pertain to two (or more) intermolecular binding sites influencing the behaviour of each 
other. The most widely recognized example of this is the mechanism of oxygen binding 
to haemoglobin, where binding of the first oxygen molecule induces a conformational 
change promoting the binding of three further oxygen species.
12,13
 Chelate 
cooperativity, meanwhile, is the most recognizable multivalent effect and was 
formalized as arising from the establishment of one or more intramolecular binding 
interaction.
5
 Chelate cooperativity is represented on the right-side of the middle row in 
Figure 1.2.  
The final regime was defined by Ercolani as interannular cooperativity, which can be 
viewed as a subset of chelate cooperativity as it also arises from the interplay of 




 The differentiator between chelate and interannular 
cooperativity is the multiplicity of the interactions involved, and it is well explained by 
an instructive example from the work of Shinkai and co-workers.
14
 In particular, the 
team led by Shinkai created a system containing two porphyrin ‘wheels’ each decorated 
with pyridinyl binding sites which were able to rotate relative to each other around a 
cerium ‘axle.’ When both ‘wheels’ simultaneously established interactions with a di-
carboxylic acid guest molecule, the wheels became locked in place relative to each 
other, facilitating the binding of subsequent guest molecules, Figure 1.3.
14
    
 




Much like monovalent interactions, the free energy of multivalent interactions, 𝛥𝐺𝑚𝑢𝑙𝑡𝑖, 
can be calculated. It remains difficult to quantify the individual interactions between a 
host and a guest, and rather easier to focus on comparisons of the free energies of the 
fully bound and fully unbound states. As with all free energies, 𝛥𝐺𝑚𝑢𝑙𝑡𝑖 is composed of 
enthalpic and entropic factors. Of these, it is the entropic component which courts most 
literature discussion.  
It is widely acknowledged that the entropy change upon binding, 𝛥𝑆𝑏𝑖𝑛𝑑, has 
translational, rotational and conformational components, in addition to less well 
understood contributions from the associated/surrounding solvent(s).
15
 The reduction in 
conformational entropy associated with the formation of the first binding interaction 
between the multivalent host and the guest is most often considered, although there are 
contradictory models for determining the significance and/or magnitude of these 
interactions.
15
 For example, Jencks
16
 suggested a maximum loss of entropy of 
localization for an unrestrained rotor of 1.4 kcal mol
-1
 while Whitesides and co-workers 
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suggested a much smaller value,
17
 although not without attracting criticism from other 
authors in the process.
18
 Overall, the widespread consensus seems to be that entropic 
factors are not as influential as has been previously thought in the past, with Huskens 
and Reinhoudt going so far as to suggest that in certain situations “entropic concerns 
should not be taken too seriously”7 however, in reality, the traditional view of 
multivalent interactions being governed by entropy remains.
15,17
   
The enthalpic component of the free energy of binding, 𝛥𝐻𝑏𝑖𝑛𝑑, is also difficult to 
quantify for multivalent interactions, either by experimental or theoretical methods.
4
 
The biggest challenge is to deconvolute the effects of the linker group which connects 
the multiple ligand groups together from the binding groups, as the linker may itself 
interact somewhat with the host. The geometry and rigidity of the linker can also affect 
the relative enthalpy of interactions as, unless ligand pre-organization is highly 
complementary with the host, the distortion required to establish interaction is likely to 
lead to so-called enthalpically diminished binding.   
As informative as these thermodynamic parameters can be, a more widely used concept 
is that of effective molarity (or effective concentration), EM (or Ceff), which serves to 
quantify the amount of ligand sites in close proximity to the host. In multivalent 
systems, once the first ligand group has bound, the effective concentration of ligand 
groups proximal to the host is increased due to the aforementioned ‘tethering’ of the 
binder to the host: indeed the subsequent interactions are intramolecular rather than 
intermolecular. The advantages associated with this increased EM have been 
demonstrated to be mostly entropic and can be utilised to afford exceptionally high local 
concentrations of ligand groups.
16,19
 The EM parameter has also been used to measure 
the affinity enhancement associated with the use of multivalent interactions.
20,21
   
One of the key factors influencing the enhanced binding of multivalent systems over 
their monovalent counterparts is their significantly different dissociation kinetics. By 
their very nature, the dissociation of a monovalent host from a guest molecule requires 
only a single interaction to be broken. In a multivalent system, multiple interactions 
need to be broken for host-guest dissociation back to two physically discrete species. 
This rate is determined by the concentration of the host-guest complex in which the two 
species are held together by only a single interaction (i.e. all other interactions have 
broken). As discussed above, it is common for partially-bound multivalent guests to re-
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bind to the host due to the increased effective concentration, Ceff, of ligand groups 
proximal to the host, and for this reason the concentration of this monovalently bound 
species is often very low. This phenomenon is a key reason why multivalent 
interactions are so robust. 
Dissociation of a multivalent complex can be promoted through introduction of a 
species which will compete for binding to the host. This competitor can be monovalent 
or multivalent and can establish its’ own interactions with the host as the original 
multivalent guest begins to dissociate, thereby preventing multivalent re-binding. This 
leads to a step-wise dissociation process in the manner depicted in Figure 1.4.   
 
Figure 1.4 – Schematic cartoon of stepwise dissociation of a multivalent binder in the 
absence and presence of a competitor.  
1.1.1.4 Multivalency in Action 
Many varieties of multivalent binding arrays, ranging from systems targeted specifically 
for biological applications to templates to assist in covalent synthesis, have been studied 
by supramolecular chemists. For example, a programme of work in the group of 
Whitesides examined the multivalent interactions of the important antibiotic drug 
vancomycin through comparison against synthetically modified derivatives.
22-26
 
‘Native’ vancomycin interacts most favourably with a D-Ala-D-Ala host through the 
formation of five non-covalent interactions, however vancomycin-resistance can be 
increased when the host is mutated to D-Ala-lactate, as one of the hydrogen bonding 
opportunities is lost, Figure 1.5.
22
 In reality, the multivalency of the system still enables 
vancomycin to bind to D-Ala-lactate, albeit at reduced affinity.
22
 Whitesides and co-
workers then developed a vancomycin dimer and trimer which were shown to exhibit 
significantly enhanced binding to dimeric
23,24
 and trimeric hosts.
25,26
 Indeed, binding of 
the trivalent guest to the trivalent host occurred with an association constant ten orders 
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of magnitude higher than the native monomeric derivatives, producing one of the 




Figure 1.5 – Schematic depiction of trivalent vancomycin host-guest complex (top) 
along with comparison of monomeric vancomycin binding to D-Ala-D-Lys (bottom left) 
and mutated D-Ala-lactate (bottom right). 
Pseudorotaxanes are supramolecular constructs formed when alkyl threads possessing 
dialkylammonium ions, R2-NH2
+
, interpenetrate the macrocyclic interior of crown ether 
structures.
27
 Dibenzo[24]crown-8 (DB24C8) is a much studied host in this context and, 
in work somewhat analogous to the vancomycin example above, the cooperativity of 





 form, has been studied. Fusions of three DB24C8 hosts around a 
triphenylene core by Stoddart and co-workers generated a multivalent system in which 
complexation of the alkylammonium guests within the crown ether hosts was enhanced 
by the favourable stacking of aromatic rings on the host and the guest, Figure 1.6.
30
 
Pseudorotaxanes such as this can also be ‘switchable’ owing to the pH controllability of 
the dialkylammonium species, and this makes them of wide interest in the design of 
molecular machines.
31
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 to demonstrate the acute sensitivity of the multivalent 
interactions to the length of the spacer unit between alkylammonium groups. Indeed, 
lengthening the linker unit by only one additional methylene group from the optimum 




Although host-guest complementarity is often very sensitive to small structural 
alterations, careful molecular design can reward the chemist with remarkable positive 
cooperativity. A notable example of this is found in the porphyrin wheels of Anderson 
and co-workers which showcase almost perfect host-guest preorganization and, 
somewhat assisted by the rigidity of the systems, form superb multivalent interactions, 
Figure 1.7.
36
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Figure 1.7 – Exquisite ligand preorganization gives Anderson’s porphyrin wheel well 




Molecular self-assembly, as defined by Whitesides in the early 1990s, is the 
spontaneous association of molecules under equilibrium conditions into stable,  
structurally well-defined aggregates held together by non-covalent bonds.
38
 Such self-
assembly is ubiquitous in nature, with the tobacco mosaic virus, which is able to 
spontaneously arrange several thousand amino acid based subunits into a 
complementary helical sheath able to surround single RNA strands, providing a notable 
example.
39,40
 Molecular self-assembly also provides a useful tool for chemists designing 
systems for operation on the nanoscale.
38,41
 Indeed, production of relatively small 
molecular building blocks endowed with the ability to self-assemble and generate 
nanosized objects is often a far more attractive proposition than the synthesis of 
covalent structures of the same size.
42
 
The most widely used approach to this type of self-assembly involves the synthesis of 
amphiphilic molecules able to organize and assemble themselves in aqueous solution in 
processes driven by the hydrophobic effect.
43
 As the concentration of monomer 
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molecules in solution increases, the non-polar regions within their structures tend to 
aggregate together, thereby excluding water molecules ‘frozen’ around their surface 
from the aggregate interior. The entropy increase associated with the liberation of these 
water molecules into solution is widely thought to outweigh the decrease in entropy 
associated with the aggregation of the non-polar components.
43
 The aggregation of 
amphiphilic monomers in this way is completely reversible and, as we shall see, the 
type of aggregates which form are dependent on several factors such as concentration 
and monomer geometry.
44
 The aggregates which do form often have dimensions on the 
nanometer scale and so their study has many connections with colloid science; a long-
standing research area recognized by Nobel prizes as early as the 1920s.   
In 1976, Israelachvili et al. published a seminal discussion of the effects of monomer 
geometry and degree of hydrophobicity upon the subsequent mode of self-assembly.
45
 
A critical packing parameter was defined, which allowed the morphology of an 
aggregate to be predicted based on the relative volumes of the hydrophobic and 
hydrophilic groups within the structure. As shown in Figure 1.8, when the monomer 
hydrophilic group is much larger than the hydrophobe, a spherical micelle displaying 
the polar groups at the surface is favoured. As the volume of the hydrophobic group is 
increased with respect to the hydrophilic surface group, cylindrical morphologies 
become more favourable as a means of minimising unfavourable interactions with the 
aqueous solvents. When the hydrophobicity continues to increase, often through the 
introduction of a second aliphatic tail, vesicles or liposomes become the optimum mode 
of self-assembly. When the head and tail groups are of comparable size-in-space, planar 
bilayer structures form, while when the hydrophobe is significantly larger than the tail 
group, inverted micelles form with the non-polar groups expressed at the surface and the 
hydrophilic groups internalised.       
Chapter 1 - Introduction 
35 
 
Figure 1.8 – The work of Israelachvili allowed aggregate morphology in aqueous 
solution to be predicted as a function of critical packing parameter. 
1.1.3 Self-Assembling Multivalency (SAMul) 
With the potential of multivalent binding and power of molecular self-assembly 
established, it is not surprising that chemists have combined these two concepts in order 
to generate nanoscale binding arrays for interaction with large biomolecules through so-
called ‘self-assembling multivalency’ or ‘SAMul’. As we shall see, this is often 
achieved through the use of polar binding groups conjugated to an apolar hydrophobe to 
generate amphiphilic species with the ability to self-assemble in aqueous conditions. 
This approach carries many advantages over covalent synthesis for the generation of 
nanoscale ligands arrays.  
For example, self-assembling monomers are individually more synthetically tractable 
than larger covalent arrays, and their subsequent assembly to generate the nanosystem is 
spontaneous (under appropriate conditions). The simplified synthetic access additionally 
makes structural modifications of the monomer units relatively straightforward, 
introducing the potential for the polar binding groups to be tuned/altered to allow 
different targets to be bound by structurally related monomers. Alteration of the apolar 
hydrophobe also allows for the morphology of the resulting nanostructure to be easily 
altered. These smaller monomer building blocks are typically more ‘drug-like’ than 
their larger covalent counterparts, which can increase the likelihood of promising 
candidates receiving clinical approval.   
The SAMul binding approach also makes creation of mixed binding systems 
straightforward, as different monomer units can be co-assembled into a single 
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nanostructure leading to synergistic effects, which can be relatively difficult to achieve 
using covalent methodology. A further key advantage of SAMul binding is the 
reversibility of the nanosystem assembly event, which allows multivalency to be 
switched-off in a controllable way. As well as ‘switching-off’ binding events, this 
disassembly minimizes the persistence of the binding ligand array which, in turn, can 
reduce toxicity of biologically relevant SAMul systems.   
Given these multiple advantages, the employment of self-assembled multivalent 
(SAMul) techniques is becoming more widely applied and the area was reviewed 
recently by Barnard and Smith.
46
 In the following sub-sections some of the key SAMul 
systems are discussed; selected examples have been chosen which fall into the 
categories of sugar arrays, DNA binding arrays and ligand arrays targeting other 
species.  
1.1.3.1 SAMul saccharide arrays 
One of the first examples of self-assembling multivalency came from the group of 
Whitesides, who developed an amphiphilic system to bind the protein hemagglutinin, 
Figure 1.9.
47
 They conjugated a sialic acid residue onto a lipid chain to promote the self-





Figure 1.9 – The hydrophobically modified sialic acid derivative from the group of 
Whitesides was one of the earliest examples of self-assembled multivalency (SAMul).
47
 
Since this early work, many systems have been developed to express sugar residues on 
the exterior of self-assembled nanosystems in order to bind lectin targets such as 
concanavalin A (Con A). For example, Ravoo and co-workers decorated cyclodextrin 
vesicular structures with maltose and other sugar residues through coupling of the 
sugars with adamantane groups, which could then become encapsulated within the CD-
cavities.
48
 This created a sugar ligand array which exhibited considerably higher-affinity 
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for targets than the monomeric non-assembled sugars. Interestingly, within this ternary 
complex, the multivalent binding to Con A templates a further organization event for 




Figure 1.10 – Cartoon of Ravoo and co-workers’ cyclodextrin vesicles (large grey 
structure) decorated with adamantane-maltose ligands (red and orange) for Con A 
binding (green). Image reproduced from reference 
49
. 
In a similar manner, Kim and co-workers decorated the surface of cucurbit[6]uril 
vesicles with mannose groups although, rather than adamantane groups, the sugar 
residue was conjugated to a cationic spermine group as polyamines are more readily 
encapsulated by cucurbiturils.
50
 Carbon nanotubes (CNTs) have also been employed as 
‘templates’ by Bertozzi and co-workers, who functionalised an α-N-galactose-amine 
residue with an aliphatic tail such that the sugar could be ‘self-assembled’ along the 
CNT surface in order to promote enhanced-affinity binding to cell surface lectins, 
Figure 1.11.
51
     
   
Figure 1.11 – Amphiphilic galactosamine-conjugate from the group of Bertozzi self-
assembled along CNTs to achieve high-affinity lectin binding.
51
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Of the SAMul examples presented so far, many require some form of template such as a 
cyclodextrin vesicle or CNT around which the multivalent ligand array can be 
constructed. Work from the group of Brunsveld adopts a different approach by 
programming monomers with the ability to self-assemble with each other rather than 
with a unifying template to generate a nanoscale ligand array for effective target 
binding. A particular speciality of the Brunsveld group is the production of photoactive 
discotic molecules containing C3-symmetric aromatic cores consisting of three 2,2’-
bipyridine-3,3’-diamine molecules connected to a central benzene-1,3,5-tricarbonyl 
unit.
52
 These units, being planar and aromatic, are readily able to self-assemble into 
columnar stacks.
53,54
 The density of ligands at the assembly surface can be easily tuned 
using this approach by carefully controlling the ratio of mono-, di- and/or tri-
functionalised discotics present within a ‘mixed’ columnar stack. When the core is 
functionalized with water-solubilizing glycol, and suitable binding groups such as 
mannose are attached, the resulting columnar stacks become able to bind targets such as 
Con A with enhanced affinity over the non-assembled discotics. Brunsveld and co-
workers have adapted this approach to generate SAMul binders able to interact with 
targets such as Con A and other lectins, E. coli and streptavidin, demonstrating the 




Figure 1.12 – Self-assembling multivalent mannose-functionalised lectin-binding 
discotic molecules from Brunsveld and co-workers. Figure adapted from reference 
52
.  
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One of the most interesting observations from the work of Brunsveld and co-workers 
was that increasing the number of binding groups displayed along each stack did not 
necessarily correlate with increased target binding. Indeed, in the case of their mannose-
functionalized SAMul discotics, tri-functionalization of each monomer disc offered no 
valency-corrected binding enhancement over the mono-functionlaised derivative.
52
 As 
we shall see later in this thesis, the concept of ‘more is not always better’ is a key 
feature of many multivalent binding phenomena.
56,57
  
1.1.3.2 Binding other targets 
All of the examples presented above employ sugar units as the ligand groups, which 
lead primarily to lectin-type species being targeted for binding. Several other groups 
have developed SAMul binding approaches targeting different species. For example, 
work in the group of Urbach employed cucurbit[8]uril to host self-assembly events 
between scaffolds decorated with methyl viologen, and tryptophan groups,
58
 while 
Merkx and co-workers developed self-assembling collagen binding micelles.
59
 The 
groups of Williams and Hunter, meanwhile, developed a cholesterol-dansylamine 
amphiphile in which the hydrophobic cholesterol became embedded along membrane-
water interfaces generating a multivalent display of Cu(II)-binding dansyl ligand 
groups.
60
 This work provided a notable example of a SAMul approach being used to 
bind a smaller target species, Cu(II), rather than a large biomolecule.   
Work from the group of Smith and co-workers employed a similar amphiphilic design 
consisting of a hydrocarbon aliphatic tail connected to a hydrophilic Arg-Gly-Asp 
(RGD) ligand group.
56
 This ligand group was selected to endow the system with 
integrin binding ability and the study directly compared the performance of this self-
assembling monomer against a non-assembling analogue and a larger non-assembling 
‘multivalent’ binder, Figure 1.13. The results showed both the larger system and the 
self-assembling analogue exhibited similarly enhanced binding over the non-assembling 
monomer due to the multivalency of binding, however the achievement of this 
enhancement by the self-assembling system required much less effort during the 
synthetic preparation of the compounds.
56
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Figure 1.13 – Integrin binding systems from the work of Smith and co-workers.56  
Smith and co-workers then continued this fundamental study by modifying the 
hydrophobic component of the monomers to alter the self-assembled morphologies of 
the nanosystems.
61
 Spherical and cylindrical micelles along with rod-like vesicles were 
examined, and a spherical micellar RGD array was shown to be the optimum 
architecture for solution-phase integrin binding.
61
 This work demonstrated that the 
display of multivalent binding ligands holds significant influence over integrin binding 
ability.  
1.1.3.3 SAMul approaches to DNA binding 
DNA has been targeted by several research groups employing self-assembled binding 
technologies, demonstrating wide awareness of the potential of a SAMul approach to 
medicinal treatments of genetic diseases
62
 and even cancer.
63
   
The naturally occurring DNA-binding ligand spermine is amongst the most often 





 The approach of Cheng and co-workers directly 
functionalized spermine with two oleyl hydrophobes, while Smith and co-workers 
adopted a similar methodology to that used in their integrin binding work by decorating 
the surface of a low-generation amphiphilic dendron with spermine. Other workers, 
such as the team led by Ravoo, developed switchable SAMul DNA binders by 
functionalizing spermine with an azobenzene moiety able to become encapsulated 
within cyclodextrins at the surface of CD-vesicles.
66
 Example compounds from these 
approaches are shown in Figure 1.14. 
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 and (c) Smith.
65
  
The team of Smith and co-workers went on to rigorously investigate their systems 
through structural modifications at the monomer surface,
67
 within the dendritic 
branching scaffolds
68,69
 and of the hydrophobe,
70
 as well as examining the effects of co-
assembling PEG-additives into the self-assembled nanostructures.
71
 Overall, their most 
optimized potential gene delivery agent contained a DAPMA binding group, a 
degradable polyester scaffold and a reducible disulfide-containing cholesterol 
hydrophobe, all of which enabled the system to controllably release its DNA payload 
before itself degrading into small species with low individual DNA binding affinity.
70
 
Other workers have developed related systems targeted at binding siRNA, with the 
work of Haag, Smith and co-workers
72
 in particular showing good in vitro activity and 
significant promise by provoking no inflammatory response during in vivo testing.
73
 
As emphasized by the numerous works discussed in this section, the approach of self-
assembled multivalency is receiving ever more attention in the development of novel 
high-affinity binding systems for a wide variety of molecular targets. From a biological 
and medicinal standpoint, SAMul approaches present real pharmacological advantages 
with the smaller monomer structures more easily finding regulatory approval and it is 
believed by some authors that this approach may eventually lead to ‘undruggable’ 
conditions becoming treatable through the use of these ‘middle weight’ drugs.74   
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1.2 Heparin Therapy 
1.2.1 Heparin: the anti-coagulant of choice 
Heparin is most widely known as an anti-coagulant drug and finds applications, for 
example, during major surgical procedures to prevent blood clots from forming.
75
 
Ironically, heparin was discovered by Jay McLean in 1916 during his studies of 
cephalin, a suspected clotting accelerant.
76,77
 In the two decades following discovery, 
methods were developed for the effective extraction and purification of heparin and by 
1935 pure samples were being used for anti-coagulation in clinical settings, although a 
reasonable understanding of the mechanism by which anti-coagulation was being 
achieved was not forthcoming until the early 1970s.
78,79
    
Heparin is a member of the glycosaminoglycan (GAG) family of linear polysaccharides 
and has a molecular weight range between 2500 – 25000 Da.80 Structurally, heparin 
consists primarily of 1–4 linked uronic acid and glucosamine subunits, Figure 1.15, and 
the varying degrees of sulfation along these sugar components makes heparin the most 
complex member of the GAG family.
81
 The high levels of sulfation also lead heparin to 
be the most charge dense polyanion naturally occurring in biological systems, although 
the absolute biological roles of heparin remain a matter of discussion.
82-84
 Heparin is 
naturally biosynthesised as a proteoglycan and expressed in connective-tissue-type mast 





Figure 1.15 – An example heparin polysaccharide (top) along with the predominant 
disaccharide repeat unit (bottom left) and the specific pentasaccharide sequence 
required to confer anticoagulant activity (bottom right).  
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Given the highly polydisperse nature of heparin, it is typically fractionated into 
narrower molecular weight ranges before clinical application. Low molecular weight 
heparin (LMWH) consists of polysaccharides with Mrs typically between 4000 – 6000 
Da while unfractionated heparin, as the name suggests, encompasses the whole Mr range 
and tends to have an average Mr of ca. 15000 Da.
85
 Of the two, the less-polydisperse 
LMWH is preferred for use in most types of general and orthopaedic surgeries, where it 
is introduced either intravenously or through subcutaneous injection, as it offers a more 
appealing pharmacokinetic profile.
86
 Typically, LMWH is metabolised with a half-life 
anywhere between 3 – 6 hours, whereas the larger UFH is removed much more rapidly 
in ca. 30 minutes.
75
  
Metabolism of heparins tends to occur through two pathways: saturable binding to 
receptors on endothelial cells and macrophages or renally through the kidneys, although 
several factors including the degree of sulfation influence the overall rate of heparin 
metabolism.
86,87
 Further complications in accurately predicting the dose-response of 
heparin include the amount of plasma-protein binding (PPB) in which heparin becomes 
involved. LMWH has a more predictable dose-response than UFH as it participates in 
much less PPB.
86
 Indeed, greater predictability underpins the preference of LMWH for 
most applications. Extracorporeal procedures such as cardiopulmonary bypass circuits 
or haemodialysis provide notable exceptions, where the faster metabolism of UFH is 
highly attractive. Here, the use of UFH allows the anticoagulant effect to be removed 
more quickly, in some instances without the introduction of a rescue agent.
88
  
The blood coagulation cascade in vivo is far from straightforward, although it can be 
simplified into two distinct pathways, Figure 1.16. The ‘intrinsic’ pathway originates 
from a surface contact trauma event while the ‘extrinsic’ pathway originates from tissue 
damage.
89,90
 Both pathways involve a plethora of clotting factors, distinguished by 
roman numerals, becoming activated or deactivated through interaction or reaction with 
each other, before converging and sharing the final few steps of the cascade to 
ultimately generate a fibrin-reinforced clot.
91
 At the convergence of this ‘common’ 
pathway sits Factor-Xa, which plays a key role catalysing the production of thrombin, 
the species responsible for catalysing the production of the insoluble fibrin fibre and the 
final clot. It is the ability of heparin to directly inhibit the catalytic activity of thrombin, 
thereby retarding the production of fibrin, which primarily confers the anti-coagulant 
activity.
86,92
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Figure 1.16 – Schematic representation of the blood coagulation cascade. 
In order to effectively inhibit thrombin, a specific pentasaccharide sugar sequence 
within heparin forms a ternary complex with thrombin and the naturally occurring 
thrombin inhibitor, antithrombin III (ATIII). The presence of heparin accelerates the 
natural inhibition of thrombin by ATIII by several orders of magnitude.
93
 Despite these 
impressive credentials, the requirement of the specific penatsaccharide sequence shown 
in Figure 1.15 renders larger amounts of every heparin dose inactive as an anti-
coagulant as the structural variability of heparin leads to only 15–25% of all LMWH 
and 30–40% of UFH being composed of this specific pentasaccharide sequence, or so-
called High Affinity Material (HAM).
94
 It is for this reason that, within clinical settings, 
heparin amounts are discussed in terms of anticoagulant activity, measured in terms of 
‘international units’, rather than in terms of mass. 
It is not uncommon for drugs to be standardised in terms of activity and the definition of 
the heparin unit has evolved since its implementation by Howell in the 1920s.
78,95
 This 
so-called ‘Howell unit’ was first defined as the amount of heparin required to prevent 
one millilitre of cat’s blood coagulating at 0°C.78,95 Following this, the first of many 
international standards of heparin was established in 1943 before being superseded 16 
years later.
96,97
 In its current, and sixth, manifestation, the international heparin standard 
(IHS) is calibrated by using all current major assay methods to determine the amount of 
heparin required to cause one millilitre of sheep plasma to half-clot when held for one 
hour at 37°C.
94
 Most often, assays such as the activated partial thromboplastin time 




 and anti-factor Xa assay
99
 are used for these purposes.
92
 These 
procedures will be discussed in more detail in the Heparin Sensing section below.  
Commercially, heparin is also sold in terms of activity rather than mass, and so each 
individual batch is tested post-extraction and assigned an activity. It is possible 
therefore to purchase, for example, 100 KIU (that is 100,000 IU) of heparin with a 
designated activity of 185 IU mg
-1
.   
1.2.2 Heparin Rescue 
At the conclusion of a procedure in which heparin has been used, there is usually an 
immediate need to neutralise the anti-coagulant effects and allow the patient to return to 
homeostasis. To do this, a so-called ‘heparin rescue’ agent is often introduced into the 
patient. Currently, protamine sulfate – an arginine rich shellfish protein of ill-defined 
structure – is the only licensed heparin rescue agent available in the clinic, although its 
use is not without consequence.
100
 Structurally, the protamine protein strand is 
composed of approximately 70% arginine amino acids which confer highly cationic 




Figure 1.17 – An example protamine structure (a) with the prevalent arginine residues 
depicted as wedges, adapted from reference 
101
 and (b) a molecular dynamic modelling 
snapshot of protamine, taken from reference 
102
.  
Much like UFH, protamine itself is usually introduced intravenously to the patient and 
once there, it is relatively short-lived with an in vivo half-life of less than 10 
minutes.
103,104
 This transient presence can cause problems with the use of protamine, 
particularly given the previously mentioned tendency of heparin to bind to plasma 
proteins (PPB).
105
 Often by the time such PPB-heparins are released back into the 
systemic blood flow, any free protamine may have already been metabolized away. This 
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can lead to the phenomenon of ‘heparin rebound’ where the now-released heparin 
causes a second anti-coagulant event.
106,107
 Such rebound is widely regarded as an 
associated risk of protamine use and some authors recommend a second, smaller, dose 
of protamine should be administered to avoid it, although interestingly other authors go 
so far as to regard heparin rebound as “much ado about nothing.”108,109 
A further major problem associated with the clinical use of protamine is the toxicity risk 
presented to a significant number of patients, and it is this which prevents a larger dose 
of protamine being administered in the first place to negate heparin rebound. Adverse 
reactions are known in up to 10% of protamine-treated patients, with up to 2.6% of 
cardiac surgeries experiencing significant respiratory complications and/or 
hemodynamic instability when protamine is used.
110-112
 Nybo and Madsen have 
systematically reviewed the serious allergic reactions to protamine and demonstrated 
that factors as diverse as allergy to fish and whether a patient is infertile or has 
previously had a vasectomy can impact on the likelihood of an allergic response.
113
 
Kimmel and co-workers added to this discussion by suggesting that such allergic 
reactions are often under-reported and so these statistics may actually provide an under-
estimate of the true hazards associated with protamine.
114
   
A further limitation to the clinical usefulness of protamine is its inability to fully 
neutralise LMWH.
115
 This intermittent effectiveness has been investigated by Chan and 
co-workers who found that resistance to protamine came primarily from very low 
molecular weight heparin chains, which possess lower-than-normal levels of 
sulfation.
116
 LMWH contains a higher proportion of these shorter, less anionic 
polysaccharides than UFH and this accounts for the decreased effectiveness of 
protamine in the neutralization of LMWH.  
Given the many problems associated with protamine, it is perhaps surprising that it still 
finds such prevalent use. In reality, the situation was aptly surmised by Stafford-Smith 
and co-workers in 2005: “in the absence of a safer replacement, undesirable effects [are] 
outweighed by its utility as the only available heparin-reversal agent.”110 As we shall 
see in the Heparin Binding section below, there has been much research undertaken in 
the search for an equally effective but less risky method for heparin reversal.   
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1.3 Heparin Sensing  
1.3.1 Monitoring heparin levels  
1.3.1.1 During surgery 
Throughout a procedure in which heparin is administered, there are two periods of time 
during which it is critical to monitor the anti-coagulation level of the patient. Firstly, 
whilst the procedure is in progress, suitable heparin levels must be maintained to ensure 
that clotting does not begin prematurely and hinder the surgical team. To do this, a 
range of so-called ‘clotting time assays’ are widely applied in the clinic.117 As the name 
suggests, these record the time taken for samples of the patient’s blood to clot.118 Put 
simply, a longer clotting time indicates higher levels of anti-coagulation and a higher 
level of active heparin.   
There are many different clotting time assays capable of monitoring the anti-coagulancy 
of a clinical sample and there is much literature discussion and comparison of their 
relative effectiveness and reliabilities.
117,119,120
 Two of the most widely used clotting 
time assays are the activated partial thromboplastin time (aPTT assay)
98
 and the anti-Xa 
assay.
121
 The aPTT technique specifically monitors clotting time via the ‘intrinsic’ 
clotting pathway, while the anti-Xa technique relies on the formation of a ternary 
complex between a known excess of Factor-Xa, ATIII and heparin. Following the 
introduction of a chromogenic mimic of the natural Xa substrate, the amount of non-




The reliability of each of these assays has been questioned by several authors. For 
example, Rosenberg and co-workers
121
 pointed to limitations of the aPTT approach due 





 shared the view that particular care must be taken to select the most 
appropriate technique for the procedure being undertaken. It is widely accepted however 
that the various clotting time techniques do afford reasonably accurate measures of the 
anti-coagulancy of a sample and, therefore, the levels of active heparin.
118,120
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1.3.1.2 At the conclusion of surgery 
At the conclusion of a procedure in which heparin has been used, the focus of the 
clinicians immediately switches from needing to know how much active heparin is 
present (i.e. the level of anti-coagulancy) to how much total heparin polysaccharide is 
present (i.e. irrelevant of anti-coagulant activity). The indiscriminate binding of 
protamine to heparin, regardless of the polysaccharide’s activity, is the underlying 
reason for this change in viewpoint. The aforementioned risks associated with incorrect 
protamine dosing further emphasizes the importance of accurately quantifying the 
amount of heparin remaining in the patient.
123
 It is perhaps surprising therefore that in 
the clinic, residual heparin levels are still determined through clotting time based 
techniques such as aPTT or anti-Xa measurements.  
As discussed in the previous section, these techniques can each provide a good measure 
of the anti-coagulant activity of heparin within a given sample.
124
 It is not 
straightforward however to determine the global load of polysaccharide from these 
values as the proportion of active heparin present in any given dose varies from batch to 
batch. Consequently, there is a real need for an alternative methodology whereby the 
total load of heparin polysaccharide present systemically within the patient can be 
accurately and rapidly determined. 
As we shall see in the sub-sections which follow, there have been a variety of 
approaches to this problem, often from supramolecular chemists specializing in 
controlling non-covalent interactions between different molecular species. It must be 
remembered however that developing a system to interact with, or sense, heparin within 
the regime described here requires the non-covalent interactions to be established 
selectively with heparin within a complex biological medium such as serum, plasma or 
even whole blood. This challenge is far from trivial.  
The detection and quantification of polysaccharides in aqueous media is an important 
task in many medicinal and industrial contexts.
125
 As such, there is an impressive body 
of literature on sugar sensing, with much focus falling on the utilization of boronic acid 
moieties.
126,127
 Boronic acids are particularly effective as sugar or diol targeting species, 
where interactions result in the reversible formation of boronate esters.
128
 When suitable 
chromogenic or fluorescent groups are appended onto them, the establishment of these 
interactions can facilitate a sensing event, which in turn can be tuned through molecular 
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 As we shall see below, boronic acid derivatives were also amongst the 
first synthetic systems to be investigated for heparin sensing.      
1.3.2 Electrochemical sensing  
Several researchers have developed systems able to exhibit a potentiometric response 
upon heparin binding.
133,134
 Such systems were designed such that binding occurred 
with all regions of the polysaccharide regardless of anti-coagulant activity, and so the 
measurements could be taken as representative of the global amount of heparin within a 
given sample. As an example, Yang and co-workers developed a system incorporating 
cationic units into PVC membranes and films and, impressively, were able to obtain a 
quantitative heparin binding response even when using relatively non-functional 
quaternary ammonium groups as the cationic species within the membrane, Figure 
1.18.
135
 Optimization of this system can be achieved by altering the cationic polymer 
within the membrane, and most impressively, sensing in this manner can operate within 
full human blood. A limitation of this methodology, however, is the irreversibility of 
heparin binding to the membranes, as this necessitated a rinsing step between sensing 
events; something of a detraction for clinicians. Nonetheless, numerous groups have 











1.3.3 Colorimetric sensing 
By far the most prevalent approaches to developing heparin sensors are those targeting 
spectrophotometric or fluorescent dye systems, primarily due to their potential for a 
simple read-out. As we shall see in some of the following examples, it is possible to 
develop systems which can in some cases respond to heparin in preference to other 
anionic species. 
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Early fluorescence-based approaches monitored the inhibition activity of heparin when 
binding to a fluorescent thrombin substrate.
139,140
 This is an example of an indirect 
approach to heparin quantification as only non-heparin-bound thrombin reacted with the 
substrate to generate the fluorescent response. Although this approach was relatively 
fast in the clinic, with the requisite filtration and measurement of the resulting plasma 
sample taking only 5 minutes, it has not widely being employed due to problems 
maintaining and reliably calibrating the instruments.
120
       
1.3.3.1 Switch-off sensors 
It is preferable for heparin detection to be direct, and for that reason much attention has 
focused on indicator dye systems capable of exhibiting significant switch-on or switch-
off response upon direct interaction with the heparin polysaccharide. In the same way as 
the binding of protamine to heparin, direct detection in this manner can quantify the 
total amount of heparin present, rather than only the anti-coagulantly active portion.  
Commercial thionine-derived dyes were amongst the first to be investigated for this 
purpose, although not without problems.
141,142
 In particular, although Azure A, a simple 
commercial cationic dye, was purported to be able to monitor heparin levels in 
plasma,
141
 it was also known to be acutely sensitive to many of the electrolytes present 
in biological samples.
143
 These issues are examined in detail in Chapter 2.  
Given the general unreliability of commercial systems, as typified by the Azure A 
example, interest was fuelled in the design and development of bespoke synthetic 
systems. Landmark work came in 2002 from the laboratory of Anslyn and co-workers 
who synthesised a tris-boronic acid species able to indicate indirectly through 
displacement of a pyrocatechol violet indicator dye.
144
 In order to allow for direct 
heparin response, the system was elegantly modified to incorporate the fluorophore into 
the binding site, Figure 1.19.
145





 to be determined in 10 mM HEPES buffered at pH 7.4, and also for binding to 
be observed in human serum. Upon binding to heparin within Anslyn’s system, the 
associated spectroscopic signal exhibits a decrease in intensity. This type of system can 
be categorized as a switch-off sensor.  
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Figure 1.19 – Anslyn’s heparin sensors operating (a) in an indicator displacement 
regime
144
 and (b) using a single molecule fluorescent sensor.
145
 These structures are also 
shown in Figure 3.2. 
Many switch-off sensors have been developed, with a notable example within the last 
decade coming from the work of Egawa and co-workers. Their strategically sage 
approach involved the functionalization of protamine with fluorescent fluorescein 
moieties which, upon binding heparin, became located within the Förster distance 
required for self-quenching, leading to the ‘switch-off’ of the observed signal.146 
Clearly, the key advantage of this approach is that the heparin binding array is 
protamine itself and so the reported binding for each sample of heparin should be 
indicative of precisely what protamine will be able to bind to. 
Other fluorescent switch-off sensors came from the group of Chen and co-workers who 
created an array of cationic sugars by appending them onto a conjugated polymer 
scaffold, Figure 1.20.
147
 The fluorescence of this scaffold became quenched when the 
cationic groups bound to heparin as it led to aggregation of the scaffold units. A similar 
approach from Bhosale and co-workers functionalized a kanamycin A derivative with a 
pyrene moiety, which became quenched as the sugars bound to heparin.
148
 Although 
effective, this system only responded at relatively high concentrations of heparin.  
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Figure 1.20 – Fluorescent sugar-containing heparin sensors from the groups of (a) 
Chen
147
 and (b) Bhosale.
148
  
A particularly interesting switch-off sensor came from the work of Schrader and co-
workers, who designed a multi-binding methacrylamide polymer which, clearly inspired 
by the landmark work of Anslyn,
145
 was decorated with o-aminomethylphenyl-boronate 
derivatives, along with fluorescent dansyl groups.
149
 Most impressively, even in the 
absence of any charge, near micromolar heparin binding was observed in the presence 
of 25 mM HEPES buffer. In this system, the interactions were not strictly non-covalent 
as covalent boronate-esters form between the polymer and heparin, but these bonds 
were fully reversible, as demonstrated by their cleavage upon the addition of protamine. 
1.3.3.2 Switch-on sensors 
As insightful as the plethora of switch-off sensors can be, switch-on sensors carry the 
advantage of even easier detection, as the spectroscopic signal increases from zero upon 
heparin binding. Often, the signal switch-on is the result of a triggered aggregation 
event. An example from Zhang, Zhu and co-workers involved the use of an ammonium 
functionalized silole species which aggregated in the presence of heparin leading to a 
switch-on response.
150
 The system was shown to be effective in the presence of sulfate 
rich HEPES buffer and also in horse serum although there was a need to manually 
subtract the signals from the fluorescence of serum itself. In a related, albeit more 
synthetically complex, example from Wang and co-workers, a pyrene functionalized 
quinine exhibited switch-on fluorescence in the presence of heparin due to the formation 
of an excimer complex between two molecules of dye and the heparin biopolymer.
151
 
Selectivity for heparin over other GAGs was demonstrated for this example and 
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rationalised by Wang and co-workers to be due to structural compatibility between 
heparin and the indicator dye.  
Selective heparin binding was also achieved by Liu and co-workers who developed a 
range of versatile conjugated polyelectrolyte structures appended onto a polyfluorene 
backbone, Figure 1.21.
152-154
 Their system was able to respond to heparin either in a 
switch-on, direct colorimetric or ratiometric fashion as a result of aggregation. Indeed, 
the colour change upon heparin binding in 2 mM PBS was so vivid that it could be 
observed by the naked eye, and was easily differentiable from binding to other GAGs 
such as hyaluronic acid. Other examples of this type of aggregation-induced 
fluorescence can be found in the work of Wang and co-workers, who developed similar 
cationic conjugated polyfluorene systems to Liu.
155
 Král and co-workers, meanwhile, 
focussed on the development of polymethinium salts which exhibited selective heparin 
binding at the more acidic pH of 5.53 in 1 mM phosphate although it was not clear 





Figure 1.21 – A polyfluorene heparin sensing derivative from Liu and co-workers.154 
One of the main limitations of developing fluorescent sensors which are able to sense 
heparin in biological conditions such as serum is the problem of serum auto-
fluorescence. Specifically, the hydrophobic regions of serum tend to exhibit 
fluorescence following excitation with short wavelengths of light and, at concentrations 
as low as ca. 5% serum, this effect becomes sufficient to render any sensing response 
meaningless. In order to overcome this, there have been several efforts to develop 
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sensors which fluoresce at longer wavelengths. A particularly eye-catching attempt at 
this came from Nitz and co-workers with a system based around the polyelectrolyte 
effect.
157
 They developed a cationic sensor which had its fluorescence quenched by 
chloride counter ions meaning that a switch-on response was observed upon binding to 
heparin, as this caused chloride anions to be expelled from the binding ensemble. 
Disappointingly though, the system was too insensitive to detect heparin at clinically 
relevant concentration levels. A more promising longer-wavelength fluorescent sensor 
came from Krämer and co-workers who synthesised a perylene diimide species, Figure 
1.22, which fluoresced at 615 nm following excitation at 485 nm and was able to 




Figure 1.22 – A perylene diimide sensor structure from Krämer and co-workers.158 
Other researchers have employed different methods for working around serum auto-
fluorescence. For example, Yam and Yeung developed an alkynylplatinum(II) complex 
which emitted in the near infra-red (NIR) region upon binding to heparin.
159
 Their 
system also gave useful circular dichroism signals; the magnitude of which allowed 
differentiation between UFH, LMWH and other GAGs such as chondroitin sulfate. 
Arguably the most promising, and fundamentally impressive, switch-on fluorescent 
sensor to date came from the work of Chang and co-workers, who employed a high-
throughput diversity-oriented fluorescent library approach (DOFLA) in their search for 
an effective sensor.
160
 This approach is significantly different to the previous examples 
presented above, which generally originated from some modicum of semi-rational 
design. Chang’s DOFLA approach was able to screen a large number of molecules and 
identified two particularly promising functionalized benzimidazolium dyes, named 
heparin orange and heparin blue after their respective colours, Figure 1.23. These dyes 
were able to respond significantly to clinically relevant concentrations of heparin, even 
in the presence of 20% human plasma. Moreover, these sensors are only dicationic at 
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physiological pHs which further suggests that the DOFLA approach identified well 
optimized structures. 
 
Figure 1.23 – Heparin orange and heparin blue, discovered via a diversity-oriented 
library approach in the group of Chang.
160
 
1.3.3.3 Ratiometric sensors   
In addition to the work involving single sensor dyes presented above, there is a growing 
interest in sensing systems involving more than one indicator dye. This approach 
usually takes the form of ratiometric sensing, which involves monitoring spectroscopic 
changes at two wavelengths to provide internal calibration of the system: a key 
advantage over a single dye approach. 
The team lead by Zhang adopted this methodology and their two component binding 
ensemble provides an excellent recent example of ratiometric heparin sensing.
161
 The 
ensembles consisted of an alkyl-ammonium functionalised anthracene derivative which 
exhibited a decrease upon binding to heparin as a result of aggregation-caused 
quenching (ACQ), and an alkyl-ammonium tetraphenylethene (TPE) species which 
exhibited enhanced fluorescence upon binding due to aggregation-induced emission 
(AIE), Figure 1.24. The unusual phenomenon of AIE is widely thought to be associated 
with the enhanced conjugation which results from the coplanarisation of 
photoluminescent groups, such as TPE, upon intermolecular assembly.
162,163
 
Consequently, when both components in Zhang’s system bind to heparin, in a 10 : 11 
ratio, monitoring the relative ratio of their fluorescence intensities affords ratiometric 
data. Although more robust than some single-dye approaches, correction factors still 
needed to be introduced when heparin sensing was carried out in serum.  
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Figure 1.24 – Two-component heparin sensor from Zhang and co-workers.161 
Similar AIE approaches have recently been adopted by other researchers such as Tang, 
Liu and co-workers who developed a fluorene-based system which adopted a propeller-
like conformation to exhibit a fluorescence enhancement upon interaction with 
heparin.
164
 A particularly selective AIE-based heparin sensor has also recently been 
forthcoming from Tong and co-workers, which in addition to high selectivity, exhibited 





Krämer and co-workers, meanwhile, built on their earlier approach of using long 
wavelength fluorescent dyes by developing a pair of cationic ruthenium complexes in 
which, upon co-assembling on heparin, the proximity of the second complex quenched 
the fluorescence of the first leading to a detectable optical output at 630 nm.
166
 
Although this system was able to detect heparin within a clinically useful concentration 
range in the presence of serum, the system was not selective for heparin and so 
responded somewhat to the presence of other GAGs.  
Other recent attempts to work around serum-autofluorescence from Zhao, Liu and 
Huang employed a phosphorescent conjugated polyelectrolyte (PCPE) containing an 
Ir(III) complex which was able to selectively respond to heparin in a ratiometric manner 
both in aqueous solution and in the presence of serum, Figure 1.25a.
167
 Most 
impressively, this system was able to respond to heavily diluted samples of heparinized 
human blood. In separate work, the fluorescently-labelled peptide of Lee and co-
workers was not tested directly in human blood, although it did offer remarkable 
sensitivity, in the picomolar (pM) range, in aqueous solutions across a range of pHs and 
also in samples containing 5% serum or plasma, Figure 1.25b.
168
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Figure 1.25 – Selective ratiometric sensors: (a) phosphorescent conjugated 
polyelectrolyte  structure from Zhao, Liu and Huang
167
 and (b) peptide structure from 
Lee.
168
   
1.3.4 Solid/nanoparticle supported sensing 
All of the heparin sensors presented so far operate within the homogeneous solution 
phase, however there are a growing number of heterogeneous and/or nanoparticle 
approaches to heparin sensing. For example, the aforementioned sensors developed by 
Krämer and co-workers have been immobilised on SiO2 beads in an attempt to increase 
the commercial appeal of the system.
166
 Disappointingly, this modification retarded the 
heparin on-rate, decreasing the efficacy of the system and meaning further development 
is still required if such a system is to become commercialised. This gives a suitable 
reminder that molecular-scale chemical considerations are not the only drivers which 
must be addressed in the search for viable heparin sensing systems. 
The group of Martínez-Máňez, Marcos and co-workers functionalised silica 
nanoparticles with both thiols and cationic amines to generate a sensing system in which 
a fluorescent squaraine dye was perturbed in the absence of heparin due to the 
nucleophilic attack of the surface thiols.
169
 In the presence of heparin, the surface 
amines interacted with the polysaccharide causing it to wrap around the NPs and 
prevent the thiol-induced perturbation of the squaraine, thereby leading to the detection 
event. Unfortunately, the poor solubility of the NPs within this system necessitated 
operation in the clinically unappealing presence of 45% DMSO and 10% CH3CN.  
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Gold nanoparticles (AuNPs) have been investigated in heparin, and indeed protamine, 
sensing situations by several groups trying to utilise the distance-dependant optical 
properties of the AuNPs.
170
 For example, Li and Cao functionalized AuNPs with 
cationic cysteamine groups and were able to observe an absorbance change at 670 nm as 
the AuNPs aggregated along the heparin chain.
171
 This system was demonstrated to be 
operable in the presence of 1% human serum with a detection limit of 0.1 µg mL
-1
. 
Another well thought out method involving AuNPs came from the work of Chen and 
co-workers, who monitored the change in surface plasmon resonance signals as AuNPs 
aggregated on a graphene oxide (GO) surface, Figure 1.26.
172,173
 In this example, the 
AuNPs were capped with anionic citrate groups and protamine was used to bridge 
between the GO and the AuNPs, assisting their aggregation along the surface. Upon the 
addition of heparin, protamine was sequestered from this bridging role by forming 
preferential electrostatic interactions with the polysaccharide, and the AuNPs thereby 
deaggregated away from the GO surface. The resulting ‘blue-to-red’ colour shift 
indicated the extent of de-aggregation, which in turn corresponded directly to the 
amount of heparin present. Remarkably for such a complex-sounding methodology, 
heparin could be quantified down to 1.0 µg mL
-1
 at pH 7.4, and also in fetal bovine 
serum.  
 
Figure 1.26 – Graphene-AuNPs sensing system from Chen and co-workers. Figured 
adapted from reference 
172
. 
As we have seen throughout this section, there have been a variety of promising 
approaches to developing a novel heparin sensing system able to accurately determine 
the residual systemic amount of heparin in a biological sample, however to date none of 
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these approaches have reached the clinic. Our attempts to address this problem are 
detailed in Chapter 2. The next section considers some of the landmark efforts to 
address the problem of heparin reversal in vivo, through the search for an alternative to 
the current heparin rescue agent, protamine.     
1.4 Heparin Binding 
The focus on developing novel heparin binding systems with the potential to replace the 
clinical use of protamine has understandably centered on cationic systems. Indeed, 
protamine itself uses multiple arginine and lysine cationic amino acids to establish 
favourable electrostatic and hydrogen bonding interactions with the anionic heparin 
biopolymer. In order to have clinical potential, synthetic protamine alternatives must 
readily bind heparin in competitive biological media and, crucially, possess more 
appealing toxicity profiles than protamine. Much like heparin sensing, heparin binding 
has attracted a significant amount of attention although, as yet, no fully-functional 
protamine replacement has been found. In the following sub-sections, some of the 
landmark work in the area will be discussed.    
1.4.1 Enzymatic, protein-based and polymeric systems 
Given that protamine is itself a protein, there have been several attempts to apply other 
protein-based or enzymatic systems in its place. An early enzymatic approach involved 
the use of heparinase I enzymes to cleave glycosidic bonds between heparin saccharides 
effectively fragmenting the biopolymer into smaller units and removing its anti-
coagulant properties. Although somewhat effective, the use of heparinase I in trials was 




Lactoferrin is an iron binding protein released from neutrophils, which is thought to 
play an active role in heparin control owing to having superior binding ability to 
protamine in vitro.
176
 As such, there has been some focus on promoting the natural 
release of lactoferrin at inflamed sites post-surgery in order to study the effects on 
heparin. Bacteriophage Qβ is a large icosahedral RNA virus containing 180 copies of a 
14.1 kDa coat protein, which has a high tolerance to genetic insertions and/or point 
mutations.
177
 This has enabled it to be established as a multivalent platform for heparin 
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binding following the insertion of multiple arginine groups.
178
 Although this approach 
did generate some systems with superior neutralisation effects than protamine in 
clotting assays, their time-consuming preparation is a significant detraction, as is the 
current absence of toxicology studies. 
Unsurprisingly, several researchers have focussed on producing smaller shorter-chain 
peptide structures. For example, Yang and co-workers developed a range of low-
molecular-weight-protamine (LMWP) systems by digesting native protamine strands 
with thermolysin.
179
 This technique produced arginine rich peptide sequences such as 
VSRRRRRRGGRRRR which could effectively neutralise heparin in vivo whilst 
provoking less immunogenicity than native protamine, although the complex digestion 
step again restricted genuine clinical interest.
180-182
 A similar study by Wakefield and 
co-workers observed that a range of cationic peptides were significantly less toxic than 
protamine, although they also suggested that treatment with these peptides resulted in 
incomplete reversal of heparin.
183
 A further range of synthetic peptides has been 
developed from residues 27–38 of human serum amyloid P.184 Despite not possessing a 
high density cluster of basic amino acids, this specific sequence still demonstrated the 
ability to bind heparin at micromolar levels. The inactivity of a sequence scrambled 
version of this peptide suggested that the binding mode of residues 27–38 is 




Some of the earliest work in the area came in 1958, when the synthetic polymer 
polybrene – hexadimethrine bromide, Figure 1.27a – was examined as a protamine 
alternative.
185-187
 Polybrene has a much simpler cationic polymer structure than 
protamine and was tested in vivo, where it showed promise but ultimately was only 
around 70% as effective as protamine.
188
 Interestingly, development of this system 
appeared to halt and it seems likely that toxicity problems hindered its progress. 
Toxicity of cationic synthetic polymers can however be tempered by careful design of 
the polymeric backbone. For example, dextran and hydroxypropylcellulose polymers 
have been functionalised with cationic groups and shown to have relatively good 
biocompatibility, with heparin binding affinity increasing with degree of cationic 
decoration.
189,190
 A further advantage of such sugar-based systems is their wide 
commercial availability.    
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Figure 1.27 – Cationic heparin binding polymers: (a) Quaternary ammonium-based 
cationic polymer polybrene and (b) an arginine functionalised PAH.
191
 
Recently, Szczubiałka, Nowakowska and co-workers reported the preparation and 
rigorous preliminary testing of an arginine functionalised poly(allylamine 
hydrochloride) (PAH) polymer, Figure 1.27b.
191
 Impressively, across a variety of 
solution phase and biological assays including in vitro plasma clotting (aPTT) and in 
vivo coagulation studies in rats, the heparin neutralisation performance of the polymers 
was shown to be similar or superior to protamine. Initially, the argininylated structures 
also appeared to be non-toxic to cells although, as acknowledged by the authors, more 
systematic pharmacokinetic and toxicity studies are still required for this promising 
candidate.  
A different family of cationic polymers are the commercially available 
poly(amidoamine) (PAMAM) dendrimers, and these well-defined species have been 
examined for their heparin binding ability.
192
 Xu, Cheng and co-workers observed some 
insightful generational effects, where the most highly charged dendrimer was not 
necessarily the best heparin binder. The binding of PAMAM dendrimers to LMWH has 
also been studied in rats, although in this example no reversal of anti-coagulation was 
observed.
193,194
 Instead, it was suggested that the PAMAM dendrimers may be used in 
this setting to enhance the absorption and assist delivery of the LMWH, hinting at the 
potential for use as deep vein thrombosis prevention agents. Indeed, this is an example 
of how heparin binders could be developed into delivery vehicles rather than rescue 
agents. Our own studies involving PAMAM (and related) dendritic systems are 
presented in Chapter 3. 
1.4.2 Small molecules 
Despite heparin being a large somewhat polydisperse polysaccharide, there are several 
examples of heparin neutralization being attempted using more traditional well-defined 
‘drug-like’ small molecules. One of the earliest small molecules to be considered as a 
potential heparin rescue agent was known heparin sensor methylene blue, although, 
presumably owing to its monocationic nature, it was shown to be ineffective.
186,195
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An important ‘small molecule’ system emerged in the form of Delparantag, a penta-
cationic species derived from alternating aromatic and lysine amino acid units, Figure 
1.28.
196,197
 The lysine side-chains confer heparin binding ability while the aromatic units 
confer some rigidity to the species. Impressively, an in vivo clinical trial in six male 
humans, along with animal studies, suggested Delparantag was as effective as 
protamine at neutralizing heparin without creating complications such as a heparin 
rebound effect. Following Phase II clinical trials, considerations of the suitability of 
Delparantag in different clinical situations continue.
198
    
 
Figure 1.28 – Delparantag is a lysine-containing penta-cationic heparin binder.  
Eye-catching work from the group of Cunsolo and co-workers developed polycationic 
calix[8]arenes and demonstrated their ability to neutralise heparin in blood. In vitro 
studies showed that neutralization was faster and more efficient than protamine, 
although hemolysis did occur at high calix[8]arene concentrations.
199,200
 On the 
molecular level, it was proposed that the flexibility of the scaffold maximized heparin 
binding as the cationic groups had some freedom to optimize their individual 
interactions with the biopolymer. Indeed, an ‘octopus-like’ chelate effect was observed 
computationally, Figure 1.29.  Follow-up work from the same group then immobilized 
these structures onto a polymer matrix to yield a filter-like structure which may have 
potential for the ‘clean-up’ of a patients’ bloodstream following a procedure such as 
coronary bypass.
201
 It can be envisaged that the blood could be passed through the filter-
like structure, thereby avoiding the need to directly introduce antidote molecules 
directly into the bloodstream. 
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Figure 1.29 – Calix[8]arene from Cunsolo and co-workers with structure (left) enabling 
chelate effect to be maximized through adoption of ‘octopus-like’ conformation (right, 




Foldamers are small peptide-protein mimics which establish well-defined 
conformations. The group of DeGrado and co-workers established an octa-cationic 
arylamide-derived foldamer decorated with amine and/or guanidinium groups which 
exhibited heparin antagonism in vitro, Figure 1.30.
202,203
 Their controlled structure-
activity studies demonstrated that guanidinium cations enhanced the heparin binding of 
the system 2.5-fold over simple amines. Recently published follow-up studies 
demonstrated further activity of these systems against ATIII in Factor-Xa type heparin 
binding assays, and the systems were also shown to be sufficiently versatile to 
neutralise fondaprinux (a synthetic analogue of the specific penatsaccharide sequence 








As a final example, surfen – bis-2-methyl-4-amino-quinolyl-6-carbamide, Figure 1.31 – 
was investigated as a heparin binder by Esko and co-workers in 2008.
205
 It was 
demonstrated that protonation of the quinoline rings was sufficient to confer heparin 
binding activity, despite the low molecular charge. Surfen had first been studied by 
Chapter 1 - Introduction 
64 
Hunter and Hill in 1961, who suggested that the small amount of charge per molecule 
made heparin-reversal performance inferior to protamine.
206
 This lower potency 
ultimately leads to unacceptably high IC50 values and so further investigation of surfen 
has been halted. 
 
Figure 1.31 – Surfen, one of the smallest synthetic heparin binders to be examined as a 
potential heparin rescue agent.
205
  
1.4.3 Self-assembling systems 
Given the many advantages of creating large multivalent ligand arrays from smaller, 
more synthetically tractable and biologically compatible building blocks, it is perhaps 
surprising that there are so few examples of self-assembling multivalent (SAMul) 
approaches to heparin binding. The maiden example came from Stupp and co-workers 
in 2006 with a complex lipopeptide capable of self-assembling into heparin binding 
cylindrical micellar nanostructures, Figure 1.32.
207-209
 Structurally, a known heparin 
binding sequence consisting of three lysine and one arginine group was installed within 
the hydrophilic region of the self-assembling lipopeptide, while an n-alkyl chain 
conferred amphiphilicity.
210
 In the presence of heparin, the individual self-assembled 
nanofibres were able to nucleate a further assembly event to form gel-based 
materials.
209
 Stupp and co-workers then demonstrated that the heparin within these gels 
was able to stimulate the formation of new blood vessels (angiogenesis), opening up 
further biomedical interest. Subsequent studies additionally showed that by co-
assembling a fluorescently-labelled lipopeptide into the system, fluorescein-tagged 
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Other noteworthy approaches to self-assembling heparin binders came from Smith and 
co-workers in 2011, who adapted a low generation analogue of a known DNA binding 
SAMul dendron and demonstrated its potential for binding to the heparin biopolymer, 
Figure 1.33.
211
 An attractive feature of this approach is the relative synthetic 
accessibility of the molecular building block. The initial work from the group of Smith 
established that the amphiphile self-assembled to afford nanoscale micellar structures 
which appeared to bind heparin due to the multivalent cationic ligand array displayed at 
the assembly surface. There were some limitations to this initial work and these are 
discussed in more detail in Chapter 4.  
 
Figure 1.33 – Self-assembling heparin binding compound subjected to preliminary 
testing by Smith and co-workers.
211
 This Figure is also shown as Figure 4.2. 
1.5 Project Aims 
The overarching theme of this project is heparin therapy, the clinical use of heparin as 
an anti-coagulant during surgery or other medical procedures. In particular, the focus 
falls on two distinct areas: (i) heparin sensing, and the need for a more effective and/or 
reliable methodology for quantifying the amount of heparin remaining within a patient 
during, and at the conclusion of, treatment; and (ii) heparin binding, and the need for a 
better heparin rescue agent capable of neutralizing the anti-coagulant effect of heparin at 
the conclusion of surgery, without presenting risks such as those associated with the 
clinical use of protamine. By considering these two clinical problems from a 
supramolecular chemistry perspective, it was hoped that fundamental insights into 
heparin binding and sensing might be revealed, which, in turn, may be able to inform 
future developments in the area.  
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1.5.1 Heparin sensing 
The heparin sensing arm of this project adopted the goal of identifying a more suitable 
methodology for the determination of the overall residual load of heparin – that is the 
complete biopolymer, regardless of anti-coagulant activity – remaining systemically 
within a patient at the conclusion of surgery. Building on the many promising examples 
presented earlier, a colorimetric sensing regime was targeted. It was hoped that this 
would offer significant advantages over clotting based techniques, which are based 
exclusively on heparin activity, by binding indiscriminately to heparin in a manner more 
simulative of protamine binding characteristics.  
In order to maximize the clinical appeal of a potential heparin sensing system, 
commercial indicator dyes were considered first to examine whether any ‘off-the-shelf’ 
species would be suitable for such heparin sensing applications. Should an already-
commercial option not be forthcoming, the intention was to design a bespoke heparin 
sensor with a major focus on synthetic simplicity. Indeed, one of the drawbacks of even 
the most promising colorimetric systems discussed previously is their often unattractive, 
multi-step syntheses. The ease of uptake for a potential end-user remained a 
consideration throughout the study of our sensing systems.  
It is worth noting that from a supramolecular chemistry perspective, developing and 
testing such a colorimetric heparin sensor is far from trivial.  Establishing selective 
supramolecular interactions with any target (but in our case heparin) within highly 
competitive media such as high buffer and/or salt concentrations, or biological media 
such as human serum or plasma, is a great challenge. Also, any output signal from the 
sensor must remain quantitative, unperturbed and easy-to-calibrate within such media.  
1.5.2 Heparin binding  
The heparin binding part of the project aimed, ultimately, to advance the understanding 
of the potential for self-assembling multivalent (SAMul) systems to be applied in 
heparin rescue treatments. To do this, initially, a range of well-defined cationic species 
such as commercial PAMAM dendrimers were studied for their relative heparin binding 
properties. This study hoped to give insights into some fundamental binding preferences 
of heparin.  
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Subsequently, the project moved on to consider, initially through further investigation 
of the previously reported SAMul heparin binder from within the Smith group, the 
potential of a SAMul approach for heparin binding in competitive conditions.
211
 The 
SAMul-heparin-binding concept is cartooned in Figure 1.34.  
 
Figure 1.34 – Cartoon showing the concept of self-assembled multivalency (SAMul) in 
for heparin effective heparin binding. 
In particular, there was to be a focus on examining the effects of electrolytic 
competition and biological conditions upon the heparin binding performance, and more 
fundamentally, the properties of such self-assembled nanosystems. Meaningfully 
probing heparin binding under such conditions may require the careful development of 
a sufficiently robust assay technique, as this was a limitation previously acknowledged 
by Smith and co-workers in their preliminary studies.
211
 Further insights into the 
physical and theoretical properties of our SAMul systems were to be targeted through 
collaborations with the laboratories of Dr Marcelo Calderon at Freie Universität Berlin, 
Germany and Professor Sabrina Pricl at University of Trieste, Italy. It was intended that 
Dr Calderon would provide solution phase insights through dynamic light scattering 
techniques which would be ideal for comparison against our own microscopy imaging 
and the computational molecular dynamic modelling approaches employed by Professor 
Pricl. 
Once some understanding of the SAMul systems had been gained, it was intended to 
evolve the approach by re-designing the monomer unit(s) in response to these 
observations. It was hoped that promising candidates would be subjected to clinically 
relevant plasma clotting assays through collaboration with Professor Jeremy Turnbull at 
University of Liverpool, UK. This application-driven design, test, review, modify 
approach was intended to permit progress towards a clinically relevant understanding of 
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the real-world requirements of SAMul systems, and allow a meaningful assessment of 
the potential of SAMul approaches for use in heparin rescue treatments.  
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2 Chapter 2 – A Simple Robust Heparin Sensor 
2.1 Introduction 
At the conclusion of a surgical procedure involving the use of heparin as an anti-
coagulant drug, there is an immediate need to reverse the effect and allow clotting to 
begin.
212
 This heparin reversal is achieved through introduction of the only licenced 
heparin reversal agent: protamine. Due to the toxicity risks associated with the clinical 
use of protamine, dosing is crucial in order to minimise the risk to patients. In order to 
dose protamine appropriately, the amount of heparin remaining in the patient at the end 
of surgery must be accurately quantified.  
While a surgical procedure is in progress, the level of heparin in the patient must be 
closely monitored in order to maintain sufficient levels of anti-coagulation. Clotting 
time assays such aPTT or anti-Xa techniques can be particularly effective in this role; 
giving a good measure of the active heparin levels in a blood sample, from an anti-
coagulation viewpoint.
117,118
 Currently, at the conclusion of surgery, these same 
techniques are employed to calculate the amount of residual heparin remaining in the 
patient. The use of clotting time based techniques at this stage of the process is not 
ideal.
122
 Rather than determining the amount of heparin remaining in the patient from an 
anti-coagulancy viewpoint, it would be more informative to quantify the amount of 
global heparin remaining in the patient, irrespective of its activity. Protamine, the 
heparin antidote, is unable to differentiate between active and inactive regions of 
heparin when neutralising the anti-coagulant effects and so a measure of total amount of 
heparin in the patient may help with more accurate dosing.
213
   
Colorimetric sensors have great potential for quantifying the global amount of heparin 
in a sample.
212
 Colorimetric detection involves an indicator dye exhibiting a change in 
photospectroscopic or fluorescent signal intensity upon interaction – usually, but not 
exclusively, in a non-covalent manner – with heparin. This type of measurement is able 
to give a direct read-out of heparin levels by simple comparison to known standards. A 
key advantage of a colorimetric approach to heparin monitoring is the ability of the dye 
to bind to / interact with all of the heparin chains indiscriminately, regardless of whether 
they contain the correct sequence of sugars to confer anti-coagulant activity. This leads 
to quantification of the total amount of heparin – not just the amount of active heparin – 
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which in turn should allow for more accurate protamine dosing and, ultimately, 
improved clinical outcomes. 
A sensor dye capable of detecting heparin in a clinically relevant situation has many key 
challenges to overcome. Firstly, the sensor must be able to establish interactions with 
heparin. Most widely, heparin sensors contain cationic functional groups which can 
establish electrostatic interactions with the anionic sulfate and carboxylate groups on the 
heparin biopolymer. Secondly, the sensor must exhibit a quantifiable spectroscopic 
change upon establishing these interactions with heparin either in the form of an 
increase (switch-on sensing) or decrease (switch-off sensing) in signal intensity. 
Thirdly, for the sensor to be of potential clinical relevance, it must be able to exhibit this 
response to heparin when heparin is present at clinically relevant concentration levels, 
and, most challengingly, in an electrolytically competitive media such as human 
plasma.  
To date, a wide variety of spectrophotometric and fluorescent heparin sensors have been 
investigated, with some demonstrating a particularly impressive ability to detect and 
quantify heparin levels in complex biological media such as human plasma.
158,160
 An 
important factor for any potential heparin sensor wishing to find application at the 
point-of-care in the clinic is synthetic accessibility. Understandably, this is not always 
maintained as a high priority during the development of candidate sensors and so 
promising molecules can often be accompanied by unwieldy synthetic baggage.  Indeed, 
one of the significant detractions of many of these systems is the complex, multi-step, 
syntheses required in their creation. As a consequence of this, the Smith group became 
interested in the challenge of identifying a synthetically-simple, or ideally already 
commercial, sensor dye able to detect/respond to heparin in a clinically relevant sample.   
2.2 Considering Commercial Options 
Our search for an accessible heparin sensor began by considering commercially 
available species, starting with the thionine family of dyes. Thionine consists of a 
heteroaromatic phenothiazine-like core functionalised with two pendant amines. 
Thionine is the parent member of a family of dye analogues, each of which contains the 
same aromatic core functionalised to differing degrees by methylation of pendant 
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amines. At one extreme is the tetra-methylated analogue methylene blue, while at the 
other is non-methylated thionine, see Figure 2.1.  
 
Figure 2.1 – A selection of dyes from the thionine family.  
Thionine dyes have been known and studied from as early as 1884
214
 and have been 
used commercially throughout the twentieth century. In the early-to-mid part of the 
century, commercial samples were routinely of unreliable purity
215
 and much effort had 
to be put into purifying them.
216-218
 Thionine dyes can be readily protonated to give 
cationic species, and consequently have previously been investigated in systems to bind 
biological polyanions such as DNA.
219
  
Methylene blue (MB) has been investigated as a heparin reversal agent in its own right 
in several studies, although dosing was found to be unreliable,
220
 there were toxicity 
problems
221-223
 and, most potently, it was widely shown to be ineffective.
186,195
 A 
straightforward explanation of MBs inability to neutralize heparin in these clinical 
studies lies with its mono-cationic nature.  
The spectrophotometric study of the heparin binding site by Liu and co-workers showed 
that increasing the amount of competitive electrolytes in the test system interfered with 
the MB-heparin interaction, and so the spectroscopic response was reduced.
142
 These 
observations marry-up well with the observations of Smith and co-workers, who found 
the MB-heparin interaction was no longer spectroscopically evident even in the 
presence of relatively low concentrations of NaCl.
211
 Similarly, the acute sensitivity of 
di-methylated thionine analogue Azure A (AA) to increasing electrolyte concentrations 
has also been well documented.
143
  





utilising mono-cationic Azure A for heparin quantification in samples of human plasma 
are somewhat surprising. Human plasma contains a plethora of charged electrolytes and 
so it would be reasonable to expect the AA-heparin interactions to be disrupted. One of 
the limitations in the works of Klein and Yang is the absence of attempts to control the 
pH in their systems. Thionine derivatives, including Azure A, are known to exhibit 
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perturbed spectrophotometric responses under different pH regimes, and it seems likely 
that in changing the relative concentrations of heparin or protamine during their assays, 
Klein and Yang may have unwittingly also altered the pH of the system.
225-227
 This 
change may account for their observed spectrophotometric responses.   
Thionine – often referred to as Lauth’s violet in honour of pioneering French dye 
chemist Charles Lauth – is the only member of the dye family in which neither of the 
pendant amines is decorated with methyl groups. The absence of methyl groups allows 
native thionine to carry two positive charges at biologically relevant pHs (e.g. pH 7). 
For this reason, the ability of thionine to spectrophotometrically respond to heparin in 
the presence of 5 mM KCl in the work of Baumgärtel and co-workers can begin to be 
understood.
228
 Their work charted the change in UV-vis spectra as different amounts of 
thionine were added to samples of heparin. It was suggested that the spectroscopic 
signal was independent of the proportion of heparin covered by dye; that is to say an 
‘all-or-none’ binding model was declared valid. One self-acknowledged limitation of 
their study was the use of a relatively high concentration of thionine (200 µM). They 
were concerned that the previously studied phenomenon of thionine aggregation may 
have played a role in their results.
229
 The response of thionine to heparin in the presence 
of some competitive electrolyte showed promise, although the tolerance to more 
biologically relevant electrolytes (e.g. NaCl) was not studied. This was taken as the 
starting point for our investigations. 
 The ultimate goal of this work was to identify a heparin sensor able to 
spectroscopically respond to heparin in biologically relevant media such as human 
serum/plasma. For initial screening, it was decided to test candidate sensors in 150 mM 
NaCl. This concentration of electrolyte was chosen to somewhat mimic the electrolyte 
concentration present in human plasma, which are known to be 150 mM Na
+
, 110 mM 
Cl⁻ and HCO3⁻.
230
 A propensity to operate within this regime would indicate a potential 
for heparin binding, and therefore spectroscopic response, in the even more competitive 
conditions presented by human serum. These ‘intermediate’ salt-containing conditions 
also allow sub-standard dyes to be dis-regarded without consumption of the more 
expensive serum. In order to minimise any pH changes, all test solutions were buffered 
at pH 7 using Tris HCl. 
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Thionine was optimised at a concentration of 16 µM, which gave a satisfactory 
absorbance of ca. 1 at 595 nm. This concentration additionally ensured thionine was 
operating below previously observed critical aggregation concentrations.
229
  As shown 
in Figure 2.2, in the absence of salt, a strong ‘switch-off’ response is seen upon 
introduction of heparin to a cuvette containing thionine and buffer. Disappointingly, the 
same response was not observed upon addition of heparin to a cuvette additionally 
containing 150 mM NaCl. This suggests that the doubly-charged thionine is unable to 
out-compete the mono-cationic sodium at the heparin surface although this is perhaps 
not surprising as in total there is only 0.2% as much cationic charge in the solution from 
thionine (32 µM) as there is from Na
+
 (150 mM). Using a higher concentration of 
dyestuff, in the manner of Baumgärtel and co-workers may help to overcome this 
however a significant increase may lead to absorbance intensity becoming above 
detectable levels. 
 
Figure 2.2 – UV-vis absorbance spectra of thionine acetate (16 µM) in salt (150 mM) 
and buffer (1 mM Tris HCl) in presence (grey) and absence (solid black) of heparin. 
Thionine acetate (16 µM) in the presence of heparin with no NaCl present is included 
for comparison (dashed black).  
Following the failure of dicationic thionine to bind heparin in biologically relevant 
concentrations of salt, a second cheap commercially available dicationic indicator dye 
was studied. Methyl green (MG) is a triphenylmethane-derivative, Scheme 2.1, and 
presents a different charge profile to heparin than the smaller thionine molecule. 
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Delocalisation of the second cationic charge across two aromatic rings allows MG to 
present a reasonably charge diffuse binding patch to heparin when compared directly to 





 through a decrease in absorbance intensity at 640 nm. 
In particular, Scott showed MG was able to retain interaction with polyanions such as 
DNA/RNA/heparin in the presence of electrolytic species (e.g. sodium acetate).
232
 This 
led us to examine MG for spectroscopic response in biologically relevant salt 
concentrations. 
In our studies, an optimised MG concentration of 30 µM exhibited a switch-off 
response upon introduction of heparin in the presence of 150 mM NaCl although the 
decrease in signal intensity (~17%) was significantly less than in the absence of salt 
(~32%), Figure 2.3. This perturbation suggests that although more robust than thionine, 
MG is not able to fully out-compete sodium cations for binding to heparin.  
 
Figure 2.3 – UV-vis absorbance spectra of methyl green (30 µM) in salt (150 mM) and 
buffer (1 mM Tris HCl) in presence (grey) and absence (solid black) of heparin. Methyl 
green (30 µM) in the presence of heparin with no NaCl present is included for 
comparison (dashed black). 
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Scheme 2.1 – Molecular rearrangement of coloured methyl green to colourless carbinol.   
A further detraction presented by MG is the practical limitation of bleaching. MG 
bleaching occurs through incorporation of a hydroxyl group at the centre of the 
molecule. Following molecular re-arrangement, the colourless species carbinol is 





 who collectively demonstrated that dilution and 
pH were important factors. In particular, Hahn suggested carbinol would be rapidly 
generated at pH values above 5. Our work, which is buffered at pH 7 by 1 mM Tris 
HCl, served to confirm this observation as the absorbance signal intensity at 640 nm fell 
by ~25% in only 90 minutes upon standing. In line with Hahn’s observations, a control 
solution buffered at pH 3 retained full colour intensity over a 7 day period.   
With MG dimissed, Alcian blue (AB) was identified as a more highly charged 
commercial heparin binding system. Alcian blue, Figure 2.4, is an aromatic copper 
complex possessing 4 positive charges which has been widely studied as a histological 
heparin stain.
233
 Despite prevalent histological use, influential biochemist J. E. Scott 
suggested true understanding and investigation of AB was often controversially 
hindered by “commercial secrecy and entrepreneurial dishonesty.”234 Whiteman has 
previously shown AB to be capable of interacting with many glycosaminoglycans in 
biological fluids such as urine, presumably due to guanidinium-like functionalities 
which decorate its surface.
235
 The electrolyte tolerance of AB is also known to be high 
with the aforementioned Scott and co-worker Willet reporting that AB is able to retain 
interaction with heparin up to NaCl concentrations of 900 mM. More recently, 
Bjornsson employed AB in spectrophotometric studies, where response was observed in 
the presence of sulfated GAGs such as chondroitin-4-sulfate.
236,237
  
In our studies, an optimised solution of 38 µM AB in 150 mM NaCl and 1 mM Tris 
HCl exhibited an absorbance maximum at 618 nm, however upon addition of heparin, 
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no change in absorbance intensity was observed, Figure 2.4. Several of the 
aforementioned studies left AB-heparin mixtures over an extended time period to ensure 
complexation had reached its maximum. Our solution was allowed to stand for 5 hours, 
after which there was still no absorbance change. Instead, a precipitate was clearly 
visible in the cuvette. Bjornsson, in the second part of his 1993 study, relied upon the 
precipitation of AB-GAG complexes for quantification.
237
 It had been hoped that the 
non-acidic buffered pH in our system would circumvent this precipitation event, 
however this was not the case. As a result of this undesired precipitation and absence of 
spectroscopic change, AB was dis-regarded for further investigation.        
 
Figure 2.4 – UV-vis absorbance spectra of alcian blue (38 µM) in salt (150 mM) and 
buffer (1 mM Tris HCl) in presence (grey) and absence (black) of heparin. Inset: 
structure of alcian blue.  
2.3 A New Dye is Born 
With an effective, affordable commercial heparin sensor not forthcoming, attention 
turned instead to designing a synthetically straightforward dye. Any successful heparin 
sensor requires two key components: (i) chromophoric or fluorogenic character and (ii) 
heparin binding groups. In sourcing a chromophoric core, inspiration was sought from 
the previously discussed thionine family of dyes. In particular, thionine itself was 
considered an attractive building block due to its possession of two aniline-like 
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The search for a suitable heparin binding motif began by considering the way in which 
proteins interact with heparin. Most prolifically, the amino acid arginine is used to 
achieve high-affinity heparin binding, with the guanidinium group thought to play a key 
role in establishing electrostatic interactions with the sulfate groups along the 
polysaccharide chain.
82,239
 Arginine is the key heparin binding component of the 
clinically used reversal agent protamine, with arginine making up around 70% of the 
sequence.
100,179
 It was envisaged that a straightforward peptide coupling reaction 
involving the nucleophilic amines on thionine and the carboxylic acid on arginine 
should allow the chromogenic core to be functionalised with two arginine residues. It 
was hoped that, if successful, this new member of the thionine family may have greatly 
enhanced heparin binding ability, and may be robust enough to remain bound to heparin 
in the presence of competitive electrolytes such as salt.  
In order to maintain regioselectivity during synthesis and minimise the potential for 
arginine polymerisation, the pendant primary α-amine and both amine components of 
the guanidinium group required protection. It is relatively unusual to tri-protect 
arginine; however with previous functionalization of thionine proceeding in relatively 
low yields, it seemed prudent to increase the odds in our favour as much as possible.
240
 
Tri-Boc-protected arginine, Arg(Boc)3, was identified as a suitable reagent because it is 
commercially available and all of the amine groups are protected with the same acid-
labile tert-butoxycarbonyl (Boc) protecting group.  
Although available commercially, Arg(Boc)3 can be readily prepared on a multi-gram 
scale by heating arginine with an excess of di-tert-butyl dicarbonate in the presence of 
sodium hydroxide. The relatively low yield of ca. 10% can be accounted for by the 
well-known difficultly of installing the second protecting group on the guanidinium 
moiety.
241
 As shown in Scheme 2.2, once in hand, two equivalents of Arg(Boc)3 were 
readily appended onto thionine acetate in a TBTU-mediated peptide coupling reaction 
to afford the fully protected dye molecule, after purification by silica flash column 
chromatography. The yield of 30% is respectable as, although low, it is an improvement 
on the 9% yield observed by Barton and co-workers for functionalization of a thionine 




 A final global Boc deprotection using HCl gas in methanol afforded the new 
dye 2.2 in a near quantitative yield.  
 
Scheme 2.2 – Synthesis of Mallard Blue 2.2. Although commercial, conditions for 
preparation of Arg(Boc)3 also shown. 
The preparation of this modified thionine derivative in two synthetically straightforward 
steps from commercial starting materials is highly attractive, and appears reliable 
enough to withstand scale-up. 
2.4 Mallard Blue: Initial Studies 
With new dye 2.2 in hand, it was examined by UV-visible spectroscopy. As shown in 
Figure 2.5, dye 2.2 is blue in appearance and has a strong absorbance band at 615 nm. 
The blue colour of the dye is remarkably similar in appearance to the livery of the 
world-record-holding A4 steam locomotive Mallard 4468, which is housed at the 
National Railway Museum in York. For that reason, the new dye 2.2 was christened 
Mallard Blue (MalB). 
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Figure 2.5 – UV-vis absorbance spectrum of MalB (25 µM) in salt (150 mM) and Tris 
HCl (1 mM) in the presence (grey) and absence (black) of heparin. Inset: Picture 
showing colour similarilty of MalB and Mallard.    
Mallard Blue was first tested in the manner previously applied to thionine, methyl green 
and alcian blue. Pleasingly, upon introduction of heparin to a solution of MalB (25 µM) 
in the presence of 150 mM NaCl, a strong spectroscopic response was observed, Figure 
2.5. This response is significant when compared against the previously tested dyes. The 
58% switch-off in signal intensity indicates that the introduction of the arginine groups 
has dramatically increased the ability of our thionine derivative to out-compete sodium 
cations at the heparin surface when compared directly to native thionine. Following this 
qualitative promise, a titration experiment was set up in order to probe this response 
more quantitatively.  
An optimised MalB concentration of 25 µM was titrated with second portion of the 
same dye solution which had additionally been endowed with heparin. The titration was 
repeated in the absence and presence of 150 mM NaCl, and all solutions were buffered 
at pH 7 using 1 mM Tris HCl. In order to provide a performance comparison against an 
unmodified member of the thionine family, methylene blue (MB) was subjected to the 
same heparin titration in the absence/presence of 150 mM NaCl. A MB concentration of 
10 µM was chosen in line with previous studies by Smith and co-workers.
211
 The 
resulting titration curves are shown in Figure 2.6. 
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Figure 2.6 – Binding curves resulting from titration of heparin into a solution of 
methylene blue (10 µM, left) or Mallard blue (25 µM, right) in the absence (top) or 
presence (bottom) of 150 mM NaCl.  
Before discussing the binding curves, it is worth re-emphasising that the 
‘concentrations’ of heparin plotted in Figure 2.6 do not refer to the global concentration 
of heparin polysaccharide but rather to the concentration of the predominant 
disaccharide repeat unit (Mr: 665.40 g mol
-1
). For both dyes, binding to heparin results 
in a decrease in spectroscopic signal intensity, however for visual appeal, the magnitude 
of spectroscopic change at λmax is plotted in the binding curves. 
In the absence of salt, the binding curve for MB indicates the dye is fully bound to 
heparin at concentrations above ca. 22 µM, indicated by the plateau region. The 
requirement for so much heparin may be a consequence of electrolytic competition from 
the Tris HCl buffer for interaction with MB. This hypothesis may be supported by the 
observation of no MB-heparin interaction at all in the presence of 150 mM NaCl.  
In the absence of salt, 25 µM MalB appears to be fully bound to 13 µM heparin, while 
in the presence of 150 mM NaCl, the value increases to ca. 27 µM. Without salt present, 
the MalB-heparin binding curve does not plateau in a traditional manner. As further 
heparin is added beyond 13 µM, the absorbance change value begins to decrease again 
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suggesting a reduction in the total amount of heparin-bound MalB. As more heparin is 
added beyond the point of initial saturation, new interactions may form between this 
‘new’ heparin and molecules of MalB which were already interacting with the heparin 
present. This disruption may lead to the overall MalB-heparin interactions being 
reduced as multiple heparin chains compete for binding to MalB, giving rise to the 
apparent regression of saturation observed. When salt is present, however, the 
disruptive effect of further heparin addition is not seen. This suggests that the sodium 
cations are able to ‘screen’ newly-added heparin preventing it from disrupting already-
established MalB-heparin interactions. Consequently, in the presence of salt, the 
binding curve exhibits a traditional plateau region.  
Close inspection of the MalB-heparin binding curves reveals a slightly sigmoidal line 
shape. This may be a consequence of the polydisperse nature of heparin, which is likely 
to dictate a different binding mode for different regions of the heparin chain with 
specific regions exhibiting preferential interactions. For MB, this sigmoidal character is 
less evident. This is likely to be a consequence of MB interacting in a monovalent 
manner with individual anionic charges on heparin rather than a larger region containing 
several anionic charges, as is the case with MalB.  
The significant binding of MalB to heparin in the presence of 150 mM NaCl and 1 mM 
Tris HCl suggested that the MalB-heparin interaction is tolerant of electrolytic 
competition. To that end, an experiment was set up to determine the effect of further 
increasing concentrations of NaCl and Tris HCl buffer on the spectroscopic response of 
MalB. An optimised solution of heparin-saturated MalB (25 µM MalB, 27 µM heparin) 
was separately titrated with increasing amounts of NaCl or Tris HCl up to a final 
electrolyte concentration of 1 M. The disruptive effect on the MalB-heparin interaction 
is plotted in Figure 2.7, where disruption is normalised between the absorbance 
intensity at 615 nm of a solution of MalB alone and when saturated with heparin.    
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Figure 2.7 – Extent to which increasing concentrations of Buffer/Electrolyte disrupt 
MalB-heparin interaction.  
The tolerance of the MalB-heparin interaction in the presence of increasing 
concentrations of electrolyte is impressive. As electrolytic competition increases 
though, so too does the disruption of the MalB-heparin interaction. Tris HCl causes 
more perturbation than NaCl, although spectroscopic responses are still detectable up to 
600 mM and 800 mM respectively. Perhaps most impressive is the minimal disruption 
caused by the presence of 400 mM NaCl. In this particular scenario, sodium cations are 
present in a 1600-fold excess to MalB itself, yet MalB is still able to bind to heparin 
preferentially. The performance of MalB under these conditions is far superior to those 
previously reported for unmodified thionine dyes, further emphasising the performance 
enhancement resulting from functionalisation with arginine.
143
 
With the MalB-heparin interaction appearing to be so robust, our collaborators led by 
Professor Sabrina Pricl at University of Trieste, Italy studied the MalB-heparin 
interaction using molecular dynamics (MD) modelling. Their experiments represented 
heparin as a repeating sequence of the predominant disaccharide and allowed an 
optimised binding trajectory to be visualised, Figure 2.8. The observed binding mode 
suggests that two MalB molecules interact with a tetra-saccharide segment of the 
heparin chain, in complete agreement with our observed binding stoichiometry. 
Unsurprisingly, the interaction is dominated by electrostatics. In particular, the 
guanidinium groups play a key anchoring role with the arginine α-amines 
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supplementing the interaction and the cationic charge on the phenzothiazine-like ring 
angling towards the polysaccharide. It appears that the crescent shaped geometry of 




Figure 2.8 – Equilibrated MD snapshot of MalB-heparin interactions. Heparin is 
represented as purple (D-glucosamine) and green (L-iduronic acid) space-filling spheres, 
while MalB is shown as pink stick model.  
So far, Mallard Blue had demonstrated an impressive tolerance to electrolytic 
competition and appeared to be well-suited for establishing robust non-covalent 
interactions with heparin. The next stage was to challenge the heparin binding ability of 
MalB in more biologically relevant situations. 
2.5 Mallard Blue: Establishing Clinical Relevance  
One of the biggest challenges facing any heparin sensor with clinical potential is 
selectivity. As previously discussed, biological media is a complex mixture of 
electrolytes and serum/albumin proteins.
230
 In addition to establishing interactions 
within this electrolytically rich media, an effective heparin sensor must be able to bind 
heparin selectively over structurally similar glycosaminoglycans (GAGs). In total, there 
are six structurally related GAGs: heparin, heparan sulfate (HS), dermatan sulfate (DS), 
chondroitin sulfate (CS), keratin sulfate (KS) and hyaluronic acid (HA).
81
 Influential 
work from the group of Ansyln in 2005 demonstrated a heparin sensor with selectivity 
over HA and CS, and so these were selected for benchmarking the performance of 
MalB, Figure 2.9.
145
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Figure 2.9 – Three structurally related GAGs: heparin, hyaluronic acid (HA) and 
chondroitin sulfate (CS). 
In turn, each GAG was titrated into a solution of MalB (25 µM) endowed with NaCl 
(150 mM) and buffered at pH 7 with Tris HCl (10 mM). The resulting absorbance 
intensity at 615 nm was plotted against increasing GAG concentration, Figure 2.10. The 
polydisperse nature of the GAGs along with the differing degrees of variability along 
the polysaccharide chains make defining absolute concentration values difficult. For 
that reason, in line with the earlier comments about heparin, the concentration values in 
Figure 2.10 refer to the concentration of the most common disaccharide repeat unit 
rather than the global concentration of polysaccharide.  
It can be clearly seen that neither HA nor CS produce a large spectroscopic response 
from MalB when compared to heparin. Of the two, MalB interacts more significantly 
with CS. This is most likely due to the repeating disaccharide of CS possessing one 
more sulfate group than HA and consequently presenting more anionic character to 
MalB for binding. Whilst effective binding constants could be calculated from the data 
in Figure 2.10, it was reasoned that any values would remain somewhat ambiguous due 
to the variability in polydispersity and/or polysaccharide structures from batch to batch 
of each GAG. The data show that MalB is able to match the selective heparin binding 
performance of Anslyn’s benchmark work. 
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Figure 2.10 – Normalised response of MalB to glycosaminoglycans HA, CS and 
heparin.  
With heparin selectivity over other GAGs in the presence of biological concentrations 
of NaCl demonstrated, the next challenge was for MalB to respond to heparin in a 
clinically relevant sample. Human serum is a real biological fluid containing all of the 
proteins (except those involved in blood clotting), antibodies, antigens, hormones and 
other exogenous and endogenous species naturally present in blood. The combination of 
these species with the electrolytes mentioned previously makes selective binding in 
serum particularly challenging. Taking further inspiration from the work of Ansyln,
145
 
an experiment was set up in which samples of 100% human serum were endowed with a 
concentration of heparin. Aliquots (0.5 mL) of this solution were then introduced to a 
cuvette containing MalB (1.5 mL, 25 µM) buffered at pH 7 with Tris HCl (20 mM). The 
absorbance intensity at 615 nm could then be recorded and plotted in response to 
different concentrations of heparin.  
In the clinic, surgical teams dose heparin in terms of anticoagulant activity – measured 
in international units per millilitre of blood (IU mL
-1
) – rather than in terms of raw 
amount. The clinically relevant range for cardiovascular surgery routinely lies within 
the range 2 – 8 IU mL-1.243,244 It was therefore decided to probe the ability of MalB to 
detect heparin in the concentration range 0 – 10 IU mL-1. The resulting heparin 
detection curve is plotted in Figure 2.11.   
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Figure 2.11 – Mallard Blue response to heparin delivered in 100% human serum (solid 
circles) or 100% horse serum (open triangles) within a clinically relevant range. 
This experiment is an excellent mimic of the clinical setting, where a blood sample from 
a patient could easily be filtered using a cellulose filter such as those present in the 
blood electrolyte monitors carried by paramedics, thereby removing the blood cells and 
affording a relatively colourless sample of heparin-containing human plasma.
245
 
Titration of this sample into a pre-prepared Mallard Blue solution in the clinic would be 
exactly analogous to the titration carried out here. Our choice of serum rather than 
plasma was expected to have no material bearing on the experiment as serum is simply 
plasma with some of the clotting factors (e.g. fibrinogen) removed.  
Impressively, Mallard Blue showed a significant spectroscopic response upon addition 
of heparin in 100% human serum. Heparin can be clearly detected down to 
concentrations as low as 1 IU mL
-1
. From these results, it can be envisaged that this 
assay could readily be adapted to operate with different concentrations of heparin, 
through increasing/decreasing amounts of MalB or by diluting the serum sample during 
pre-treatment. A comparable detection range was additionally observed in horse serum, 
further demonstrating the robustness of MalB for heparin detection. 
In addition to matching the performance of Ansyln’s landmark work, MalB also offers 
the advantage of greater synthetic accessibility. At this stage, the opportunity was taken 
to re-examine the previously reported work of Klein and co-workers who detected 
heparin across the same concentration range as us ‘in plasma’ using commercial 
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thionine derivative Azure A.
141
 For direct comparison against MalB, AA was examined 
under the same conditions of our assay. Specifically, heparin-containing serum samples 
were titrated into a solution of AA (25 µM) which was buffered at pH 7 with Tris HCl 
(20 mM). As shown in Figure 2.12, under these conditions, AA was unable to respond 
at all to the addition of heparin. Interestingly, and further in contrast to the observations 
of Klein and co-workers,
141
 even when the buffering was removed, there was still no 
observable spectroscopic change from AA upon heparin-in-serum titration, regardless of 
the wavelength chosen for monitoring.   
 
Figure 2.12 – Mallard Blue (solid circles) and Azure A (open squares) response to 
heparin delivered in 100% human serum within a clinically relevant range. 
The data in Figure 2.12 clearly indicate that heparin detection by MalB occurs within a 
clinically relevant range and that the performance is significantly better than other 
thionine dyes such as Azure A. The performance benefit of introducing arginine groups 
into the thionine system is clear to see. This simple synthetic modification not only 
makes Mallard Blue the best-in-class for this dye family but also makes the dye an 
attractive proposition to non-synthetic chemists.
246
  
2.6 Mallard Blue: Further Studies 
In order for Mallard Blue to be used clinically, it would be desirable to incorporate it 
into an ‘assay kit’ such as those routinely used in biological protein binding studies, for 
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example. Such kits are routinely prepared some time (e.g. weeks) in advance of their 
use to allow for shipping, storage etc. so it was decided to scope out the potential of 
MalB. A crucial property which MalB must exhibit therefore is stability. Two options 
were considered for how such an assay kit may operate: (i) the MalB solution would be 
provided pre-dissolved in buffer at the correct concentration, or (ii) the MalB would be 
supplied as solid to be dissolved in appropriate amounts of buffered solution (which 
would be supplied separately).  
In order to probe the stability of MalB in solution – to simulate delivery option (i) – a 
solution of MalB (25 µM) was made up in the related conditions of 150 mM NaCl and 
10 mM Tris HCl and left to stand in either light or dark and under either an air or 
nitrogen atmosphere. Stability was probed by monitoring the absorbance intensity at 
615 nm every 24 hours, and is plotted in Figure 2.13.   
 
Figure 2.13 – Stability traces of MalB in the presence of light or dark under either air or 
nitrogen. 
When exposed to light, MalB de-colours rather quickly with a half-life of approximately 
30 hours regardless of the atmosphere of storage. Thionine dyes are known to be 
susceptible to photo-bleaching, and the phenomenon has been studied previously.
247,248
 
The tri-cyclic ring of methylene blue, for example, can be reduced through introduction 
of a proton to generate the colourless leuco species, although oxidative bleaching of 
thionines is also known.
249-251
 For MalB, it seems likely that in the presence of light, a 
proton could transfer from either of the arginine amine or guanidinium groups onto the 
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thiazine nitrogen atom causing the photoreductive bleaching to occur in a similar 
manner to that observed for thionines by Usui and Koizumi.
252
 In darkness, the half-life 
of MalB is considerably extended to >9 days, with the solution stored under an inert 
nitrogen atmosphere least affected by bleaching. Clearly, it is not ideal for potential 
development into an assay kit device if MalB solutions require long-term storage in 
darkness under an inert atmosphere.  
The possibility of providing a solid sample of MalB ready for dissolution in buffer 
shortly before use was probed next, to simulate delivery option (ii). This approach was 
also found to have problems associated with it. Most notably, when solid MalB is 
dissolved in aqueous buffer, the solution is not immediately blue. At room temperature 
(ca. 20°C), the blue colouration actually develops rather slowly: over a period of 
approximately 96 hours, as shown in Figure 2.14. This slow colour development is 
assigned to the slow de-aggregation kinetics of the dye system or, more specifically, the 
un-stacking of the tri-cyclic aromatic cores.      
 
Figure 2.14 – Time-lapse photographs showing development of MalB colour over time 
at room temperature. 
Aggregation of thionine based dyes is well known and has been widely studied.
253,254
 In 
general, as concentration of the dye increases, so does the propensity for π-π 
intermolecular interactions between the aromatic cores and dye-stacking. Thionine 
aggregation has been studied previously by Mackay and co-workers who showed that 
aggregation of the dye enhanced its water solubility compared to theoretical solubility 
predictions.
229
 An often-employed way of monitoring dye aggregation is by monitoring 
the UV/visible absorbance maxima for a dye (λmax) as concentration changes; 
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aggregation causes λmax to be shifted. For our system, titrating increasing amounts of de-
aggregated MalB into a cuvette of water, up to a final concentration of 500 µM, resulted 
in the absorbance spectra shown in Figure 2.15. A linear increase in absorbance 
intensity was observed as concentration increased but, importantly, there was no change 
in λmax. This suggests that MalB aggregation is not playing a role at the concentrations 
used in any of the heparin detection assays carried out in our studies. The critical 
aggregation concentration of MalB was not determined as the CAC of native thionine is 
known to be in the millimolar concentration range and so such experiments would be 
compound expensive.
229
      
 
Figure 2.15 – UV-visible absorbance spectra for MalB in water as concentration 
increases. Inset: Plot of absorbance at λmax between 0 – 500 µM.  
The MalB de-aggregation event upon dissolution can be accelerated by incubating the 
MalB solution for ca. 24 hours at 50°C. Although effective, the requirement of such 
preparation is not appealing from the perspective of designing an ‘assay kit.’ 
Nonetheless, the stability, preparation and storage studies have all served to inform the 
current use of MalB, where all solutions are incubated for 24 hours at 50°C before use, 
and stored in the dark.   
2.7 Conclusions & Future Work 
A selection of commercial cationic indicator dyes were examined and shown to be 
unable to reliably respond to heparin in the presence of competitive electrolytes such as 
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150 mM NaCl. Taking inspiration from the commercial thionine family of dyes, a novel 
heparin sensor was synthesised in two straightforward steps through coupling of two 
arginine residues onto a thionine core. The new dye, named Mallard Blue, was not only 
shown capable of responding to heparin in the presence of 150 mM NaCl – something 
none of the commercial thionines can do – but also of doing so selectively over 
structurally related glycosaminoglycans such as chondroitin sulfate and hyaluronic acid.  
Mallard Blue was shown to be capable of responding to heparin delivered in 100% 
human serum. This impressive performance matches landmark work in the heparin 
sensing field and shows real clinical promise as the assay was carried out in a manner 
which directly simulated the clinical setting. Crucially, heparin detection occurred 
within a clinically relevant heparin concentration range. Through direct comparison 
against Azure A, MalB was also shown to be the new best-in-class for the thionine 
family of dyes.  
The incorporation of MalB into a chemically applicable heparin-sensing assay kit was 
considered. The MalB de-aggregation event upon dissolution was identified as a 
limiting factor and shown to take around 96 hours at room temperature or 24 hours at 
50°C. Concentration dependant aggregation of MalB in aqueous solution was shown 
spectrophotometrically not to occur below 500 µM. 
A time-resolved stability study of MalB revealed a gradual bleaching event which 
occurred in the presence of light and was assigned to a slow photo-reduction of the 
phenothiazine-like ring structure. This photo-degradation was significantly retarded 
upon storing MalB in darkness.  
Future work in this area could focus on increasing the commercial viability and appeal 
of the sample preparation post-synthesis. This may include enhancing the photo-
stability of the dye solution or re-designing the system to reduce sample preparation 
time (eg. by removing the necessity for incubation). These improvements are likely to 
involve modification of the chromophoric dye core. A sensible, and convenient, starting 
point may be the use of a close structural analogue of thionine such as proflavine. 
Proflavine offers a slightly different heteroaromatic dye core which may have different 
susceptibility to the reductive processes identified as the cause of MalB bleaching. 
Much like thionine, proflavine also offers two aniline-like functional handles although it 
is noteworthy that previous work from Smith and co-workers focussed on non-covalent 
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interactions between these groups and carboxylic acids, rather than direct reaction 
between them.
255,256
 This may suggest that the different dye core affects the reactivity of 
the pendant amines. Other functionalisable chromogenic or fluorescent dye cores such 
as, for example, fluorescein could also be considered.        
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3 Insights into Heparin Binding 
3.1 Introduction 
Given the well-documented toxicity problems associated with the clinical use of 
protamine for heparin neutralization, there is a growing interest in the development of 
novel chemical agents which are able to provide the same neutralization role in the 
absence of the associated side-effects.
212
 During the development of such systems, there 
is a key requirement to probe the performance ability of the candidate molecules. Often, 
researchers choose to move quickly to clinically relevant heparin neutralization assays 
to assess potential efficacy. Techniques such as the anti-factor Xa assay, which directly 
measures the inhibition of clotting Factor-Xa in the presence of heparin, or other direct 
‘clotting-time’ measurements such as the activated partial thromboplastin time (aPTT 
assay) or prothrombin time (PT assay) are often employed for this purpose. Indeed, as 
examples, early developmental studies of foldamer systems in the work of DeGrado and 
co-workers
202
 focused on anti-factor Xa results for compound comparisons, while ex 




Although such clotting based assays are well accepted for providing measures of 
anticoagulancy, and therefore provide some measure of the potential clinical 
effectiveness of the candidate being tested, the results can mask more fundamental 
performance information.
118,257
 Such clotting-based techniques typically operate in 
genuine biological media such as human plasma, which is a highly competitive mixture 
of serum and albumin proteins, electrolytes, antibodies, antigens and hormones, along 
with other exogenous and endogenous species naturally present in blood. Successful 
heparin neutralization in this medium therefore indicates the ability of a binder molecule 
to selectivity form interactions with heparin in preference to the many other 
aforementioned components. Conversely, in the event of a candidate molecule failing to 
neutralise anticoagulation, it can be difficult to de-convolute the reason for failure in to 
terms of, for example, an inability to bind heparin, or a preferential ability to bind some 
other biological species in plasma (i.e. off-target binding). Consequently, most studies 
additionally employ a complementary assay technique to interrogate heparin binding 
ability. 
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An early report on the development of calix[8]arenes for heparin neutralisation from the 
group of Cunsolo
200
 provides a typical example of the use of a variety of heparin 
binding assays. Initially, Cunsolo and co-workers probed heparin binding performance 
using a fluorescence-based indicator displacement assay in the presence of low 
concentrations of buffer. Subsequently, NMR titration experiments were carried out to 
validate the indicator displacement results and further interrogate the binding under 
more competitive conditions containing 150 mM NaCl. Comparison of the data from 
these studies gave insight to heparin binding performance.
200
 Interestingly, further 
developments in the aforementioned work of DeGrado and co-workers developing 
foldamer systems employed isothermal titration calorimetry (ITC) to probe heparin 
binding in 150 mM NaCl as a complementary technique to the anti-Xa data reported 
previously.
204
 Indeed, these two examples appear representative of researchers’ desires 
to probe heparin binding in electrolytically competitive conditions alongside the more 
clinically-relevant plasma clotting assays.  
Although NMR titration experiments and ITC investigations are well-suited to studying 
heparin binding, it can be argued that they are not ideal for initial screening of novel 
heparin binding systems at the early stages of development. Each technique is relatively 
compound intensive and may present unattractively high associated costs. It is perhaps 
not surprising therefore that a variety of other techniques such as affinity co-
electrophoresis
258
 and competitive inhibition assays
259
 have emerged as alternative 
approaches.  A particularly eye-catching recent approach involved the employment of 
turbidimetric screening by Koide and co-workers, where the ability of heparin to inhibit 
the spontaneous formation of insoluble fibrils by collagen was the key tool in probing a 
candidate’s heparin binding ability.260 Upon introduction of an effective heparin binder, 
collagen fibril formation was no longer inhibited and the associated turbidity increase 
could be used to quantify the relative heparin binding ability of the candidate 




Building on our interest in heparin sensing systems, we became interested in simple 
spectroscopic screening methods able to quickly determine the relative heparin binding 
ability of a range of candidate systems under electrolytically competitive, or even 
biologically relevant, conditions. Indicator displacement assays (IDA) were identified as 
well-suited for this type of monitoring owing to their requirement of a relatively small 
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amount of compound and straightforward titration-based methodology.
261,262
 Indeed, the 
development of chemical bioprobes is an ever-expanding field, and is readily applicable 
to this type of heparin binder screening.
263
 For a successful heparin binding IDA, a 
spectroscopically active dye must exhibit a characteristic signal change when displaced 
into free solution by the formation of preferable binder-heparin complexes. The IDA 
concept is shown in cartoon form in Figure 3.1.   
 
Figure 3.1 – Cartoon concept of an indicator displacement assay (IDA). 
Of the many heparin sensors presented in the previous Chapter, several have explicitly 
been shown to be suitable for application in an IDA regime. The commercial thionine 
dyes azure A
143
 and methylene blue
142
 are both operable within such systems, although 
their monocationic nature has limited their widespread use due to their intolerance of 
high levels of competitive electrolytes.
143,211
 The landmark tris-boronic acid scaffold 
from Ansyln and co-workers was amongst the first synthetic systems to be developed 
into an IDA system although the sensor initially required the presence of pyrocatechol 
violet as the indicator dye.
144
 The system was then elegantly modified to embed the 
fluorophore into the host structure. Addition of protamine to a complex of this modified 
sensor and heparin was shown to ‘strip’ heparin out of the scaffold binding site, leading 
to the re-establishment of the initial fluorescent signal, Figure 3.2.
145
 Other works, for 




 also demonstrated the reversibility of 
sensor-heparin interactions by introduction of protamine and displacement of the sensor 
dye, although neither group appeared to capitalise on the potential insight which could 
be gained from displacement assays utilizing their robust fluorescent sensors.  
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Figure 3.2 – Ansyln’s heparin sensing systems: (a) tri-boronic acid receptor and 
pyrocatechol violet indicator;
144
 (b) modified fluorophore-containing receptor.
145
 These 
structures are also shown in Figure 1.19. 
Arguably the most impressive heparin sensing systems published recently are the 
benzimidazolium derivatives ‘heparin blue’ and ‘heparin orange’ from the work of 
Chang and co-workers.
160
 Having exhibited fully reversible binding to both 
unfractionated and low-molecular-weight heparins, these molecules ostensibly appear 
ideal candidates for further development. A major drawback associated with 
investigation of these compounds, however, is their multi-step syntheses. Ease-of-
preparation is a key consideration in the development of systems with the potential for 
widespread applicability. In order to maximize the potential uptake of any new assay, it 
was therefore reasoned to be important that the assay be composed of easily accessible 
or, at the very least, synthetically tractable components. The investigation for this 
purpose of an indicator dye requiring a multi-step synthesis was considered a futile 
exercise and so our attention turned away from these benzimidazolium-based sensors.  
As shown in the previous Chapter, we recently developed a new heparin sensor, Mallard 
Blue (MalB), which demonstrated comparable heparin sensing abilities to the systems 
of Chang.
242
 A key feature of MalB was that it could be synthesised in two 
straightforward synthetic steps from commercially available starting materials, and as 
such presents a much more attractive, less daunting synthetic challenge for researchers 
without specialisms in synthetic chemistry. It was therefore decided to investigate our 
newly developed dye, Mallard Blue, within an indicator displacement assay regime.  
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3.2 Mallard Blue Heparin Binding Competition Assay 
3.2.1 Electrolytically Competitive Conditions 
Although the heparin binding ability of MalB had been studied and rationalised using 
molecular dynamics modelling studies, up to this point, utilizing the reversibility of 
MalB-heparin interaction had not been considered. The earlier work had demonstrated 
that the MalB-heparin complex could be perturbed by the titration of increasing 
amounts of electrolytes – namely Tris HCl and and NaCl – and so it was reasoned that 
introduction of protamine to a sample of heparin-containing MalB should result in 
formation of a heparin-protamine complex and release of MalB into solution. Based on 
the data from the previous Chapter, it was decided to introduce protamine into a sample 
containing 25 µM MalB, 27 µM heparin, 150 mM NaCl and 10 Tris HCl. Pleasingly, as 
shown in Figure 3.3, this resulted in an increase in absorbance intensity at 615 nm.  
 
Figure 3.3 – UV-visible absorbance spectra for MalB (25 µM) in the absence and 
presence of heparin (27 µM), and following the subsequent addition protamine in the 
presence of NaCl (150 mM) and Tris HCl (10 mM).  
Following this qualitative observation, it was decided to quantitatively titrate protamine 
into a sample of MalB and heparin as this would permit the calculation of binding 
parameters and thereby enable the performance of different molecular species to be 
compared. Specifically, three appropriate parameters were identified: (i) CE50 – charge 
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excess, that is the number of cationic binder charges required per heparin anionic charge 
at 50% dye displacement. Rationalising binding ability in terms of charge excess 
enables the efficiency of each individual charge to be calculated, allowing the 
performances of binders possessing different numbers of charges to be meaningfully 
compared. (ii) EC50 – the effective concentration of binder at the same point. This 
provides a measure of the molarity of binder present at 50% dye displacement. (iii) 
Effective dose – the raw amount (mass) of binder required to displace 50% of the dye 
from 100IU of heparin. This is a clinically relevant parameter. The binding curve 
resulting from titration of protamine into MalB-heparin is shown in Figure 3.4 along 
with the numerical data in Table 3.1. 
Table 3.1 – Heparin binding data for protamine, calculated from MalB assay. 
Assay Conditions EC50 / μM CE50  
Dose /                    
mg per 100IU 
25 µM MalB, 27 µM heparin, 
150 mM NaCl, 10 mM Tris HCl 
(2.34 ± 0.23) (0.52 ± 0.05) (0.32 ± 0.03) 
 
Figure 3.4 – Heparin binding curve for protamine, with the point of 50% dye 
displacement indicated. 
The data shows that under this regime only 0.52 (± 0.05) protamine cationic charges are 
required to bind to each negative charge along the heparin polysaccharide, equating to a 
concentration of 2.34 (± 0.23) µM at 50% MalB displacement. Under these conditions, 
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the data suggests that 0.32 (± 0.03) mg of protamine would be able to bind to 100 IU of 
heparin. It should be stressed that these values should not be taken as ‘absolute’ bona 
fide binding parameters as the binding assay operates under competition and all binding 
of protamine to heparin is being measured relative to the binding ability of MalB. 
Calculation of values for other compounds under the same assay conditions would 
however allow for valid performance comparisons between different molecular species.   
3.2.2 Clinically Relevant Conditions 
Having established that the MalB IDA was able to operate in the presence of 150 mM 
NaCl, it was decided to investigate the robustness of the same system in the presence of 
more challenging, and biologically relevant, media. Following the MalB sensing studies 
in the previous Chapter, human serum was identified as a suitable biological medium. It 
was also reasoned that a heparin binding assay able to operate in the presence of human 
serum may provide a useful tool for assessing the clinical potential of candidate 
systems, and for beginning to understand the effects of different serum components.  
Practically, the IDA protocol from the MalB assay in buffer and salt was modified by 
employing a multiple-cuvette approach. Rather than gradually titrating binder into a 
single cuvette, several individual cuvettes were prepared with each containing a 
different amount of binder, so as to correspond with different points on the overall 
‘titration’ curve. Once prepared, an overly-concentrated solution of heparin in serum 
was delivered into each cuvette such that the MalB-heparin conditions were 25 µM 
MalB and 27 µM heparin in all samples to replicate the original assay. In this way, the 
serum percentage present in the assay could be controlled through modifying the 
heparin-containing solution (e.g. by dilution with buffer). In order to probe the effects 
of serum on the assay, the modified protocol was applied to protamine with heparin 
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Table 3.2 – Heparin binding data for protamine from MalB assay with heparin 
delivered in 10 and 100% human serum. 
Assay Conditions 
Protamine 
EC50 / μM CE50  
Dose /                    
mg per 100IU 
Salt and Buffer (2.34 ± 0.23) (0.52 ± 0.05) (0.32 ± 0.03) 
Heparin in 10% Human Serum (2.80 ± 0.26) (0.63 ± 0.06) (0.39 ± 0.04) 
Heparin in 100% Human Serum (3.51 ± 0.12) (0.79 ± 0.03) (0.49 ± 0.02) 
 
Figure 3.5 – Heparin binding curves for protamine obtained from MalB assay with 
heparin delivered in 10% and 100% human serum.  
The data show that the presence of human serum leads to an increase in the charge 
excess and effective concentrations of protamine required to displace 50% of MalB 
from heparin. This effect can be rationalised through off-target interactions between 
protamine and any of the electrolytes or charged patches on serum proteins present 
within the media. The progressive deterioration in protamine binding efficiency as the 
percentage of serum present increases supports this. In the presence of serum, 
normalized absorbance values continue above the theoretical maximum of 1 even 
though the presence of serum was taken into account by its inclusion in the baseline 
reading. Despite this, some signal drift away from the baseline was observed during the 
experiment. This enhanced absorbance is thought to be caused by the increased turbidity 
associated with the formation of heparin-protamine complexes within this medium.
264
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Indeed it is known from the work of Mäntele and co-workers that the turbidity 
associated with heparin-protamine aggregates has greater influence on direct absorbance 




3.3 Studying Generational Effects in PAMAM Dendrimers 
Having established protocols for incorporation of Mallard Blue into an indicator 
displacement assay (IDA), and demonstrated that insights to heparin binding could 
potentially be gained, it was decided to attempt to validate the assay by examining a 
selection of known heparin binding systems for their relative binding abilities.   
3.3.1 PAMAM Dendrimers 
PAMAM (poly(amidoamine)) dendrimers were identified as suitable molecules with 
which to validate our novel assay as they are well-known commercially available 
materials and so could be easily sourced for testing. PAMAM dendrimers were first 
reported by Tomalia and co-workers in 1985 and result from the tetra-functionalisation 
of an ethylene diamine central core through exhaustive Michael addition with methyl 





Figure 3.6 – Structure of G2-PAMAM with the generation levels G0 – G2 shown. The 
higher generations result from larger iterations of the dendritic structure. 
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In general, dendritic systems are well known to be able to mimic many aspects of 
protein behaviour in both structural and functional aspects.
268,269
 Indeed PAMAMs have 
been widely applied in biological and biomimetic applications,
270-272
 for example as 
drug delivery vehicles able to encapsulate hydrophobic drugs within their core 
branching structure
273
 or as macromolecular MRI contrast agents through chelation with 
Gd(III) species.
274
 Most relevant to our current study, several previous groups have 
demonstrated PAMAM dendrimers to have heparin binding ability.
192,193,275
 As large 
cationic structures, however, it is perhaps not surprising that PAMAMs are known to 
possess inappropriate toxicity profiles for clinical deployment as heparin rescue agents, 
and so have not been applied for this use in a clinical setting.
276,277
 Here, with the focus 
on validating our new assay and gaining insights into generational effects upon heparin 
binding, PAMAMs offered an ideal molecular family to examine.  
3.3.2 Heparin Binding in Competitive Conditions 
3.3.2.1 Experimental Study 
Six generations of PAMAM dendrimers (G0 – G4, and G6) were each tested for heparin 
binding ability in the Mallard Blue heparin binding assay. The assay was carried out 
under the previously optimised conditions of 25 µM MalB, 27 µM heparin, 150 mM 
NaCl and 10 mM Tris HCl. Each titration was carried out in triplicate and the results, as 
calculated from the point of 50% MalB displacement, are presented in Table 3.3.   
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Table 3.3 – Heparin binding data for PAMAM dendrimers tested in MalB assay in 
buffer and salt. Protamine data included for comparison. 
Compound 
  Heparin Binding 
Charge 
(+) EC50 / μM CE50  
Dose /                                                    
mg per 100IU 
Protamine 24 (2.34 ± 0.23) (0.52 ± 0.05) (0.32 ± 0.03) 
G0-PAMAM 4 Not achieved - binding too weak 
G1-PAMAM 8 (10.10 ± 0.32) (0.75 ± 0.02) (0.44 ± 0.01) 
G2-PAMAM 16 (2.55 ± 0.32) (0.38 ± 0.04) (0.25 ± 0.03) 
G3-PAMAM 32 (1.53 ± 0.21) (0.45 ± 0.06) (0.32 ± 0.04) 
G4-PAMAM 64 (0.64 ± 0.04) (0.38 ± 0.02) (0.27 ± 0.02) 
G6-PAMAM 256 (0.22 ± 0.04) (0.53 ± 0.09) (0.39 ± 0.06) 
The first parameter of interest is the EC50, or effective concentration, for each of the 
dendrimers. As generation number, and molecular size increases, the concentration 
required to effectively displace 50% MalB into free solution decreases. This is a 
straightforward consequence of each subsequent dendritic generation possessing 
exponentially more cationic charge than the preceding one and accounts for the EC50 
decrease from 10.10 (± 0.32) µM at G1 to 0.22 (± 0.04) µM at G6. Given the effects of 
molecular size upon effective concentration, a more informative measure of the relative 
binding performances is that of CE50, the charge excess or charge efficiency.  
In order to calculate the CE50 values, the number of protonated sites per PAMAM 
generation needed to be carefully considered. The 10 mM Tris HCl component of the 
solutions buffers the assay at pH 7.0; a regime under which only the peripheral primary 
amines of PAMAMs are protonated.
278,279
 This leads to the molecular charges listed in 
Table 3.3.  
The first striking observation is that the smallest dendrimer, G0-PAMAM, is unable to 
displace 50% MalB from heparin, even when present in a concentration excess towards 
the end of the titration. Ostensibly, G0-PAMAM (517 Da, 4+) and MalB (542 Da, 5+) 
have comparable molecular properties, and so their markedly different heparin binding 
abilities further supports the structurally optimised nature of the crescent-shaped MalB 
compared to the more spherical PAMAM. In turn, this performance difference also 
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suggests charge is not the only factor controlling heparin binding; a view at odds with 
previous suggestions from Krämer and co-workers.
280
  
The remaining PAMAM systems were all able to bind heparin well enough to at least 
displace 50% MalB into solution and allow CE50 values to be calculated. Comparison of 
the CE50 derived for each system revealed an interesting trend. The data in Table 3.3 
show that the next smallest (G1) and the largest (G6) dendrimers were the least efficient 
heparin binders on a per-charge basis, requiring 0.75 (± 0.02) and 0.53 (± 0.09) cationic 
charges per negative charge respectively. It is worth noting that the performance of the 
largest dendrimer tested, G6, is comparable to that of protamine (which has a CE50 of 
0.52 (± 0.05)), although the larger molecular weight of the PAMAM system leads to a 
higher clinically relevant dose value. 
The ‘medium-size’ PAMAMs (G2, G3, G4) all exhibited quite similar heparin binding 
performances with comparable CE50 and dosage values being observed. In all cases, the 
data suggest each PAMAM positive charge is used more efficiently than each positive 
charge in protamine. Overall, the data suggest that the low generation systems (G0, G1) 
are too small to establish effective binding interactions, while the medium sized systems 
(G2-G4) appear best able to marshal their individual charges to bind heparin in the most 
charge-efficient manner. The overwhelming charge density of the largest (G6) 
dendrimer surface inhibits effective use of each individual charge. Importantly, these 
observations are similar to those observed using isothermal calorimetry to probe 
heparin-PAMAM binding, which therefore served to support the results obtained from 
our novel MalB competition assay.
193
 
The assertion that the medium sized PAMAM systems are the most charge-efficient 
heparin binders is itself an interesting one. The well documented toxicity of PAMAM 
dendrimers often restricts their consideration in new biological investigations, yet G2-
PAMAM is one of the less toxic PAMAMs.
276,277
 It could be suggested therefore that 
G2-PAMAM could be a useful ‘lead’ compound as a basis for future developmental 
work towards finding a suitable protamine alternative. 
3.3.2.2 Computational Study 
In order to further validate the PAMAM heparin binding results obtained using the new 
assay, a molecular dynamics (MD) modelling study was carried out in collaboration 
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with Professor Sabrina Pricl and her team at University of Trieste, Italy. The 
computational study simulated the binding interactions between different generation 
PAMAM systems and a representative heparin polysaccharide, enabling the energetics 
of binding to be calculated. In particular, the simulations were able to identify how 
many of the available surface charges interacted directly with heparin, Qeff, as well as 
determining the effective free energy of binding, 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
, for each system. The 
contribution of each interacting surface charge to this energy could then be deduced to 
give the effective-charge-normalised free energy of binding, 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff. This 
parameter is analogous to the charge excess values derived from the experimental study 
and so it was hoped that comparison of these two independently obtained datasets 
would reveal similar trends. The data calculated from the MD study is shown in Table 
3.4. 
Table 3.4 – MD simulation data for PAMAM dendrimers interacting with heparin. 
Protamine data included for comparison. Qtot: number of binder charges; Qeff: number of 
interacting charges; 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
: effective free energy of binding; 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff: effective-
charge-normalised free energy of binding. 
Compound 
Qtot       
/ (+) 
Qeff        
/ (+) 
   𝜟𝑮𝒃𝒊𝒏𝒅
𝒆𝒇𝒇
         
/ kcal mol-1 
𝜟𝑮𝒃𝒊𝒏𝒅
𝒆𝒇𝒇
/Qeff                        
/ kcal mol-1 
Protamine 24 12 ± 1 -3.96 ± 0.41 -0.33 ± 0.04 
G1-PAMAM 8 6 ± 1 -1.14 ± 0.22 -0.19 ± 0.05 
G2-PAMAM 16 13 ± 1 -16.9 ± 0.5 -1.30 ± 0.11 
G3-PAMAM 32 15 ± 1 -15.9 ± 0.3 -1.06 ± 0.07 
G4-PAMAM 64 16 ± 3 -14.6 ± 0.8 -0.91 ± 0.18 
G6-PAMAM 256 45 ± 5 -18.0 ± 1.3 -0.40 ± 0.05 
In general, the computational data are in agreement with the experimental data. The Qeff 
values are representative of the number of cationic charges per dendrimer which directly 
interact with a single heparin polysaccharide. Comparison of these values against the 
molecular charge, Qtot, gives an insight into how well each PAMAM generation is able 
to marshal its charges. For example, ca. six of the eight cationic charges (75%) in G1-
PAMAM make direct contact with heparin, although the overall effective free energy of 
binding 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
 is very low at –1.14 (± 0.22) kcal mol-1. This leads to each binding 
charge contributing only –0.19 (± 0.05) kcal mol-1 to the binding interaction. At the 
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other extreme, only 45 (± 5) of the available 256 cationic charges (18%) on G6-
PAMAM directly interact with a heparin polysaccharide. In reality, of course, it is likely 
that G6-PAMAM may interact simultaneously with more than one polysaccharide chain 
but owing to the computer-time-intensive nature of such simulations, this was not 
modelled. The resulting 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff for G6-PAMAM, despite being double that 
calculated for G1-PAMAM, was still relatively small at –0.40 (± 0.05).  
Of the medium sized dendrimers (G2-G4), it was G2-PAMAM which utilised the 
highest percentage of the available charges for direct interactions with heparin, with 13 
(± 1) of the 16 surface amines (82%) interacting directly with the polysaccharide. 
Distribution of the calculated free energy of binding, 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
, between these 13 (± 1) 
resulted in the most energetic individual interactions observed for any of the systems 
tested with an 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff of –1.30 (± 0.11) kcal mol
-1
. These data compare favourably 
with the experimentally observed CE50 value, for which G2-PAMAM had the joint 
lowest (i.e. most efficient) value, and confirms our initial suggestions that heparin 
binding using PAMAMs is not a straightforward ‘higher generation is better’ situation. 
Indeed, the concept of ‘less is more’ in multivalent binding has previously been 
examined in similar studies using MD modelling to interrogate dendritic systems 
interacting with DNA.
281
    
The computational study also allowed for further comparison against the performance 
of protamine, the modelling structure of which was built and refined from a consensus 
protein sequence.  It is interesting to note that despite being regarded as the benchmark 
heparin binder, owing to its clinical application, protamine is only able to establish 
interactions directly with 12 (± 1) of the 24 cationic charges (50%) within its structure. 
Overall it does not interact particularly strongly either, with a 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
 of –3.96 (± 0.41) 
kcal mol
-1
 leading to a per-binding-charge free energy 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff, of only –0.33 (± 
0.44) kcal mol
-1
. These relatively small interaction energies could be interpreted as 
surprising, although as visualised below in Figure 3.7, this may be a consequence of the 
relative rigidity of the protamine structure compared to the PAMAM dendrimers.  
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Figure 3.7 – Equilibrated MD snapshots of heparin binding to selected PAMAM 
dendrimers and protamine. Binders are represented as blue stick models while heparin is 
shown as red and orange space-filling structures.  
An additional benefit of this MD modelling study is that it allowed snapshots of the 
binding events to be visualised, as shown in Figure 3.7. Perhaps most clear to see from 
these images is the struggle as PAMAM generation, and consequently molecular size, 
increases for all the binding groups to establish interactions with the polysaccharide 
chain. This is particularly clear, for example, when comparing the visibility of terminal 
amine group in the snapshots of G2-PAMAM-heparin against G6-PAMAM-heparin. 
The snapshot image of the heparin-protamine interaction is also insightful as it suggests 
so rigid is the protamine tertiary structure, that the normally extended heparin 
polysaccharide ‘wraps around’ the protein structure in an attempt to optimise the 
electrostatic binding interactions.  
3.3.3 Heparin Binding in Clinically Relevant Conditions 
Having established that G2-PAMAM was a more charge efficient heparin binder than 
protamine (and the other PAMAMs) in electrolytically competitive aqueous solution, 
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we next wanted to challenge these binding interactions in the more biological, and 
clinically relevant, conditions of human serum. This enabled the newly developed MalB 
assay with heparin delivered in serum to be employed. The data obtained for G2-
PAMAM are displayed in Table 3.5.  




EC50 / μM CE50  
Dose /                    
mg per 100IU 
Salt and Buffer (2.55 ± 0.32) (0.38 ± 0.04) (0.25 ± 0.03) 
Heparin in 100% Human Serum (2.15 ± 0.05) (0.32 ± 0.01) (0.21 ± 0.01) 
G2-PAMAM fully maintained its relative heparin binding performance in human serum 
when compared against the data obtained in buffer and salt. This is particularly 
impressive given the decrease in efficiency of protamine observed earlier, see Table 3.2. 
Although the data appears to suggest that G2-PAMAM slightly increased its charge 
efficiency, the nature of this competition assay must be remembered. It is unlikely that 
G2-PAMAM actually improves in absolute terms but rather that its heparin binding 
ability improves relative to MalB in this more competitive biological media.  
3.3.4 Summary 
Overall, the data from the MalB assay have given insights into differing generational 
effects of PAMAM dendrimers when binding heparin. In particular, the ‘medium sized’ 
systems such as G2-PAMAM have been demonstrated as the most able to marshal their 
surface charges and establish meaningful efficient interactions with heparin. Molecular 
dynamics modelling corroborated the experimental findings. As mentioned above, G2-
PAMAM is one of the least toxic PAMAM dendrimers and therefore may be suitable 
for consideration as a lead compound for further developmental work.  
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3.4 Studying Effects of Rigidity and Flexibility with Transgeden 
Dendrimers 
3.4.1 Transgeden (TGD) Dendrimers 
Following the insights into generational effects for PAMAM revealed by our new MalB 
heparin binding assay, we took an interest in the hybrid dendrimers being synthesised 
under the direction of our collaborator Professor Julián Rodríguez-López at Universidad 
de Castilla-La Mancha, Ciudad Real, Spain. For some time now, Rodríguez-López and 
co-workers have been interested in the study of hybrid dendrimers,
282-284
 with a 
particular focus on systems possessing poly(phenylenevinylidene) (PPV) character.
285-
287
 PPV dendrimers consist, as the name suggests, of a series of phenyl rings conjugated 
through trans-alkene connections as shown in the top structure in Figure 3.8. The team 
of Rodríguez-López have taken an interest in controlling the surface functionality of 
PPV systems,
288
 for example through the introduction of specific electron-donating or 
electron-withdrawing groups in order to tune the photoluminescent properties of the 
system.
289
 Two of the most relevant approaches to our current study involved the 
hybridization of PPV dendrimers with PAMAM systems, firstly with PPV-groups 
installed at the PAMAM surface
290
 and more recently with PAMAM-groups installed at 
the PPV surface.
291-293
 It was this lattermost family of compounds, known as 
Transgeden (TGD) dendrimers, in which we took particular interest. 
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Figure 3.8 – Structure of Transgeden (TGD) dendrimers showing the PPV core unit and 
G1-G3 PAMAM surface groups.   
It was decided to examine the heparin binding abilities of the first three generations of 
Transgeden dendrimers (TGD-G1, -G2, -G3) and to compare them against the 
corresponding native PAMAM dendrimers of equivalent generations. This allowed the 
increased rigidity of the TGD dendrimers conferred by the PPV cores, and more 
particularly its effect on the ability of the surface PAMAM ligand array to bind heparin, 
to be probed.  
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3.4.2 Heparin Binding Studies in Competitive Conditions 
3.4.2.1 Experimental  Study I: Mallard Blue Displacement Assay 
The Transgeden dendrimers (G1-G3) were tested for their heparin binding ability using 
the MalB competition assay under the same conditions as had been applied earlier to the 
PAMAM dendrimers; namely 25 µM MalB, 27 µM heparin, 150 mM NaCl and 10 mM 
Tris HCl (pH 7.0). The resulting data, along with that shown earlier for the native 
PAMAMs, expressed in terms of dose, effective concentration and charge excess at 
50% MalB displacement (EC50 and CE50 respectively) are displayed in Table 3.6.    
Table 3.6 – Heparin binding data from MalB assay in buffer and salt for G1-G3 TGD 
dendritic systems, along with G1-G3 PAMAM data for comparison. 
Compound 
  Heparin Binding 
Charge 
(+) EC50 / μM CE50  
Dose /                                                    
mg per 100IU 
TGD-G1 9 (7.73 ± 0.32) (0.64 ± 0.03) (0.38 ± 0.02) 
TGD-G2 18 (3.78 ± 0.25) (0.63 ± 0.04) (0.42 ± 0.03) 
TGD-G3 36 (2.00 ± 0.15) (0.67 ± 0.05) (0.47 ± 0.04) 
G1-PAMAM 8 (10.10 ± 0.32) (0.75 ± 0.02) (0.44 ± 0.01) 
G2-PAMAM 16 (2.55 ± 0.32) (0.38 ± 0.04) (0.25 ± 0.03) 
G3-PAMAM 32 (1.53 ± 0.21) (0.45 ± 0.06) (0.32 ± 0.04) 
The data show that despite the rigidification of the dendritic core, all three generations 
of TGD dendrimers were able to bind heparin effectively, and could displace MalB 
during the competition assay. The EC50 for each TGD dendrimer decreased from 7.73 
(± 0.32) µM at G1 to 2.00 (± 0.15) µM at G3, and this is again a straightforward 
consequence of each successive generation possessing a larger number of cationic 
binding sites per mole and so becoming able to out-compete MalB due to the sheer 
amount of charge present at lower concentrations. In terms of required dose, TGD-G1 
was suggested to be marginally the best performer although the lower molecular weight 
of the smaller dendrimer exerts an influence over this observation.  
In terms of the binding efficiency of each individual cationic charge, the CE50 values 
suggest binding performance is essentially equivalent across all three TGD generations; 
an observation in marked contrast to the PAMAM systems, which exhibit significant 
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performance improvement with increasing size to G2 and G3. Direct comparisons 
between equivalent generations of the two dendritic families showed that at G1, the 
TGD system was able to employ its 9 cationic charges in a more efficient manner than 
the PAMAM could its 8, while in the larger G2 and G3 systems, the native PAMAMs 
were the more charge efficient, despite possessing less overall charge in both cases. As 
informative as these CE50 values can be, it must be remembered that they only reflect 
the binding events at one specific point; namely that at which 50% MalB has been 
displaced from heparin. The full binding curves for each pair of dendrimers were 
therefore considered, Figure 3.9, in an attempt to rationalise the observed differences 
between the dendritic systems and probe the effects of molar dendrimer/heparin ratios.  
 
Figure 3.9 – Heparin binding curve comparisons for TGD (closed shapes) and 
PAMAM (open shapes) dendrimers at G1 (top left), G2 (top right) and G3 (bottom) 
from MalB assay in buffer and salt.    
The binding curves for the smallest pair of dendrimers, TGD-G1 and G1-PAMAM 
shows that the hybrid TGD system is the superior heparin binder throughout the whole 
titration range. In this case, the single CE50 value is therefore representative of the 
overall binding. On moving to the larger G2 and G3 systems, this is not necessarily the 
case, as when only small amounts of dendrimer are present, the TGD systems exhibit 
superior binding to the native PAMAMs. As dendrimer concentrations increase beyond 
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a charge ratio of ca. 0.2 for these systems, the TGD performance drops off, leading to 
the observed superiority of PAMAM at the CE50 value. These observations suggest that 
the TGD dendrimers are better optimized for forming interactions with multiple heparin 
chains under the regime where heparin is present in significant excess, but when the 
stoichiometry of dendrimer to heparin is more even, the PAMAM systems are better 
optimized. The inherent rigidity imposed by the PPV cores upon the TGD systems may 
be central to these observations as, particularly at higher charge-excess values when the 
amount of heparin becomes limited, the hybrid dendrimers may be less well able to 
adapt and re-organise their ligand array to interact with a single heparin chain most 
optimally, while the more flexible PAMAMs may be able to more freely contort to bind 
the polysaccharide.     
3.4.2.2  Computational Study: MD Modelling 
In an attempt to validate these experimental observations, our collaborators, led by 
Professor Sabrina Pricl at University of Trieste, once again employed molecular 
dynamics (MD) modelling to study the dendrimer-heparin interactions. Binding was 
simulated at two different charge ratios in an attempt to understand the effect of 
stoichiometry on binding performance. Firstly, atomistic modelling was undertaken at a 
charge ratio of 0.4 as at this point on the binding curves the larger (G2 and G3) 
PAMAMs were significantly outperforming their TGD counterparts, while at G1 
differences were minimal.  
In order to compare the different dendrimers at the same charge ratio, the concentration 
of heparin within the simulation was kept constant and the number of individual 
dendrimer molecules adjusted to afford the desired charge ratio. This approach differed 
from the per-residue free energy decomposition technique employed in the previous 
section and, in practice, resulted in four (or five) G1, two G2 and one G3 dendrimer 
being present in each simulation. As before, the overall free energy of binding, 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
, 
could be calculated to give an insight to the energetics of the overall binding interaction. 
The data show that each of the TGD dendrimers, along with G1-PAMAM, interact with 
a free energy of around –10 kcal mol-1. The larger PAMAM dendrimers bind more 
efficiently with G2-PAMAM affording –44.7 (± 2) kcal mol-1. 
Division of these total free energy values by the total number of cationic charges 
present, Qtot, in each simulation – which is coincidentally 36 for all three TGD 
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dendrimers – afforded the charge normalized free energy of binding, 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qtot, as 
detailed in Table 3.7. These values, which are analogous to the experimentally 
determined CE50 values, were equivalent at ca. 0.28 kcal mol
-1
 for each TGD dendrimer 
and G1-PAMAM, with only the larger PAMAM systems offering more energy per 
charge.  
Table 3.7 – MD simulation binding parameters at a charge excess of 0.4. Qtot: number 
of binder charges; Qeff: number of interacting charges; 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
: effective free energy of 
binding; 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qtot: charge-normalised free energy of binding; 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff: effective-
charge-normalised free energy of binding. 
Compound Nmol 
Qtot      
/ (+) 
Qeff       
/ (+) 
    𝜟𝑮𝒃𝒊𝒏𝒅
𝒆𝒇𝒇
      








/ kcal mol-1 
TGD-G1 4 36 26 ± 2 -9.6 ± 0.8 -0.27 ± 0.02 -0.37 ± 0.03 
TGD-G2 2 36 21 ± 1 -9.9 ± 0.6 -0.28 ± 0.02 -0.47 ± 0.03 
TGD-G3 1 36 14 ± 1 -10.1 ± 0.7 -0.28 ± 0.02 -0.72 ± 0.05 
G1-PAMAM 5 40 35 ± 2 -10.2 ± 1.1 -0.26 ± 0.03 -0.29 ± 0.03 
G2-PAMAM 2 32 29 ± 1 -44.7 ± 2.0 -1.40 ± 0.06 -1.54 ± 0.07 
G3-PAMAM 1 32 15 ± 1 -15.9 ± 1.1 -0.50 ± 0.03 -1.06 ± 0.07 
The simulations again allowed the number of dendrimer charges directly involved in 
heparin interactions, Qeff, to be calculated. It is interesting to note that the smallest 
TGD-G1 structure is best able to utilise its charges with 72% of the available surface 
amines directly interacting with heparin. As size increases, this proportion drops to 58% 
for TGD-G2 and 39% for TGD-G3. Division of the total free energy of binding, 𝛥𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
, 
by Qeff calculates the effective ‘strength’ of each individual amine-heparin interaction 
for the systems. These values indicate that TGD-G3 established the most energetic 
individual amine-heparin interactions while those of TGD-G1 were the weakest.  
The smaller (G1 and G2) PAMAM dendrimers were shown to be superior to any of the 
TGDs at involving individual amine surface groups in direct interactions with heparin. 
At G1, 87.5% of the available 40 cationic charges were directly involved in binding, 
while at G2, this increased to an impressive 91% of the available 32 charges. These data 
suggest the flexibility of the PAMAM core interior structures, compared to the rigid 
TGD systems, significantly enhances their ability to re-organise and optimize their 
interactions. We termed this process ‘adaptive multivalency.’294 Adaptive multivalency 
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is a similar concept to that previously observed for DNA binding
295
 with large 
multivalent dendritic systems such as PAMAMs
296
 and PEI dendrimers.
297
   
Further atomistic MD modelling snapshots of these interactions were captured, Figure 
3.10, and these illustrate well the adaptivity of the PAMAM systems compared to the 
TGD-modified dendrimers. For example, inspection of the snapshots of TGD-G2-
heparin and G2-PAMAM-heparin shows several large regions of TGD-system 
positioned away from the polysaccharide while the PAMAM-system has adapted its 
conformation to interact more completely with the heparin chain. 
 
Figure 3.10 – MD simulations for TGD (red structures, top) and PAMAM (green 
structures, bottom) binding heparin (light and dark blue structures) at a charge excess of 
0.4 across generations 1, 2 and 3 (left-to-right).  
 In the second part of this study, mesoscale dissipative particle dynamics (DPD) 
modelling was carried out at a charge excess of 0.1; a regime under which the MalB 
data suggested the more rigid TGD dendrimers were superior heparin binders to 
PAMAMs. DPD was employed for these simulations as this technique is coarse-grained 
and therefore allowed multiple heparin chains in constant contact with the dendrimer, 
and more complex binding stoichiometries, to be studied. Views of these simulations 
are shown in Figure 3.11.   
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Figure 3.11 – Snapshots of the mesoscale simulations between dendrimers and heparin 
(light and dark blue structures) at CE = 0.1 for TGD (pink structures, top) and PAMAM 
(dark green structures, bottom) at G1 (left), G2 (middle) and G3 (right). In all panels, 
positively charged sites are shown in light green.   
At G1, mesoscale models indicated that the heparin-dendrimer interactions are well 
defined, with each dendrimer appearing to interact with a single heparin polysaccharide. 
For TGD-G1, it seems likely that the rigidity of the PPV core plays a key role in locally 
organizing the surface groups for binding. At higher generations, meanwhile, binding is 
less well defined as both G2 and G3 systems appear to interact with multiple heparin 
chains simultaneously. The formation of these high-affinity interactions between 
multiple heparins and each of the TGD dendrimers appears to suggest that the same 
rigidity which limits effective multivalent interactions at higher CE (e.g. 0.4) is actually 
beneficial at lower CE (e.g. 0.1). Indeed, it seems these locally organized regions at the 
TGD surfaces are better optimized for interaction with heparin than the native 
PAMAMs, but only if there is enough heparin present for them to interact with it 
without having to deform their structures. We therefore categorized TGD dendrimers as 
exponents of a new concept: namely ‘shape-persistent multivalency.’294  
3.4.2.3 Experimental Study II: Utilizing TGD Fluorescence 
An attractive feature of the TGD dendrimers over the native PAMAM systems is that 
they possess a PPV core, which endows photophysical activity. As such, it was 
anticipated that these structures might also be able to act as heparin sensors by self-
indicating interactions with heparin. To that end, solutions of each TGD dendrimer (1 
µM) were titrated with heparin in the presence of 150 mM NaCl and 10 mM Tris HCl 
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(pH 7.0). Previous studies employing TGD-G1 in clean water observed an absorbance 
maximum of 319 nm giving fluorescence output at 413 nm however, under our buffered 
conditions, irradiation was optimised at 318 nm while the emission maximum was 
shifted to 427 nm.
293
 The term heparin ‘concentration’ again refers to the concentration 
of tetraanionic disaccharide rather than global heparin polysaccharide. The resulting 
titration curves are shown in Figure 3.12.  
 
Figure 3.12 – Heparin titration curves for TGD dendrimers (G1-G3) in 150 mM NaCl 
and 10 mM Tris HCl, probed by fluorescence of PPV-core. 
The titration curve for TGD-G1 did not result in a conventional binding lineshape, and 
consequently is rather uninformative. It seems likely that interaction of heparin at the 
surface of the relatively small dendrimer brought the polysaccharide into close enough 
proximity with the PPV-core to effect some form of direct quenching event. This 
proposal is supported by the observation of more conventional binding curves for the 
larger TGD-G2 and TGD-G3 systems, in which heparin is necessarily positioned further 
from the photoactive core upon binding. On these binding curves, the point at which the 
line begins to plateau can be taken to indicate the concentration of heparin disaccharide 
required to saturate 1 µM of Transgeden dendrimer. The data suggests each mole of 
TGD-G2 is saturated by two moles (2 µM in this experiment) of heparin disaccharide 
Chapter 3 – Insights into Heparin Binding 
118 
while TGD-G3 requires six moles (6 µM) to be present. Interestingly, and convincingly, 
these data are in agreement with the atomistic MD modelling snapshots for these 
interactions, Figure 3.10, which show individual dendrimer residues appearing to bind 
to the corresponding number of heparin saccharides suggested here.     
Given the obvious spectroscopic responses of the larger TGD dendrimers in 
electrolytically competitive conditions (150 mM NaCl and 10 mM Tris HCl), these 
systems may be of interest for further heparin sensing investigations such as those 
presented in the previous Chapter. Clearly, PAMAM dendrimers have no direct heparin 
sensing capability owing to their lack of photoactive groups and so their modification to 
yield TGD dendrimers offers significant advantages in this regards.  
3.5 Modified Transgeden Dendrimers 
In a final set of experiments, attempts were made to study the importance of each 
individual charge within the TGD-G1 structure by removing some of them from the 
system. To do this, our collaborators in the group of Professor Julián Rodríguez-López 
at Universidad de Castilla-La Mancha, Ciudad Real, Spain synthesised a small family of 
TGD-G1 derivatives, in which differing numbers of the surface primary amines were 
replaced non-selectively with alcohol groups. This was achieved in a statistical manner 
during synthesis and the degree of amine functionalization was determined using a 
Kaiser test. Specifically, three compounds were produced in which 82%, 69% and 45% 
of the surface amine groups were present when compared to the original TGD-G1. From 
these Kaiser test values, the average molecular charge for each new dendrimer could be 
estimated (+ 7.4, + 6.2 and + 4.0 respectively) and these values were used for charge 
excess calculations. Each molecule, along with a completely anionic control molecule 
TGD-G1(OH)9, was tested for heparin binding ability in the MalB assay in buffer and 
salt. The data are reported in Table 3.8 and Figure 3.13.    
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EC50 / μM CE50  
Dose /                                                    
mg per 100IU 
TGD-G1 (7.73 ± 0.32) (0.64 ± 0.03) (0.38 ± 0.02) 
TGD-G1 (+7.4) (19.2 ± 2.7) (1.31 ± 0.18) (0.94 ± 0.13) 
TGD-G1 (+6.2) Not achieved - binding too weak 
TGD-G1 (+4.0) Not achieved - binding too weak 
TGD-G1(OH)9 No binding observed 
 
Figure 3.13 – Heparin binding curves for TGD-dendrimers containing differing 
numbers of surface amines.  
The data show that in all cases, the removal of surface amines decreases the heparin 
binding performance. Whilst this observation may not be surprising, it is interesting to 
note that removal of only ca. 20% of the surface amines decreases the heparin binding 
efficiency by around half. In the previous section, MD modelling suggested that only 
around 72% of the TGD-G1 surface amines actively interact with heparin upon binding, 
yet here, although around ca. 80% of the amines remain present, binding efficiency is 
significantly reduced. This suggests that the surface amines may be acting in pre-
organised clusters of 3 amines each on the TGD surface. Loss of even one of these 
amines will significantly disturb the shape persistent multivalent binding. Furthermore, 
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when only ca. 70% of the amines are present, TGD-G1 (+ 6.2), binding is so perturbed 
that less than 50% of MalB is displaced from heparin during the assay. As would be 
expected, the anionic control molecule, TGD-G1(OH)9, showed no evidence of heparin 
binding.   
3.6 Conclusion and Future Work 
Following consideration of the currently available methods for rapidly probing and 
comparing the heparin binding ability of different molecules, a novel straightforward 
competition assay was developed. The new assay employed our recently developed 
heparin sensor Mallard Blue (MalB) in an indicator displacement assay (IDA) regime. 
The performance of different candidate molecules was determined by their propensity to 
displace MalB from its complex with heparin and into solution, thereby causing an 
observable spectroscopic change. It was reasoned that the binding performance of new 
(and existing) molecules – measured in terms of charge excess and effective 
concentration at 50% MalB displacement, along with clinically relevant dose – could 
then be benchmarked against the clinically used heparin rescue agent, protamine to 
assess initial clinical potential.  
The potential of this assay was initially demonstrated using protamine, and proved 
operable both in the presence of competitive electrolytes – specifically 150 mM NaCl 
and 10 mM Tris HCl – and also with the heparin component of the mixture delivered in 
100% human serum. Although many existing dye systems have the potential to operate 
in this manner, it is believed that this work marks the first concerted attempt to develop 
such a straightforward assay for screening heparin binding under competitive 
conditions. Furthermore, the ease-of-synthesis associated with MalB makes the assay an 
attractive proposition for a wide range of researches, even those without specialist 
knowledge in synthetic chemistry such as, for example, biologists/biochemists.  
The new competition assay was then validated through a study of the commercially 
available family of PAMAM dendrimers. The experimental data, supplemented by MD 
modelling, gave new insights into the multivalent binding behaviour of these systems 
and highlighted the importance of size dendritic size/generation for heparin binding. 
The results showed that the bigger, more charge dense dendrimers (e.g. G6), were not 
necessarily the best for heparin binding, while the smallest (e.g. G0, G1) were not 
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optimal either. Interestingly despite possessing a comparable number of cationic 
charges to MalB, G0-PAMAM was unable to displace MalB from heparin even when 
present in excess. The medium sized dendrimers (G2-G4) were shown to bind heparin 
in the most charge efficient manner indicating that these systems were best able to 
marshal their surface charges to maximize interactions with the polysaccharide. The 
MD modelling showed that G2-PAMAM was able to utilise the highest percentage 
(91%) of the available surface amines for interaction with heparin, and that each did so 
in the most energetic manner of any PAMAM system tested. Importantly, from the 
viewpoint of the novel assay, these results concurred with previous literature 
observations, indicating the suitability of the new technique for probing the relative 
performance of different binders.  
Following this, in order to gain further understanding of multivalent effects in the 
binding of PAMAM-type systems to heparin, a range of hybrid dendrimers containing a 
rigid poly(phenylenevinylidene) (PPV) core functionalized with PAMAM surface 
groups were tested. Comparisons of these so-called ‘Transgeden’ (TGD) dendrimers 
with the native PAMAMs across low (G1) and medium (G2 and G3) generation sizes 
unveiled some key concepts relating to the flexibility of large dendritic systems on 
heparin binding. At low charge excess values – that is when heparin is present in 
significant excess to the binder – the rigidity of the TGD-core was beneficial to the 
relative binding performance of these systems by assisting in locally organizing ligand 
binding clusters at the dendrimer surface, while under the same regime, PAMAMs were 
less well organized. On moving to a larger charge excess – that is where the 
stoichiometric ratio is less in favour of heparin – the rigidity of the TGD core becomes 
detrimental to their performance as it reduces the extent to which the dendrimers can 
adapt their shape to maximize the number of interacting sizes with heparin. Under this 
latter regime, the flexibility of the PAMAM dendrimers allowed them to re-organise the 
ligand array presented to heparin for binding. These two dendrimer families were 
categorized a prime exponents of “shape persistent multivalency” and “adaptive 
multivalency” respectively. All observations, again, were supplemented by MD 
modelling data.    
The rigid PPV core present within the TGD systems offered the additional benefit of 
photophysical activity and was exploited to self-indicate the interactions of the TGD 
dendrimers with heparin. The titration data obtained in this manner suggested that the 
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larger systems (G2 and G3) required more heparin for binding to become saturated. 
Impressively, the saturation stoichiometries suggested by the data for TGD-G2 (2 : 1, 
anionic disaccharide : TGD) and TGD-G3 (6 : 1) correlated closely with the values 
obtained computationally during the MD modelling studies of the same systems. The 
self-indicating fluorescent study of TGD-G1was unsuccessful owing to the relatively 
small PAMAM surface groups being unable to enforce a large enough distance between 
the PPV-core and the bound heparin to prevent a direct quenching event occurring. This 
quenching interfered with the fluorescent output of the dendrimer and resulted in the 
observed ‘binding curve’ being uninformative.  
In a final experiment, the new assay was used to examine the relative heparin binding 
abilities of a family of modified TGD-G1 dendrimers. The compounds possessed 
different numbers of amines at their surface, with some groups replaced by alcohol 
functionalities. Most interestingly, the absence of less than 20% of the surface amines 
was sufficient to decrease the heparin binding ability of the system by greater than half. 
This is particularly profound as the complementary MD modelling work of the original 
TGD-G1 suggested that only 72% of the surface amines present actually interact 
directly with heparin. Such a decrease in performance with around 80% of the amines 
remaining intact supports the view that the loss of only one of the three amines in each 
cluster is significantly detrimental to the shape persistent multivalency. The absence of 
ca. 30% of the original charge is sufficient to prevent the dendrimer from displacing 
MalB during the entire titration.        
The insight into fundamental multivalent binding phenomena gained from further 
investigations of the initial experimental data obtained from the novel MalB 
displacement assay is clear. This assay will now be taken forward to probe a variety of 
different compounds and molecular systems for their heparin binding potential, with a 
view to identifying molecules of interest for the development of novel heparin rescue 
agents. In particular, such a study could focus on self-assembling dendritic systems, 
which may present clinically-relevant advantages over large covalent systems for 
heparin binding.  
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At the conclusion of surgery during which heparin has been used, there is an immediate 
need to neutralize the anti-coagulant effect of the heparin and allow the patient to begin 
clotting. This heparin neutralization, known widely as ‘heparin rescue’, involves the 
introduction of a heparin antidote into the bloodstream. Currently, there is only one 
licensed heparin rescue agent: protamine sulfate.
100
 Protamine is an arginine-rich 
protein of ill-defined structure and was first demonstrated as a potential heparin rescue 
agent as early as 1937.
298
 Although mostly effective, the use of protamine is not without 
consequence as up to 10% of patients treated with the shell-fish or salmon derived 
protein at the conclusion of surgery experience some adverse effects, and close to 3% of 
all cardiac surgery patients experience serious problems.
110
 Consequently there is a 
significant interest in finding an alternative heparin rescue agent which is able to confer 
the desired heparin neutralization without conferring toxicity in patients.
299
 
Much of the work to develop a novel heparin rescue agent can be categorized broadly 
into one of two sub-sets: small, well-defined ‘drug-like’ molecules or larger, less well-
defined systems.
212
 Each approach has associated pros and cons. Small molecules, such 
as surfen for example, are often very well defined and can be easily produced to a high 
level of purity in large quantities.
205
 From a pharmacological perspective, smaller 
molecules can be more appealing than larger systems as they can offer more predictable 
pharmacokinetic profiles. A significant limitation of smaller systems however, can be 
their limited heparin binding ability when compared against their larger counterparts. 
Indeed although systems such as surfen are somewhat optimized for heparin binding, 
their low molecular weight is often associated with a low molecular charge, which in 
turn results in effective heparin neutralisation requiring unacceptably large amounts of 
binder, as measured by IC50 values. Given these factors, it is perhaps not surprising that 
relatively few small molecule heparin binders have received serious consideration in 
clinical settings.  
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In contrast, larger systems can offer more appeal as potential protamine alternatives 
because their more massive and highly charged structures can lead to more effective and 
robust heparin binding on a per molecule basis. Larger structures, such as the covalent 
dendrimers discussed in Chapter 3 do not come without problems however. For 
example, synthesis of larger polymeric or dendritic structures is frequently far from 
trivial with purification often being troublesome. Unpredictable and unfavourable 
pharmacokinetic profiles can also detract from the employment of larger heparin 
binding systems. For example, the absence of a biocompatible degradation pathway can 
lead to toxicity problems, often as a consequence of the persistence of large cationic 
charge arrays in the bloodstream. As discussed in Chapter 3, this is one limitation to the 
use of PAMAM dendrimers in a clinical setting.
276,277
  
An effective way of generating a large ligand array whilst minimizing the synthetic 
challenge can be to use molecular self-assembly. This process involves multiple copies 
of the same ‘building-block’ molecule spontaneously organizing with one another to 
form a larger hierarchical structure.
300
 Such systems are routinely held together by non-
covalent interactions and as seen in Chapter 1, self-assembly processes can be used to 
multiply-up the number of binding groups from a single monomer ligand in order to 
produce a self-assembled multivalent (SAMul) ligand array. Most commonly, 
amphiphilic monomeric building-blocks are used to promote self-assembly as they are 




Self-assembling approaches have been widely used to achieve binding to biological 






 In each of these cases, the 
individual monomer units contain hydrophilic binding groups attached to a hydrophobic 
unit. The molecular geometry is designed such that when solubilized in aqueous 
biological conditions, the apolar units are internalized as a consequence of the 
hydrophobic effect leading to the display of hydrophilic binding groups at the assembly 
surfaces. Of particular relevance to us is the body of work from Smith and co-workers 
which has focused on developing self-assembling agents able to bind either DNA or 
integrin for clinical purposes.
56,303
 An example of an amphiphilic binder targeted at 
binding integrin from Smith and co-workers is shown in Figure 4.1. The geometry of 
the building block, as dictated by the relative size of the hydrophobic and hydrophilic 
domains, promotes the formation of a spherical micellar assemblies in which the 
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resulting multivalent array of ligands achieve superior integrin binding compared with 




Figure 4.1 – An amphiphilic integrin binder from Smith and co-workers.56 
4.1.2 Preliminary Work211 
In 2011, Smith and co-workers extended their approach of self-assembly based ligand 
design to target interaction with heparin. Specifically, an amphiphilic system similar to 
that presented above was designed and synthesised. The building block C22G1DAPMA, 
shown in Figure 4.2, comprised several key features: (i) a twenty-two carbon aliphatic 
tail, which endowed the building block with amphilicity and promoted spontaneous 
formation of nanoscale assemblies in aqueous conditions; (ii) positively charged, 
heparin-binding DAPMA – N,N-di-(3-aminopropyl)-N-methylamine – surface groups; 
(iii) an ester-containing linker unit between the hydrophobic moiety and the hydrophilic 
head group, to encourage hydrolytic degradation in biological conditions.  
 
Figure 4.2 – Structure of heparin binder C22G1DAPMA along with cartoon 
representation of self-assembly. This Figure is also shown as Figure 1.33. 
It was hoped that designing the molecular building block in this way would maximize 
the advantages of both small and large heparin binding systems. The self-assembled 
system should be large enough (in assembled form) to establish meaningful interactions 
with heparin and act as an effective binder, while minimizing the unnecessary 
persistence of a cationic ligand array after administration.  
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The preliminary work with C22G1DAPMA established that the system was able to self-
assemble in aqueous conditions at concentrations above ca. 4 µM.
211
 Transmission 
electron microscopy (TEM) images of dried samples of C22G1DAPMA showed 
spherical assemblies and the nanostructures were thereby categorized as micellar in 
nature. The micelles were sized at approximately 8.5 (± 1.5) nm in diameter and, 
importantly, appeared to remain intact upon heparin binding, Figure 4.3. The TEM 
images of C22G1DAPMA in the presence of heparin appeared to show micelles aligned 
in an ordered fashion along the polysaccharide surface. In reality, this patterning is 
likely to arise from an integrated nanostructure composed of binder micelles distributed 
throughout the heparin polysaccharide chains. Such observations are similar to those 
previously observed by Kostiainen and co-workers for self-assembling systems when 
binding viruses.
304,305
 Indeed, direct interactions between our SAMul binder and heparin 
polysaccharide chains were held responsible for the observed ‘beads on a string’ 
binding motif.  
 
Figure 4.3 – TEM images of C22G1DAPMA in absence (left, scale bar: 100 nm) and 
presence (right, scale bar: 50 nm) of heparin.  
In this previous preliminary work, having established C22G1DAPMA’s aptitude for 
interaction with heparin, the relative binding efficiency of the system with respect to 
protamine was probed using a methylene blue (MB) indicator displacement assay. 
Under this regime, C22G1DAPMA required only 78% as much charge as protamine to 
bind any given amount of heparin, indicating that the self-assembling binder was 
employing each surface charge more efficiently than protamine. Whilst these results 
were impressive, the MB assay limited the scope of investigation owing to the 
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intolerance of MB-heparin interactions to electrolytic conditions above 1 mM Tris HCl 
and 5 mM NaCl; a significant way short of biologically relevant conditions.  
Overall the data from the preliminary study suggested C22G1DAPMA was a more 
charge efficient heparin binder than protamine in the presence of low concentrations of 
competitive electrolytes, although the SAMul system remained some way from being 
established as a promising heparin rescue agent. Several important factors remained 
unaddressed. For example, heparin binding performance was not studied under 
biologically relevant conditions; primarily due to the lack of a sufficiently robust 
straightforward assay. The role of self-assembly in conferring the apparent multivalent 
heparin binding performance was not unequivocally proven either. Furthermore, despite 
an ester linkage being incorporated into the scaffold to promote degradation, the validity 
of this molecular design was not examined. Following the development of the Mallard 
Blue heparin binding assay, presented in Chapters 2 and 3, it was decided to address 
some of these outstanding questions.  
The C22G1DAPMA compound used for testing was synthesised according to previously 




4.2 Effects of Different Media on Heparin Binding 
4.2.1 Heparin Binding in Competitive Conditions 
4.2.1.1 Heparin Binding Assays 
The Mallard Blue assay provided an ideal tool with which to investigate the effects of 
different media on the heparin binding ability of C22G1DAPMA. The MalB assay 
operates in the presence of 150 mM NaCl and 10 mM Tris HCl, and so provided much 
sterner electrolytic competition for the SAMul system than the methylene blue assay 
regime. The heparin binding data for C22G1DAPMA from both assays are presented in 
Table 4.1 along with protamine for comparison.   
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Table 4.1 – Heparin binding data for C22G1DAPMA and protamine in the absence and 
presence of salt. Assay conditions: [a] 10 μM MB, 178 μM heparin, 1 mM Tris HCl. [b] 
25 μM MalB, 27 μM heparin, 150 mM NaCl, 10 mM Tris HCl. 
Binder 
Methylene Blue[a] Mallard Blue[b] 
(Buffer) (Buffer/Salt) 
Protamine 
EC50 / µM (22 ± 1) (2.34 ± 0.23) 
CE50 (0.74 ± 0.04) (0.52 ± 0.05) 
Dose / mg (0.46 ± 0.03) (0.32 ± 0.03) 
C22-G1-DAPMA 
EC50 / µM (102 ± 3) (7.50 ± 1.22) 
CE50 (0.58 ± 0.02) (0.28 ± 0.05) 
Dose / mg (0.47 ± 0.01) (0.23 ± 0.04) 
Data are reported in terms of their charge efficiency at 50% dye displacement, that is the 
number of cationic binder charges required per heparin anionic charge; effective 
concentration at the same point; and effective dose, that is the raw amount of binder 
required to neutralise 100IU of heparin. The MB data have been recalculated using the 
current working definitions of heparin and protamine, and so differ slightly from that 
published in the original study. Specifically, the Mr of heparin is assumed to be that of 
the sodiated analogue of the predominating disaccharide repeat unit, namely 665.402 g 
mol
-1
, while the Mr of protamine is assumed to arise from a typical amino acid sequence 
of 5854.23 g mol
-1
. 
Both in the absence and presence of salt, a higher concentration of C22G1DAPMA is 
required to displace 50% dye than is required of protamine. This discrepancy is a 
straightforward consequence of C22G1DAPMA being relatively small and drug-like, 
and possessing only four cationic charges per mole compared to the larger protamine 
protein, which possesses twenty-four charges. Under both sets of conditions, the 
effective concentration values are greater than the CAC value of ca. 4 µM, suggesting 
self-assembly of C22G1DAPMA is required for effective multivalent binding of the 
system to occur. The importance of self-assembly is discussed further below.  
A more representative, size-independent measure of relative binding performance can 
be obtained through consideration of the charge efficiency values. The data show that 
both C22G1DAPMA and protamine exhibit enhanced charge efficiency in the presence 
of 150 mM NaCl. This observation agrees with suggestions in the original paper that 
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salt may be acting as a screen preventing further heparin interfering with already 
established heparin-binder interactions. The extra electrolytes also serve to weaken the 
dye-heparin interactions with which the synthetic binder molecule (or protamine) has to 
compete, artificially enhancing the apparent binder performances. Although the absolute 
improvement in binding ability upon introduction of salt could therefore not be 
calculated, insight could be gained from the relative improvements of C22G1DAPMA 
and protamine.  
On moving to 150 mM NaCl, the charge efficiency of protamine increased by around 
30% from 0.74 (± 0.04) to 0.52 (± 0.05) while C22G1DAPMA improved by around 50% 
from 0.58 (± 0.02) to 0.28 (± 0.05). These values suggest that C22G1DAPMA is a more 
robust binder than protamine in the presence of 150 mM NaCl and may hint at some 
type of ‘ligand sacrifice’ behaviour where the flexibility of the self-assembled system 
allows one or more arms within the assembly to sacrifice binding interactions in order 
to shield the remaining binding interactions from disruption by salt. Such effects have 
previously been reported for structurally related systems.
295
 
4.2.1.2 Modelling Heparin Binding  
In an attempt to rationalise the improved performance of C22G1DAPMA relative to 
protamine in the presence of more electrolytically rich conditions, a molecular dynamics 
modelling study was carried out in collaboration with Professor Sabrina Pricl at 
University of Trieste, Italy. The simulations allowed the assembly structure of 
C22G1DAPMA to be visualised, Figure 4.4, and assisted in assessing sizes and 
properties of the binding aggregates.  
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Figure 4.4 – Mesoscale (top) and atomistic (bottom) representations of C22G1DAPMA 
in the presence (left) and absence (right) of 150 mM NaCl.  
The modelling suggested the formation of C22G1DAPMA aggregates with markedly 
different sizes in the presence and absence of 150 mM NaCl. The simulations predicted 
that in the absence of NaCl, C22G1DAPMA might be expected to form aggregates 
containing 11 (± 3) individual molecules with an approximate aggregate diameter of 6.3 
(± 0.5) nm. In the presence of 150 mM NaCl, a larger aggregate of 9.3 (± 0.1) nm in 
diameter containing around 24 (± 1) molecules might be expected. Based on these 
predictions, the aggregate in the presence of salt would be expected to have 96 (± 4) 
cationic charges compared to only 44 (± 12) in the absence. These predictions are 
significant, as the larger size of C22G1DAPMA assemblies in the presence of salt may 
go some way to accounting for the relative improved performance of C22G1DAPMA 
over protamine in the presence of greater electrolytic competition. Other authors have 
previously observed size increases for micellar aggregates in response to an increase in 
ionic strength, with the change thought to be due to a combination of charge screening 
and an enhancement of the hydrophobic effect.
306,307
  
In order to experimentally validate the predictions made computationally, dynamic light 
scattering (DLS) was carried out on aggregates of C22G1DAPMA in the solution phase 
both in the presence and absence of 150 mM NaCl. The data, shown in Table 4.2, was 
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in complete agreement with the modelling predictions, as the presence of 150 NaCl 
increased the observed micelle diameter by ca. 3 nm.  
Table 4.2 – Experimental solution-phase diameters of C22G1DAPMA aggregates, as 
measured by DLS. 
Media Diameter / nm Peak Width / nm 
10 mM Tris HCl (5.8 ± 0.5) 2.0 
10 mM Tris HCl, 150 mM NaCl (9.1 ± 0.1) 2.1 
In addition to allowing the binding of C22G1DAPMA to heparin in the absence and 
presence of salt to be visualised, Figure 4.5, the molecular simulations were also able to 
give insight into the relative efficiency of each binding interaction, Table 4.3. In the 
absence of salt, 18 of the 44 cationic charges (41%) per assembly appeared to be 
interacting with heparin (Qeff), while the total effective free energy of binding (∆𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓 ) 
was predicted at –30.2 (± 1.0) kcal mol-1. The effective charge normalized free energy 
of binding, that is the average energy of each binding group-heparin interaction 
(∆𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff), was therefore calculated as –1.68 (± 0.19) kcal mol
-1
. In the presence of 
salt, 32 of the 96 cationic charges (33%) shared the effective free energy of 
binding -65.0 (± 1.6) kcal mol
-1
, with each charge therefore contributing –2.03 (± 0.08) 
kcal mol
-1
. These data suggest not only that the C22G1DAPMA aggregates are larger in 
the presence of 150 mM NaCl, but also that each individual binding charge within the 
assembly interacts with heparin in a more efficient manner. As discussed in Chapter 3, 
the employment of each binding charge in protamine is relatively inefficient in 
comparison.      
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Figure 4.5 – Atomistic models of self-assembled C22G1DAPMA (top) or protamine 
(bottom) binding heparin in absence (left) and presence (right) of 150 mM NaCl.  
Table 4.3 – Modelling interpretations of effective charges per binder (Qeff), effective 
free binding energy (∆𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
) and effective charge-normalised free energy of binding 
(∆𝐺𝑏𝑖𝑛𝑑
𝑒𝑓𝑓
/Qeff) for C22G1DAPMA and protamine. 








/ kcal mol-1 
0 mM 
NaCl 
C22G1DAPMA (18 ± 2) −(30.2 ± 1.0) −(1.68 ± 0.19) 
Protamine (10 ± 1) −(2.60 ± 0.30) −(0.26 ± 0.04) 
150 mM 
NaCl 
C22G1DAPMA (32 ± 1) −(65.0 ± 1.6) −(2.03 ± 0.08) 
Protamine (12 ± 1) −(3.96 ± 0.41) −(0.33 ± 0.04) 
One of the limitations of the molecular dynamics simulations is that in each case only 
one single binder molecule and one single heparin polysaccharide can be studied 
together, and this situation is of course not totally representational of reality. Simulation 
of the true solution phase picture would involve representing interactions between each 
single C22G1DAPMA assembly and multiple heparin chains, which is prohibitively 
computer-time-intense. In lieu of this, dynamic light scattering (DLS) was employed to 
probe the aggregate size in solution at different binder:heparin ratios. DLS studies were 
carried out in collaboration with Dr Marcelo Calderon at Freie Universität Berlin, 
Germany. As shown in Table 4.4, as the relative amount of heparin to C22G1DAPMA is 
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increased, the aggregate sizes in solution also increased. This observation supports the 
proposal that individual binder micelles interact with multiple heparin polysaccharide 
chains. Such aggregation processes are well known when protamine binds heparin.
264,265
  
Table 4.4 – DLS sizes observed for C22G1DAPMA in the absence and presence of 
different amounts of heparin. 
  
Concentration               
/ mg mL-1 
Molar 
Ratio 




Heparin 0.33 - 8.7 0.316 
C22G1DAPMA 1 - 9.0 0.641 
C22G1DAPMA + Heparin - 0.1 : 1 13.0 0.276 
C22G1DAPMA + Heparin - 0.5 : 1 68.9 0.155 
C22G1DAPMA + Heparin - 1 : 1 Too big - 
 
4.2.1.3 Studying Self-Assembly Effects 
To this point, the multivalent binding of C22G1DAPMA has been assumed to be the 
result of a self-assembly event producing the cationic heparin binding ligand array 
cartooned earlier in Figure 4.2. In an attempt to prove this, a non-assembling negative 
control molecule was synthesised. Specifically, as shown in Scheme 4.1, a propyne-
functionalised intermediate, generated during the preparation of C22G1DAPMA, was 
subjected to a Boc-deprotection using HCl gas in methanol to afford partial binder 
PG1DAPMA 4.1 in a good yield, with no additional requirement for purification. The 
disappearance of characteristic signals at 1.40 ppm in 
1
H and 79 ppm and 28 ppm in 
13
C 
NMR spectra respectively confirmed effective removal of the protecting group. 
Compound 4.1 was expected to mimic the monomeric ligand array of individual 
C22G1DAPMA molecules and therefore provide a suitable comparison against the self-
assembling system.   
 
Scheme 4.1 – Preparation of negative control molecule PG1DAPMA. 
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PG1DAPMA was tested for heparin binding ability using the Mallard Blue heparin 
binding assay in salt and buffer and was shown to be unable to displace MalB to any 
significant extent. The respective performances of PG1DAPMA, C22G1DAPMA and 
protamine can be seen in the heparin binding curves plotted in Figure 4.6.   
 
Figure 4.6 – Heparin binding curves for PG1DAPMA, C22G1DAPMA and protamine 
from MalB heparin binding assay.  
These data confirm the previous observation that self-assembly of C22G1DAPMA 
drives the multivalent heparin binding interactions as suggested by the earlier TEM 
images, Figure 4.3, where the observed integrated nanostructure appeared to contain 
intact micelles. Similarly, a new experimental determination of the C22G1DAPMA 
CAC in the presence of heparin demonstrated aggregate formation was not prevented by 
the presence of the polysaccharide, although the CAC value did increase to ca. 14 µM 
suggesting some micelle destabilisation may have occurred. Nonetheless, aggregation of 
C22G1DAPMA in the presence of heparin was clearly evident. 
4.2.2 Heparin Binding in Clinically Relevant Conditions 
4.2.2.1 Heparin Binding in Serum 
Having demonstrated the ability of C22G1DAPMA to bind heparin more efficiently than 
protamine under electrolytically competitive conditions, the next challenge was to 
examine performance under more biologically relevant conditions. To do this, 
Chapter 4 – SAMul Binders I: DAPMA 
135 
C22G1DAPMA was tested using the previously described Mallard Blue assay with 
heparin delivered in 100% human serum. The data are shown in Table 4.5. 
Table 4.5 – Heparin binding data from MalB assay with heparin delivered in 100% 
human serum. 
Compound EC50 / μM CE50  
Dose           
mg/100IU 
PG1DAPMA Binding too weak 
C22G1DAPMA (25.9 ± 1.6) (0.96 ± 0.06) (0.79 ± 0.05) 
Protamine (3.51 ± 0.12) (0.79 ± 0.03) (0.49 ± 0.02) 
The data show that in the presence of serum, the binding efficiency of both protamine 
and C22G1DAPMA decreased, although of these two systems, protamine was least 
adversely affected. The CE50 of protamine increased from 0.52 (± 0.05) in the absence 
of serum to 0.79 (± 0.03) in its presence, and this performance difference can be 
somewhat accounted for by consideration of off-target interactions, for example 
between protamine and charged patches on serum proteins. Relatively, C22G1DAPMA 
was affected to a greater extent with CE50 increasing from 0.28 (± 0.05) to 0.96 (± 
0.06). Clearly, serum exerted a more disruptive effect on the ability of C22G1DAPMA 
to bind heparin in a multivalent manner than it did for protamine. A likely explanation 
could be the disruption of the micellar binding arrays by hydrophobic serum 
components such as albumin or globulin proteins.
308-310
 Interestingly, C22G1DAPMA 
may inadvertently be well optimized for disruption by serum as long straight alkyl 
chains are known to interact effectively with albumins, and interaction of the 
hydrophobic unit in this way could be envisaged as ‘pulling monomers out’ of the 
micellar ligand array.
311
 In order to probe this disruption mechanism, attempts were 
made to saturate serum albumin binding sites by introduction of 1-docosanol prior to 
carrying out the heparin binding assay although the insolubility of the fatty alcohol 
made these attempts unsuccessful. 
The heparin binding performance of C22G1DAPMA was found to be acutely sensitive 
to the presence of serum. For example, as shown in Figure 4.7, the disruptive effects of 
heparin delivery in 0 – 10% human serum were roughly linear when delivered into a 
cuvette containing a fixed amount of binder. Interestingly, the disruption caused by 
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delivery in 10% human serum found to be broadly equivalent to that when heparin was 
delivered in 100% human serum.  
 
Figure 4.7 – Measured absorbance for heparin delivered into solution of 
C22G1DAPMA at a (+ : –) = 0.67 in 0 – 10 % human serum.  
Whilst the micellar assemblies of C22G1DAPMA appeared to be somewhat disrupted in 
the presence of serum, the inability of PG1DAPMA to displace MalB from heparin 
under these conditions, Table 4.5, nonetheless suggested that a significant amount of 
C22G1DAPMA assemblies remained intact, or in other words, self-assembly was not 
being completely switched-off by the presence of serum. In order to examine this 
further, our collaborators led by Dr Marcelo Calderon at Freie Universität Berlin, 
Germany, used dynamic light scattering (DLS) to monitor the size of a binder-heparin 
complex over time in the presence of albumin. As shown in Table 4.6, the aggregates 
decreased in size over time, suggesting some destabilization of the assemblies occurred, 
but the aggregates clearly did not completely disassemble and heparin binding was not 
completely switched-off. This retention of heparin binding ability, as indicated by 
successful displacement of 50% MalB during the assay motivated us to test 
C22G1DAPMA under even more challenging clinically relevant conditions.   
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Table 4.6 – DLS sizes observed for C22G1DAPMA-heparin aggregates in the absence 
and presence of albumin (1 mg mL
-1








 + Heparin 0.5 : 1 68.9 0.155 
 + Heparin + albumin 0.5 : 1 62.6 0.272 
 + Heparin + albumin (after 30 min) 0.5 : 1 55.9 0.220 
 
4.2.2.2 Plasma Clotting Assays 
Despite being more adversely affected through disruption by hydrophobic serum 
components than covalent protamine, the non-covalent assemblies of C22G1DAPMA 
still exhibited impressive heparin binding ability (CE50 < 1). Combined with the other 
advantages of a SAMul approach, this suggested clinical potential. To that end, 
C22G1DAPMA was tested for its ability to neutralise heparinized plasma samples. 
As insightful as the plethora of available heparin binding assays can be, the ultimate test 
of a potential heparin rescue agent is its ability to reverse the anti-coagulant effect of 
heparin in a clinically relevant sample. Plasma clotting assays such at the PT assay, 
which monitors the prothrombim clotting time of the ‘extrinsic’ clotting pathway 
originating from tissue damage, and the aPTT assay, which monitors the activated 
partial thromboplastin time of the ‘intrinsic’ clotting pathway originating from surface 
contact trauma are two widely employed clinical assays.
312
 Practically, each of these 
assays involves measuring the time taken for a heparinized sample of plasma, which is 
extracted from blood by centrifugation in the clinic, to clot. A longer clotting time is 
indicative more anti-coagulation and higher heparin levels. For the present study, 
C22G1DAPMA was tested in each of these assays for its ability to reverse anti-
coagulation. These experiments were carried out in the laboratory of Professor Jeremy 
Turnbull at University of Liverpool, UK.   
Firstly, a sample of human plasma was taken and allowed to clot in the absence of 
heparin or binder. The sample clotted in 35.7 (± 0.7) seconds in the aPTT assay and 
12.8 (± 0.8) seconds in the PT assay. When this procedure was repeated in the presence 
of heparin, clotting was not observed in either assay as heparin exerted its anticoagulant 
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effect. C22G1DAPMA was then introduced into these samples at an appropriate dose 
and clotting was re-established, indicating functional heparin reversal. Practically, 
samples in the aPTT assay contained 2.5 units of heparin and those in the PT assay 
contained 5 units, while both assays had C22G1DAPMA dosed at 0.79 mg/100IU. The 
results are shown in Table 4.7.  
Table 4.7 – Plasma clotting data for C22G1DAPMA in aPTT and PT assays. 
Compound 
Clotting Time / s 
aPTT Assay PT Assay 
Plasma only (35.7 ± 0.7) (12.8 ± 0.8) 
+ Heparin No clot No clot 
.+ C22G1DAPMA (81.8 ± 4.6) (13.1 ± 0.4) 
The heparin rescue performance of C22G1DAPMA in these clinically relevant heparin 
neutralization assays is highly significant. In particular, the re-establishment of a 
clotting time of ca. 13 seconds in the PT assay indicates full heparin neutralization, 
while the slight extension of the clotting time in the aPPT assay may be an artefact of 
the previously observed disruption of the SAMul system by plasma components such as 
albumins. Importantly, despite this perturbation of the binding nanostructures, they 
remained operational in reversing the anti-coagulant effect of heparin. Clearly, if the 
stability of the nanostructures in the presence of serum can be enhanced, SAMul 
systems such as C22G1DAPMA could have high clinical potential as functional heparin 
rescue agents.  
4.2.3 Degradation Studies 
Heparin binding ability is not the only important consideration when designing a 
heparin rescue agent of clinical relevance. Degradability and the potential for toxicity 
are important factors. As mentioned in the introduction to this Chapter, degradation of 
SAMul nanostructures can occur either through straightforward disassembly of the 
nanoparticles or through triggered bond cleavage. An ester group was specifically 





 had established ester hydrolysis as an effective way of 
achieving temporary multivalency and minimizing the biopersistence of multivalent 
ligand arrays. Hydrolysis of the ester linkage in C22G1DAPMA was expected to 
Chapter 4 – SAMul Binders I: DAPMA 
139 
disconnect the hydrophobic and hydrophilic regions thereby negating self-assembly and 
‘switching off’ the multivalent ligand array. 
The degradation of C22G1DAPMA was probed using two complementary approaches.     
4.2.3.1 Nile Red Release Assays 
To probe the disassembly of C22G1DAPMA, a Nile Red (NR) release assay was carried 
out. NR is a fluorescent hydrophobic dye, which exhibits high fluorescence output when 
dissolved or encapsulated in a hydrophobic environment such as the interior of a 
micelle, while fluorescence is readily quenched in aqueous conditions.  
Practically, a solution of C22G1DAPMA was made up at a concentration above the 
CAC – namely 50 µM – and an aliquot of NR was added. Following irradiation at 550 
nm, the fluorescence intensity at 635 nm was measured at short time intervals over a 35 
hour period to afford the degradation curve represented by solid circles in Figure 4.8.  
 
Figure 4.8 – Fluorescence intensity of NR in PBS buffer over time in the presence of 
C22G1DAPMA in the absence (solid circles) and presence (open circles) of heparin. 
The degradation curve indicated that NR was released from the C22G1DAPMA 
assemblies with a half-life of approximately 7 hours in PBS buffer, although it is not 
possible to state unequivocally whether NR release is due to micelle disassembly, 
molecular degradation, or a combination of both. Interestingly, and importantly, when 
the experiment was repeated in the presence of heparin, NR release was significantly 
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retarded with the micelles appearing to remain almost completely intact after 24 hours. 
This outcome suggested NR release in the absence of heparin may be caused primarily 
by molecular degradation, as this would correlate with the previously mentioned works 
of Smith and Fréchet. Specifically, interaction of the surface binding groups with 
heparin can be thought of as ‘tying up’ the arms of C22G1DAPMA, preventing them 
folding back on themselves to intramolecularly catalyse the hydrolysis of the ester 
group, thereby leading to the enhanced stability and retention of NR in the presence of 
heparin.  
This degradation profile is pharmacologically interesting as once C22G1DAPMA has 
established interactions with heparin, thereby neutralizing anticoagulancy, the complex 
formed appeared to remain stable. This would permit the binder-heparin aggregates to 
be metabolized as one species, potentially in a similar process to that of heparin-
protamine aggregates.
316
 Meanwhile, excess C22G1DAPMA would degrade, thereby 
limiting biopersistence and toxicity.   
Heparin re-bound is a widely acknowledged problem associated with heparin therapy, 
and particularly heparin rescue, whereby the release of plasma-protein-bound heparin 
back into the systemic bloodstream confers a second anticoagulation event, some time 
after initial neutralization.
109
 Although used clinically, protamine is not well suited for 
dealing with heparin re-bound owing to its rapid in vivo half-life of ca. 8 minutes.
104
 
Consequently, in the event of re-bound, a second protamine dose is often required as the 
toxicity problems associated with a larger initial dose preclude this ‘front-loading’ 
approach being an option.
103,104
 A ca. 7 hour half-life of unbound C22G1DAPMA may 
offer a suitable compromise between minimising overall biopersistence of cationicity 
and remaining present long enough to deal with any potential heparin rebound events, 
however it should be noted that the half-life of C22G1DAPMA in vivo may be 
significantly shorter than 7 hours due to the increased competition and effects of 
shear/flow processes. Despite conjecture in the literature, considerations of heparin re-
bound remain important.
106,108
      
4.2.3.2 Mass Spectrometric Studies 
To confirm that NR release over time was due to molecular degradation, a mass 
spectrometric degradation assay was carried out with the aim of identifying the 
evolution of molecular species over time. Practically, mass spectra of C22G1DAPMA 
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were obtained in the presence of a Gly-Ala dipeptide internal standard before and after 
incubation at 37°C for 24 hours.
69
 Degradation events were revealed through 
comparison of the relative amounts of different species against the non-degradable 
internal standard. The molecular species of interest, along with some example spectra 
are shown in Figure 4.9. 
As shown in Figure 4.9, at time zero, the molecular ions associated with C22G1DAPMA 
(m/z = 433 [M]
2+
 and 289 [M]
3+
) could be seen, along with some evidence of ester 
hydrolysis (alcohol, m/z = 408 [M]
1+
; carboxylic acid, m/z = 239 [M]
2+
). After 24 hours, 
the molecular ions for intact C22G1DAPMA had completely disappeared and the peaks 
for the ester hydrolysis products were dominant, along with a new signal corresponding 
to decarboxylation of the carboxylic acid hydrolysis product (m/z = 217 [M]
2+
). These 
data show degradation of C22G1DAPMA occurs under biologically relevant aqueous 
conditions at pH 7, and support the NR released in the previous assay being due to a 
triggered disassembly event induced by molecular degradation rather than an 
independent disassembly event. 
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 Figure 4.9 – Mass spectrometric degradation assay: observed species (top) after 0 
hours (middle) and 24 hours (bottom) incubation at 37 °C. 
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4.3 Conclusions and Future Work 
Following the preliminary studies from Smith and co-workers,
211
 the heparin binding 
ability of self-assembling system C22G1DAPMA was studied in the presence of more 
competitive and biologically relevant conditions using the Mallard Blue heparin binding 
assay. The results showed that introducing competitive electrolytes such as 150 mM 
NaCl to the system increased the apparent heparin binding efficiencies of both 
C22G1DAPMA and protamine. The performance improvement of the SAMul system 
over-and-above that of protamine was especially noteworthy. Molecular dynamics 
modelling revealed that introduction of salt into the assay triggered an enlargement of 
the self-assembled nanosystems formed by C22G1DAPMA, leading to an increased 
number of monomer units coming together to form each aggregate and, consequently, 
an increase in the number of cationic binding groups expressed at each assembly 
surface. Experimental DLS studies corroborated these suggestions by characterising 
larger aggregates in the presence of salt.  
The C22G1DAPMA system was also tested for heparin binding in the presence of 
human serum, where the relative performance was shown to decrease somewhat, 
becoming inferior to that of protamine. Hydrophobic serum components such as 
albumin proteins were shown to interfere with the aggregation and performance of 
C22G1DAPMA to some extent although, significantly, control experiments 
demonstrated the self-assembled nanosystem remained intact to some extent, as a non-
self-assembling control molecule was unable to interact with heparin in the presence (or 
indeed absence) of serum.  
Despite this disruption by serum proteins, C22G1DAPMA was shown to be effective at 
reversing the anticoagulant effect of heparin in clinically relevant PT and aPTT plasma 
clotting assays. This heparin neutralization performance is highly significant given the 
non-covalent nature of C22G1DAPMA assemblies, and the attractive advantages over 
similarly-sized covalent structures that this approach brings; for example, the relative 
simplicity of synthesis. 
In a final set of experiments, a Nile Red release assay was used to show that 
C22G1DAPMA degraded over a clinically interesting time scale, with a half-life of ca. 7 
hours. The same assay also demonstrated that the presence of heparin stabilized the 
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assemblies, making the overall degradation process potentially more appealing from a 
heparin re-bound perspective than protamine. A further mass spectrometric assay 
indicated degradation occurred through hydrolysis of the linker unit ester groups, 
validating the molecular design, and leading to disconnection of the hydrophobic and 
hydrophilic regions of binder molecule. Ultimately, this led to the desired ‘switching-
off’ of self-assembled multivalency.  
Future work in this area will focus on enhancing the stability of the self-assemblies 
formed in the presence of serum. This could be achieved by increasing the 
hydrophobicity of the aliphatic unit by, for example, introducing branching or dendritic 
character into the alkyl chain. Alternative approaches could target bio-derived 
hydrophobic units such as cholesterol-like steroid units or bile acids. Choosing a 
hydrophobic unit of biological origin may additionally reduce the potential for toxicity 
from the degradation products. Variation of the hydrophobic unit will additionally 
impact upon the geometry of the binder molecule, which may in turn affect the 
morphology of the assembly formed. Other modifications could include variation of the 
surface binding groups to examine the effects of different cationic ligands on heparin 
binding performance. Careful selection of the appropriate building blocks may permit 
both stability and morphology effects on SAMul heparin binders not only to be probed 
but also optimised.   
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5 Self-Assembling Multivalent Heparin Binders II: 
Lysine-containing systems 
5.1 Introduction 
The use of a self-assembled multivalent approach to binding biological targets has many 
advantages. As exemplified in Chapter 4, a SAMul approach allows: (i) the heparin 
binding ligand array to be generated spontaneously as a consequence of molecular self-
assembly; (ii) the individual building blocks to be relatively small and ‘drug-like’, well-
defined and easy-to-make; (iii) the SAMul activity to be switched off through 
disassembly which in turn can be triggered by predictable degradation of the individual 
building blocks. A further key advantage of this approach is that the system is highly 
tunable, making it relatively straightforward to change the heparin binding properties of 
the system, for example through simple synthetic modification of the surface groups. 
Following on from the C22G1DAPMA SAMul system presented in Chapter 4, it was 
decided to further investigate the success of this approach by modifying the molecular 
building blocks used. In particular, increasing the biomimetic character of the system 
became an aim with the hydrophilic heparin binding DAPMA groups identified as a 
potential region for modification. Much like in the design of Mallard Blue in Chapter 2, 
the manner in which proteins establish strong interactions with heparin was 
considered.
82
 From this consideration, the amino acid lysine was selected as a suitable 
alternative surface group to use in place of DAPMA.  
Much like DAPMA, lysine is able to interact effectively with heparin due to the two 
cationic charges within its structure. Alongside arginine – another cationic amino acid – 
lysine is present in a wide array of heparin binding proteins, including protamine.
82,100
 
This known heparin binding ability has led to lysine been incorporated into several 
noteworthy attempts to develop novel heparin rescue agents. For example, work on 
calix[8]arene systems by Cunsolo and co-workers, and foldamer systems in the group of 
DeGrado both demonstrated lysine to be amongst the most effective heparin binding 
groups studied.
200,202
 Within our system, the incorporation of an amino acid such as 
lysine in place of DAPMA may also reduce the potential for toxicity within our system, 
as well as tuning heparin binding performance.  
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In order for both lysine amine groups to be available for interaction with heparin in the 
final SAMul construct, the entire building block required a modest structural redesign. 
Specifically, the functional group connecting the surface group to the rest of the binder 
molecule was modified from a carbamate to an ester. This change was expected to 
increase the (bio)degradability of the system, potentially enhancing the pharmacological 
appeal of the system.  
As an amino acid, lysine also introduced a new variable to our SAMul approach which 
was not present within C22G1DAPMA: chirality. It was reasoned that chirality could 
prove to be an interesting property for this study as the binding target heparin is itself 
chiral. As mentioned in Chapter 1, the heparin polysaccharide is composed primarily of 
an α-1,4-linked D-glucosamine–L-iduronic acid disaccharide repeat unit and, indeed, the 
investigation of chirality effects with heparin is not new.
317
 Previous studies have shown 
heparin to be able to discriminate between a variety of chiral substrates. For example, 
several groups have used heparin as a chiral additive in capillary electrophoresis to 
enantiomerically separate underivatised drugs such as anti-malarials and anti-
histamines.
318-320
 It was proposed that heparin was able to chirally discriminate in this 
way due to a combination of ionic, hydrogen bonding and hydrophobic interactions with 
a specific arrangement of nitrogen containing aromatic heterocyclic or ionisable 
substituents.
318
 Other, more recent studies from the group of Rabenstein, showed a 
sequence of exclusively D amino acids interacted with heparin in exactly the same 
manner as the corresponding sequence of L amino acids.
321,322
 It was suggested that the 
specific spatial arrangement of lysine and arginine residues in this peptide sequence 
promoted heparin interaction, rather than the presence of an enantiomerically 
complementary structure to heparin.
321
  
Despite these studies, to the best of our knowledge, there has been no study in which the 
chirality of the heparin binding system was expressed at the surface of a self-assembled 
nanostructure. Indeed, there are no examples in which chirality effects in the binding of 
self-assembled nanostructures have been explored. To investigate this new area through 
the use of a more biomimetic SAMul design, an initial pair of lysine-containing target 
molecules was identified for synthesis. These target molecules, C22G1LLys and 
C22G1DLys, are shown in Figure 5.1. 
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Figure 5.1 – Target molecules C22G1LLys, C22G1DLys.          
5.2 Generation 1 Systems 
5.2.1 Synthesis of C22G1LLys and C22G1DLys 
The synthesis of the first generation (G1) structures C22G1LLys and C22G1DLys was 
achieved in a convergent manner. For the purposes of synthesis, the binder molecules 
were broken up into three segments – the aliphatic tail, ester-rich linker unit and lysine 
surface group, Figure 5.2 – which were each prepared separately. The linker unit was 
then functionalized with two suitably-protected lysine surface groups before the 
aliphatic tail was installed to afford, after removal of the remaining protecting groups, 
the binder target molecules. A negative control molecule lacking hydrophobic 
functionalisation was also synthesised to allow the effects of self-assembly to be 
quantified for our new system.  
 
Figure 5.2 – The three distinct components of G1 target molecules C22G1LLys and 
C22G1DLys, where ‘PG’ represents a protecting group. 
5.2.1.1 Preparation of the aliphatic tail211 
In line with the previous work described in Chapter 4, the hydrophobic unit of the new 
target molecules took the form of a twenty-two carbon n-alkyl chain. The same 
methodology applied in the preparation of C22G1DAPMA was used here to prepare the 
hydrophobic unit for connection to the binder scaffold. Specifically, as shown in 
Scheme 5.1, commercial fatty alcohol 1-docosanol (aka. behenoyl alcohol) was reacted 
with methanesulfonyl chloride in the presence of triethylamine to produce mesylate 5.1 
in a good yield, characterized by the appearance of a methyl signal at 3.00 ppm in the 
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1
H NMR spectrum.  Refluxing 5.1 with sodium azide in DMF successfully transformed 
the alkyl-mesylate into the desired 1-azidodocosane (aka. behenoyl azide) 5.2 in a good 
yield with no need for further purification. Once in hand, species 5.2 was ready for 
connection to the rest of the binder scaffold at a later stage using copper(II) mediated 
click chemistry.  
 
Scheme 5.1 – Synthesis of alkyl hydrophobic tail unit. 
5.2.1.2 Preparation of the lysine surface group 
Lysine possesses two primary amine groups and a carboxylic acid within its structure. 
In order to facilitate connection of the lysine carboxylic acids to the alcohol termini of 
the linker unit, the amine groups required suitable protection to avoid unwanted side 
reactions such as lysine polymerization. The tert-butyloxycarbonyl (Boc) protecting 
group was identified as suitable owing to its acid-lability, as its removal in the final step 
would not expose the ester linkages present in the final binder molecule to nucleophilic 
or basic conditions. This protection strategy for lysine is well-known and has been 
widely utilised previously by, amongst others, Smith and co-workers.
323,324
 As shown in 
Scheme 5.2, LLys(Boc)2 5.3 or DLys(Boc)2 5.4 can be prepared in a good yield by 
treatment of lysine with di-tert-butyl-dicarbonate and sodium hydroxide in THF/water.  
 
Scheme 5.2 – Preparation of LLys(Boc)2 or DLys(Boc)2. 
The lysine carboxylic acid group was then activated to increase its reactivity to 
nucleophilic attack. This activation was found to be necessary as when not activated, 
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reaction with the alcohol termini of the linker unit was found to be extremely slow or in 
some cases non-existent. For example, DCC-mediated, TBTU-mediated and general 
base-catalysed esterification conditions were all unable to successfully furnish the linker 
unit with lysine surface groups 5.3 or 5.4. N-hydroxysuccinimide was chosen as a 
suitable activating group and installed in a good yield through reaction with DCC in 
DMF to produce activated lysine species 5.5 and 5.6, which were then carried forward 
in the synthesis.      
5.2.1.3 Preparation of G1 linker group 
The linker unit is derived from the commercial starting material 2,2-
bis(hydroxymethyl)propionic acid (aka. bis-MPA). Ultimately, the lysine surface groups 
were connected to the alcohol functionalities of bis-MPA but, initially, the carboxylic 
acid of bis-MPA had to be converted to an alkyne to prepare the molecule up for 
installation of the aliphatic tail via ‘click’ methodology. To do this, the methodology of 
Sharpless and Hawker was applied.
325
 Firstly, the two alcohol groups of bis-MPA were 
protected as acetal 5.7 in a moderate yield using 2,2-dimethoxypropane in the presence 
of a p-toluenesulfonic acid catalyst and acetone. The appearance of two methyl signals 
at 1.45 and 1.41 ppm in the 
1
H NMR spectrum indicated successful protection. The 
remaining carboxylic acid functionality of 5.7 was then coupled to another molecule of 
itself using DCC to mediate the process and generate the more reactive symmetric 
anhydride 5.8 in a reasonable yield. Anhydride 5.8 was promptly reacted with propargyl 
alcohol to afford propyne-functionalised species 5.9 in a near-quantitative yield. 
Appearance of a 
1
H NMR triplet signal at 2.47 ppm indicated successful installation of 
the alkyne functionality. Subsequent deprotection of 5.9 under acidic condition unveiled 
the alcohol groups in a good yield to afford desired linker 5.10.  The synthetic scheme is 
shown in Scheme 5.3. 
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Scheme 5.3 – Synthetic scheme for preparation of G1 linker unit.325  
5.2.1.4 Connecting the pieces 
With the three components of the binder in hand, connection could now proceed. 
Firstly, lysine-succinimide-ester 5.5 or 5.6 was coupled to G1-linker 5.10 in a base 
catalysed esterification reaction to generate protected partial-binder 5.11 or 5.12 
respectively in a reasonable yield, after purification by gel permeation chromatography 
in 95:5 DCM:methanol. At this stage, a small amount of L-partial binder 5.11 was 
deprotected using HCl gas in methanol to afford negative control molecule 5.13 for use 
as a self-assembly comparison tool in subsequent studies. Next, the hydrophobic azide-
containing building block was introduced into the system. The pre-prepared 1-
azidodocosane 5.2 was reacted with alkyne functionalized components 5.11 or 5.12 in a 
copper(II) catalysed ‘click’ reaction to generate the still-protected final binders 
molecules 5.14 and 5.15 in good yields, after purification by gel permeation 
chromatography in 100% DCM. The appearance of a 
1
H NMR signal at 8.06 ppm was 
diagnostic of presence of the 1,2,3-triazole moiety. In a final step, the acid-labile Boc-
protecting groups were removed in an excellent yield using HCl gas in methanol to 
afford the target molecules C22G1LLys 5.16 and C22G1DLys 5.17. The synthetic scheme 
showing the connection of the component units is shown in Scheme 5.4. 
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Scheme 5.4 – Synthetic scheme showing connection of the component parts to generate 
PG1LLys, C22G1LLys and C22G1DLys. 
With the two target molecules in hand, circular dichroism spectroscopy was used to 
probe the chiral character of the final products to ensure amino acid chirality had been 
successfully preserved throughout the synthesis. As can be seen in Figure 5.3, at 
concentrations of 10 mM, the molar ellipticity for the two systems is effectively equal 
and opposite. This indicates that the two target molecules are of approximately equal 
enantiopurity, and crucially that chirality has not been scrambled during synthesis.   
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Figure 5.3 – Circular dichroism spectra of target molecules C22G1LLys and C22G1DLys 
(10 mM in methanol) indicating opposing chirality. 
Now in hand, the G1 target molecules were interrogated for their ability to self-
assemble into nanosized aggregates and subsequently bind heparin. 
5.2.2 Self-Assembly Studies 
5.2.2.1 Nile Red Data 
The amphiphilic design of the G1 lysine-containing systems should promote molecular 
self-assembly in aqueous conditions. The hydrophobic aliphatic units are expected to 
assemble together on the interior of the formed aggregate, leading to the heparin binding 
groups being displayed at the surface. In order to experimentally probe this, and to 
determine an approximate critical aggregation concentration (CAC), a Nile Red (NR) 
encapsulation assay was used. NR is a hydrophobic dye, Figure 5.4, which exhibits a 
fluorescence signal at 635 nm following irradiation at 550 nm.
326
 When ‘free’ in 
aqueous solution, this NR fluorescence signal is readily quenched, for example by 
nearby solvent molecules, while when solubilized in a hydrophobic environment, such 
as the interior of a micelle, the signal remains intense. As the concentration of self-
assembling material C22G1LLys or C22G1DLys increases across a titration range, the 
point at which aggregates form is indicated by a sharp rise in fluorescence intensity (If) 
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at 635 nm.The Nile Red encapsulation assay has been widely used in this manner by, 






Figure 5.4 – Chemical structure of hydrophobic dye probe, Nile Red (NR) 
The data from the NR encapsulation assay for PG1LLys, C22G1LLys and C22G1DLys 
are shown numerically in Table 5.1 and graphically in Figure 5.5.  
Table 5.1 – Nile Red encapsulation assay data for PG1LLys, C22G1LLys and 
C22G1DLys. 
G1 Systems CAC / μM 
P-G1-L-Lysine N/A 
C22-G1-L-Lysine (29 ± 9) 
C22-G1-D-Lysine (27 ± 13) 
 
Figure 5.5 – Nile Red encapsulation curves for C22G1LLys and C22G1DLys. 
Both C22G1LLys and C22G1DLys were able to assemble into nanostructures at ca. 28 
µM. When compared directly against C22G1DAPMA in Chapter 4 (CAC of ca. 4 µM), 
it can be seen that these lysine-containing systems have higher CAC values. This may 
suggest that the increased size-in-space of the lysine residues at the surface somewhat 
hinders the formation of the assembly. Additionally, the lysine-containing systems may 
form assemblies composed of a greater number of individual monomer building blocks 
than the DAPMA system. Nonetheless it is clear from the data that chirality does not 
have any meaningful impact on CAC values observed for these systems, and nor would 
it be expected to, given that chirality should only influence the ‘handedness’ of the 
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resulting assemblies, rather than the specifics of formation/morphology. Importantly, 
the negative control molecule PG1LLys was unable to assemble up to concentrations of 
1 mM, demonstrating the self-assembly process is indeed driven by the amphiphilic 
nature of the structure conferred by the presence of the aliphatic tail.  
The data in Table 5.1 are calculated from three runs of this self-assembly assay, with 
error values reported as one standard deviation of the triplicated data. These relatively 
large error values are thought to arise from a degradation event occurring on the 
timescale of the assay. This is discussed further in Section 5.2.5.  
Whilst the NR encapsulation data convincingly suggests C22G1LLys and C22G1DLys 
self-assemble in aqueous solution, the data are unable to provide information about the 
size or morphology of the assemblies formed. To that end, TEM imaging was carried 
out.  
5.2.2.2 TEM Images 
Transmission Electron Microscopy (TEM) imaging was used in order to observe the 
self-assembled morphologies of C22G1LLys and C22G1DLys. For the purpose of 
imaging, solutions were prepared at concentrations of 200 µM (i.e. above [CAC]) to 
ensure binders were present in their assembled form. Each binder was also imaged in 
the presence of heparin. Heparin was introduced to the samples at a charge ratio (+ : –) 
of 2 as, under this concentration regime, both binders exhibited significant interaction 
with heparin, see section 5.2.3. Once prepared, aliquots of each solution were loaded on 
a formvar grid, negatively stained with uranyl acetate and allowed to dry before 
imaging. Solutions were prepared in clean water as the presence of buffer or other 
electrolytes are known to interfere with the imaging process. The images for C22G1LLys 
in the absence and presence of heparin are shown in Figure 5.6 and Figure 5.7 
respectively, while the equivalent images for C22G1DLys are shown in Figure 5.8 and 
Figure 5.9 respectively. The observations are discussed below. 
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Figure 5.6 – TEM image of 200 µM C22G1LLys (scale bar: 50 nm).  
 
Figure 5.7 – TEM image of 200 µM C22G1LLys in the presence of heparin (scale bar: 
100 nm).  
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Figure 5.8 – TEM image of 200 µM C22G1DLys (scale bar: 50 nm).  
 
Figure 5.9 – TEM image of 200 µM C22G1DLys in the presence of heparin (scale bar: 
100 nm).  
As can be seen in both Figure 5.6 and Figure 5.8, each of the binders C22G1LLys and 
C22G1DLys assemble into small spherical objects which decorate the grid in a uniform 
manner. This is suggestive of micellar aggregation similar to that seen for the DAPMA 
system in Chapter 4. Each aggregate has an approximate diameter of ca. 7 nm, which is 
comparable to the size of the earlier system. In the heparin-containing samples shown in 
Figure 5.7 and Figure 5.9, the larger shaped objects are assigned to be integrated binder-
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heparin aggregates, with the smaller, spherical patterning recognized as the SAMul 
binders distributed throughout the heparin chains. There are clearly some meaningful 
interactions between the heparin and nanoscale binder assemblies as the micelles appear 
organized into a pattern not dissimilar to the beads-on-a-string motif previously 
observed by Smith and co-workers.
211
 
One of the limitations of using TEM to characterize the morphology of the SAMul 
aggregates in this way is that only dried samples can be imaged. Micelles (or other 
aggregates) exist primarily in the solution phase and so dynamic light scattering 
measurements (DLS) were carried out in collaboration with Dr Marcelo Calderon at 
Freie Universität Berlin to measure the solution-phase size of C22G1LLys and 
C22G1DLys. Each binder was measured under two different sets of electrolytic 
conditions: 10 mM Tris HCl, and the same conditions additionally endowed with 150 
mM NaCl. The results are shown in Table 5.2. 
Table 5.2 – DLS data for C22G1LLys and C22G1DLys under different electrolytic 
conditions. 
Compound 
Average Diameter / nm 
10 mM Tris HCl 
only 
10 mM Tris HCl, 
150 mM NaCl 
C22-G1-L-Lysine (7.6 ±  0.3) (9.0 ±  0.2) 
C22-G1-D-Lysine (7.8 ±  0.2) (9.0 ±  0.2) 
In the presence of 10 mM Tris HCl, the DLS results show each of C22G1LLys and 
C22G1DLys to form aggregates which are ca. 7.7 nm in diameter. This sizing correlates 
well with the TEM imaging. When the conditions are more electrolytically rich, the 
aggregates form larger aggregates with diameters of ca. 9 nm. This increase in size with 
increasing electrolyte concentration is analogous to the results observed for 
C22G1DAPMA in Chapter 4 and is thought to be due to a combination of charge 
screening and an enhancement of the hydrophobic effect.
306,307
     
5.2.3 Heparin Binding in Competitive Conditions  
The compounds PG1LLys, C22G1LLys and C22G1DLys were then tested for their ability 
to bind heparin in competitive conditions using the Mallard Blue heparin binding assay 
described in Chapter 3. As before, the data are reported in terms of charge excess at 
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50% MalB displacement (CE50), binder concentration at 50% MalB displacement 
(EC50) and effective dose (raw amount of binder required to neutralise 100 IU heparin). 
The data are presented in Table 5.3  with the binding curves shown in Figure 5.10.    




EC50 / μM CE50  Dose / mg 
Propyne-G1-L-Lysine Not achieved - binding too weak 
C22-G1-L-Lysine (52 ± 10) (1.94 ± 0.38) (1.45 ± 0.29) 
C22-G1-D-Lysine (30 ± 5) (1.13 ± 0.19) (0.85 ± 0.14) 
 
Figure 5.10 – Heparin binding curves for PG1LLys, C22G1LLys and C22G1DLys.  
The data shows PG1LLys is unable to displace MalB from heparin, as indicated by the 
binding curve remaining proximal to the baseline throughout titration. This is an 
interesting observation as each PG1LLys molecule (433 Da, 4+) is not dissimilar in size 
and charge to MalB (545 Da, 5+) yet negligible MalB displacement is observed, even 
when PG1LLys is present in excess.  In addition to behaving as a negative control for 
self-assembly, the PG1LLys data additionally reinforces just how optimised the charge 
organisation and crescent shape of MalB must be.  
With the aliphatic tail in place the heparin binding ability of the system increased 
significantly. Clearly, the multivalent binding of C22G1LLys is a direct result of 
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molecular self-assembly as each individual molecule possesses the same number of 
cationic charges as PG1LLys yet is now able to displace MalB from heparin; a clear 
SAMul effect. Despite this improvement over the negative control molecule, the heparin 
binding of C22G1LLys is not especially charge efficient. The data shows 1.94 (± 0.38) 
times as much cationic charge as anionic charge must be present to displace 50% of 
MalB from heparin. At this point the effective concentration of C22G1LLys is 52 (± 10) 
µM – well above the CAC value – and so it can confidently be asserted that the binder 
is operating in micellar form. The effective dose of C22G1LLys is 1.45 (± 0.29) mg per 
100IU heparin, which is relatively high compared to previously tested systems.
102,328
 
Nonetheless, C22G1LLys is another exponent of self-assembled multivalency.   
C22G1DLys, meanwhile, is able to achieve 50% MalB displacement with a charge 
efficiency of 1.13 (± 0.19) at an effective concentration of 30 (± 5) µM, leading to an 
effective dose of 0.85 (± 0.14) mg per 100IU. Again, these data suggest C22G1DLys is 
operating in micellar form. These data are very interesting because C22G1DLys utilizes 
its charges almost twice as efficiently as C22G1LLys, with only 59% as much cationic 
binder charge being required to displace half of the MalB from heparin. Despite the 
sizeable uncertainty values associated with each parameter (the origins of this are 
discussed below), the difference between enantiomers is statistically significant; that is 
to say ‘real’.  
It must be noted that the data presented in Table 5.3 are calculated from a single, albeit 
averaged, point during the titration: that at which exactly 50% MalB has been displaced 
from heparin. As such, they only provide a limited window of insight into the overall 
binding process. Consideration of the full binding curves in Figure 5.10 is more 
informative and provides insights into the binding mode of the systems. The respective 
lineshapes of C22G1LLys and C22G1DLys are essentially identical over the first period 
of titration up to charge ratio ca. 0.65, after which the two lines diverge, almost 
mirroring each other in shape as amount of binder and cationic charge increases. This 
may indicate that heparin binding interactions are first established between heparin and 
the outermost terminal amines of the binder and that only in the presence of sufficient 
heparin do the α-amines, located 5 bonds from the binder surface, need to become 
involved in the interaction with heparin. These α-amines are attached directly to the 
lysine chiral centres and so it follows that the observed line shape divergence appears to 
relate to these sites becoming involved in binding interactions. Importantly, this 
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observation suggests that the spatial arrangement of cationic charge, and not just 
charge-density, is an important consideration for binding heparin with these SAMul 
systems as the chirality is the only difference between C22G1LLys and C22G1DLys. This 
is particularly noteworthy as is contradicts the previously mentioned observations of 
Rabenstein, which suggested that only charge density played a significant role.
321
 
Indeed we reason that these observations are of significance for all chemists involved in 
micellar or nanostructure binding events.  
5.2.4 Heparin Binding in Clinically Relevant Conditions 
The data from the heparin binding assay carried out in the presence of buffer and salt 
suggested that C22G1DLys was a more efficient heparin binder than C22G1LLys and 
therefore required a lower dose per unit of heparin. For that reason, C22G1DLys was 
carried forward for testing under more clinically relevant conditions. As discussed in 
earlier chapters, the Mallard Blue heparin binding assay can also be carried out with 
heparin delivered in 100% human serum to simulate more realistically the clinical 
situation experienced by a heparin rescue agent. C22G1DLys was tested using the MalB 
assay in serum and the resulting data are shown in Table 5.4 and Figure 5.11, and 
discussed below.  
Table 5.4 – Heparin binding data for C22G1DLys obtained from MalB assay carried out 
in salt and buffer, and with heparin delivered in 100% human serum. 
Assay Conditions 
Heparin Binding: C22-G1-D-Lysine 
EC50 / μM CE50  Dose / mg 
Salt and Buffer (30 ± 5) (1.13 ± 0.19) (0.85 ± 0.14) 
Heparin in 100% Human Serum (68 ± 2) (2.52 ± 0.08) (1.83 ± 0.06) 
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Figure 5.11 – Heparin binding curves for C22G1DLys obtained from MalB assay carried 
out (i) in salt and buffer (black) and (ii) with heparin delivered in 100% human serum 
(grey).  
The heparin binding efficiency of C22G1DLys decreases in the presence of human 
serum, with more than twice as much cationic charge being required to neutralize a 
given amount of heparin than in the absence of serum. It is worth noting that 50% MalB 
displacement fell marginally outside the titration range and so the parameters reported 
in Table 5.4 were calculated by extrapolation. It seems likely that the presence of 
hydrophobic species such as albumins in serum may be disrupting the micellar ligand 
array of C22G1DLys in a similar manner to that previously observed for C22G1DAPMA. 
Given their similar structures, C22G1DLys and C22G1DAPMA could reasonably be 
expected to have comparable propensities for disruption by serum. Impressively, despite 
the disruption, C22G1DLys still showed significant heparin binding under these more 
challenging conditions. Building on this promise, C22G1DLys was tested in a plasma 
clotting based prothrombin assay (PT assay) to examine its ability to not only interact 
with heparin, but also to neutralize its anticoagulant activity in a clinically relevant 
assay. Once again, clotting studies were carried out in the laboratory of Professor 
Jeremy Turnbull at University of Liverpool, UK.  
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Table 5.5 – Plasma clotting data for C22G1DLys in PT assay. 
Compound 
Binder Dose, Clotting time 
 mg / 100IU  / seconds 
None - (12.8 ± 0.8) 
Heparin  - no clot 
C22-G1-D-Lysine 0.85 (19.7 ± 2.7) 
C22-G1-D-Lysine 1.83 (19.4 ± 2.6) 
The PT assay results shown in Table 5.5 show that introduction of heparin to the sample 
of plasma led to a suspension of clotting as heparin exerted its anticoagulant effect. 
Subsequent introduction of C22G1DLys at the dose calculated from the MalB assay in 
buffer and salt (0.85 mg per 100IU) resulted in clotting been reestablished, although the 
clotting time was somewhat extended compared to the control sample. The extended 
clotting time may be due to disruption of a portion of the binder by some of the 
hydrophobic plasma components. Introduction of C22G1DLys at the higher dose 
suggested by the MalB assay in serum (1.85 mg per 100IU) also resulted in clotting 
being reestablished, but did not result in a shortening of the clotting time. From these 
limited clotting studies, it would appear that regardless of applied dose, the clotting time 
for C22G1DLys remained roughly consistent in the PT assay at around 19 seconds.  
Despite this extended clotting time, it is particularly impressive that C22G1DLys, a self-
assembling binder which is less efficient in its use of individual charges than other 
systems tested, is able to clot heparinized human plasma samples. It is another excellent 
demonstration of the genuine potential of this simple and biocompatible SAMul 
approach in the development of functional heparin rescue agents.  
5.2.5 Degradation 
5.2.5.1 Nile Red Release Assay 
Part of the rationale behind the SAMul approach to heparin binding is the enhanced 
degradability of the binder molecules compared to larger covalent systems, which gives 
SAMul binders greater pharmacological appeal. To that end, the ability of C22G1DLys 
to degrade and/or disassemble under biologically relevant conditions was tested. It was 
hoped that comparison against data for C22G1DAPMA may give insights into the 
effects of connecting the surface groups through ester linkages rather than carbamates. 
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Although only the D-system was tested here, in vivo each of C22G1LLys and C22G1DLys 
may have subtly different degradation profiles owing to their opposing chiralities. In 
particular, the D-system might be metabolized more slowly owing to the natural absence 
of D-amino acids in humans. Indeed it is known that humans have no natural mechanism 
for utilizing or dealing with D-lysine derivatives yet they can derive around 1% of their 
nutritional intake from L-lysine derivatives.
329,330
  
The propensity of C22G1DLys to degrade was tested using the same time-resolved Nile 
Red release assay employed for C22G1DAPMA in Chapter 4. Specifically, a solution of 
C22G1DLys was made up at a concentration above the CAC (50 µM) in PBS buffer at 
pH 7. An aliquot of Nile Red was added to the cuvette before inversion ensured 
thorough mixing. Thereafter, the fluorescence intensity (If) at 635 nm following 
irradiation at 550 nm, was recorded at 10 minute intervals over 6.5 hours to monitor the 
release of dye from the micellar interior. The resulting values were normalised between 
If at the start of the experiment and If of a PBS-Nile Red control. The resulting 
degradation curve is shown in Figure 5.12.    
 
Figure 5.12 – Time resolved degradation curve of C22G1DLys. Discontinuities are 
indicated where the sample was vigorously shaken to simulate blood-flow shear forces.  
As shown in Figure 5.12, C22G1DLys degrades with a half-life (t1/2) of ca. 1.25 hours. 
This half-life is significantly shorter than for C22G1DAPMA, which exhibited a half-life 
of ca. 7 hours under the same conditions. Clearly, the connection of the surface groups 
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to the linker unit through ester bonds rather than carbamates significantly increases 
degradability. It seems likely that the degradation process of C22G1DLys is driven by an 
intramolecular base-catalyzed hydrolysis process, much like that previously reported by 
Smith and co-workers.
69
 Indeed the closer proximity of the ester groups to the surface 
amine in C22G1DLys may assist in this increased degradation rate over C22G1DAPMA. 
The short t1/2 of C22G1DLys is significant with respect to much of the data reported 
earlier in this chapter. For example, all the parameters calculated from MalB heparin 
binding assays have relatively large uncertainty values associated with them; in some 
cases as much as ca. 19% of the mean value. The instability of the binder molecules 
would appear to account for this uncertainty because MalB heparin binding assays can 
take around 3 hours to perform in triplicate, during which time the binder may have 
degraded somewhat. Degradation during MalB assays will likely be slower than 
suggested by the Nile Red release study however, as any solutions containing binder 
also contain heparin and, as shown in Chapter 4, interaction with heparin significantly 
retards degradation as the binder amines are bound to heparin and less able to 
intramolecularly catalyse the hydrolytic degradation process.   
An important further consideration for any potential heparin rescue agent is the effect of 
dosing into the fast-flowing bloodstream. In particular, the role of shear forces is 
especially important for our non-covalent assemblies. In order to simulate the effect of 
shear forces on our SAMul system, the cuvette was shaken vigorously between the 
acquisitions of two data points. These points are indicated in Figure 5.12. The shear 
forces manifest themselves as clear discontinuities in the line shape, indicative of an 
accelerated degradation event. Interestingly, the points following the shaking appear to 
revert back to the initial degradation regime. Importantly, in the bloodstream such shear 
forces would be constant rather than intermittent, albeit somewhat lower in intensity. 
That is to say, the half-life of C22G1DLys in a flowing bloodstream would be expected 
to be significantly shorter than the 1.25 hours observed in this degradation experiment.  
5.2.5.2 Mass Spectrometric Studies 
Whilst the Nile Red release assay is indicative of degradation, it is unable to identify 
which bonds specifically are being broken, or whether indeed the assembly is simply 
disrupted rather than degraded over time. A mass spectrometric degradation assay was 
carried out in order to identify the species resulting from degradation. As for 
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C22G1DAPMA in Chapter 4, mass spectra were obtained in the presence of a Gly-Ala 
non-degradable internal standard before and after incubation at 37°C for 24 hours. Some 
example spectra, along with the molecular species of interest are shown in Figure 5.13. 
At time zero, the molecular ions associated with C22G1DLys (m/z = 391 [M]
2+
 and 261 
[M]
3+
) were clearly visible. After 24 hours, these molecular ions had disappeared and 
peaks corresponding to the hydrolysis products of the linker ester (alcohol, m/z = 408 
[M]
1+
; carboxylic acid, m/z = 391 [M]
1+
) were now visible, albeit at low relative 
intensity to the standard. This suggests that the connection of the surface groups to the 
scaffold by ester groups rather than carbamates, as was the case for C22G1DAPMA, 
promoted further degradation of the carboxylic acid fragment, although direct evidence 
of such secondary degradants was not seen.    
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Figure 5.13 – Mass spectrometric degradation assay: observed species (top) after 0 hours 
(middle) and 24 hours (bottom) incubation at 37°C. 
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5.2.5.3 Plasma Clotting Study 
The Nile Red release data presented above demonstrated that molecular degradation 
switched off the self-assembly processes of C22G1DLys, however it did not 
unequivocally indicate a switch off in heparin binding activity. Therefore, to confirm 
that a degraded sample of C22G1DLys would be unable to operate as a heparin rescue 
agent (i.e. the activity had been lost), a solution of binder was made up in aqueous 
solution and left to stand for 24 hours before being tested in the prothrombin plasma 
clotting assay (PT assay) as before. The results, shown in Table 5.6, indicate that after 
degradation, the heparin-neutralizing activity was lost and no plasma clotting was 
observed.  
Table 5.6 – Plasma clotting data for C22G1DLys in PT assay before and after 
degradation. 
Compound 
Binder Dose, Clotting time 
 mg / 100IU  / seconds 
C22-G1-D-Lysine 0.85 (0 hours) (19.7 ± 2.7) 
C22-G1-D-Lysine 0.85 (24 hours) no clot 
In a further experiment to probe binder degradability, a sample of C22G1DLys was taken 
approximately 18 months after synthesis and analysed by NMR spectroscopy. Despite 
refrigeration under an inert atmosphere, comparison of the spectra obtained after this 
extended time period with those from immediately following synthesis indicated the 
molecule had degraded somewhat. The most informative signals in the spectra 
corresponded to the -CH2 positioned between the linker unit ester group and the 1,2,3-
triazole ring. As shown in Figure 5.14, the individual signals observed after synthesis in 
1
H spectrum (a) and 
13
C spectrum (c) became accompanied by new signals in spectra (b) 
and (d). These new signals were assigned to the degradant product resulting from 
hydrolysis of the adjacent ester group. The ratio of intact binder to hydrolysed binder 
was estimated from these spectra to be approximately 3 : 1, suggesting slow degradation 
had occurred during prolonged storage.  
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Figure 5.14 – 1H and 13C NMR spectra for C22G1DLys before (left) and after (right) 
refrigeration under an inert atmosphere for 18 months.     
The effect of this apparent partial-degradation on heparin binding performance was also 
studied by re-testing the ‘old’ samples of C22G1LLys and C22G1DLys using the Mallard 
Blue heparin binding assay in buffer and salt. As shown in Figure 5.15, the degradation 
affected the performance of both binder systems. It is noteworthy, however, that the 
binding curves obtained (shown in grey) mimic those obtained initially by following the 
same lineshape up to a charge ratio of ca. 0.65 before diverging, with C22G1DLys again 
emerging as the superior heparin binder of the pair.  
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Figure 5.15 – Heparin binding curves for C22G1LLys and C22G1DLys obtained using 
the MalB assay in buffer and salt initially following synthesis (black) and after 18 
months of storage (grey). 
5.2.6 DNA Binding 
5.2.6.1 A Different Chiral Biological Polyanion 
Following the chiral preferences exhibited by C22G1LLys and C22G1DLys when binding 
heparin, we became interested in whether such differences would be observed when 
binding an alternative chiral biological polyanion. To that end, DNA was identified as a 
suitable binding target.  
The double-helical structure of DNA was famously first solved by Watson and Crick in 
1952.
331
 DNA consists of a backbone of alternating phosphate groups and 2-
deoxyribose sugar residues, each of which is functionalised with a nucleobase. There 
are four nucleobases, which can be categorised into two classes: the purine-bases, 
adenine and guanine; and the pyrimidine bases, thymine and cytosine. Direct hydrogen 
bonding interactions between pairs of these nucleobases bring together two DNA 
strands. Specifically, adenine interacts with thymine, and guanine interacts with 
cytosine, as shown in Figure 5.16.  
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Figure 5.16 – Segment of DNA showing the 2-deoxyribose sugar-phosphate backbone 
and the hydrogen bonding interactions between the labelled nucleobases.  
Genetic code allowing the synthesis of every protein within an organism is contained 
within DNA. When errors are present within this code, an incorrect or mutated gene is 
synthesised within cells, which can lead to genetic diseases such as sickle-cell anaemia 
or cystic fibrosis. Gene Therapy (also known as gene delivery) is a medicinal approach 
which has been developed in attempt to remedy these conditions through correcting 
these genetic code errors.
332,333
 The process involves delivering a section of healthy 
DNA into a cell, which can code for a working version of a faulty/mutated gene or a 
therapeutic protein drug. Generally, delivery of such genetic material (DNA) is 
achieved by vectors, which act to protect the DNA as it enters cells. Vectors tend to 
‘package up’ DNA, often inside themselves, to mediate transport across cell membranes 
such that once inside the cell, and access is gained to the cell-machinery, coding can 
begin to produce the therapeutic protein or gene.  
Over recent years, many synthetic (or non-viral) vectors have been designed to bind 




 and cationic lipids
336,337
 are 
the two largest molecular classes showing promise as effective gene delivery vectors 
although dendritic systems are also becoming increasingly studied.
338
 Indeed, of interest 
to us is work from the group of Smith, which has focussed on this dendritic approach 
and produced a range of DNA binding system, some of which utilise the same self-




Chirality in DNA arises from the deoxyribose sugar moieties along its backbone and 
leads to the famous right-handed double helix.
331
 There has been much interest in 
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studying and harnessing this chirality for applications ranging from enantiomeric 
purifications to asymmetric catalysis. In a similar manner to that discussed earlier for 
heparin, DNA has found roles in chromatographic fields where it has been employed as 
a straightforward chiral selector to, amongst other things, achieve enantiomeric 
separations of bovine milk proteins.
341,342
  
Considerations have been made of how different chiral substrates interact differently 
with left- and right-handed DNA.
343
 In a related area, the multiple works of Sforza and 
Marchelli have examined in detail the propensity of individual DNA strands to act as 
chiral selectors when forming a duplex with chirally-modified peptide nucleic acid 
(PNA) strands.
344,345




 amino acids 
were incorporated into identical PNA stands to endow chirality within their structure, 
for example see Figure 5.17. The studies which followed convincingly rationalized that 
it was generation of a PNA strand with complementary helical handedness to DNA 





Figure 5.17 – An example PNA strand containing a lysine functionalised region; a so-
called ‘chiral box’.348 
Other work has focussed on using DNA chirality as a scaffold for catalysis. For 
example an early review by Roelfes showed that using DNA in stoichiometric chemical 
reactions could allow enantioselection of chiral substrates.
349
 A more widely used 
approach, however, involves a reaction catalyst being anchored onto DNA through 
supramolecular interactions.
350
 These catalyst-DNA interactions often take the form of 
intercalation events
351
 and can be applied successfully to a wide variety of organic 
reactions provided the reagents are water soluble.
352
 For example, the efforts of Feringa 





 and even Friedel-Craft alkylations.
355
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5.2.6.2 Testing C22G1LLys and C22G1DLys 
In order to test the ability of C22G1LLys and C22G1DLys to bind DNA, an indicator 
displacement assay involving ethidium bromide was employed. The ethidium bromide 
assay is well-known, having being used for many decades, and has been utilized 
previously in the Smith group.
68,356
  
Ethidium bromide (EthBr), shown in Figure 5.18, is a planar aromatic indicator dye 
which is able to intercalate between base pairs of free DNA. Once intercalated in this 
manner, EthBr exhibits a strong fluorescence signal at 595 nm following excitation at 
550 nm. When a DNA-binder is added to a solution of EthBr and DNA, EthBr becomes 
indirectly displaced into free solution as binder-DNA interactions are established. Once 
in free solution, EthBr fluorescence is readily quenched, and the change in fluorescence 
intensity (ΔIf) can be used to calculate the degree of DNA-binding. Normalised binding 
curves can be plotted in the same manner applied to the heparin binding studies, with 
data similarly reported in terms of charge efficiency (CE50) and effective concentration 
(EC50) at 50% EthBr displacement. This assay is useful for comparing families of 
related molecules and quantifying their DNA binding ability.  
 
Figure 5.18 – Chemical structure of fluorescent dye ethidium bromide. 
The EthBr DNA binding assay was used to test PG1LLys, C22G1LLys and C22G1DLys 
under conditions of 5.07 µM EthBr and 4 µM DNA (with respect to each base) in the 
presence of SHE buffer (2 mM HEPES, 0.05 mM EDTA and 150 mM NaCl) at pH 7.5. 
The resulting DNA binding data are shown numerically in Table 5.7 and graphically in 
Figure 5.19.   
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Table 5.7 – DNA binding data from EthBr assay for PG1LLys, C22G1LLys and 
C22G1DLys. *EC50 and CE50 are numerically equivalent due to experimental conditions. 
Compound 
DNA Binding 
EC50 / μM CE50  
Propyne-G1-L-Lysine Not achieved - binding too weak 
C22-G1-L-Lysine* (1.99 ± 0.54) (1.99 ± 0.54) 
C22-G1-D-Lysine* (3.51 ± 0.37) (3.51 ± 0.37) 
 
Figure 5.19 – DNA binding curves from EthBr assay for PG1LLys, C22G1LLys and 
C22G1DLys. 
The DNA binding data shows that in the absence of a hydrophobic unit, PG1LLys is 
unable to displace EthBr from DNA even when there are seven times as many binder 
cationic charges present as DNA anionic charges. When the alkyl chain is in place 
however, DNA binding ability increases significantly with C22G1LLys displacing 50% 
EthBr at a charge excess of (1.99 ± 0.54) and binder concentration of (1.99 ± 0.54) μM. 
These values are numerically equivalent as, under the conditions of the assay, one mole 
of DNA possesses one anionic charge and is present at 4 µM, while the SAMul binders 
each possess four cationic charges per mole. The presence of the aliphatic tail is having 
an effect on the DNA binding ability of C22G1LLys despite, according to the data in 
Table 5.1, being present at a concentration significantly below the CAC. This may 
suggest that the CAC is lowered in the presence of DNA as interactions between 
individual non-assembled molecules and DNA may serve to enhance the assembly of 
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subsequent binder molecules, which in turn enhance DNA binding by promoting 
multivalent interactions. This phenomenon may indicate that multivalency enhanced 
self-assembly is a corollary of self-assembled multivalency.  
In order to examine the CAC of the system in the presence of DNA, the Nile red 
encapsulation assay was repeated for C22G1DLys under the conditions of the DNA 
binding assay (i.e. in the presence of 4 µM per DNA base, 0.05 mM EDTA, 150 mM 
NaCl and 2 mM HEPES). The resulting encapsulation curve, Figure 5.20, gave a CAC 
value for C22G1DLys of 11 (± 2) µM.  
 
Figure 5.20 – Nile red encapsulation curve for C22G1DLys in the presence of DNA. 
Although the presence of DNA served to lower the CAC somewhat, this observed value 
is still over three times larger than the concentration required to displace half of the 
ethidium bromide in the DNA binding assay. This suggests that DNA is assisting the 
formation of the self-assemblies somewhat although it appears to suggest that effective 
DNA binding is being achieved in the absence of full micellar assemblies. This leads to 
the possibility that in the presence of DNA, several monomers may cluster together at 
the DNA surface in order to establish multivalent interactions with the polyanion. This 
may account for the superior binding over the alkyne-tailed negative control molecules 
while explaining the NR encapsulation data.  
The charge efficiency of both C22G1LLys and C22G1DLys is significantly reduced when 
binding DNA compared to binding heparin. This is most likely a straightforward 
consequence of heparin being a more charge-dense polyanion and so presenting each 
cationic charge with more opportunities to establish meaningful interactions than DNA.  
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Comparison of the DNA binding data for C22G1LLys and C22G1DLys suggests that each 
enantiomer binds DNA with a significantly different charge efficiency. Specifically, 
C22G1LLys is the more charge efficient of the pair requiring (1.99 ± 0.54) positive 
charges per negative charge of DNA, while C22G1DLys requires (3.51 ± 1.37) positive 
charges. The difference in binding efficiency between the opposing enantiomers is 
likely to arise as a result of the differing interaction of each chiral centre with the 
anionic target. Importantly, the observation that the L-system is the more charge 
efficient DNA binder of the pair is in direct contrast to observations from the heparin 
binding data, where the D-system was the more charge efficient. Excitingly, the data 
therefore suggests the C22G1Lys SAMul systems have opposing chiral preferences 
when binding to different biological polyanions. To the best of our knowledge, these 
contrasting preferences for heparin and DNA binding have not previously been 
reported; particularly not with chirality expressed at the surface of a self-assembled 
nanosystem.  
It is often proposed that charge density is the only factor of importance when 
establishing multivalent ion-ion interactions,
280
 however the data presented here clearly 
demonstrate the arrangement of the individual charges in space can have a significant 
impact. It is perhaps not surprising that an enantiomeric pair of substrate molecules 
would have different binding efficiencies when interacting with a chiral target, or, 
arguably, that this preference may change for chiral binding targets. Rather more 
noteworthy is that for our SAMul binders these chiral differences are brought about 
only by very small changes at the molecular level. Physically, the only difference 
between the systems lies at the α-carbon positions on each lysine residue, five bonds 
from the surface of the assembly. Consequently for C22G1LLys and C22G1DLys, it is 
only the orientation of this part of the molecules that differ, suggesting that heparin and 
DNA can be acutely sensitive to the spatial arrangement of binding ligand arrays. 
Interestingly this also suggests that oligosaccharides and oligonucleotides have different 
chiral preferences when binding to arrays of cationic, lysine-based amino acids. This 
observation may have biological or evolutionary significance.   
In order gain more meaningful insights to these chiral differences, a molecular 
dynamics modelling study has been carried out in collaboration with Professor Sabrina 
Pricl at University of Trieste, Italy. Unfortunately the results from this study are not 
available for inclusion here.  
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5.3 Generation 2 Systems 
Following on from the exciting chiral recognition observations for the G1 lysine-
containing SAMul binders in the previous section, it was decided to design and 
synthesise some larger second generation (G2) analogues. Specifically, C22G2LLys and 
C22G2DLys were identified as suitable target molecules, shown in Figure 5.21. The G2 
analogues differ from their G1 counterparts in the degree of dendritic branching present 
within the linker unit. At G2, the additional branching points result in the surface being 
decorated by four, rather than two, lysine groups. It was postulated that the larger 
system, in possession of more binding groups at the assembly surface, might be capable 
of more charge efficient heparin binding. Similarly sized systems have previously been 




 to be effective DNA/RNA delivery agents. 
It was also hoped that increasing the number of chiral centers at the binding surface may 
serve to amplify the chiral differences observed when binding to different chiral target 
molecules such as heparin and DNA.  
 
Figure 5.21 – G2 target molecules C22G2LLys and C22G2DLys.  
5.3.1 Synthesis of C22G2LLys and C22G2DLys 
5.3.1.1 Preparation of G2 linker group 
The G2 target molecules were synthesized in the same convergent manner as the G1 
systems. In order to create the extra layer of branching within the G2 linker unit, 
alkyne-functionalised-diol 5.10 was reacted with symmetrical anhydride 5.8 in a 
moderate yielding base-catalysed coupling reaction.
325
 This generated G2-
isopropylidene 5.18 which was deprotected using DOWEX-50WX2 to afford G2-linker 
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5.19. Although concentrated sulfuric acid was able to unveil the alcohol groups, 
DOWEX resin was found to be a more reliable approach for the larger system. This 
observation agrees with work from the group of Hult.
357
 The synthetic scheme showing 
the preparation of G2-linker is shown in Scheme 5.5. 
 
Scheme 5.5 – Synthetic scheme showing preparation of G2-linker.325,357    
5.3.1.2 Connecting the pieces 
In the same manner utilised in the preparation of the G1 system, the alcohol groups of 
G2-linker 5.19 were coupled with either LLys(Boc)2 or DLys(Boc)2 to afford protected 
partial binders 5.20 and 5.21 respectively, in good yields after purification by gel 
permeation chromatography in 95:5 DCM:methanol. Once again, a small portion of 
L-enantiomer 5.20 was deprotected using HCl gas in methanol to generate negative 
control for self-assembly 5.22 in excellent yield. Partial binders 5.20 and 5.21 were then 
connected to alkyl azide 5.2 using copper(II) mediated ‘click’ chemistry to afford, after 
purification by gel permeation chromatography in 100% DCM, protected final binder 
molecules 5.23 and 5.24. The yields of the G2 click reactions were very low (ca. 8 %) 
when compared with the G1 systems (ca. 70%). This is thought to be due to the steric 
crowding around the G2 alkyne functionality perturbing the interaction with the copper 
catalyst. Hindering the alkyne-Cu interaction prevents the alkyl LUMO becoming 
reduced in energy sufficiently to permit easy electron transfer from the azide HOMO. 
There are also a significant number of coordinating ligands present which could provide 
competitive binding sites for copper. Consequently, a low product yield of 5.23 and 
5.24 is observed. Copper-free ‘click’ approaches may circumvent some of these issues, 
however this was not attempted here. The material obtained was deprotected in an 
excellent yield using HCl gas in methanol to afford target molecules C22G2LLys 5.25 
and C22G2DLys 5.26. The reaction scheme for the preparation of these target molecules 
is shown in Scheme 5.6. 
Chapter 5 – SAMul Binders II: Lysine 
178 
 
Scheme 5.6 – Synthetic scheme for production of target molecules PG2LLys, 
C22G2LLys and C22G2DLys. 
With C22G2LLys and C22G2DLys in hand, circular dichroism spectroscopy was used to 
establish whether amino acid chirality had been successfully preserved throughout the 
synthesis. As can be seen in Figure 5.22, at concentrations of 10 mM, the molar 
ellipticity for the two systems is essentially equal and opposite. This indicates that the 
two target molecules are of approximately equal enantiopurity, and crucially that 
chirality has not being scrambled during synthesis.   
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Figure 5.22 – Circular dichroism spectra of target molecules C22G2LLys and 
C22G2DLys indicating opposing chirality. 
5.3.2 Self-Assembly Studies 
5.3.2.1 Nile Red Data 
The self-assembling ability of C22G2LLys and C22G2DLys was tested using the Nile 
Red encapsulation assay discussed earlier. The data are shown numerically in Table 5.8 
and graphically in Figure 5.23.   
Table 5.8 – Nile Red encapsulation assay data for PG2LLys, C22G2LLys and 
C22G2DLys. 
G2 Systems CAC / μM 
P-G2-L-Lysine N/A 
C22-G2-L-Lysine (25 ± 8) 
C22-G2-D-Lysine (20 ± 6) 
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Figure 5.23 – Nile Red encapsulation curves for C22G2LLys and C22G2DLys. 
These data clearly demonstrate once more that the aliphatic tail provides the driving 
force for aggregation of the SAMul systems. In the absence of the hydrophobic unit, 
PG2LLys is unable to encapsulate Nile Red up to concentrations of 1 mM. The data do 
suggest that C22G2DLys self-assembled at marginally lower concentrations than 
C22G2LLys although, given the large error values associated with each measurement, 
this is not a significant difference. As discussed for the G1 systems, the opposing 
chiralities would not be expected to influence any parameter, such as CAC, where 
handedness is unimportant.  
The data suggests that these larger G2 molecules assemble, on average, at lower 
concentrations to their G1 counterparts. The greater number of lysine residues at the 
surface makes the G2 system significantly larger and bulkier than the G1. Fewer 
molecules may therefore be required to form each individual micelle, thereby 
accounting for the reduced CAC. These observations also align with work from the 
group of Haag which noted that an increase in hydrophilicity can sometimes lead to a 
decrease in observed CMC values.
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With the self-assembly of C22G2LLys and C22G2DLys evidenced, TEM imaging was 
carried out in an attempt to characterize the approximate size and morphology of the 
self-assembled architecture.  
5.3.2.2 TEM Images 
Transmission electron microscopy (TEM) was used to image samples of C22G2LLys 
and C22G2DLys both in the absence and presence of heparin. Solutions of C22G2LLys 
and C22G2DLys were prepared in clean water at concentrations of 125 µM to ensure the 
binder molecules were present in assembled form. Heparin was introduced at a charge 
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ratio of 2.25 as, under this concentration regime, both binders exhibited significant 
interaction with heparin. Once prepared, aliquots of each solution were loaded onto a 
formvar grid, negatively stained with uranyl acetate and allowed to dry before imaging. 
The images for C22G2LLys in the absence and presence of heparin are shown in Figure 
5.24 and Figure 5.25 respectively, while the equivalent images for C22G2DLys are 
shown in Figure 5.26 and Figure 5.27 respectively. The observations are discussed 
below.  
 
Figure 5.24 – TEM image of 125 µM C22G2LLys (scale bar: 50 nm).  
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Figure 5.25 – TEM image of 125 µM C22G2LLys in the presence of heparin (scale bar: 
50 nm).  
 
Figure 5.26 – TEM image of 125 µM C22G2DLys (scale bar: 50 nm).  
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Figure 5.27 – TEM image of 125 µM C22G2DLys in the presence of heparin (scale bar: 
100 nm).  
The TEM images in Figure 5.24 and Figure 5.26 each show roughly spherical objects 
which decorate the grid in an even manner, suggesting C22G2LLys and C22G2DLys form 
micelles. Each micelle appears to be ca. 9 – 11 nm in diameter which, logically, is 
slightly larger than those formed by the smaller G1 systems and equates roughly to 
double the molecular length of monomer units. In the presence of heparin, the micelles 
appear to be arranged throughout heparin structure suggesting an integrated nanoscale 
aggregate, although the micelles appear somewhat reduced in size with apparent 
diameters of ca. ≤7 nm. It is worth noting that approximate sizing of the micelles from 
the TEM images was complicated by the tendency of the samples to deteriorate under 
the electron beam, which had the effect of ‘blurring’ the images.  
With the self-assembly of the system demonstrated and characterized, the compounds 
were examined for heparin binding ability.   
5.3.3 Heparin Binding in Competitive Conditions 
The compounds C22G2LLys and C22G2DLys were tested for their ability to bind heparin 
using the Mallard Blue heparin binding assay carried out in buffer and salt. As before, 
the data were reported in term of charge efficiency and effective concentration at 50% 
MalB displacement along with the effective dose of binder required to neutralize 100 IU 
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of heparin. The data are reported numerically in Table 5.9 with the binding curves 
shown in Figure 5.28. 
Table 5.9 – Heparin binding data for PG2LLys, C22G2LLys and C22G2DLys obtained 
from MalB assay. 
Compound 
Heparin Binding 
EC50 / μM CE50  Dose / mg 
Propyne-G2-L-Lysine Not achieved - binding too weak 
C22-G2-L-Lysine (15 ± 3) (1.07 ± 0.20) (0.68 ± 0.13) 
C22-G2-D-Lysine (17 ± 4) (1.28 ± 0.26) (0.81 ± 0.17) 
 
 
Figure 5.28 – Heparin binding curves for PG2LLys, C22G2LLys and C22G2DLys 
obtained from MalB assay. 
The data again show that in the absence of hydrophobic unit, PG2LLys is unable to 
displace MalB from heparin to any significant extent even when present in excess. 
Close comparison of the binding curve for PG2LLys against that for PG1LLys however, 
shows the additional positive charges on the larger system do increase MalB 
displacement slightly, but not sufficiently to make PG2LLys a noteworthy heparin 
binder in its own right.  
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Following introduction of the hydrophobic unit, the heparin binding ability ‘switches-
on’ with 50% MalB readily being displaced by C22G2LLys at a concentration of (15 ± 
3) µM and at a charge efficiency of (1.07 ± 0.20). The binding ability is clearly driven 
by the ability of the system to self-assemble although, according to the data in Table 
5.8, C22G2LLys appears to be operating in a self-assembled multivalent manner at a 
concentration below the apparent CAC. It is possible, as discussed in the previous 
section, that the presence of heparin in the solution may assist the self-assembly leading 
both to a reduction in CAC and improvement in binding ability. Comparison against 
C22G1LLys – CE50 of (1.94 ± 0.38), Table 5.4 – shows the larger G2 system to be 
almost twice as efficient at marshalling its charges and interacting with the anionic 
biopolymer. It is possible that this increased binding efficiency indicates a better size-
matching of the larger system with heparin. Additionally, it is plausible that the greater 
flexibility in the larger system aids C22G2LLys in arranging its charges into a more 
favourable configuration for interaction with heparin. 
The D-enantiomer, C22G2DLys, exhibits comparable heparin binding performance to 
C22G2LLys with a charge efficiency of (1.28 ± 0.26) achieving 50% MalB displacement 
at a concentration of (17 ± 4) µM. Within error, each of the binding parameters for 
C22G2LLys and C22G2DLys can be considered the same. This equivalence is supported 
by the heparin binding curves for each enantiomer in Figure 5.28 which show the same 
lineshape throughout the titration; in contrast to the G1 heparin binding curves which 
exhibited a discernable lineshape divergence beyond a charge ratio of ca. 0.65.  
The lower charge efficiency values for the G2 systems indicate that each individual 
charge is used more effectively in the larger system. This would seem to suggest that 
the four amines positioned directly at the chiral centres in C22G2LLys and C22G2DLys 
are more heavily involved in interacting with heparin than the two equivalent positions 
in C22G1LLys and C22G1DLys yet, paradoxically, there is minimal difference in heparin 
binding ability between the G2 enantiomers. It appears that despite ‘more’ chirality 
being present in the G2 binders, it is less apparent to heparin upon binding. This may 
suggest that the increased steric crowding at the surface of the dendritic structure masks 
the subtle difference in chiral expression between C22G2LLys and C22G2DLys. The 
closer proximity of the binder charges to each other may simply lead heparin to respond 
to the greater electrostatic attraction, hence accounting for the more efficient binding, 
without registering any difference in how the ligand array is expressed.                
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5.3.4 Degradation 
5.3.4.1 Nile Red Release Assay 
Having characterized the heparin binding ability of C22G2LLys and C22G2DLys, the 
degradation profile of these larger systems was assessed. In possessing an extra layer of 
branching, and double the number of surface groups, C22G2LLys and C22G2DLys each 
have a total of eight ester linkages present within their structures; five more than their 
G1 counterparts. For consistency, C22G2DLys was selected for testing using the Nile 
Red release assay. The resulting degradation curve is shown in Figure 5.29. 
 
Figure 5.29 – Time resolved degradation curve for C22G2DLys. Discontinuities are 
indicated where the sample was vigorously shaken to simulate blood-flow shear forces. 
The data show that C22G2DLys degrades with a half-life (t1/2) of ca. 1.4 hours. The 
lineshape is somewhat sigmoidal in nature suggesting the initial degradation rate upon 
introduction to solution is relatively slow before accelerating considerably. This initial 
regime may correspond to the binder molecules being tightly packed into self-
assembled nanostructures and it being hard for nucleophilic attack of the ester groups to 
occur due to their concealment away from the assembly surface. The steepest section of 
the curve may correspond to a situation where some binder molecules have degraded to 
an extent, for example through loss of one arm from the dendritic surface. Once 
partially degraded, it may become easier for a hydrolysis event to occur in which the 
hydrophobic unit is detached, removing the amphiphilicity and liberating Nile Red into 
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free solution. The absence of sigmoidal character in the G1 lineshape in Figure 5.12 
may also hint at a more complex mechanism for the larger G2 system. This more 
convoluted pathway may also account for the slightly longer observed t1/2 for 
C22G2DLys compared to C22G1DLys, although this difference may also fall within 
experimental error as each degradation plot was obtained from a single experimental 
run. 
After the half-life had been observed, the cuvette containing the sample was vigorously 
shaken to simulate shear forces which would be experienced in a fast-flowing system 
such as the bloodstream. The two marked discontinuities in Figure 5.29 suggest that 
agitation may cause a reorganization of the remaining assemblies, during which some of 
the remaining ester bonds become temporarily more accessible and so are also broken. 
This assertion would seem to fit the line-shape, which reverts to the slower degradation 
rate once the remaining assemblies have re-stabilised.  
5.3.4.2 Mass Spectrometric Studies 
In order to identify the species resulting from the degradation events, mass spectrometry 
was used to probe a sample before and after 24 hours incubation at 37°C under the same 
conditions applied previously. Examples spectra along with the species of interest are 
shown in Figure 5.30.  
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Figure 5.30 – Mass spectrometric degradation assay: observed species (top) after 0 hours 
(middle) and 24 hours (bottom) incubation at 37°C. 
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At time zero, the molecular ions associated with C22G2DLys (m/z = 424 [M]
3+
 and 318 
[M]
4+
) were clearly visible along with that of the same species having lost a lysine 
residue (m/z = 381 [M]
3+
). This observation of this lattermost species was assigned as a 
mass spectrometric artefact as no evidence of incomplete lysine functionalization was 
observed from orthogonal characterization techniques such as NMR. After 24 hours, 
these molecular ions had disappeared and peaks corresponding to the hydrolysis 
products of both G1 and G2 linker ester groups (alcohol, m/z = 408 [M]
1+
; carboxylic 
acid, m/z = 391 [M]
1+
) were now visible, albeit at low relative intensity to the standard. 
No evidence was seen for the presence of an intact G2-lysine carboxylic acid species 
despite inspecting higher charge-to-mass ranges, which may suggest that once formed, 
further degradation of such a species occurs to afford the observed G1-lysine carboxylic 
acid fragment. Similarly, the relatively low intensity of the observed degradant at m/z 
391 appears to suggest that further degradation, for example, through cleavage of the 
ester groups connecting the lysine moieties to the scaffold occurred. Unfortunately, no 
direct evidence of these lower mass species was seen. Importantly, however, the mass 
spectrometric assay did demonstrate that the premise of installing ester groups within 
the linker unit was valid, because direct evidence relating to cleavage of these bonds 
was seen.  
5.3.5 DNA Binding 
The larger SAMul systems C22G2LLys and C22G2DLys were also tested for their ability 
to bind to DNA in order to probe whether the chiral trends observed previously were 
evident. The compounds were tested using the ethidium bromide displacement assay 
and the data are reported numerically in Table 5.10 and graphically in Figure 5.31.  




EC50 / μM CE50  
Propyne-G2-L-Lysine Not achieved - binding too weak 
C22-G2-L-Lysine (1.07 ± 0.15) (2.15 ± 0.31) 
C22-G2-D-Lysine (1.02 ± 0.12) (2.03 ± 0.25) 
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Figure 5.31 – DNA binding curves from EthBr assay for PG1LLys, C22G1LLys and 
C22G1DLys. 
The data show, once again, that in the absence of an aliphatic tail, minimal indicator dye 
is displaced from DNA. After the introduction of the hydrophobic unit, binding ability 
significantly increases. In line with their G1 counterparts, the G2 systems bind DNA 
less efficiently than heparin, presumably as a consequence of the less charge-dense 
character of the polyanion.  
The most noteworthy observation here is that C22G2LLys and C22G2DLys bind DNA 
with almost identical efficiencies. Indeed, the two binding curves are ostensibly 
overlaid, suggesting the opposing chirality of each enantiomer has no bearing on DNA 
binding ability. A possible explanation for this could be that the amine groups attached 
to the lysine chiral centres may not be directly involved in the interactions with DNA 
or, alternatively, the steric crowding at the surface of the G2 dendritic structures 
prevents the differing chiralities being expressed fully. Whilst it is difficult to pinpoint 
the reasoning, the evidence is consistent: C22G2LLys and C22G2DLys exhibit minimal 
chiral differences when binding to DNA, or heparin. 
Attempts are underway to understand this absence of binding differences between 
C22G2LLys and C22G2DLys using molecular dynamic modelling approaches in 
collaboration with Professor Sabrina Pricl at University of Trieste, Italy. Unfortunately 
the results from this study are not available for inclusion here.     
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5.4 Conclusions and Future Work 
5.4.1 Conclusions  
A small family of lysine-containing self-assembling multivalent (SAMul) systems were 
synthesized and studied for their abilities to interact with heparin under a variety of 
conditions including in human plasma, and also with DNA. The effects of size, charge 
and chirality were considered from a binding perspective and the degradation profile of 
each system was also characterized.  
The smaller enantiomeric pair of SAMul binder molecules, C22G1LLys and C22G1DLys, 
were shown to form micellar aggregates in aqueous solution of ca. 7 nm diameter and to 
be able to bind heparin effectively in the presence of biologically relevant salt 
concentrations. Interestingly, the system containing D-lysine surface groups was able to 
marshal its charges more efficiently than the system containing L-lysine surface groups 
when interacting with heparin. Furthermore, when the polyanionic binding partner was 
changed to DNA, rather than heparin, this chiral binding preference was shown to be 
reversed, with the L-binder being the more charge efficient. 
Following on from the promising heparin binding results, C22G1DLys was shown to be 
able to bind heparin in the presence of human serum, although binding was less 
efficient. This decrease in performance was assigned to disruption of the self-assembled 
nanosystem by hydrophobic components of serum such as albumins. Despite this 
performance decrease, C22G1DLys was shown to be largely able to reverse the anti-
coagulant effect of heparin in clinically relevant plasma clotting assays.  
The degradation of C22G1DLys was demonstrated to occur with a first half-life of ca. 
1.25 hours, and to be accelerated by shear forces. This degradation time scale would 
likely be too short to be of clinical relevance due to the constant high velocity flow- and 
shear-forces experienced in the systemic bloodstream. Nonetheless, the greater number 
of ester groups compared to the C22G1DAPMA system reported in Chapter 4 clearly 
accelerated the degradation process.  
A larger pair of SAMul binders, C22G2LLys and C22G2DLys, were synthesized and 
tested for heparin and DNA binding. These systems possessed four lysine surface 
groups and were able to bind the anionic target molecules in a more charge efficient 
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manner than their G1 counterpart, presumably owing to the greater charge per self-
assembling unit and better size-matching. The micelles formed by these G2 systems 
were ca. 11 nm in diameter. Interestingly, the opposing surface group chiralities were 
shown to have no influence over binding ability, with C22G2LLys and C22G2DLys 
exhibiting equivalent heparin and DNA binding performances. It was reasoned that the 
increased crowding at the surface of the G2-system prevented the subtle difference in 
ligand spatial arrangement being fully expressed. It was reasoned that in this sense the 
greater charge density at the binder surfaces, rather than their specific spatial 
arrangements, dictated the increased binding efficiencies of C22G2LLys and C22G2DLys 
with heparin and DNA.  
The C22G2DLys species was also shown to degrade with a first half-life of ca. 1.40 
hours, and to be affected by shear forces caused through agitation in the same manner as 
C22G1DLys.   
5.4.2 Future Work 
Future work in this area will include investigating the observed chiral preferences 
between systems containing L-lysine and D-lysine surface groups using molecular 
dynamic modelling techniques, in collaboration with Professor Sabrina Pricl at 
University of Trieste. It is hoped that these modelling studies will give an insight into 
why chiral preferences appear to be reversed when binding DNA as opposed to heparin; 
and, additionally, why this chiral preference appears to be lost as the size of the binder 
increases.  
In order to understand these differing chiral preferences, it may be interesting to carry 
out a control study using a straightforward monoamine such as 6-aminohexanoic acid in 
place of lysine as this would afford binder molecules lacking the primary amine groups 
attached to the chiral α-carbons. Performance comparison against the lysine-surfaced 
binders would allow the binding contribution of the α-amines to be quantified. An 
alternative approach to study this could involve use of a shorter amino acid such as 
ornithine at the binder surface. The carbon backbone of ornithine is one -CH2 unit 
shorter than lysine and so would position the chiral centres slightly closer to the binder 
group surface without greatly affecting the overall structure. This subtle change may 
serve to amplify the effects of the chiral centres.  
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From the perspective of developing a novel heparin SAMul heparin rescue agent, the 
hydrophobic character of the next generation of binders should be enhanced in order to 
increase the robustness of assemblies in the presence of hydrophobic serum 
components. This could be achieved by introducing branching into the alkyl-tail moiety, 
for example through use of biologically relevant hydrophobes such as dual- or tri-tailed 
bile acids or cholesterol units. In making these modifications, it may be prudent to 
reduce the number of ester groups present in the system as connection of the surface 
groups to the linker unit through ester bonds here promoted degradation to unacceptably 
fast levels.   
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6 Hydrophobically-Enhanced Self-Assembling 
Heparin Binders 
6.1 Introduction 
Chapter 4 established self-assembled multivalency (SAMul) as an effective approach 
for developing novel heparin rescue agents, while Chapter 5 demonstrated that 
employing chiral binding groups at the surface could influence the heparin binding 
ability of the SAMul systems. One common feature shared by the families of SAMul 
binder molecules studied in the previous chapters was possession of a single twenty-two 
carbon atom aliphatic tail to promote self-assembly of the nanoscale heparin binding 
architectures. Although capable of heparin binding; these aggregates were susceptible to 
disruption and/or destabilisation by hydrophobic serum components such as albumin 
proteins. It was postulated that the long alkyl chain making up the hydrophobic unit 
may have inadvertently been rather optimised for interaction with albumin-type species, 
and that this therefore promoted disruption.
311
 Although this disruption did not normally 
prevent the SAMul systems from binding heparin in serum, it did impact on the relative 
effectiveness of binding when compared against measurements made in aqueous buffer. 
This disruption also manifested itself in other ways, for example by extending the 
observed clotting time in clinically relevant plasma clotting assays. It was reasoned that 
an alternative hydrophobic unit might be able to overcome some of this serum 
disruption and help stabilise the self-assembled nanostructures.  
Through its role promoting molecular self-assembly, the hydrophobic unit is also able to 
influence the morphology of the nanosized aggregates formed.
45
 To this point, all of the 
SAMul systems studied in this project have formed spherical, or roughly spherical, 
assemblies as dictated by the geometry of the individual ‘building block’ monomers. 
This was partly due to their mutual construction from the same ester-containing 
dendritic linker unit. It was therefore decided to redesign the heparin binding building 
block such that the monomer unit had a different molecular geometry, which would 
then in turn be able to generate a different (i.e. non-spherical) self-assembled 
architecture.  
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The work reported in previous chapters reported the effects of changing chirality on 
heparin binding performance and so, in order to probe this further, the amino acid lysine 
was retained as the heparin binding group to be displayed at the surface of the self-
assembled structure. A second amino acid, aspartic acid, was chosen to form the linker 
unit of the new binding system. The choice of an amino acid within the linker unit made 
chirality inherent within the entire building block structure, rather than only being 
present at the terminus. It was hoped that this linear arrangement of amino acids and 
therefore chirality throughout the monomer structure might amplify the chiral effects 
previously seen in our earlier SAMul constructs. 
Aspartic acid was identified as a suitable linker unit as the two terminal carboxylic acid 
groups were suitable for functionalisation with hydrophobic groups while the pendant 
amine group could be furnished with a cationic lysine moiety, through an amide 
linkage. The linear twelve-carbon alkyl chain of 1-dodecanol was selected as an 
appropriate hydrophobe owing to its similar, albeit shorter, character to the twenty-two 
carbon hydrophobic units used previously. Following this design, the two first 
generation (G1) species (C12)2LAspLLys and (C12)2DAspDLys, Figure 6.1, were 
identified as target molecules.    
 
Figure 6.1 – Twin-tailed G1 target molecules (C12)2LAspLLys and (C12)2DAspDLys.  
It was anticipated that these twin-tailed target molecules may self-assemble into non-
spherical architectures owing to their differing geometries compared to the previously 
synthesised systems. According to the packing parameters outlined by Israelachvili and 
co-workers in 1976, an increase in relative hydrophobicity might be expected to lead to 
the formation of cylindrical, rather than spherical, assembly structures.
45
 In turn it was 
reasoned that these structures may have the potential to better ‘shape-match’ the 
approximately linear polysaccharide heparin chains, which may result in improved 
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heparin binding over spherical constructs and potentially lead to more promising 
candidates for development as novel protamine alternatives. 
The initial syntheses of the G1 systems in this part of the project, along with the 
associated heparin and DNA binding studies were undertaken, under my supervision, by 
final year MChem student Ellis Wilde. Optimisation of the synthetic route to the G1-
lysine-containing systems was carried out, also under my supervision, by summer 
project student Mark Dowsett.   
6.2 Generation 1 (G1) Systems 
6.2.1 Lysine-containing system (G1) 
6.2.1.1 Synthesis of (C12)2LAspLLys and (C12)2DAspDLys 
The Asp-Lys binders were synthesised in a step-wise manner from the three molecular 
components shown in Figure 6.2: the hydrophobic chains of 1-dodecanol, the aspartic 
acid linker unit, and heparin binding lysine group. For the purposes of synthesis, 
aspartic acid was first derivatised with the alkyl tails before the lysine group was 
attached.  
 
Figure 6.2 – The three component pieces of G1 target molecules (C12)2LAspLLys and 
(C12)2DAspDLys.  
Initially, L-Asp(Boc) 6.1, a commercially available reagent, was identified as a suitable 
starting point for synthesis owing to the potential for functionalization of both 
carboxylic acid groups along with the acid lability of the amine Boc protecting group, 
Scheme 6.1. This species was firstly functionalised with two molecules of 1-dodecanol 
in a modestly yielding ester-forming reaction facilitated by DCC and DMAP to afford 
protected intermediate 6.3. Removal of the Boc protecting group was achieved using 
trifluoroacetic acid (TFA) conditions to afford intermediate salt 6.5 in an excellent 
yield. With the aspartic acid amine group now available, this was next coupled with the 
carboxylic acid of L-Lys(Boc)2 in a TBTU-mediated peptide coupling reaction to afford, 
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after purification by silica gel flash column chromatography, the protected final binder 
6.7 in reasonable yield. Final subjection of this compound to TFA deprotection 
conditions once again removed the Boc protecting groups and afforded the final ‘LL’ 
target molecule (C12)2LAspLLys 6.9 in a good yield. Synthesis of the ‘DD’ system 
proceeded in an analogous fashion except at the first stage where the commercial 
unavailability of D-Asp(Boc) required the reaction of native D-Asp with di-tert-butyl-
dicarbonate and sodium hydroxide in a water/dioxane mixture to generate D-Asp(Boc) 
6.2 for use in the production of (C12)2DAspDLys 6.10.  
 
Scheme 6.1 – Preparation of G1 target molecules (C12)2LAspLLys and (C12)2DAspDLys. 
A key consideration in the preparation of these target molecules was the retention of 
chirality. To that end, circular dichroism (CD) spectroscopy was carried out at each 
stage to interrogate the relative enantiomeric character of the growing systems. As 
shown in Figure 6.3, throughout the synthesis, CD spectroscopy suggested each system 
remained of equal and opposite enantiomeric character. Importantly, these data 
demonstrated that the synthetic steps undertaken do not appear to have scrambled, or in 
any identifiable way damaged, the chiral information within the systems.  
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Figure 6.3 – Circular dichroism data at different stages during the preparation of 
(C12)2LAspLLys (solid lines) and (C12)2DAspDLys (dashed lines) measured at 10 mM in 
methanol. 
6.2.1.2 Self-Assembly Studies 
The twin tailed SAMul molecules (C12)2LAspLLys and (C12)2DAspDLys were tested for 
their ability to self-assemble using the Nile Red encapsulation assay. The data suggested 
the CAC values for each of these systems were 67 (± 10) µM for the ‘LL’ analogue and 
74 (± 5) µM for ‘DD’. The encapsulation curves are shown in Figure 6.4.  
 
Figure 6.4 – Nile Red encapsulation curve for (C12)2DAspDLys. 
The CAC value is significantly larger than for the single-tailed systems reported in 
previous Chapters. This is an interesting observation as thermodynamically the CAC 
value might be expected to decrease as the degree of hydrophobic character within the 
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assembling monomers increases. Such a decrease in CAC would be likely to arise from 
the larger entropic benefit associated with the liberation of ‘frozen’ water molecules at 
the interface with the hydrophobic groups, although an increase in CAC may be seen if 
the difficulty associated with packing the charged surface groups together increases. 
The CAC values for these twin-tailed systems are around 20 µM higher than for single-
tailed analogues such as C22G1Lys, which appears to suggest that that there may be 
increased difficulty associated with positioning the charge surface groups close together 
at the assembly surface. This seems particularly likely as qualitative macroscopic 
observations, such as aqueous solubility, do not corroborate the possibility that each 
monomer is ‘less’ hydrophobic in relative terms than the single-tailed systems in earlier 
Chapters. In order to examine whether these structural changes have had an effect on 
the morphologies of the self-assembled architectures, they were examined by 
transmission electron microscopy.    
6.2.1.3 TEM Images  
TEM imaging was carried out on the (C12)2DAspDLys system in the absence and 
presence of heparin in clean water, at a concentration of 100 µM to ensure the 
compound was present in self-assembled form. Heparin was introduced at a charge ratio 
(+ : –) of 2, as under this concentration regime, the binder was known to interact well 
with heparin. Samples were negatively stained with uranyl acetate and allowed to dry on 
the formvar grid before imaging. The images are shown in Figure 6.5 and Figure 6.6.    
 
Figure 6.5 – TEM images of 100 µM (C12)2DAspDLys (scale bars: 100 nm (left), 50 nm 
(right)). 
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Figure 6.6 – TEM image of 100 µM (C12)2DAspDLys in the presence of heparin (scale 
bars: 200 nm (left), 100 nm (right)).  
The TEM images of (C12)2DAspDLys alone showed aggregates of different sizes, 
ranging approximately between 80 – 140 nm in diameter. The surfaces of the aggregates 
appeared textured, which may suggest the formation of closely packed lamellar 
aggregates by (C12)2DAspDLys. Lamellar structures are theoretically predicted when the 
critical packing parameter takes a value larger than 1; the situation when the overall 
molecular volume-in-space is composed of slightly more hydrophobic than hydrophilic 
domains.
45
 This observation suggests that the re-design of the self-assembling system 
has increased the overall hydrophobicity of the monomer building blocks so 
significantly that the cylindrical and vesicular-assembly morphologies – corresponding 
to critical packing parameters between 0.3 and 1 – have been completely bypassed. 
With the increase in relative hydrophobicity evidenced, the decrease in aqueous 
solubility of the twin-tailed systems compared to their single-tailed counterparts can be 
understood. The different (i.e. non-spherical) morphology may also account for the 
relative increase in CAC values discussed in the previous section as surface groups must 
be packed closely together in lamellae.   
In the presence of heparin, the images showed a variety of textured assemblies of sizes 
somewhat larger than observed in the absence of polysaccharide. This may suggest that 
in the presence of heparin we are observing a mixed heparin-binder aggregate in order 
to maximise binder-heparin interactions, as within a lamellar assembly some of the 
surface binding groups may be less accessible to heparin. Such rearrangement processes 
further emphasise the adaptability of a SAMul approach to heparin binding.   
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6.2.1.4 DLS Measurements 
In order to further assess the sizes of the aggregates formed in the absence of heparin, 
(C12)2LAspLLys and (C12)2DAspDLys were probed by dynamic light scattering (DLS) in 
collaboration with Dr Marcelo Calderon at Freie Universität Berlin. In line with work 
reported in earlier chapters, each compound was examined in 10 mM Tris HCl both in 
the absence and presence of 150 mM NaCl. The data are shown in Table 6.1. 
Table 6.1 – Dynamic Light Scattering (DLS) data for (C12)2LAspLLys and 
(C12)2DAspDLys in 10 mM Tris HCl in the absence and presence of 150 mM NaCl. 
Compound 
Average Diameter / nm 
10 mM Tris HCl 
only 
10 mM Tris HCl, 
150 mM NaCl 
(C12)2-L-Asp-L-Lys (138.4 ± 3.6) (172.4 ± 6.4) 
(C12)2-D-Asp-D-Lys (183.4 ± 9.8) (204.1 ±  11.6) 
The DLS data shows that (C12)2LAspLLys and (C12)2DAspDLys form relatively large 
solution-phase aggregates of 138.4 (± 3.6) nm and 183.4 (± 9.82) nm diameters 
respectively. The solution-phase diameters are somewhat larger than those observed for 
dried samples by TEM imaging, which further supports the formation of vesicles or 
lamellar assemblies. It is likely that in the solution phase, some aqueous solvent media 
becomes encapsulated inside the vesicular assembly causing the apparent aggregate size 
to ‘swell’. The observed size difference between the LL and DD systems is surprising as 
the difference in chiral expression between the two systems should not impact on 
assembly size. The difference may indicate a discrepancy in relative compound purity 
although other spectroscopic data does not support this. Alternatively, the difference 
may merely serve to highlight the variability of the aggregates of the aspartic acid-
lysine system dependent on preparation. It is also noteworthy that DLS showed the 
presence of a small proportion of superaggregates measuring larger than 4 µM diameter, 
which may result from the fusion and/or hierarchical aggregation of individual 
assembled species. In future it may be desirable to exert more control over aggregate 
size during preparation, for example, by subjecting samples to ultrafiltration or casting 
the compound as a thin film prior to solubilisation. Such techniques are often employed 
by colloid chemists during vesicle formation.      
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When DLS measurements were repeated in the presence of 150 mM NaCl, both 
compounds formed larger aggregates. This expansion is analogous to observations made 
previously for the other SAMul systems; specifically that the electrolytes both ‘shield’ 
the formed aggregates from one another and enhance the hydrophobic effect.    
6.2.1.5 Heparin Binding in Competitive Conditions 
With the self-assembling ability of (C12)2LAspLLys and (C12)2DAspDLys established 
and characterised, the compounds were examined for their heparin binding ability using 
the Mallard Blue assay. Each compound was tested under the standard experimental 
conditions of 25 µM MalB, 27 µM heparin, 150 mM NaCl and 10 mM Tris HCl. The 
heparin binding results are shown numerically in Table 6.2 and the binding curves are 
shown in Figure 6.7.  
Table 6.2 – Heparin binding data for (C12)2LAspLLys and (C12)2DAspDLys obtained 
from MalB assay in 150 mM NaCl and 10 mM Tris HCl. 
Compound 
Heparin Binding 
EC50 / μM CE50  
Dose /                                                    
mg per 100IU 
L-LysOMe No binding observed 
(C12)2-L-Asp-L-Lys (59.9 ± 11.3) (1.11 ± 0.21) (1.43 ± 0.27) 
(C12)2-D-Asp-D-Lys (52.2 ± 0.3) (0.97 ± 0.01) (1.25 ± 0.01) 
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Figure 6.7 – Heparin binding curves for (C12)2LAspLLys and (C12)2DAspDLys obtained 
from MalB assay in 150 mM NaCl and 10 mM Tris HCl.  
The heparin binding data suggest that there is little difference in heparin binding charge 
efficiency (CE50) between (C12)2LAspLLys and (C12)2DAspDLys, with both compounds 
requiring around one cationic charge per anionic heparin charge to displace 50% MalB 
into solution. This efficiency is comparable with the performance of C22G1DLys in 
Chapter 5 although the (C12)2AspLys system achieves the same effect with less charge 
per monomer (2+ vs 4+). The effective concentrations of (C12)2LAspLLys and 
(C12)2DAspDLys at 50% MalB displacement are 59.9 (± 11.3) µM and 52.2 (± 0.3) µM 
respectively; values which are slightly below the calculated CACs. This trend matches 
observations in earlier Chapters and may support the postulation that heparin serves to 
artificially lower the CAC through multivalently ‘templating’ the assembly process.   
In order to study the effect of self-assembly on this system, a commercial L-lysine 
methyl ester (L-LysOMe) was tested using the MalB heparin binding assay. This amino 
acid, which represents just the surface group of the self-assembling monomers, was 
completely unable to displace MalB from heparin. The appearance of some of the 
normalised absorbance values slightly below zero suggests not only that individual 
lysine residues are ineffective binders but also that at higher concentrations they may 
also interfere with the buffering of the system, impacting upon the spectrophotometric 
properties of MalB. Despite this, the evidence clearly indicates the heparin binding 
ability of (C12)2LAspLLys is primarily conferred by a SAMul process.  
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The relatively similarity in heparin binding abilities of (C12)2LAspLLys and 
(C12)2DAspDLys contrasts with the differences observed for the C22G1Lys structures in 
Chapter 5. Structurally, there are several important differences between the two 
enantiomeric pairs which may account for the absence of chiral binding preferences in 
the aspartic acid-lysine systems. In particular, although the families both contain the 
same number of chiral centres per molecule (two), within the new aspartic acid-lysine 
systems they are arranged in a linear manner along the molecule rather than being 
present only at the surface. This arrangement results in the chiral centres of 
(C12)2AspLys being located more closely to the hydrophobic unit, which may serve to 
supress the chiral expression of the system thereby restricting differentiability of the 
enantiomeric molecules. As shown in Figure 6.8, this contrasts against C22G1Lys, in 
which the achiral linker unit enforces a distance between the ‘frozen’ hydrophobic 
micellar interior and the chiral binding groups at the surface.     
 
Figure 6.8 – Comparison of the relative proximity of the hydrophobic units (blue 
squares) and chiral region (red circles) of (C12)2AspLys and C22G1Lys systems.  
Additionally, the lamellar nature of the (C12)2AspLys assemblies may also contribute to 
the suppression of chiral binding differences as this architecture dictates that the surface 
groups are packed very closely together. 
6.2.1.6 Heparin Binding in Clinically Relevant Conditions 
In order to probe the robustness of the assemblies in the presence of human serum, 
(C12)2DAspDLys was tested for heparin binding ability using the MalB assay with 
heparin delivered in 100% serum. The results are shown in Table 6.3.   
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Table 6.3 – Heparin binding data for (C12)2DAspDLys with heparin delivered in 100% 
human serum. 
Assay Conditions 
Heparin Binding: (C12)2-D-Asp-D-Lys 
EC50 / μM CE50  
Dose /                    
mg per 100IU 
Salt and Buffer (52.2 ± 0.3) (0.97 ± 0.01) (1.25 ± 0.01) 
Heparin in 10% Human Serum (57.0 ± 6.7) (1.06 ± 0.12) (1.42 ± 0.17) 
Heparin in 100% Human Serum (50.5 ± 8.8) (0.93 ± 0.16) (1.25 ± 0.22) 
The data suggests that in the presence of human serum, the heparin binding performance 
of (C12)2DAspDLys remains, within error, approximately the same as in the absence of 
serum. Interestingly, the percentage of serum present did not impact of the degree of 
binding observed. This may suggest that the lamellar assemblies formed are 
substantially more robust in the presence of hydrophobic serum and albumin proteins 
than the spherical aggregates formed by our previous SAMul systems. Alternatively, if 
the aggregates rearrange to incorporate heparin into their assemblies as hinted at by the 
TEM images, the apparent lack of serum disruption may suggest interactions between 
the binder and heparin are preferable to interactions between the binder and serum 
components. It may also be possible that the bilayer-character of the vesicle/lamellar 
walls remains intact during any rearrangement/heparin encapsulation event. If this were 
the case, the tightly packed nature of the monomer units which make up the bilayer may 
prevent serum components from gaining access to the ‘frozen’ hydrophobic interior of 
such a bilayer to cause disruption. 
It is worth emphasising that the maintenance of heparin binding performance by 
(C12)2DAspDLys is noteworthy as this ligand array is held together entirely by non-
covalent interactions. When compared against our earlier SAMul systems, this 
performance is most impressive, and is even superior to the covalent protamine 
structure which was somewhat affected by serum/albumin proteins. The retention of 
performance by (C12)2DAspDLys has so far only been matched by the larger covalent 
PAMAM-G2.  
6.2.1.7 Plasma Clotting Assays 
Having retained heparin binding performance in human serum, (C12)2DAspDLys was 
tested in both the prothrombin (PT) and activated partial thromboplastin (aPTT) plasma 
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clotting assays in order to assess the potential for heparin neutralisation in clinically 
relevant samples. These experiments were carried out in the laboratory of Professor 
Jeremy Turnbull at University of Liverpool, UK. No reversal of anticoagulation was 
observed, Table 6.4, although this may be due to solubility problems experienced during 
the preparation of the stock solutions. These issues may have resulted in the 
concentration of test compound being below the intended 1.25 mg/100IU dosed into the 
assay. It is thought that if the protocol was modified to avoid the preparation of a 
concentrated stock solution, the observed performance may improve.  
Table 6.4 – Plasma clotting data for (C12)2DAspDLys from PT and aPTT assays. 
Compound 
Clotting Time / s 
aPTT Assay PT Assay 
None (35.7 ± 0.7) (12.8 ± 0.8) 
Heparin only no clot no clot 
(C12)2-D-Asp-D-Lys no clot no clot 
 
6.2.1.8 DNA Binding  
Given the absence of chiral preference between (C12)2LAspLLys and (C12)2DAspDLys 
when binding to heparin, the compounds were tested for their abilities to bind DNA. 
The compounds were tested using the Ethidium Bromide (EthBr) displacement assay 
employed in Chapter 5, using the same conditions of 5.07 μM EthBr, 4 μM DNA (with 
respect to each base) in SHE buffer (2 mM HEPES, 0.05 mM EDTA and 150 mM 
NaCl) at pH 7.4. The results are shown numerically in Table 6.5 while the binding 
curves are shown in Figure 6.9. 
Table 6.5 – DNA binding data for (C12)2LAspLLys and (C12)2DAspDLys obtained in 
EthBr displacement assay. 
Compound 
DNA Binding 
EC50 / μM CE50  
(C12)2-L-Asp-L-Lys (3.11 ± 0.07) (1.55 ± 0.04) 
(C12)2-D-Asp-D-Lys (8.97 ± 0.32) (4.39 ± 0.16) 
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Figure 6.9 – DNA binding curves for (C12)2LAspLLys and (C12)2DAspDLys obtained 
from EthBr displacement assay. 
Significantly, the data shows the enantiomeric systems bound DNA with very different 
charge efficiencies. The L-system employed its positive charges much more effectively 
than the D-system, as emphasised by relative CE50 values of 1.55 (± 0.04) and 4.39 (± 
0.16) respectively. This performance difference is also reflected in the effective 
concentration at the same point, with (C12)2DAspDLys requiring over double the amount 
of binder as (C12)2LAspLLys. The EC50 values of  3.11 (± 0.07) and 8.97 (± 0.32) 
suggest the twin-tailed SAMul systems are operating below their CAC values although, 
as discussed in previous Chapters, the presence of DNA may be serving to artificially 
lower the assembly concentration of the binders, allowing multivalent binding to occur 
during this assay concentration range. The non-assembling control molecule 
L-Lys-OMe was unable to displace EthBr to any significant extent during the assay 
suggesting DNA binding is a SAMul-driven process. 
These chiral binding preferences are interesting on several levels. Firstly, the 
observation of a performance difference between the systems for DNA binding where 
none was observed for heparin binding suggests DNA is more acutely sensitive to the 
spatial arrangement of binding ligands. Heparin is a more charge-dense polyanion than 
DNA and these data may suggest heparin is more promiscuous; being less sensitive to 
spatial arrangement and/or in-space complementarity of its binding partner. The second 
interesting feature of the DNA data is the relative inefficiency with which the binder 
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molecules, particularly the D-system, are using their individual charges. Such large 
values – 1.55 (± 0.04) for LL and 4.39 (± 0.16) for DD – may suggest that only one of the 
two cationic charges per binder molecule interacts directly with DNA. If this is the case, 
it is arguably more surprising that such profound chiral difference was observed.  
6.2.2 Ornithine-containing systems 
Given the interesting chiral preferences observed for the aspartic acid-lysine SAMul 
systems, a family of related molecules were designed and synthesised. The new systems 
contained an ornithine residue at the binder surface in place of the lysine group, Figure 
6.10. Ornithine is structurally related to lysine, with the two species differing only in 
one –CH2 group within the side-chain. The shortening of the alkyl chain should serve to 
marginally increase the charge-density of the resulting binders, and was hoped to 
increase heparin (or DNA) binding ability. Additionally, shortening the chain positioned 
the outermost chiral centre closer to the extremity of the binder, and it was anticipated 
that this may amplify any chiral differences exhibited upon binding with anionic 
partners.   
 
Figure 6.10 – Ornithine-containing twin-tailed target molecules (C12)2LAspLOrn and 
(C12)2DAspDOrn. 
6.2.2.1 Synthesis of (C12)2LAspLOrn and (C12)2DAspDOrn 
(C12)2LAspLOrn and (C12)2DAspDOrn were synthesised in an analogous strategy to their 
lysine-containing counterparts, as shown in Scheme 6.2. Specifically, ornithine was 
Boc-protected using di-tert-butyl-dicarbonate and sodium hydroxide in dioxane to 
produce 6.11 and 6.12 in a moderate yield, before the carboxylic acid was coupled to 
the corresponding alkylated aspartic acid moiety 6.5 or 6.6. The resulting protected 
target molecules 6.13 or 6.14 were obtained in a modest yield, after purification by 
silica gel flash column chromatography. Removal of the remaining protecting groups 
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using trifluoroacetic acid deprotection conditions proceeded in a near-quantitative yield 
to afford the target molecules (C12)2LAspLOrn 6.15 and (C12)2DAspDOrn 6.16.  
 
Scheme 6.2 – Preparation of modified twin-tailed SAMul systems (C12)2LAspLOrn and 
(C12)2DAspDOrn.    
Once synthesised, the compounds were examined by circular dichroism spectroscopy to 
ensure that the chirality had been retained during synthesis. As shown in Figure 6.11, 
the molar ellipticity traces demonstrated the equal and opposite enantiomeric character 
of the two target molecules.  
 
Figure 6.11 – Circular dichroism spectra for (C12)2LAspLOrn and (C12)2DAspDOrn.    
6.2.2.2 Self-Assembly Studies 
The self-assembling ability of the ornithine-containing twin-tailed systems was tested 
using the Nile Red encapsulation assay. The critical aggregation concentration was 
found to be 30 (± 5) µM for (C12)2LAspLOrn and 44 (± 8) µM for (C12)2DAspDOrn. The 
Nile red encapsulation curves are shown in Figure 6.12.  
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Figure 6.12 – Nile Red encapsulation data for (C12)2LAspLOrn and (C12)2DAspDOrn. 
The ornithine-containing derivative self-assembled at a lower concentration than its 
lysine-containing counterpart. This may be a reflection of the small difference in 
hydrophobicity between the two systems. Nonetheless, with the self-assembling ability 
of the twin-tailed aspartic acid-ornithine system demonstrated, TEM imaging was 
employed to observe the morphology of the assemblies formed. 
6.2.2.3 TEM Imaging 
The compounds (C12)2LAspLOrn and (C12)2DAspDOrn were imaged both in the absence 
and presence of heparin on a formvar grid following negative staining with uranyl 
acetate and drying.  Heparin was introduced into the samples at a charge ratio (+ : –) of 
2.5 as, under this regime, the binders were known to interact favourably with heparin. 
The images are shown below. 
 
Figure 6.13 – TEM images of 100 µM (C12)2LAspLOrn (scale bars: 500 nm (left), 100 
nm (right)). 
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Figure 6.14 – TEM images of 100 µM (C12)2LAspLOrn in the presence of heparin 
(scale bars: 100 nm (both images)). 
 
Figure 6.15 – TEM images of 100 µM (C12)2LAspLOrn (scale bars: 500 nm (left), 100 
nm (right)). 
 
Figure 6.16 – TEM image of 100 µM (C12)2DAspDOrn in the presence of heparin (scale 
bar: 100 nm (left), 50 nm (right)). 
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The TEM images show the aspartic acid-ornithine structures form aggregates of 
differing sizes between ca. 20 – 100 nm diameters in a similar manner to the lysine-
containing analogues. In the absence of heparin, the images are suggestive of vesicular 
or lamellar assemblies. The images also appear to show some evidence of collapsed 
vesicles and smaller assemblies appearing ‘inside’ larger structures, which is typical for 
lamellar structures, although this could simply be a drying effect. In the presence of 
heparin, the textured appearance and variety of aggregate sizes again appears indicative 
of mixed binder-heparin aggregates. The difference in appearance of the species 
observed in the absence and presence of heparin for the (C12)2AspOrn systems seems 
much greater than for the (C12)2AspLys systems. 
6.2.2.4 Heparin Binding in Competitive Conditions 
The ornithine-containing systems were tested for their heparin binding ability using the 
Mallard Blue assay in the presence of buffer and salt. The data are shown numerically in 
Table 6.6 with the binding curves in Figure 6.17.  
Table 6.6 – Heparin binding data for (C12)2LAspLOrn and (C12)2DAspDOrn obtained 
from MalB assay. 
Compound 
Heparin Binding 
EC50 / μM CE50  
Dose /                                                    
mg per 100IU 
(C12)2-L-Asp-L-Orn (135 ± 5) (2.50 ± 0.09) (3.29 ± 0.12) 
(C12)2-D-Asp-D-Orn (125 ± 9) (2.35 ± 0.17) (3.09 ± 0.22) 
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Figure 6.17 – Heparin binding curves for (C12)2LAspLOrn and (C12)2DAspDOrn 
obtained from MalB assay. 
The data show that a concentration of ornithine-containing monomer in excess of 125 
µM was required to displace 50% MalB from heparin. The CE50 values of 2.50 (± 0.09) 
for LL and 2.35 (± 0.17) for DD confirm this rather inefficient heparin binding. Indeed, 
counter-intuitively, despite being marginally more charge dense than their lysine-
containing counterparts, the (C12)2AspOrn systems exhibit inferior heparin binding 
efficiencies. Clearly, this is another example of charge density not being the only factor 
controlling binding ability.  
Additionally, positioning the chiral centres closer to the binder extremity did not 
enhance the ability of heparin to discriminate between the enantiomeric systems. To 
some extent however, this absence of discrimination may be influenced by the 
inefficiency of binding and failure of the amines closest to the chiral centres to interact 
with heparin.    
6.2.2.5 Heparin Binding in Clinically Relevant Conditions 
Although less efficiently than the lysine-containing systems, (C12)2LAspLOrn and 
(C12)2DAspDOrn both successfully displaced MalB from heparin in the presence of 
competitive electrolytes. Next, the robustness of the heparin binding interactions was 
challenged by subjecting (C12)2DAspDOrn to the MalB assay with heparin delivered in 
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100% human serum. For consistency with our earlier studies, the DD-system was 
examined. The data are shown in Table 6.7. 
Table 6.7 – Heparin binding data for (C12)2DAspDOrn with heparin delivered in 100% 
human serum. 
Assay Conditions 
Heparin Binding: (C12)2-D-Asp-D-Orn 
EC50 / μM CE50  
Dose /                    
mg per 100IU 
Salt and Buffer (127 ± 9) (2.35 ± 0.17) (3.09 ± 0.22) 
Heparin in 100% Human Serum (121 ± 7) (2.23 ± 0.12) (2.94 ± 0.16) 
The data show that (C12)2DAspDOrn fully maintained heparin binding performance in 
the presence of human serum. This result further supports the earlier observations that 
the assemblies formed by the twin-tailed systems are robust enough to maintain 
effective heparin binding interactions even in the presence of serum and its many 
hydrophobic components.  
6.2.2.6 DNA Binding 
The ornithine-containing systems were also tested for their ability to bind DNA using 
the ethidium bromide assay under the same conditions previously employed. The data 
are presented numerically in Table 6.8 along with the binding curves in Figure 6.18.   




EC50 / μM CE50  
(C12)2-L-Asp-L-Orn (3.24 ± 0.19) (1.61 ± 0.10) 
(C12)2-D-Asp-D-Orn (5.89 ± 0.39) (2.93 ± 0.19) 
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Figure 6.18 – DNA binding curves for (C12)2LAspLOrn and (C12)2DAspDOrn obtained 
from EthBr assay. 
The DNA data are interesting as the ornithine-containing binders were able to displace 
50% EthBr at comparable concentrations to their lysine-containing counterparts. In 
terms of charge efficiency (CE50), the DD-ornithine-system outperformed the DD-lysine-
system while the LL-ornithine system was inferior to its LL-lysine counterpart. This 
observation contrasts somewhat with the heparin binding data, where both lysine-
containing systems were significantly more charge efficient than the ornithine-
derivatives. This hints, once again, at fundamental binding differences for heparin and 
DNA. Further differences between the polyanion preferences were observed when 
considering the relative performance of (C12)2LAspLOrn and (C12)2DAspDOrn. With 
DNA as the binding target, the LL-system was clearly a superior binder, requiring only 
60% as much charge as the DD-system (1.61 (± 0.10) vs 2.93 (± 0.19)) to effectively 
displace 50% of EthBr and, although striking, this discrimination is less than observed 
for the lysine-containing systems (1.55 (± 0.04) vs 4.39 (± 0.16)). This LL superiority 
here correlates with the aspartic acid-lysine data and again points to DNA being more 
sensitive than heparin to the spatial arrangement of the interaction sites within binding 
partners.     
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6.3 Generation 2 (G2) Lysine-containing System  
A limitation of the twin-tailed heparin binders presented in the previous section was 
their poor raw heparin binding ability. It was reasoned that the heparin binding ability of 
the system might be increased through introduction of a larger, more highly charged, 
binding group at the assembly surface. This size increase was achieved through the 
introduction of further lysine residues to afford a ‘G2’ version of the aspartic acid-lysine 
structure presented in the previous section. An advantage of this approach was that it 
increased the number of chiral centres per monomer from two to four and it was hoped 
that this may enhance the ability of heparin to discriminate between the enantiomeric 
systems. It was also noted that the additional lysine residues may enhance the solubility 
of the binder monomers. Specifically, the target molecules shown in Figure 6.19 were 
designed.  
 
Figure 6.19 – Two G2 aspartic acid-lysine target molecules (C12)2LAspLLys(LLys)2 and 
(C12)2DAspDLys(DLys)2.   
Each of the new target molecules contained a dendritic lysine tri-peptide as the heparin 
binding surface group. Dendritic lysine structures are well-known
359
 and have been 
widely studied for medicinal applications.
360
 For example, recent work led by 
Kostarelos and Al-Jamal demonstrated the ability of high generation lysine dendrimers 
to delay tumour growth both through systemic antiangiogenic activity
361
 and the ability 
of such dendrimers to complex with, and enhance the cytotoxicity of, known 
chemotherapeutic drugs such as doxorubicin.
362
 Lysine dendrimers have also shown 
potential as gene transfection agents in vitro
363
 and been investigated in a variety of soft 
materials
364
 and gel-based studies.
365,366
 Most commonly, however, lysine moieties are 
appended onto a molecular scaffold such as another dendrimer,
367
 a growing polymer
368
 
or are themselves functionalised in some other way
369
 to generate functional species. In 
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particular, the haemolytic compatibility of Hashida and co-workers’ PEG-functionalised 
lysine dendrimers
369
 fuelled our optimism about the potential biocompatibility of our 
enlarged aspartic acid-lysine species.  
6.3.1 Synthesis of (C12)2LAspLLys(LLys)2 and (C12)2DAspDLys(DLys)2 
These new target molecules were synthesised from the same 1-dodecanol, aspartic acid 
and lysine building blocks as the smaller G1 systems, however the chronology of each 
synthetic step required careful consideration here. It was considered that the generation 
and installation of the dendritic lysine moiety at the binder surface could proceed in 
either a convergent or divergent manner, whereby the tri-peptide would be either 
synthesised and then attached to the binder or generated layer-by-layer once on the 
‘growing’ binder molecule. As demonstrated by Smith and co-workers in 2003, only the 
divergent methodology – that is the layer-by-layer approach – was appropriate here in 
order to retain the chiral integrity of the lysine residues within the final structure.
370
 
Practically, this approach involved the peptide coupling of ‘additional’ protected lysine 
residues to the already-synthesised (C12)2LAspLLys 6.9 or (C12)2DAspDLys 6.10, 
Scheme 6.3. The yield of this coupling was low, although it is thought that either an 
increased stoichiometric excess of Lys(Boc)2, a longer reaction time and/or an increased 
reaction temperature may assist in fortifying this yield. The final target molecules 
(C12)2LAspLLys(LLys)2 6.19 and (C12)2DAspDLys(DLys)2 6.20 were afforded in good 
yields following Boc-deprotection under trifluoroacetic acid conditions. Only a very 
small amount of (C12)2LAspLLys(LLys)2 6.19 (<7 mg) was produced and this restricted 
some of the studies presented below.    
 
Scheme 6.3 – Preparation of (C12)2LAspLLys(LLys)2 and (C12)2DAspDLys(DLys)2.   
Once synthesised, the relative chiral character of the systems was probed using optical 
rotation and the approximately equal and opposite values (LLLL: + 8.0, DDDD: – 6.5) 
confirmed the opposing chirality had been retained following the introduction of the 
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new amino acids. Owing to the limited amount of (C12)2LAspLLys(LLys)2 available, 
circular dichroism studies were not conducted. 
6.3.2 Self-Assembly Studies 
6.3.2.1 Nile Red Assay 
The ability of the G2 twin-tailed system to self-assemble was studied using a Nile red 
encapsulation assay. Again, owing to the limited amount of (C12)2LAspLLys(LLys)2 
available, only the D-system was examined. In previous examples, both members of 
each enantiomeric pair of molecules exhibited comparable CAC values so this was not a 
concern. The data, Figure 6.20, showed the CAC to be 14 (± 3) µM. 
 
Figure 6.20 – Nile Red encapsulation curve for (C12)2DAspDLys(DLys)2. 
The introduction of the lysine tri-peptide at the surface of the monomer unit resulted in 
a significant decrease in the observed CAC value. This observation appears counter-
intuitive as the additional lysine groups increase the overall monomer hydrophilicity, 
which may be expected to hinder aggregation/self-assembly. The observations do agree 
with other previous studies however, for example the recent work of Haag and co-
workers, which noted a decrease in CACs as hydrophilic character of their systems 
increased.
72
 In order to assess whether aggregate architecture may be influencing the 
observed CAC values, TEM imaging was carried out. 
6.3.2.2 TEM Images 
Having established that self-assembly was occurring, (C12)2DAspDLys(DLys)2 was 
examined by transmission electron microscopy to probe the morphology of the 
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aggregates formed. As before, samples were prepared in the absence and presence of 
heparin at a charge ratio of 1 on a formvar grid, stained with uranyl acetate and allowed 
to dry prior to imaging. Representative TEM images are shown in Figure 6.21 and 
Figure 6.22.  
 
Figure 6.21 – TEM images of (C12)2DAspDLys(DLys)2 alone (scale bars: 50 nm (left), 
200 nm (right)). 
 
Figure 6.22 – TEM images of (C12)2DAspDLys(DLys)2 in the presence of heparin (scale 
bars: 100 nm (left), 50 nm (right)). 
The TEM images of (C12)2DAspDLys(DLys)2 alone show some interesting features; 
there is evidence of several different assembled morphologies. For example, across the 
background of the left grid in Figure 6.21, individual micelle-like aggregates can be 
seen, each ca. 5 nm in diameter. There are also larger roughly-spherical species seen in 
other regions of the grid with ca. 45 nm diameter. These larger species may arise either 
due to the formation of superaggregates, which result from the further co-assembly of 
many individual smaller micelles. It is also possible that these larger species are vesicles 
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formed by (C12)2DAspDLys(DLys)2, although the evidence of smaller apparently-
micelles species on the surfaces of these larger objects appears to support the former 
interpretation. Nonetheless, the introduction of extra lysine groups at the surface has 
clearly altered the geometry of the monomer and dis-favoured the formation of 
exclusively lamellar aggregates. Several regions of elongated, tubular assemblies were 
also seen – right grid in Figure 6.21 – which may indicate formation of some cylindrical 
assemblies. This collection of different morphologies may suggest that the geometry of 
the modified twin-tailed systems is particularly versatile, permitting the formation of 
different shaped assemblies in different situations. Indeed, controlling the self-assembly 
step in order to direct the morphology more precisely may be an interesting focus for 
further study. Nonetheless, the non-vesicular morphologies here may also account for 
the significantly lower CAC values of (C12)2AspLys(Lys)2 compared to (C12)2AspLys.  
In the presence of heparin – Figure 6.22 – the images show objects of various sizes, 
which appear to be mixed binder-heparin assemblies. The majority of these assemblies 
are spherical, or roughly oval, in shape with diameters of ca. 45 nm and all appear to 
have internal fine structures which can be identified as binder assemblies interacting 
with the heparin polysaccharide. Given the variety of morphologies observed in the 
absence of heparin, these images may suggest that the smaller binder assemblies 
observed in the presence of the polysaccharide are best able to optimise their 
multivalent ligand arrays for successful binding interactions.  
6.3.3 Heparin Binding in Competitive Conditions 
The G2 twin-tailed systems were examined for their ability to bind heparin in the 
presence of buffer and salt using the Mallard Blue assay. The data are presented 
numerically in Table 6.9, with the binding curves shown in Figure 6.23. 
Table 6.9 – Heparin binding data for (C12)2LAspLLys(LLys)2 and 
(C12)2DAspDLys(DLys)2 from MalB assay in buffer and salt.  
Compound 
Heparin Binding 
EC50 / μM CE50  
Dose /                                                    
mg per 100IU 
(C12)2-L-Asp-L-Lys(L-Lys)2 (19.6 ± 0.3) (0.73 ± 0.01) (0.75 ± 0.01) 
(C12)2-D-Asp-D-Lys(D-Lys)2 (16.9 ± 0.5) (0.63 ± 0.02) (0.64 ± 0.02) 




Figure 6.23 – Heparin binding curves for (C12)2LAspLLys(LLys)2 and 
(C12)2DAspDLys(DLys)2 from MalB assay in buffer and salt.  
The data show that increasing the number of cationic groups at the surface of the binder 
molecule through introduction of additional lysine residues served to increase the 
binding efficiency, and ability, of the twin-tailed SAMul systems. Indeed, the ‘LLLL’ 
and ‘DDDD’ systems are able to displace 50% of MalB from heparin at 19.6 (± 0.3) µM 
and 16.8 (± 0.5) µM respectively; that is approximately a third of the concentration of 
their smaller G1 counterparts. The data indicates that each of the individual charges 
within the G2-systems is employed in a more charge efficient manner than in the G1-
systems. This may be due to a combination of the increased binder charge and the 
different, more micellar, self-assembled morphologies. 
More interestingly, heparin exhibited a chiral preference between 
(C12)2LAspLLys(LLys)2 and (C12)2DAspDLys(DLys)2 upon binding, with the DDDD 
system requiring less cationic charges to be present – 0.63 (± 0.02) compared to 0.73 (± 
0.01) for LLLL – to bind to a given amount of heparin. Although the CE50 values for 
each system are relatively close, the difference is statistically significant, falling outside 
of error. The D-system being the preferred of the two is in concordance with 
observations in earlier Chapters and suggests that when heparin is able to distinguish 
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differences between the spatial arrangement of a pair of enantiomeric binders, it finds 
the charges of the D-system to be more optimally arranged.  
Comparison of the performance of these G2 SAMul binders against the C22G1Lys and 
C22G2Lys systems from Chapter 5 is insightful here. Both C22G1Lys and 
(C12)2AspLys(Lys)2 present heparin with two lysine groups and four cationic charges 
for binding yet clearly the twin-tailed systems are much superior binders. This may 
suggest that the binding charges in the twin-tailed system are displayed in a more 
complementary manner to the anionic charges along the heparin polysaccharide. In 
terms of molecular weight, the twin-tailed systems are more massive than the C22G1Lys 
monomers (858 Da vs 784 Da) and so can be argued to be less charge dense, thereby 
providing another example of charge density not being the sole factor controlling 
heparin binding ability. Additional comparison against the C22G2Lys monomer family 
gives insights into the relative chiral expression of the two systems. Each monomer 
presents heparin with four chiral centres yet the C22G2Lys systems, in which all the 
chiral groups are present at the monomer/assembly surface, exhibited no discrimination 
upon binding. The G2-twin-tailed system meanwhile, in which the chiral centres are 
arranged linearly along the monomer structure, exhibited a small chiral difference upon 
binding suggesting this arrangement promoted expression of the opposing molecular 
‘handedness.’     
6.3.4 Heparin Binding in Clinically Relevant Conditions 
With the heparin binding ability of the twin-tailed G2 SAMul binders demonstrated in 
buffer and salt, (C12)2DAspDLys(DLys)2 was examined in the presence of human serum 
using the MalB assay. The data are shown in Table 6.10. 
Table 6.10 – Heparin binding data for (C12)2DAspDLys(DLys)2 from MalB assay with 
heparin delivered in 100% human serum. 
Assay Conditions 
Heparin Binding: (C12)2-D-Asp-D-Lys(D-Lys)2 
EC50 / μM CE50  
Dose /                    
mg per 100IU 
Salt and Buffer (16.9 ± 0.5) (0.63 ± 0.02) (0.64 ± 0.02) 
Heparin in 100% Human Serum (33.5 ± 0.7) (1.24 ± 0.03) (1.27 ± 0.03) 
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The data show that in the presence of human serum, the performance of 
(C12)2DAspDLys(DLys)2 decreased significantly, with twice as much cationic charge 
required to displace 50% MalB during in the assay. This performance decrease suggests 
the hydrophobic serum components may be disturbing the self-assembled aggregates, 
thereby perturbing the display of a multivalent ligand array for binding. Such a 
significant disruptive effect by serum is perhaps surprising given the robustness of the 
smaller G1 twin-tailed aspartic acid-lysine systems in the previous section. So far, of the 
systems presented in earlier Chapters, all of those perturbed by serum have adopted 
spherical micellar self-assembled structures, while the G1 aspartic acid-lysine and 
aspartic acid-ornithine molecules, which experienced minimal serum disruption, 
adopted lamellar structures. The disruption of (C12)2DAspDLys(DLys)2, a twin-tailed 
system which forms predominantly micellar assembles, appears to suggest that the 
choice of hydrophobic unit is not the only factor to influence disruption, but rather that 
the architecture/morphology of the self-assembled systems exerts a more controlling 
role over serum stability. This suggests that serum components such as, for example, 
albumin proteins are better able to gain access to the hydrophobic interior of a micelle 
than penetrate the ‘double-layered’ nature of a vesicle wall in order to interfere with the 
hydrophobically driven assembly. This assertion suggests that the individual monomers 
are more tightly packed along the surface of a vesicle or lamellar structure than when in 




6.4 Conclusions and Future Work 
Three enantiomeric pairs of SAMul binder molecules were synthesised and examined 
for their abilities to self-assemble and to interact with anionic targets heparin and DNA. 
The first pair of molecules, (C12)2AspLys contained two twelve-carbon aliphatic tails in 
their hydrophobic unit and were connected through a central aspartic acid linker unit to 
a single lysine surface group. The use of a twin-tailed hydrophobe yielded 
hydrophobically enhanced monomer units, which exhibited different packing 
geometries to the systems examined previously. Indeed, self-assembly of these systems 
was shown by TEM imagining to produce lamellar, rather than micellar, architectures, 
which were shown to form spontaneously above ca. 70 µM by a Nile Red encapsulation 
assay.  
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These (C12)2AspLys systems were able to bind heparin in the presence of salt and 
buffer, although performance was inferior to the previously tested C22G1Lys systems. 
Importantly however, the hydrophobically enhanced (C12)2AspLys systems retained 
their heparin binding performance in the presence of human serum; a feat none of the 
previously tested SAMul binders achieved. Alongside these positive effects, the 
increased hydrophobicity impacted negatively on the water solubility of the final 
monomers, and this is thought to have affected the results of the plasma clotting assays, 
where the compounds were unable to neutralise the anticoagulant action of heparin.  
The pair of enantiomeric molecules exhibited identical heparin binding performances 
suggesting that the spatial arrangement of charge in these systems had negligible impact 
on interaction with heparin. When the same molecules were investigated for DNA 
binding, however, a chiral difference was observed, with (C12)2LAspLLys binding 50% 
of DNA at significantly lower concentrations, and more charge efficiently than 
(C12)2DAspDLys.  
In order to probe this chiral difference, a related family of twin-tailed binders containing 
ornithine as the surface binding group instead of lysine were synthesised and tested. The 
(C12)2AspOrn systems self-assembled to form lamellar aggregates above ca. 30 µM. 
When tested for their heparin and DNA binding ability, these (C12)2AspOrn systems 
were shown to bind the polyanions less efficiently than when lysine was the surface 
group. Heparin exhibited minimal chiral preference between (C12)2LAspLOrn and 
(C12)2DAspDOrn yet DNA bound the LL-enantiomer more efficiently than the DD, again 
hinting strongly at fundamental binding differences between heparin and DNA. Despite 
the poor heparin binding performance, the presence of serum caused minimal 
perturbation.      
In an attempt to increase the heparin binding performance of these twin-tailed systems, 
a final iteration of the structure afforded a larger ‘second generation’ pair of 
enantiomers (C12)2LAspLLys(LLys)2 and (C12)2DAspDLys(DLys)2, containing a lysine 
tripeptide binding group at the surface. These larger monomers exhibited more charge 
efficient heparin binding than their smaller ‘G1’ counterparts; however performance 
was significantly perturbed in the presence of human serum. The presence of two 
additional lysine groups was shown to alter the monomer geometry leading to the 
formation primarily of spherical micellar assemblies. It was noted that these species 
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shared the same morphology as the previously discussed C22G1Lys structures, which 
themselves suffered significant perturbation by serum. This lead to the suggestion that 
the relative stability of the smaller (C12)2AspLys and (C12)2AspOrn systems was 
primarily due to their non-micellar vesicular/lamellar self-assembled architectures. 
In order to investigate this suggestion more thoroughly, mesoscale modelling could be 
employed to simulate the effect of, for example, an albumin protein upon the non-
covalent interactions holding the self-assembled structures together. Future 
experimental work could target the synthesis of alternative monomer units with 
geometries specifically designed to afford cylindrical and/or vesicular assemblies. To 
achieve this, other hydrophobic units could be employed such as cholesterol-like steroid 
species or multi-tailed/branched natural fatty acids and bile acids. Maintaining lysine as 
the binding surface group may provide consistency within test conditions but would 
also permit further studies of enantiomeric pairs of binder molecules, which may further 
elucidate the fundamental binding differences between biological polyanions such as 
heparin and DNA uncovered here.   
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7 Experimental 
7.1 Synthetic Materials and Methods  
General Reagents and Methods 
All reagents were obtained from commercial sources and were used without further 
purification unless stated. In particular, thin layer chromatography (TLC) was 
performed on Merck aluminium backed plates, coated with 0.25 nm silica gel 60; flash 
column chromatography was performed on silica gel 60 (35 – 70 μm) supplied by Fluka 
Ltd and preparative gel permeation chromatography (GPC) was performed on Biobeads 
SX-1 supplied by Bio-Rad and Sephadex LH-20.  
NMR spectra were recorded on a JEOL ECX400 (
1
H 400 MHz, 
13
C 100 MHz) 









C HSQC spectra with their 1D counterparts. For some compounds, high 
molecular weight or molecular aggregation led to quaternary carbon signals not being 
observed. HRMS and ESI mass spectra were recorded on a Bruker Daltonics Microtof 
mass spectrometer. Infrared spectra were recorded on a Shimadzu IR Prestige-21 FT-IR 
spectrometer while optical rotation values were obtained using a Jasco DIP-370 digital 
polarimeter with filter fitted at 589 nm. Circular Dichroism was carried out on a Jasco 
J810 CD Spectrophotometer (150w Xe lamp). 
Where both enantiomeric forms of a compound have been made, unless stated, D-




Molecular Formula: C21H38N4O8 
Molecular Weight: 474.55 
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L-Arginine (4.00 g, 22.96 mmol, 1 eq.) and sodium hydroxide pellets (2.75 g, 68.75 
mmol, 3 eq.) were dissolved together in deionised water (70 mL). Di-tert-butyl 
dicarbonate (20.00 g, 91.64 mmol, 4 eq., pre-dissolved in THF (70 mL)) was added to 
the basic arginine solution dropwise in one portion over 55 minutes before the resulting 
reaction mixture was stirred at 45°C under an N2 atmosphere for 4 hours. The volatiles 
were removed in vacuo and the resulting residue was taken up in deionised water (300 
mL) and washed with cyclohexane (100 mL). The aqueous layer was acidified to pH 3 
(1.33 M NaHSO4, pH paper) before the product was extracted into ethyl acetate and 
washed successively with brine (75 mL, sat.) and deionised water (75 mL). The organic 
layer was collected, dried over MgSO4 and the resulting filtrate was concentrated in 
vacuo to afford the product as a golden oil, which was taken up in DCM and 
concentrated in vacuo once more to afford the product as a white crystalline solid (1.30 
g, 2.74 mmol, 12%). 
Rf = 0.56 (9 : 1, DCM : methanol, UV/ninhydrin) 
1
H  NMR (400 MHz, CD3OD) δ: 4.10 (exp dd, app q, CHNH, 
3
J = 7.2 Hz, 1H); 3.88 (t, 
CH2NH, 
3
J = 6.8 Hz, 2H); 1.90 – 1.76 (m, CHaHbCHNH, 1H); 1.67 (br s, CHaHbCHNH, 
CH2CH2NH, 3H); 1.55, 1.48, 1.44 (s, C(CH3)3, 9H). 
13
C NMR (100 MHz, CD3OD) δ: 176.26 (C=O, acid); 158.56 (C=N); 158.15 (3 × C=O, 
carbamate); 80.44, 79.85 (total 3 × C(CH3)3); 54.83 (CHNH); 41.01 (CH2NH); 30.56 






 (C21H39N4O8) m/z = 475.2762, found [M+H]
+
 m/z = 475.2769 
(error − 1.0). 
IR ν [cm-1]: 3354br w (N–H), 2979m (O–H, C–H), 1710s (C=O, acid), 1640m (C=O, 
carbamates), 1609m (C=N), 1503m (N–H), 1454w, 1391m, 1366s, 1273m, 1249s (C–
O), 1144s (C–O), 1052m, 852m, 812w. 
LαD: + 17.7 (c. 1.0, CHCl3). 
Thionine-(L-Arg(Boc)3)2 (aka. Mallard Blue(Boc)6) 
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Molecular Formula: C54H82N11O14S 
Molecular Weight: 1141.36 
Thionine acetate (124 mg, 0.43 mmol), L-Arg(Boc)3 (450 mg, 0.95 mmol), TBTU (304 
mg, 0.95 mmol) and DIPEA (330 µL, 1.90 mmol) were dissolved together in DCM (50 
mL). The resulting reaction mixture was stirred at room temperature overnight before 
volatiles were removed in vacuo to afford the crude product. This solid was purified by 
flash column chromatography (SiO2, 3 : 2 ethyl acetate : cyclohexane) to afford the pure 
product as a purple solid (145 mg, 0.13 mmol, 30%). 
Rf = 0.39 (3 : 2, ethyl acetate : cyclohexane) 
1
H NMR (400 MHz, DMSO-d6) δ: 9.76 (br s, NH, 2H); 9.07 (br s, NH, 4H); 8.43 (br s, 
NH, 2H); 7.26 (s, CHCS, 2H); 7.10 (d, ArCH, 
3
J = 8.3 Hz, 1H); 7.00 (d, ArCH, 
3
J = 8.3 
Hz, 1H); 6.60 (d, ArCH, 
3
J = 8.3, 2H); 4.04 – 3.91 (m, 2 × CHNH, 2H); 3.80 – 3.73 (m, 
2 × CH2NH, 4H); 1.66 – 1.51 (m, 2 × CH2CHCONH, 2 × CH2CH2NH, 8H); 1.43 (s, 
C(CH3)3, 18H); 1.37 (s, C(CH3)3, 36H). 
13
C NMR (100 MHz, DMSO-d6) δ: 170.37 (2 × C=O, amides); 162.84, 159.51, 154.07 
(2 × C=O, carbamates); 137.73 (C=N); 117.04 (ArCH); 115.71 (CHCS); 114.08 
(ArCH); 77.92, 77.57 (3 × C(CH3)3); 51.31 (CHNH); 43.95 (CH2NH); 27.91, 27.36 (3 × 






 (C54H84N11O14S) m/z = 1142.5914, found [M+H]
+
 m/z = 
1142.5866 (error 4.2 ppm). 
IR ν [cm-1]: 3372br m (N–H), 2978w (C–H); 1713s (C=O, amides); 1674s (C=O, 
carbamates), 1605s (C=N), 1481s, 1366m, 1242s, 1142s, 1049m, 980w, 849w, 779w, 
502s. 
LαD: – 2.2 (c. 0.5, MeOH). 
Thionine-(L-Arginine)2 (aka. Mallard Blue) (2.2) 
 
Molecular Formula = C24H38Cl5N11O2S 
Molecular Weight = 721.96 
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Thionine-(L-Arg(Boc)3)2 (108 mg, 95 μmol) was dissolved in methanol (20 mL) and 
gaseous HCl was bubbled through the solution for 20 seconds. The resulting reaction 
mixture was stirred at room temperature for 3 hours before the volatiles were removed 
in vacuo. The dissolution in methanol and HCl gas treatment was repeated until TLC 
showed no presence of starting material, and the product was afforded, after drying, as a 
dark green solid. (71 mg, 93 μmol, 98%). 
Rf = 0.00 (ammonium hydroxide). 
1
H NMR (400 MHz, DMSO-d6) δ: 8.44 (s, ArCH, 4H); 7.88 (s, ArCH, 2H); 7.43 (br s, 
NH, 14H); 3.19 (br s, 2 × CHNH, 2 × CH2NH, 6H); 1.83 (br s, CH2CHNH, 4H); 1.56 
(br s, CH2CH2NH, 4H). 
13
C NMR (100 MHz, DMSO-d6) δ: Poor solubility and compound aggregation limited 
the ability to obtain meaningful spectrum. 
ESI-MS: 271.64 [M+2H]
2+





 (C24H37N11O2S) m/z = 271.6421, found [M+2H]
2+
 m/z = 
271.6404 (error 6.3 ppm). 
IR ν [cm-1]: 3248br s (N–H); 2924br s (C–H); 1651s (C=O, amides); 1466s, 1296w, 
1227w, 1096w, 1011m, 818w. 
LαD:  – 186.4 (c. 0.5, MeOH). 
DαD: − 167.5 (c. 1.0, MeOH). 
Propyne-G1-DAPMA (4.1)  
 
Chemical Formula: C24H50Cl4N6O6 
Molecular Weight: 660.50 
Propyne-G1-DAPMA(Boc)4 (50 mg, 70 µmol) was dissolved in methanol (10 mL) and 
gaseous HCl was bubbled through the solution for 15 seconds. The resulting reaction 
mixture was stirred at room temperature for 2 hours before being concentrated in vacuo 
to afford the product as a golden solid (43 mg, 65 µmol, 93%).  
 Rf = 0.15 streak (95 : 5, methanol : ammonium hydroxide, ninhydrin). 
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1
H  NMR (400 MHz, CD3OD) δ: 4.74 (d, CH≡CCH2, 
4
J = 2.0 Hz, 2H); 4.21 (s, 2 × 
CH2O, 4H); 3.43 – 3.32 (m, 2 × CHNH3
+
, 4H); 3.31 – 3.17 (m, 4 × CH2NCH3, 8H); 
3.14 – 3.07 (m, 2 × CH2NHCO, 4H); 3.04 (t, CH≡CCH2, 
4
J = 2.0 Hz, 1H); 2.21 – 2.10 
(m, 2 × CH2CH2NH, 4H); 2.05 – 1.90 (m, CH2CH2NH2, 4H); 1.27 (s, CH3, 3H).  
13
C NMR (100 MHz, CD3OD) δ: 173.82 (C=O, Fréchet-ester); 158.58 (2 × C=O, 
carbamates); 77.93 (HC≡CCH2); 76.93 (HC≡CCH2); 67.83, 66.94 (CH2O); 55.41, 55.33 
(2 × CH2NCH3); 54.29 (2 × CH2NH2); 53.66 (HC≡CCH2); 40.63, 40.55 (NCH3); 38.75, 






 (C24H47N6O6) m/z = 515.3557, found [M+H]
+
 = 515.3571 (error 
2.7 ppm). 
IR ν [cm-1]: 3375br w (N–H), 2975m (C–H), 1735m (C=O, ester), 1687s (C=O, 





Molecular Formula: C23H48O3S 
Molecular Weight: 404.33 
1-Docosanol (5.29 g, 16.20 mmol) was suspended in DCM (130 mL) and triethylamine 
(5.23 mL, 37.52 mmol) was added. Methanesulfonyl chloride (2.00 mL, 25.84 mmol) 
was added causing dissolution of the other reagents and turning the reaction mixture 
yellow. The reaction mixture was stirred at room temperature for 4 hours before being 
washed successively with deionised water (40 mL), HCl (40 mL, 2 M), deionised water 
(40 mL), NaHCO3 (40 mL, sat.) and deionised water (40 mL). The organic phase was 
collected, dried over MgSO4 and the resulting filtrate concentrated in vacuo to afford 
the product as a yellow-white solid (6.10 g, 15.1 mmol, 93 %). The spectroscopic data 
presented below is in agreement with that previously published.  
Rf = 0.55 (9 : 1, DCM : methanol, UV).    
1
H NMR (400 MHz, CDCl3) δ: 4.21 (t, CH2O, 
3
J = 6.4 Hz, 2H); 3.00 (s, CH3SO3, 3H); 
1.74 (quint, CH2CH2O, 
3
J = 6.4 Hz, 2H); 1.25 (s, 19 × CH2, 38H); 0.88 (t, alkylCH3, 
3
J 
= 7.8 Hz, 3H). 
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13
C NMR (100 MHz, CDCl3) δ: 70.19 (CH2O); 37.36 (CH3SO3); 29.69, 29.67, 29.65, 
29.61, 29.52, 29.42, 29.36, 29.12 (alkylCH2); 29.03 (CH2CH2O); 25.41, 22.69 
(alkylCH2); 14.12 (alkylCH3).  
ESI-MS: Calcd. [M+Na]
+
 (C23H48NaO3S) m/z = 427.3216, found [M+Na]
+
 m/z = 
427.3203 (error – 3.0 ppm).  
IR ν [cm-1]: 2914s (C–H), 2848m (C–H), 2161w, 2025w, 1975w, 1469m, 1335s, 1164m, 





Molecular Formula: C22H45N3 
Molecular Weight: 351.36 
Docosyl methanesulfonate (5.80 g, 14.34 mmol) was dissolved in DMF (100 mL) and 
sodium azide (2.32 g, 35.69 mmol) was added. The reaction was stirred at room 
temperature for 30 minutes before warming to 85°C for 5.5 hours. After cooling to 
room temperature, hexane (100 mL) and deionised water (10 mL) were added. The 
organic layer was collected and washed successively with NaHCO3 (20 mL, sat.) and 
brine (20 mL, sat.). The organic layer was dried over Na2SO4 and the resulting filtrate 
was concentrated in vacuo to afford the product as a sticky white solid (4.10 g, 11.66 
mmol, 82%). The spectroscopic data presented below is in agreement with that 
previously published.   
Rf = 0.70 (9 : 1, DCM : methanol, KMnO4). 
1
H NMR (400 MHz, CDCl3) δ: 3.25 (t, CH2N3, 
3
J = 7.2 Hz, 2H); 1.59 (quint, 
CH2CH2N3, 
3
J = 7.2 Hz, 2H); 1.25 (s, 19 × alkylCH2, 38H); 0.88 (t, alkylCH3, 
3
J = 6.4 
Hz, 3H). 
13
C NMR (100 MHz, CDCl3) δ: 51.35 (CH2N3); 31.69, 29.45, 29.43, 29.41, 29.37, 
29.29, 29.23, 29.11, 28.90, 28.58, 26.45 (alkylCH2); 22.40 (CH2CH3); 13.78 (CH3). 
ESI-MS: Calcd. [M+H]
+
 (C22H45N3) m/z = 351.36. No peak found, ionisation technique 
too soft. 
IR ν [cm-1]: 2916s (C–H), 2849s (C–H), 2095s (N3), 1644m, 1351w, 1255m, 1063w, 
892w, 720m.  
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L-Lys(Boc)2 (L: 5.3, D: 5.4)  
 
Molecular Formula: C16H30N2O6 
Molecular Weight: 346.42 
L-Lysine (4.00 g, 27.36 mmol, 1 eq.) and sodium hydroxide pellets (2.19 g, 54.75 
mmol, 2 eq.) were dissolved together in deionised water (50 mL) while di-tert-butyl 
dicarbonate (12.50 g, 57.27 mmol, 2.1 eq.) was dissolved separately in THF (50 mL). 
The dicarbonate solution was added to the basic lysine solution dropwise in one portion 
over 30 minutes and the resulting reaction mixture was stirred at 45°C under an N2 
atmosphere for 3 hours. The volatiles were removed in vacuo and the resulting residue 
was taken up in deionised water (200 mL) and washed with cyclohexane (100 mL). The 
aqueous layer was acidified to pH 3 (1.33 M NaHSO4, pH paper) before the product 
was extracted into ethyl acetate and washed successively with saturated brine (75 mL) 
and deionised water (50 mL). The organic phase was collected, dried over MgSO4 and 
the resulting filtrate was concentrated in vacuo to afford the product as an off-white 
crystalline solid (9.00 g, 25.99 mmol, 95%). D-yield: 92%. 
Rf = 0.34 (9 : 1, DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 4.05 (exp dd, app q, CHNH, 
3
J = 4.4 Hz, 1H); 3.04 (t, 
CH2NH, 
3
J = 6.6 Hz, 2H); 1.91 – 1.78 (m, CHaHbCHNH, 1H); 1.73 – 1.61 (m, 
CHaHbCHNH, 1H); 1.44 (br s, CH2CH2CH2NH, 2 × C(CH3)3, 22H). 
 13
C NMR (100 MHz, CD3OD) δ: 176.47 (C=O, acid); 158.02, 157.97 (C=O, 
carbamate); 80.97, 80.40 (C(CH3)3); 55.04 (CHNH); 41.40 (CH2NH); 30.30 









 (C16H30N2O6Na) m/z = 369.1996, found [M+Na]
+
 m/z = 
369.1981 (error 3.6 ppm). 
IR ν [cm-1]: 3339br w (N–H), 2978m (C–H), 2933m (C–H), 2870w (C–H), 1710m 
(C=O, acid), 1688s (CONH, carbamates I), 1517m (CONH, carbamates II), 1452m (C–
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H), 1392m, 1365s (C–H), 1249s (C–O), 1159s (C–O), 1047m (C–N), 1018m (C–N), 
860m.   
θL: + 61.5 mdeg (211 nm, 10 mM, MeOH). 
θD: − 56.9 mdeg (211 nm, 10 mM, MeOH). 
L-Lys(Boc)2-succinimide (L: 5.5, D: 5.6) 
 
Molecular Formula: C20H33N3O8 
Molecular Weight: 443.49 
L-Lys(Boc)2 (3.50 g, 10.10 mmol), N-hydroxysuccinimide (1.16 g, 10.10 mmol) and 
DCC (2.08 g, 10.10 mmol) were dissolved together in dry DMF (60 mL) and stirred at 
room temperature under an N2 atmosphere for 24 hours. The DCU by-product was 
removed by filtration through a celite-containing sinter funnel. The resulting filtrate was 
concentration in vacuo to afford the crude product as a soft golden wax (5.10 g, 11.5 
mmol, 114% crude). This crude product carried forward in synthesis, however a portion 
of crude product (1.00 g) was taken for purification by flash column chromatography 
(SiO2, DCM : ethyl acetate, 8 : 2) to afford product as an off-white solid (750 mg, 1.7 
mmol, 86% effective yield). D-yield: 83%. 
Rf = 0.44 (9 : 1 DCM : methanol, ninhydrin). 
1




J = 8.8, 5.2 Hz, 1H); 3.05 (br s, 
CH2NH, 2H); 2.83 (s, 2 × succinimideCH2, 4H); 1.98 – 1.90 (m, CHaHbCHNH, 1H); 
1.86 – 1.78 (m, CHaHbCHNH, 1H); 1.52 (s, CH2CH2NH and CH2CH2CH2NH, 4H); 
1.45 (s, 2 × C(CH3)3, 18H). 
 13
C NMR (100 MHz, CD3OD) δ: 170.03 (C=O, lysine ester); 163.53 (2 × C=O, 
succinimide); 157.22, 156.38 (C=O, carbamate); 79.55, 78.53 (C(CH3)3); 52.04 
(CHNH); 39.60 (CH2NH); 31.08 (CH2CHNH); 29.09 (CH2CH2NH); 27.52 (2 × 
C(CH3)3); 25.21 (2 × succinimideCH2); 22.51 (CH2CH2CH2NH).   
ESI-MS: 466.22 [M+Na]
+
 (100%), 444.24 [M+H]
+
 (46%).  
HRMS: Calcd. [M+Na]
+
 (C20H33N3O8Na) m/z = 466.2160, found [M+Na]
+
 m/z = 
466.2174 (error – 3.0 ppm). 
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IR ν [cm-1]: 3380w (N–H), 3364w (N–H), 2980w (C–H), 2936w (C–H), 1814w, 1788w, 
1736s (C=O, ester), 1678s (CONH, carbamates I), 1511s (CONH, carbamates II), 
1462w (C–H), 1390w, 1368m (C–H), 1341w, 1247m, 1211m, 1159s (C–O), 1086s (C–
N), 1071m (C–N), 1046w, 998m, 961m, 868m.    
LαD: − 9.2 (c. 1.0, CHCl3). 





Molecular Formula: C8H14O4 
Molecular Weight: 174.19 
2,2-Bis(hydroxymethyl)propionic acid (15.00 g, 111.83 mmol), 2,2-
dimethyloxypropane (20 mL, 162.65 mmol) and p-toluenesulfonic acid monohydrate 
(1.00 g, 5.25 mmol) were dissolved together in acetone (60 mL) and stirred at room 
temperature until TLC showed no presence of starting material (4 h). The acid catalyst 
was neutralised by addition of ammonium hydroxide : ethanol (3 mL, 1 : 1) leading to 
formation of a white precipitate after ten minutes. The volatiles were removed in vacuo 
to afford a white sludge which was taken up in DCM (60 mL) and washed with distilled 
water (2 × 30 mL). The organic layer was collected, dried over MgSO4 and the resulting 
filtrate concentrated in vacuo to afford the product as a white crystalline sold (10.30 g, 
59.13 mmol, 53%). The spectroscopic data presented below is in agreement with that 
previously published. 
Rf = 0.56 (9 : 1, DCM : methanol, UV).    
1
H NMR (400 MHz, CDCl3) δ: 4.18 (d, CHaxHeqO, 
2
J = 12.0 Hz, 2H); 3.67 (d, 
CHaxHeqO, 
2
J = 12.0 Hz, 2H), 1.45 (s, CH3CO2, 3H); 1.41 (s, CH3CO2, 3H); 1.21 (s, 
CH3CCO, 3H). 
13
C NMR (100 MHz, CDCl3) δ: 180.32 (C=O, acid); 98.27 (C(CH3)2); 65.77 (2 × 
CH2O); 41.70 (CCOOH); 25.10, 21.96, 18.40 (CH3). 
ESI-MS: 197.08 [M+Na]
+





 (C8H14O4Na) m/z = 197.0784, found [M+Na]
+
 m/z = 197.0781 
(error  1.6 ppm).  
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IR ν [cm-1]: 2994br w (O–H), 2159s (C–H), 2028s (C–H), 1975br s, 1719m (C=O, 





Molecular Formula: C16H26O7 
Molecular Weight: 330.37 
Isopropylidene-2,2,bis(hydroxymethyl)propionic acid (9.00 g, 51.67 mmol) was 
dissolved in DCM (50 mL) before DCC (5.33 g, 25.83 mmol, pre-dissolved in DCM 
(40 mL)), was added. The resulting white reaction mixture was stirred at room 
temperature for 3 hours before the precipitate (DCU by-product) was filtered off 
through a celite-containing sinter funnel. The filter cake washings (DCM) were 
combined with the filtrate and concentrated in vacuo to afford a residue which was 
taken up in ethyl acetate, causing further by-product precipitation. The precipitate was 
filtered off as before to afford, after drying, the product as a golden viscous oil (5.90 g, 
17.86 mmol, 69%). The spectroscopic data presented below is in agreement with that 
previously published. 
Rf = 0.62 (9 : 1, DCM : methanol, UV). 
1
H NMR (400 MHz, CDCl3) δ: 4.20 (d, CHaxHeqO, 
2
J = 12.0 Hz, 4H); 3.68 (d, 
CHaxHeqO, 
2
J = 12.0 Hz, 4H); 1.43 (s, 2 × CH3CO2, 6H); 1.38 (s, 2 × CH3CO2, 6H); 
1.23 (s, 2 × CH3CCO, 6H). 
13
C NMR (100 MHz, CDCl3) δ: 169.42 (2 × C=O); 98.27 (2 × C(CH3)2); 65.59 (4 × 
CH2O); 43.57 (2 × CCOO); 25.48, 21.48, 17.56 (3 × CH3). 
ESI-MS: 353.16 [M+Na]
+





 (C16H26O7Na) m/z = 353.1571, found [M+Na]
+
 m/z = 353.1750 
(error 0.0 ppm). 
IR [cm
-1
]: 2991w (C–H), 2159m (C–H), 2032m (C–H), 1976m, 1812m (C=O, 
anhydride), 1736m (C=O, anhydride), 1455w, 1373m, 1205m, 1152m, 1133m, 1081m, 
1013s, 984m, 935w, 917w, 826s, 731w.  
  






Molecular Formula: C11H16O4 
Molecular Weight: 212.24 
Propargyl alcohol (0.73 mL, 12.54 mmol), DMAP (0.23 g, 1.88 mmol) and pyridine 
(3.06 mL, 37.79 mmol) were dissolved in DCM (11 mL) and isopropylidene-2,2-
bis(hydroxymethyl)propionic anhydride (5.00 g, 15.13 mmol, pre-dissolved in DCM 
(23 mL)), was added slowly in one portion. The reaction mixture was stirred overnight 
at room temperature before being quenched with deionised water (5 mL), diluted with 
DCM (50 mL) and washed successively with NaHSO4 (3 × 30 mL, 1.33 M), Na2CO3 (3 
× 30 mL, 10%) and saturated brine (1 × 30 mL). The organic layer was collected, dried 
over MgSO4 and the resulting filtrate was concentrated in vacuo to afford the product as 
a pale yellow oil (2.65 g, 12.49 mmol, 98%). The spectroscopic data presented below is 
in agreement with that previously published.       
Rf = 0.91 (9 : 1, DCM : methanol, UV). 
1
H NMR (400 MHz, CDCl3) δ: 4.74 (d, CH≡CCH2, 
4
J = 2.4 Hz, 2H); 4.20 (d, 
CHaxHeqO, 
2
J = 12.0 Hz, 2H); 3.70 (d, CHaxHeqO, 
2
J = 12.0 Hz, 2H); 2.47 (t, CH≡CCH2, 
4
J = 2.4 Hz, 1H); 1.43 (s, CH3CO2, 3H); 1.39 (s, CH3CO2, 3H); 1.21 (s, CH3CCO, 3H). 
13
C NMR (100 MHz, CDCl3) δ: 173.33 (C=O, ester); 98.01 (C(CH3)2); 77.37 
(CH2C≡CH); 74.94 (C≡CH); 65.80 (CH2O); 52.25 (C≡CH); 41.77 (CCOO); 24.52, 
22.48, 18.31 (CH3). 
ESI-MS: 235.09 [M+Na]
+





(C11H16NaO4) m/z = 235.0941, found [M+Na]
+ 
m/z = 235.0942 
(error – 0.8 ppm). 
IR ν [cm-1]: 2160br w (C≡C, C–H), 1737m (C=O, ester), 1453w, 1372w, 1251m (C–O), 
1218m (C–O), 1198m, 1120m, 1078s, 1040w, 997w, 934w, 830s. 
  






Molecular Formula: C8H12O4 
Molecular Weight: 172.18 
Propyne isopropylidene-2,2-bis(hydroxymethyl) propionate (2.55 g, 12.01 mmol) was 
dissolved in methanol (102 mL, 25 mg mL
-1
) and c.H2SO4 (2.04 mL, 2% v/v) was 
added. After stirring at room temperature overnight, the reaction was neutralised with 
ammonium hydroxide : methanol (8 mL, 1 : 1) causing ammonium sulfate to 
precipitate. After 30 minutes further stirring, the precipitate was filtered off through a 
celite-containing sinter funnel and the filtrate concentrated in vacuo. This crude product 
was taken up in chloroform, re-filtered as before and the resulting filtrate concentrated 
in vacuo to afford the product as a yellow oil (1.56 g, 9.06 mmol, 75%). The 
spectroscopic data presented below is in agreement with that previously published. 
Rf = 0.60 (9 : 1, DCM : methanol, UV).  
1
H NMR (400 MHz, CDCl3) δ: 4.75 (d, CH≡CCH2, 
4
J = 2.5 Hz, 2H); 3.92 (d, CHaHbO, 
2
J = 8.0 Hz, 2H); 3.72 (d, CHaHbO, 
2
J = 8.0 Hz, 2H); 2.48 (t, CH≡CCH2, 
4
J = 2.5 Hz, 
1H); 1.08 (s, CH3CCO, 3H). 
13
C NMR (100 MHz, CDCl3) δ: 174.92 (C=O, ester); 77.31 (CH2C≡CH); 75.19 
(C≡CH); 66.88 (2 × CH2OH); 52.35 (C≡CH); 49.31 (CCOO); 16.95 (CH3). 
ESI-MS: 195.06 [M+Na]
+





 (C8H12NaO4) m/z = 195.0628, found [M+Na]
+
 = 195.0629 
(error – 0.4 ppm). 
IR ν [cm-1]: 3279br w (C–H, alkyne), 2160m (C≡C), 2032m (C–H), 1971m, 1728m 
(C=O, ester), 1451w (C–H), 1030s, 1000m, 966m, 763m.  
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Propyne-[G1]-L-Lys(Boc)2 (L: 5.11, D: 5.12) 
 
Molecular Formula: C40H68N4O14 
Molecular Weight: 828.47 
L-Lys(Boc)2-succinimide (1.00 g, 2.25 mmol, 4 eq.), DMAP (138 mg, 1.13 mmol, 2 eq.) 
and DIPEA (491 μL, 2.82 mmol, 5 eq.) were dissolved together in dry DMF (15 mL). 
Propyne-[G1]-OH (97 mg, 0.56 mmol, 1 eq., pre-dissolved in dry DMF (10 mL)) was 
added to the reaction mixture, which was stirred at room temperature under an N2 
atmosphere for 48 hours. The volatiles were removed in vacuo to afford the crude 
product as a golden viscous oil. The crude product was purified in a portion-wise 
manner by gel permeation chromatography (DCM : methanol, 95 : 5) to afford the pure 
product as a golden foam (316 mg, 0.4 mmol, 68% effective yield). D-yield: 63%. 
Rf = 0.78 (9 : 1, DCM : methanol, UV/ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 4.76 (d, CH≡CCH2, 
4
J = 2.6 Hz, 2H); 4.35 – 4.22 (m, 
2 × CH2O, 4H); 4.08 (br s, 2 × CHNH, 2H); 3.04 (t, 2 × CH2NH, 
3
J = 6.4 Hz, 4H); 2.99 
(t, CH≡CCH2, 
4
J = 2.6 Hz, 1H); 1.82 – 1.73 (m, 2 × CHaHbCHNH, 2H); 1.69 – 1.57 (m, 
2 × CHaHbCHNH, 2H); 1.44 (br s, 4 × C(CH3)3, 2 × CH2CH2NH, 2 × CH2CH2CH2NH, 
44H); 1.30 (s, CH3, 3H).  
13
C NMR (100 MHz, CD3OD) δ: 173.80 (2 × C=O, lysine esters); 173.25 (C=O, Fréchet 
ester); 158.56, 158.06 (2 × C=O, carbamate); 80.61, 79.88 (2 × C(CH3)3); 78.47 
(CH≡CCH2); 76.97 (CH≡CCH2); 66.86, 66.81 (CH2O); 55.05 (2 × CHNH); 53.72 
(CH≡CCH2); 47.73 (CCOO); 40.98 (CH2NH); 32.21 (CH2CHNH); 30.56 
(CH2CH2NH); 28.89, 28.84 (2 × C(CH3)3); 24.16 (CH2CH2CH2NH); 18.09 (CH3). 
ESI-MS: 851.46 [M+Na]
+





 (C40H68N4O14Na) m/z = 851.4624, found [M+Na]
+
 m/z = 
851.4609 (error 2.0 ppm). 
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IR ν [cm-1]: 3363w (N–H), 2975w (C–H), 1745m (C=O, ester), 1689s (CONH, 
carbamates I), 1512m (CONH, carbamates II), 1454w, 1365m, 1247m, 1158s (C–O), 
1101m, 865w, 781w. 
Propyne-[G1]-L-Lysine (5.13) 
 
Chemical Formula: C20H40Cl4N4O6 
Molecular Weight: 574.37  
Propyne-[G1]-L-Lys(Boc)2 (52 mg, 63 μmol) was dissolved in methanol (10 mL) and 
gaseous HCl was bubbled through the solution for 15 seconds. The resulting reaction 
mixture was stirred at room temperature for 3 hours before being concentrated in vacuo 
to afford the product as an off-white crystalline solid (36 mg, 63 μmol, quantitative 
yield). 
Rf = 0.15 streak (95 : 5, methanol : ammonium hydroxide, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 4.81 (exp d, app s, CH≡CCH2, 2H); 4.85 – 4.40 (m, 2 
× CH2O, 4H); 4.16 (exp dd, app br s, 2 × CHNH3
+
, 2H); 3.12 (exp t, app s, CH≡CCH2, 
1H); 2.99 (exp t, app s, 2 × CH2NH3
+
, 4H); 1.98 (br s, 2 × CH2CHNH3
+
, 4H); 1.76 (br s, 
2 × CH2CH2NH, 4H); 1.59 – 1.48 (br m, 2 × CH2CH2CH2NH3
+
, 4H); 1.38 (s, CH3, 3H).  
13
C NMR (100 MHz, CD3OD) δ: 172.93 (C=O, Fréchet-ester); 170.17, 170.12 (C=O, 
lysine-ester); 78.48 (CH≡CCH2); 77.35 (CH≡CCH2); 68.18, 68.09 (CH2O); 54.09 
(CH≡CCH2); 53.77 (2 × CHNH3
+
); 47.62 (CCH3); 40.36 (CH2NH3
+
); 30.97 
(CH2CHNH2); 28.04 (CH2CH2NH2); 23.27 (CH2CH2CH2NH3
+
); 17.99 (CH3). 
ESI-MS: 215.13 [M+2H]
2+





 (C20H37N4O6) m/z = 429.2708, found [M+H]
+
 m/z = 429.2715 
(error – 2.0 ppm). 
IR ν [cm-1]:  3380br w (N–H), 3200w (C–H, alkyne), 2917s (C–H), 2850s (C–H), 
1740m (C=O, esters), 1467m, 1398w, 1216m, 1137m (C–O), 1056w, 997m, 841w.     
αD: + 7.4 (c. 1.0, MeOH). 
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C22-[G1]-L-Lys(Boc)2 (L: 5.14, D: 5.15) 
 
Molecular Formula: C62H113N7O14 
Molecular Weight: 1180.60 
Propyne-[G1]-L-Lys(Boc)2 (150 mg, 181 μmol, 1.1 eq.), behenoyl azide (58 mg, 164 
μmol, 1 eq.), CuSO4·5H2O (4 mg, 16 μmol, 0.1 eq.) and sodium ascorbate (7 mg, 33 
μmol, 0.2 eq.) were dissolved together in a mixture of degassed THF : water (4 : 1 v/v, 
10 mL). The reaction mixture was stirred at room temperature under an N2 atmosphere 
for 16 hours before being concentrated in vacuo. The resulting sludge was taken up in 
DCM (35 mL) and washed with deionised water (2 × 15 mL). The organic phase was 
collected, dried over MgSO4 and the resulting filtrate concentrated in vacuo to afford 
the crude product as an off-white sticky solid. The crude product was purified by gel 
permeation chromatography (DCM) to afford the product as an off-white sticky foam 
(135 mg, 114 μmol, 70%). D-yield: 80%. 
Rf =  0.70 (9 : 1, DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 8.06 (s, triazoleCH, 1H); 5.26 (s, (triazole)CH2O, 2H); 
4.42 (t, CH2Ntriazole, 
3
J = 7.0 Hz, 2H); 4.34 – 4.20 (m, 2 × CH2O, 4H); 4.04 (exp dd, 
app br t, 2 × CHNH, 
3
J = 4.0 Hz, 2H); 3.04 (t, 2 × CH2NH, 
3
J = 6.4 Hz, 4H); 1.91 (exp 
tt, app t, CH2CH2(triazole), 
3
J = 7.0 Hz, 2H); 1.77 – 1.69 (m, 2 × CHaHbCHNH, 2H); 
1.65 – 1.56 (m, 2 × CHaHbCHNH, 4H); 1.44 (br s, 4 × C(CH3)3, 2 × CH2CH2NH, 40H); 
1.29 (br s, 19 × alkylCH2, CH3CCO, 41H); 1.26 (br s, 2 × CH2CH2CH2NH, 4H); 0.90 (t, 
alkylCH3, 
3
J = 7.2 Hz, 3H). 
13
C NMR (100 MHz, CD3OD) δ: 172.39 (3 × C=O, esters); 157.19, 157.15, 156.67 
(total 4 × C=O, carbamate); 142.21 (triazoleCCH2O); 124.62 (triazoleCH); 79.15, 78.45 
(2 × C(CH3)3); 65.50 (2 × CH2O); 57.90 ((triazole)CH2O); 53.72, 53.68 (CHNH); 50.16 
((triazole)CH2CH2); 46.04 (Fréchet-C(CH3)); 39.80, 39.67 (CH2NH); 31.84 (2 × 
CH2CHNH); 30.82 (2 × CH2CH2NH); 30.09 ((triazole)CH2CH2); 29.58 (19 × 
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alkylCH2); 28.89 (CH3CH2CH2); 27.66, 27.61 (2 × C(CH3)3); 26.27 (CH3CH2); 22.82, 
22.51 (CH2CH2CH2NH); 16.87 (Fréchet-C(CH3)); 13.35 (alkylCH3). 
ESI-MS: 1202.82 [M+Na]
+





 (C62H113N7O14Na) m/z = 1202.8238, found [M+Na]
+
 m/z = 
1202.8224 (error 1.5 ppm). 
IR ν [cm-1]: 3356br w (N–H), 2976m (C–H), 2924s (C–H), 2854m (C–H), 1745m (C=O, 
esters), 1694s (CONH, carbamates I), 1516m (CONH, carbamates II), 1456m, 1392w, 
1366m, 1248m, 1163s (C–O), 1048m, 1019m, 866w, 781w.  
C22-[G1]-L-Lysine (L: 5.16, D: 5.17) 
 
Molecular Formula: C42H85N7O6Cl4 
Molecular Weight: 925.98 
C22-[G1]-L-Lys(Boc)2 (127 mg, 108 μmol) was dissolved in methanol (10 mL) and 
gaseous HCl was bubbled through the solution for 15 seconds. The reaction mixture 
was stirred at room temperature for 3 hours before being concentrated in vacuo to afford 
the product as a cream crystalline solid (100 mg, 108 μmol, quantitative yield). D-yield: 
quantitative. 
Rf = 0.00 (ammonium hydroxide, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 8.56 (s, triazoleCH, 1H); 5.40 (s, (triazole)CH2O, 2H); 









J = 7.0 Hz, 4H); 2.05 – 1.91 (br s, 
2 × CH2CHNH2, CH2CH2(triazole), 6H); 1.82 – 1.74 (m, 2 × CH2CH2NH3
+
, 4H); 1.66 – 
1.48 (br m, 2 × CH2CH2CH2NH3
+
, 4H); 1.37 (s, CH3CCOO, CH2CH2CH2CH2(triazole), 
7H); 1.28 (br s, 17 × alkylCH2, 34H); 0.89 (t, CH3(CH2)21, 
3
J = 6.8 Hz, 3H). 
13
C NMR (100 MHz, CD3OD) δ: 173.17, 170.04 (total 3 × C=O, esters); 141.46 
(triazoleCCH2O); 128.07 (triazoleCH); 67.88 (2 × Fréchet-CH2O); 57.91 
((triazole)CH2O); 53.80, 53.74 (CHNH3
+
); 53.05 ((triazole)CH2CH2); 47.62 (Fréchet-
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C(CH3)); 40.37, 40.28 (CH2NH3
+





); 27.88, 27.42 (CH2CH2CH2(triazole)); 23.74, 
23.16 (CH2CH2CH2NH2
+
); 18.00 (Fréchet-C(CH3)); 14.55 (alkylCH3). 
ESI-MS: 390.82 [M+2H]
2+
 (100%), 274.56 [M+2Na+H]
3+








 (C42H83N7O6) m/z = 390.8197, found [M+2H]
2+
 m/z = 
390.8179 (error 4.6 ppm). 
IR ν [cm-1]: 3393br w (N–H), 2917s (C–H), 2850s (C–H), 1743s (C=O, ester), 1600w, 
1506m, 1468m, 1380w, 1280m, 1214s, 1134s, 1054w, 998m.  
θL: + 38.9 mdeg (225 nm, 10 mM, MeOH). 





Molecular Formula: C24H36O10 
Molecular Weight: 484.23 
Propyne-[G1]-OH (1.53 g, 8.89 mmol) and DMAP (0.83 g, 6.79 mmol) were dissolved 
together in DCM (50 mL) before pyridine (2.7 mL, 34.52 mmol) was added. To this, 
isopropylidene-2,2-bis(hydroxymethyl)propionic anhydride (8.80 g, 26.64 mmol, pre-
dissolved in DCM (15 mL)) was added and the reaction was stirred overnight at room 
temperature. The excess anhydride was quenched with a mixture of pyridine : deionised 
water (1 : 1, 10 mL) and the reaction was stirred overnight once more. After diluting 
with DCM (60 mL), the reaction mixture was washed successively with NaHSO4 (3 × 
30 mL, 1.33 M), Na2CO3 (3 × 30 mL, 10%) and saturated brine (30 mL). The organic 
phase was dried over MgSO4 and the resulting filtrate was concentrated in vacuo to 
afford the crude product as an opaque cream oil. This crude product was purified by 
flash column chromatography (SiO2, cyclohexane : ethyl acetate, 3 : 1  1 : 1) to afford 
the product as a golden oil (2.65 g, 5.47 mmol, 57 %). The spectroscopic data presented 
below is in agreement with that previously published. 
Rf = 0.51 (1 : 1, cyclohexane : ethyl acetate, UV). 
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1
H NMR (400 MHz, CDCl3) δ: 4.71 (d, CH≡CCH2, 
4
J = 2.4 Hz, 2H); 4.32 (d, 2 × 
CHaxHeqO, 
2
J = 12.0 Hz, 2H); 4.15 (d, 2 × CHaxHeqO, 
2
J = 12.0 Hz, 4H); 3.61 (d, 
CHaHbO, 
2
J = 12.0 Hz, 4H); 2.46 (t, CH≡CCH2, 
4
J = 2.4 Hz, 1H); 1.40 (d, 4 × CH3, 
4
J = 
2.4 Hz, 12H); 1.35 (s, 2 × CH3, 6H); 1.30 (s, CH3, 3H). 
13
C NMR (100 MHz, CDCl3) δ: 173.58, 171.92 (total 3 × C=O, ester); 98.16 (2 × 
C(CH3)2); 77.27 (CH2C≡CH); 75.40 (C≡CH); 66.02 (6 × CH2O); 52.74 (C≡CH); 46.87, 






 (C24H36NaO10) m/z = 507.2201, found [M+Na]
+
 m/z = 
507.2196 (error 0.9 ppm). 
IR ν [cm-1]: 3264w (C–H, alkyne), 2986m (C–H), 2100w (C≡C), 1736s (C=O, esters), 





Molecular Formula: C18H28O10 
Molecular Weight: 404.17 
Propyne-[G2]-isopropylidene (2.16 g, 4.46 mmol) and DOWEX-50WX2 (3.24 g, 1.5 
eq. wt.) were dissolved in methanol (55 mL) and stirred at 40°C for 2 hours. The 
reaction mixture was filtered through a celite-containing sinter funnel and the resulting 
filtrate was concentrated in vacuo affording a sludge which was taken up in chloroform. 
A precipitate was allowed to form overnight, before being collected by filtration as a 
white crystalline solid (1.30 g, 3.22 mmol, 72%). The spectroscopic data presented 
below is in agreement with that previously published.    
Rf = 0.50 (9 : 1, DCM : methanol, UV). 
1
H NMR (400 MHz, CDCl3) δ: 4.74 (d, CH≡CCH2, 
4
J = 2.4 Hz, 2H); 4.47 – 4.25 (m, 4 
× CH2O, 8H); 3.81 – 3.62 (m, 2 × CH2O, 4H); 3.24 (br s, 4 × OH, 4H); 2.49 (t, 
CH≡CCH2, 
4
J = 2.4 Hz, 1H); 1.33 (s, CH3, 3H); 1.05 (s, 2 × CH3, 6H). 
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13
C NMR (100 MHz, CD3OD) δ: 175.87, 173.62 (total 3 × C=O); 78.52 (CH2C≡CH); 
76.72 (C≡CH); 66.28, 66.78, (3 × CH2O); 53.56 (C≡CH); 51.76 (2 × G2-CCOO); 47.83 
(G1-CCOO); 18.09, 17.29 (total 3 × CH3).  
ESI-MS: 427.16 [M+Na]
+





 (C18H28NaO10) m/z = 427.1575, found [M+Na]
+
 m/z = 
427.1579 (error – 1.1 ppm). 
IR ν [cm-1]: 3397br w (O–H), 3256m (C–H, alkyne), 2944w (C–H), 2160m (C≡C), 
1731s (C=O, esters), 1716s (C=O, ester), 1236m (C–O), 1210s (C–O), 1129s, 1065m, 
1019s, 1006s, 717m, 681m, 654m.  
Propyne-[G2]-L-Lys(Boc)2 (L: 5.20, D: 5.21) 
 
Molecular Formula: C82H140N8O30 
Molecular Weight: 1718.02 
L-Lys(Boc)2-succinimide (1.00 g, 2.25 mmol, 8 eq.), DMAP (138 mg, 1.13 mmol, 4 eq.) 
and DIPEA (442 μL, 2.54 mmol, 9 eq.) were dissolved together in dry DMF (15 mL). 
Propyne-[G2]-OH (114 mg, 0.28 mmol, 1 eq., pre-dissolved in dry DMF (10 mL)), was 
added to the reaction mixture, which was stirred at room temperature under an N2 
atmosphere for 48 hours. The volatiles were removed in vacuo to afford the crude 
product as a golden viscous oil.  The crude product was purified by gel permeation 
chromatography (DCM : methanol, 95 : 5) to afford the pure product as a golden foam 
(400 mg, 0.20 mmol, 83%). D-yield: 90%.  
Rf = 0.68 (9 : 1, DCM : methanol, UV/ninhydrin). 
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1
H  NMR (400 MHz, CD3OD) δ: 4.79 (d, CH≡CCH2, 
4
J = 2.4 Hz, 2H); 4.37 – 4.22 (m, 
6 × CH2O, 12H); 4.09 (exp dd, app br s, 4 × CHNH, 4H); 3.04 (t, 4 × CH2NH, 
3
J = 6.8 
Hz, 8H); 2.99 (t, CH≡CCH2, 
4
J = 2.4 Hz, 1H); 1.83 – 1.74 (m, 4 × CHaHbCHNH, 4H); 
1.69 – 1.60 (m, 4 × CHaHbCHNH, 4H); 1.51 – 1.36 (br s, 8 × C(CH3)3, 4 × CH2CH2NH, 
4 × CH2CH2CH2NH, 88H); 1.33 (s, [G1]-CH3CCO, 3H); 1.29 (s, 2 × [G2]-CH3CCO, 
6H).  
13
C NMR (100 MHz, CD3OD) δ: 173.84 (4 × C=O, lysine-esters); 173.39, 173.20 (total 
3 × C=O, Fréchet-esters); 158.52, 157.98 (4 × C=O, carbamates); 80.59, 79.86 (4 × 
C(CH3)3); 78.61 (CH≡CCH2); 77.17 (CH≡CCH2); 67.09, 66.75 (total 6 × CH2O); 55.07 
(4 × CHNH); 53.88 (CH≡CCH2); 48.01, 47.87 (total 3 × Fréchet-C(CH3)); 41.02 
(CH2NH); 32.23 (CH2CHNH); 30.59 (CH2CH2NH); 28.93 (8 × C(CH3)3); 24.20 






 (C82H141N8O30) m/z = 1717.9748, found [M+H]
+
 m/z = 
1717.9798 (error – 1.9 ppm). 
IR ν [cm-1]: 3368w (N–H), 2972w (C–H), 1745m (C=O, esters), 1688s (CONH, 
carbamates I), 1515m (CONH, carbamates II), 1365m, 1247m, 1160s (C–O), 1011m, 
866w, 763w, 763w.   
Propyne-[G2]-L-Lysine (5.22) 
 
Molecular Formula: C42H84Cl8N8O14 
Molecular Weight: 1208.79 
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 Propyne-[G2]-L-Lys(Boc)2 (74 mg, 43 μmol) was dissolved in methanol (12 mL) and 
gaseous HCl was bubbled through the solution for 20 seconds. The resulting reaction 
mixture was stirred at room temperature for 2.5 hours before being concentrated in 
vacuo to afford the product as transparent needle-like crystals (50 mg, 41 μmol, 96%). 
Rf = 0.00 (9 : 1, DCM : methanol, ninhydrin); 0.88 (100% ammonium hydroxide, 
ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 4.82 (exp d, app s, CH≡CCH2, 2H); 4.51 – 4.28 (br m, 
6 × CH2O, 12H); 4.20 (exp dd, app br s, 4 × CHNH3
+
, 4H); 3.13 (exp t, app s, 




J = 6.4 Hz, 8H); 2.01 (br s, 4 × 
CH2CHNH3
+
, 8H); 1.78 (br s, 4 × CH2CH2NH3
+
, 8H); 1.60 – 1.54 (br m, 4 × 
CH2CH2CHNH3
+
, 8H); 1.38 (s, 3 × CH3, 9H).   
13
C NMR (100 MHz, CD3OD) δ: 173.37, 173.12 (total 3 × C=O, Fréchet-esters); 170.21 
(4 × C=O, lysine-esters); 78.68 (CH≡CCH2); 77.46 (CH≡CCH2); 67.87, 67.50 (total 6 × 
CH2O); 54.05 (CH≡CCH2); 53.83 (4 × CHNH3
+










18.29, 18.08 (total 3 × CH3). 
ESI-MS: 230.14 [M+4H]
4+





 (C42H79N8O14) m/z = 306.5233, found [M+3H]
3+
 m/z = 
306.5220 (error 3.8). 
IR ν [cm-1]: 3384br w (N–H), 3201w (C–H, alkyne), 2918s (C–H), 2851m (C–H), 
2250w (C≡C), 1739s (C=O, esters), 1601w, 1508m, 1470m, 1397w, 1294m, 1211s, 
1132s, 996m.   
αD: + 7.1 (c. 1.0, MeOH). 
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C22-[G2]-L-Lys(Boc)2 (L: 5.23, D: 5.24) 
 
Molecular Formula: C104H185N11O30 
Molecular Weight: 2069.64 
Propyne-[G2]-L-Lys(Boc)2 (200 mg, 116 μmol, 1.1 eq.), behenoyl azide (37 mg, 106 
μmol, 1 eq.), CuSO4·5H2O (3 mg, 12 μmol, 0.1 eq.) and sodium ascorbate (4 mg, 21 
μmol, 0.2 eq.) were dissolved together in a mixture of degassed THF : water (4 : 1 v/v, 
10 mL). The reaction mixture was stirred at room temperature under an N2 atmosphere 
for 15.5 hours before being concentrated in vacuo. The resulting sludge was taken up in 
DCM (35 mL) and washed with deionised water (2 × 15 mL). The organic phase was 
collected, dried over MgSO4 and the resulting filtrated was concentrated in vacuo to 
afford the crude product was a grey-white viscous oil. The crude product was purified 
by gel permeation chromatography (DCM) to afford the product as a transparent golden 
oil (18 mg, 9 μmol, 8%). D-yield: 15%. 
Rf = 0.67 (9 : 1, DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 8.08 (s, triazoleCH, 1H); 5.29 (s, (triazole)CH2O, 2H); 
4.23 (t, CH2Ntriazole, 
3
J = 7.2 Hz, 2H); 4.36 – 4.15 (m, 6 × Fréchet-CH2O, 12H); 4.09 
(exp dd, app br t, 4 × CHNH, 
3
J = 4.0 Hz, 4H); 3.04 (t, 4 × CH2NH, 
3
J = 6.6 Hz, 8H); 
1.96 – 1.88 (m, CH2CH2(triazole), 2H); 1.82 – 1.73 (m, 4 × CHaHbCHNH, 4H); 1.68 – 
1.59 (m, 4 × CHaHbCHNH, 4H); 1.44 (br s, 8 × C(CH3)3, 4 × CH2CH2NH and [G1]-
CH3, 83H); 1.33 (br s, 4 × CH2CH2CH2NH, 8H); 1.29 (s, 19 × alkylCH2, 38H); 1.23 (s, 
2 × [G2]-CH3), 6H); 0.90 (t, CH3(CH2)21, 
3
J = 7.2 Hz, 3H). 
13
C NMR (100 MHz, CD3OD) δ: Absence of some signals due to large molecular 
weight / small amount of material in sample. 177.83, 173.87 (total 7 × C=O, esters); 
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158.57, 158.03, (4 × C=O, carbamate); expt ~142, not seen (triazoleCCH2O); 121.17 
(triazoleCH); 80.57, 79.87 (4 × C(CH3)3); 67.11, 67.08, 66.71 (2 × Fréchet-CH2O); 
60.17 ((triazole)CH2O); 55.11 (4 × CHNH); 51.42 ((triazole)CH2CH2); 48.01 (Fréchet-
C(CH3)); 41.05 (4 × CH2NH); 33.14 (4 × CH2CHNH); 32.26 (4 × CH2CH2NH); 31.41 
((triazole)CH2CH2); 30.83 (18 × alkylCH2); 30.54 (CH2CH3); 28.94 (8 × C(CH3)3); 
24.56 (4 × CH2CH2CH2NH); 18.26, 18.21, 17.76 (Fréchet-C(CH3)); 14.53 (alkylCH3). 
ESI: 1057.64 [M+2Na]
2+





 (C104H186N11O30Na) m/z = 2092.3259, found [M+Na]
+
 m/z = 
2092.3098 (error 9.0 ppm). 
IR ν [cm-1]: 3366br w (N–H), 2983m (C–H), 2924m (C–H), 2855m (C–H), 1741m 
(C=O, esters), 1694s (CONH, carbamates I), 1514m (CONH, carbamates II), 1456m, 
1392w, 1365m, 1247m, 1160s (C–O), 1047m, 1012m, 864w, 779w.  
C22-[G2]-L-Lysine (L: 5.25, D: 5.26) 
 
Molecular Formula: C64H129N11O14Cl8 
Molecular Weight: 1560.40 
C22-[G2]-L-Lys(Boc)2 (18 mg, 9 μmol) was dissolved in methanol (10 mL) and gaseous 
HCl was bubbled through the solution for 15 seconds. The reaction mixture was stirred 
at room temperature for 3 hours before being concentrated in vacuo to afford the 
product as a white crystalline solid (11 mg, 7 μmol, 78%). D-yield: quantitative. 
Rf = 0.00 (ammonium hydroxide, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 8.21 (s, triazoleCH, 1H); 5.31 (s, (triazole)CH2O, 2H); 
4.96 – 4.27 (br m, (triazole)CH2CH2, 6 × FréchetCH2O, 14H); 4.21 (exp dd, app s, 4 × 








J = 6.4 Hz, 8H); 2.09 – 1.90 (br m, 
CH2CH2(triazole), 4 × CH2CHNH3
+
, 10H); 1.78 (br s, 4 × CH2CH2NH2
+
, 8H); 1.66 – 
1.49 (m, 4 × CH2CH2CH2NH3
+
, 8H); 1.35, 1.32 (s, total 3 × CH3C(CO) and 
CH2CH2CH2(triazole), 11H) 1.29 (s, 18 × alkylCH2, 36H); 0.90 (t, alkylCH3, 
3
J = 7.2 
Hz, 3H). 
13
C NMR (100 MHz, CD3OD) δ: Absence of some signals due to large molecular 
weight / small amount of material in sample. 170.23 (total 7 × C=O, esters); expt ~145, 
not seen (triazoleCCH2O); 128 (triazoleCH); 67.97, 67.93 (total 6 × Fréchet-CH2O); 
exp ~ 58, not seen ((triazole)CH2O) 53.88 (4 × CH2NH3
+
); 51.74 ((triazole)CH2CH2); 
47.73 (Fréchet-C(CH3)); 40.38 (4 × CH2NH3
+
); 33.12 (4 × CH2CHNH3
+
); 31.00 
(CH2CH2CH3); 30.81 (17 × alkylCH2); 28.06 (4 × CH2CH2NH3
+
); 27.64 
((triazole)CH2CH2); 23.78 (CH2CH3); 23.31 (4 × CH2CH2CH2NH3
+
); 18.21 (3 × 
Fréchet-C(CH3)); 14.50 (alkylCH3). 
ESI-MS: 634.96 [M+2H]
2+
 (100%), 570.91 [M–Lys+2H]2+ (99%) where Lys = 
C6H13N2O and lysine-loss is a likely mass spectrometric effect. 
HRMS: Calcd. [M+2H]
2+
 (C64H123N11O14) m/z = 634.9620, found [M+2H]
2+
 m/z = 
634.9585 (error 5.3 ppm). 
IR ν [cm-1]:  3396br w (N–H), 2918s (C–H), 2852s (C–H), 1736s (C=O, esters), 1601w, 
1504m, 1470m, 1398w, 1297w, 1212s, 1131s (C–O), 1060m, 997s. 
θL: + 72.9 mdeg (225 nm, 10 mM, MeOH). 
θD: − 70.6 mdeg (225 nm, 10 mM, MeOH). 
D-Asp-Boc (L: 6.1, D: 6.2) 
 
Chemical Formula: C9H15NO6 
Molecular Weight: 233.22 
D-Aspartic acid (1.70 g, 12.75 mmol) and NaOH pellets (1.02 g, 25.50 mmol) were 
dissolved together in deionised water (20 mL) before the solution was cooled to 0°C. 
Di-tert-butyl dicarbonate (3.06 g, 14.11 mmol) was dissolved separately in dioxane (20 
mL) before being added to the reaction mixture dropwise in one portion over 1 hour. 
The resulting reaction mixture was stirred at 0°C for 2 hours and room temperature for a 
Chapter 7 – Experimental 
250 
further 2 hours. Volatiles were removed in vacuo, and the resulting residue was taken 
up in deionised water and washed with diethyl ether. The aqueous layer was acidified to 
pH 2 using NaHSO4 (1.33 M, pH paper) after which the product was extracted into 
diethyl ether. This organic layer was collected, dried over MgSO4 and the resulting 
filtrate concentrated in vacuo to afford the product as a white solid (1.48 g, 6.43 mmol, 
50%). Rf = 0.26 (9 : 1 DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 5.04 (br s, NH, 2 × OH, 3H); 4.46 (exp dd, app t, 
CHNH, 
3








J = 16.6 Hz, 6.4 Hz, CHaHbCHNH, 1H); 1.44 (s, C(CH3)3, 9H). 
13
C NMR (100 MHz, CD3OD) δ: 174.66, 174.19 (C=O, acid); 157.76 (C=O, 






 (C9H15NNaO6) m/z = 256.0792, found [M+Na]
+
 m/z = 
256.0795 (error −1.6 ppm).  
IR ν [cm-1]: 3354w (N–H), 2978br m (O–H, C–H), 2930br m (O–H, C–H), 1703s (C=O, 
acid), 1700s (C=O, acid), 1688s (CONH, carbamate I), 1533m, 1514m (CONH, 
carbamate II), 1409m (C–O), 1393w, 1368w, 1336m (C–H), 1286w, 1250m (C–O), 
1157s, 1060m (C–N stretch), 1031w, 1002w, 974m, 860w, 786w, 747w. 
αD: + 4.6 (c. 1.0, CHCl3). 
(C12)2-L-Asp-Boc (L: 6.3, D: 6.4) 
 
Chemical Formula: C33H63NO6 
Molecular Weight: 569.87 
Boc-L-Asp-(OH)2 (1.00 g, 4.28 mmol, 1 eq.), 1-dodecanol (3.20 g, 17.2 mmol, 4 eq.), 
DCC (1.77 g, 8.58 mmol, 2 eq.) and DMAP (1.05 g, 8.58 mmol, 2 eq.) were dissolved 
together in anhydrous DCM (50 mL). The stirred mixture was kept for 10 minutes at 
0°C before being allowed to warm to room temperature and left overnight under an N2 
atmosphere. The DCU by-product was removed by filtration through a celite-containing 
sinter funnel and the filtrate concentrated to a residue in vacuo. This residue was taken 
up in DCM (60 mL) and washed successively with HCl (2 × 30 mL, 0.5 M) and 
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NaHCO3 (30 mL, sat.). The organic phase was collected, dried over MgSO4 and the 
resulting filtrate concentrated in vacuo to afford a clear yellow residue. Purification by 
flash column chromatography (SiO2, 95 : 5, DCM : ethyl acetate) afforded pure product 
as a white powdery solid (877 mg, 1.54 mmol, 36%). D-yield: 45%. 
Rf = 0.95 (9 : 1 DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CDCl3) δ: 5.49 (d, NH, 1H); 4.52 (exp dd, app t, CHNH, 
3
J = 4.4 
Hz, 1H); 4.18 – 4.10 (exp t, app m, CH2OC(O)CH2, 2H);  4.05 (t, CH2OC(O)CH, 
3
J = 









J = 17.2 Hz, 4.4 Hz, 1H); 1.65 – 1.59 (m, CH2CH2O, 4H); 1.44 (s, 
C(CH3)3, 9H); 1.23 (br s, 18 × alkylCH2, 36H); 0.88 (t, 2 × alkylCH3, 
3
J = 6.4 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ: 171.14, 171.03 (C=O, ester); 155.43 (C=O, carbamate); 
80.00 (C(CH3)3); 65.88, 65.19 (CH2O); 49.84 (CHNH); 36.80 (CH2CHNH); 31.90, 
29.62, 29.57, 29.51, 29.34, 29.23, 28.50, 28.45, 28.28 (alkylCH2); 25.84, 25.79 
(CH2CH2O); 22.67 (C(CH3)3); 14.11 (alkylCH3). 
ESI-MS: 592.45 [M+Na]
+





 (C33H63NNaO6) m/z = 592.4548, found [M+Na]
+
 m/z = 
592.4520 (error 3.9 ppm). 
IR ν [cm-1]: 3403w (N–H stretch), 2955w, 2918s (C–H), 2851m (C–H), 1733s (C=O, 
esters), 1709s (CONH, carbamate I), 1506m (CONH, carbamate II), 1467m, 1456w, 
1420w, 1393w (C–H), 1342m, 1209m, 1165s (C–N stretch), 1073w, 1055w, 1041w, 
781w, 721m.   
θL: + 33.6 mdeg (223 nm, 10 mM, MeOH). 
θD: − 25.0 mdeg (223 nm, 10 mM, MeOH). 
 (C12)2-L-Asp.TFA (L: 6.5, D: 6.6) 
 
Chemical Formula: C30H56F3NO6 
Molecular Weight: 583.77 
(C12)2-L-Asp-Boc (200 mg, 3.51 mmol) was dissolved in a mixture of trifluoroacetic 
acid, triisopropylsilane and deionised water (500 µL, 95 : 2.5 : 2.5 v/v) before being 
shaken until TLC indicated reaction to be complete (3.5 h). Following careful addition 
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of deionised water (1.5 mL), the reaction mixture was washed with chloroform (3 × 4 
mL) to extract non polar by-products. The aqueous layer was then evaporated to dryness 
in vacuo to afford the product as a white powdery solid (186 mg, 3.19 mmol, 91%). D-
yield: 90%. 
Rf = 0.76 (9 : 1 DCM : methanol, ninhydrin). 
1




J = 4.8 Hz, 1H); 4.26 – 
4.15 (exp t, app m, CH2OC(O)CH2, 2H);  4.10 (t, CH2OC(O)CH, 
3
J = 6.8 Hz, 2H); 3.12 
(d, CH2CHNH, 
3
J = 4.8 Hz, 2H); 1.65 – 1.58 (m, CH2CH2O, 4H); 1.25 (br s, 18 × 
alkylCH2, 36H); 0.88 (t, 2 × alkylCH3, 
3
J = 6.8 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ: 171.74, 167.92 (C=O, ester); 161.60 (C=O, acid); 
67.57, 66.39 (CH2O); 49.73 (CHNH); 33.13 (CH2CHNH); 31.91, 29.65, 29.62, 29.58, 
29.49, 29.47, 29.34, 29.22, 29.15, 28.28, 28.17, 25.72, 25.59 (alkylCH2); 14.11 
(alkylCH3).  
ESI-MS: 470.42 [M–TFA+H]+ (100%). 
HRMS: Calcd. [M+H]
+
 (C28H56NO4) m/z = 470.4204, found [M+H]
+ 
= 470.4190 (error 
2.5 ppm). 
IR ν [cm-1]: 2955w, 2918s (N–H), 2850m (C–H), 1752m (C=O, ester), 1736m (C=O, 
acid) 1665s, 1593w, 1466w, 1431w, 1399w, 1371w (C–H), 1245m (C–O), 1186s (C–N), 
1141m, 1125m, 1092w, 803m, 766w. 
θL: + 26.7 mdeg (210 nm, 10 mM, MeOH). 
θD: − 27.6 mdeg (210 nm, 10 mM, MeOH). 
 (C12)2-L-Asp-L-Lys(Boc)2 (L: 6.7, D: 6.8) 
 
Chemical Formula: C44H83N3O9 
Molecular Weight: 798.16 
L-Lys(Boc)2 (76 mg, 0.22 mmol, 1.1 eq.) was dissolved in DCM (13 mL) at 0°C and 
stirred for 10 minutes before TBTU (63 mg, 0.20 mmol, 1 eq.) was added.  After a 
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further 10 minutes, (C12)2-L-Asp.TFA (100 mg, 0.21 mmol, 1 eq., pre-dissolved in 
DCM (4 mL)) and DIPEA (52 mg, 0.40 mmol, 2 eq.) were added. The resulting reaction 
mixture was stirred at 0°C for 20 minutes before being warmed to room temperature 
and left to stir overnight. The volatiles were removed in vacuo and the resulting residue 
taken up in DCM (10 mL) and washed successively with NaHSO4 (2 × 15 mL, 1.33 M), 
NaHCO3 (2 × 10 mL, sat.), deionised water (3 × 15 mL) and brine (15 mL, sat.). The 
organic phase was collected, dried over MgSO4 and the resulting filtrate concentrated in 
vacuo to afford a white powdery solid, which was purified by flash column 
chromatography (SiO2, 1 : 1 cyclohexane : ethyl acetate) to afford the product as a white 
powdery solid (75 mg, 94 µmol, 44%). D-yield: 42%. 
Rf = 0.85 (9 : 1 DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CDCl3) δ: 6.89 (d, AspNH, 
3
J = 8.0 Hz, 1H); 5.16 (br s, 




J = 8.0 Hz, 4.4 Hz, 1H);  4.67 
(exp dd, app br s, LysCHNH, 1H); 4.17 – 4.06 (exp dd, app m, LysCHNH, 2 × CH2O, 




J  = 17.2 Hz, 4.4 




J  = 17.2 Hz, 4.4 Hz, 1H); 1.81 – 1.71 (m, 
CH2CH2NH, 2H); 1.67 – 1.58 (m, 2 × CH2CH2O, LysCH2CHNH, 6H); 1.43 (s, (CH3)3, 
18H); 1.25 (s, 18 × alkylCH2, CH2CH2CHNH, 38H); 0.87 (t, 2 × alkylCH3, 
3
J = 7.2 Hz, 
6H). 
13
C NMR (100 MHz, CDCl3) δ: 171.78, 170.97 (C=O, ester); 170.44 (C=O, amide); 
156.08 (2 × C=O, carbamate); 79.94, 79.93 (C(CH3)3); 66.03, 65.31 (CH2O); 48.45 
(AspCHNH); 36.17 (AspCH2CHNH, AspCH2CHNH); 31.88 (CH2CH2NH); 29.62, 
29.60, 29.56, 29.50 29.32, 29.23, 29.19 (alkylCH2); 28.34, 28.21 (C(CH3)3); 25.76, 






 (C44H83N3NaO9) m/z = 820.6022, found [M+Na]
+
 = 820.5995 
(error 2.8 ppm). 
IR ν [cm-1]: 3356w (N–H), 3331w (N–H), 2918s (C–H), 2850m (C–H), 1746m (C=O, 
ester), 1730m (C=O, ester), 1682s (CONH, amide I), 1656s (CONH, carbamates I), 
1528s (CONH, amide II), 1471w, 1403w, 1392w, 1365w,  1301m, 1275m, 1247m (C–
O), 1170s (C–N), 1087w, 1053w, 1019w, 783w, 766w, 732w, 719w. 
LαD: + 13.5 (c. 1.0, CHCl3). 
DαD: − 11.2 (c. 1.0, CHCl3). 
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(C12)2-L-Asp-L-Lys.2TFA (L: 6.9, D: 6.10)  
 
Chemical Formula: C38H69F6N3O9 
Molecular Weight: 825.97 
(C12)2-L-Asp-L-Lys(Boc)2 (49 mg, 61 µmol) was dissolved in a mixture of 
trifluoroacetic acid, triisopropylsilane and deionised water (500 µL, 95 : 2.5 : 2.5 v/v) 
before being shaken until TLC indicated reaction to be complete (2.5 h). Following 
careful addition of deionised water (1.5 mL), the reaction mixture was washed with 
chloroform (3 × 4 mL). The combined organic layers were dried over MgSO4 and 
resulting filtrate concentrated in vacuo to afford the product as a white powdery solid 
(36 mg, 60 µmol, 98%). D-yield: 97%. 
Rf = 0.07 (9 : 1 DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CDCl3) δ: 7.82 – 7.75 (br m, CHNH3
+
, 3H); 7.34 (s, CH2NH3
+
, 
2H); 4.89 – 4.84 (exp dd, app m, AspCHNH, 1H);  4.20 (br s, AspCHNH, 1H); 4.16 – 
4.07 (exp dd, app m, CHNH3
+
, 1H); 4.07 – 4.00 (m, 2 × CH2O, 4H); 3.08 (exp t, app s, 
CH2NH3
+









J  = 17.4 Hz, 3.2 Hz, 1H); 1.96 (br s, CH2CHNH3
+
, 2H); 1.74 (s, 
CH2CH2NH3
+
, 2H); 1.58 (br s, 2 × CH2CH2O, CH2CH2CHNH3
+
, 6H); 1.25 (s, 18 × 
alkylCH2, 36H); 0.88 (t, 2 × alkylCH3, 
3
J = 6.8 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ: 171.80, 171.16 (C=O, esters); 170.51 (C=O, amide); 







); 34.00 (AspCH2CHNH); 31.89, 29.64, 29.62, 29.58, 
29.49, 29.34, 29.24, 29.18, 28.24 (alkylCH2); 28.20 (CH2CH2NH3
+
); 25.71, 25.66 






 (C34H68N3O5) m/z = 598.5153, found [M+H]
+
 = 598.5139 (error 
2.6 ppm). 
IR ν [cm-1]: 3330w (N–H), 2917s (C–H), 2850m (C–H), 1751m (C=O, ester), 1725m 
(C=O, ester), 1668s (CONH, amide I), 1539m (CONH, amide II), 1469w, 1430w, 
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1417w, 1401w, 1362w (C–H), 1345w, 1303w, 1271w, 1201s (C–O), 1178s (C–N), 
1128s, 1078w, 1064w, 1003w, 739w, 721s. 
θL: + 94.4 mdeg (215 nm, 10 mM, MeOH). 
θD: − 105.3 mdeg (215 nm, 10 mM, MeOH). 
L-Orn(Boc)2 (L: 6.11, D: 6.12) 
 
Chemical Formula: C15H28N2O6 
Molecular Weight: 332.40 
L-Ornithine (2.00 g, 11.86 mmol) and NaOH pellets (1.10 g, 27.50 mmol) were 
dissolved together in deionised water (30 mL). Di-tert-butyl dicarbonate (6.25 g, 28.60 
mmol) was dissolved separately in THF (30 mL) before being added to the reaction 
mixture dropwise in one portion over 30 minutes. The resulting reaction mixture was 
warmed to 45°C and stirred under an N2 atmosphere for 4.5 hours. Following the 
removal of volatiles in vacuo, the residue was taken up in deionised water (100 mL) and 
washed with cyclohexane (50 mL). The aqueous layer was acidified to pH 3 using 
NaHSO4 (1.33 M, pH paper) before the product was extracted into ethyl acetate (75 mL) 
and washed successively with deionised water (50 mL) and brine (50 mL, sat.). The 
organic phase was dried over MgSO4 and the resulting filtrate concentrated in vacuo to 
afford the product as a foamy white solid (3.25 g, 9.77 mmol, 65%). D-yield: 75%. 
Rf = 0.44 (9 : 1 DCM : methanol, ninhydrin). 
1
H NMR (400 MHz, CDCl3) δ: 10.10 (br s, OH, 1H); 6.19 (s, NH, 1H); 4.85 (s, NH, 
1H); 4.34 – 4.26 (exp dd, app m, CHNH, 1H); 3.12 (exp t, app s, CH2NH, 2H); 1.90 – 
1.81 (m, CHaHbCHNH, 1H); 1.71 – 1.62 (m, CHaHbCHNH, 1H); 1.60 – 1.52 (m, 
CH2CH2NH, 2H); 1.43 (s, 2 × C(CH3)3, 18H). 
13
C NMR (100 MHz, CDCl3) δ: 175.84 (C=O, acid); 156.35, 155.62 (C=O, carbamate); 
80.00, 79.99 (C(CH3)3); 52.92 (CHNH); 39.90 (CH2NH); 30.95 (CH2CHNH); 28.33, 








 (C15H28N2NaO6) m/z = 355.1840, found [M+Na]
+
 = 355.1822 
(error 4.3 ppm). 
IR ν [cm-1]: 3336w (N–H), 2977m (O–H), 2934w (C–H), 1702s (C=O, acid), 1689s 
(CONH, carbamates I), 1516m (CONH, carbamates II), 1454w, 1393m, 1366s (C–H), 
1248m (C–O) 1158s, 1050w (C–N), 1050w, 1020w, 856w, 778w. 
LαD: + 14.2 (c. 1.0, CHCl3). 
DαD: − 17.2 (c. 1.0, CHCl3).  
 (C12)2-L-Asp-L-Orn(Boc)2 (L: 6.13, D: 6.14) 
 
Chemical Formula: C43H81N3O9 
Molecular Weight: 784.13 
 L-Orn(Boc)2 (296 mg, 0.89 mmol, 1.3 eq.) was dissolved in DCM (15 mL) and cooled 
to 0°C. After 10 minutes, TBTU (252 mg, 0.78 mmol, 1.1 eq.) was added. After a 
further 10 minutes, (C12)2-L-Asp.TFA (400 mg, 0.69 mmol, 1 eq., pre-dissolved in 
DCM (5 mL)) and DIPEA (281 µL, 1.61 mmol, 2.3 eq.) were added. The reaction 
mixture was stirred for 20 minutes at 0°C before being warmed to room temperature 
and left to stir for 18 hours. The reaction mixture was then concentrated in vacuo before 
the resulting residue was taken up in DCM (10 mL) and washed with NaHSO4 (2 × 15 
mL, 1.33 M), NaHCO3 (2 × 10 mL, sat.), deionised water (3 × 15 mL) and brine (15 
mL, sat.). The organic phase was collected, dried over MgSO4 and the resulting filtrate 
concentrated in vacuo to afford a white powdery solid. The solid was purified by flash 
column chromatography (SiO2, 50 : 50 cyclohexane : ethyl acetate) to afford a white 
powdery product (246 mg, 0.31 µmol, 35%). D-yield: 46%. 




H NMR (400 MHz, CDCl3) δ: 7.00 (d, AspNH, J = 8.0 Hz, 1H); 5.18 (d, OrnNH, J = 
7.6 Hz, 1H); 4.85 – 4.81 (exp dd, app m, AspCHNH, 1H); 4.70 (br s, OrnNH, 1H); 4.21 
– 4.16 (exp dd, app m, CHNHBoc, 1H); 4.14 – 4.04 (m, 2 × CH2O, 4H); 3.16 (br s, 
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J = 17.2 Hz, 4.8 Hz, 
1H); 1.90 – 1.76 (m, CHaHbCHNHBoc, 1H); 1.61 – 1.56 (m, 2 × CH2CH2O, 
CH2CH2NHBoc, CHaHbCHNHBoc, J = 6.8 Hz, 7H); 1.41 (s, 2 × C(CH3)3; 9H); 1.23 (s, 
18 × alkylCH2, 36H); 0.86 (t, 2 × alkylCH3, 
3
J = 6.8 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ: 171.73, 170.79 (C=O, ester); 170.40 (C=O, amide); 
156.09, 155.44 (C=O, carbamate); 79.84, 79.13 (C(CH3)3); 65.96, 65.26 (CH2O); 53.70 
(CHNHBoc); 48.47 (AspCHNHOrn); 36.13 (AspCH2CHNH); 31.85 (CH2CHNHBoc); 
30.15, 29.60, 29.57, 29.53, 29.47, 29.30, 29.20, 29.16 (alkylCH2); 28.35, 28.23 
(C(CH3)3); 25.97 (CH2CH2NHBoc); 25.79, 25.71 (alkylCH2); 14.06 (2 × alkylCH3). 
ESI-MS: 806.58 [M+Na]
+





 (C43H81N3NaO9) m/z = 806.5865, found [M+Na]
+
 806.5848 
(error 1.9 ppm). 
IR ν [cm-1]: 3302m (N–H), 2918s (C–H), 2850m (C–H), 1740m (C=O, esters), 1670s 
(CONH, amide I), 1656s (CONH, carbamates I), 1538m (CONH, amide II), 1471w, 
1429w, 1401w, 1343w, 1295w, 1202s (C–O), 1179s (C–N), 1133m, 1057w, 985w, 
801m, 721w. 
 (C12)2-L-Asp-L-Orn.2TFA (L: 6.15, D: 6.16) 
 
Chemical Formula: C37H67F6N3O9 
Molecular Weight: 811.95 
(C12)2-L-Asp-L-Orn(Boc)2 (40 mg, 51 µmol) was dissolved in a mixture of 
trifluoroacetic acid, deionised water and triisopropylsilane (500 µL, 95 : 2.5 : 2.5 v/v) 
and shaken until TLC indicated the reaction to be complete (3.5 h). Deionised water 
(1.5 mL) was carefully added before the reaction mixture was washed with chloroform 
(2 × 4 mL). The combined organic layers were concentrated in vacuo to afford a white 
solid (41 mg, 50 µmol, 99%). D-yield: 98%. 
Rf = 0.29 (9 : 1 DCM : methanol, ninhydrin).
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1
H NMR (400 MHz, CDCl3) δ: 8.42 (d, AspNH, J = 8.0 Hz, 1H); 8.20 (br s, OrnNH3
+
, 
2H); 7.70 (s, OrnNH3
+
, 2H); 4.83 – 4.79 (exp dd, app m, AspCHNH, 1H); 4.15 – 4.08 
(exp dd, app m, CHNH3
+
, 1H); 4.03 – 3.94 (m, 2 × CH2O, 4H); 3.05 – 2.97 (m, 
CH2NH3
+









J = 17.2 Hz, 4.0 Hz, 1H); 2.02 – 1.94 (m, CH2CHNH3
+
, 2H); 1.86 
– 1.78 (m, CH2CH2NH3
+
, 2H); 1.56 (exp m, app s, 2 × CH2CH2O, 4H); 1.25 (s, 18 × 
alkylCH2, 36H); 0.87 (t, 2 × alkylCH3, 
3
J = 7.0 Hz, 6H).  
13
C NMR (100 MHz, CDCl3) δ: 171.47, 170.68 (C=O, ester); 168.86 (C=O, amide); 
161.72 (q, 
C-F





); 35.41 (AspCH2CHNH); 31.93, 29.74, 29.72, 29.63, 
29.43, 29.39, 28.37 (alkylCH2); 28.26 (CH2CHNH3
+
); 25.86, 25.82, 22.67 (alkylCH2); 
22.39 (CH2CH2NH2); 14.04 (2 × alkylCH3).  
ESI-MS: 292.75 [M+2H]
2+





 (C33H66N3O5) m/z = 584.4997, found [M+H]
+
 = 584.4989 (error 
1.0 ppm). 
IR ν [cm-1]: 3250m (N–H), 2918s (C–H), 2850m (C–H), 1739m (C=O, esters), 1659s 
(CONH, amide I), 1539m (CONH, amide II), 1471w, 1430w, 1401w, 1343w, 1295w, 
1225w, 1200s (C–O), 1180s (C–N), 1133m, 1058w, 985w, 800m, 721s.   
θL: + 48.0 mdeg (216 nm, 10 mM, MeOH). 
θD: − 48.7 mdeg (216 nm, 10 mM, MeOH). 
 (C12)2-L-Asp-L-Lys(L-Lys(Boc)2)2 (L: 6.17, D: 6.18)  
 
Chemical Formula: C66H123N7O15 
Molecular Weight: 1254.74 
L-Lys(Boc)2 (185 mg, 530 µmol, 2.2 eq) was dissolved in DCM (10 mL) at 0°C and 
TBTU (171 mg, 530 µmol, 2.2 eq) was added. After stirring for 10 minutes, (C12)2-L-
Asp-L-Lys.TFA (200 mg, 240 µmol, 1 eq) and DIPEA (169 µL, 970 µmol, 4 eq) were 
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added along with more cold DCM (10 mL). After 20 minutes, the reaction mixture was 
allowed to warm to room temperature, and stirred for 40 hours. The volatiles were 
removed in vacuo and resulting residue taken up in DCM (20 mL) before being washed 
successively with NaHSO4 (2 × 10 mL, 1.33 M), NaHCO3 (2 × 10 mL, sat.), deionised 
water (3 × 10 mL) and brine (10 mL, sat.). The organic phase was collected, dried over 
MgSO4 and the resulting filtrate concentrated in vacuo to afford a golden solid. This 
solid was purified by flash column chromatography (SiO2, 8 : 2, ethyl acetate : 
cyclohexane) to afford the product as a sticky white solid (31 mg, 25 µmol, 10%). D-
yield: 33%.       
Rf = 0.69 (8 : 2 ethyl acetate : cyclohexane, ninhydrin). 
1
H  NMR (400 MHz, CDCl3) δ: 7.09 (d, AspNH, J = 7.6 Hz, 1H); 6.92 (s, LysNH, 1H); 
5.95 (s, LysNH, 1H); 5.50 (s, LysNH, 1H); 4.85 – 4.77 (exp dd, app m, AspCHNH, 
1H); 4.29 (exp dd, br s, 2 × CHNHBoc, 2H); 4.13 – 3.95 (m, 2 × CH2O, LysCHNHLys 








J = 17.4 Hz, 4.6 Hz, 1H); 
1.77 – 1.70 (m, 2 × CH2CHNHBoc, LysCH2CHNHLys, 6H); 1.68 – 1.62 (m, 2 × 
CH2CH2O, 4H); 1.58 – 1.46 (m, 2 × CH2CH2NHBoc, LysCH2CH2NHLys, 6H); 1.42 (s, 
2 × C(CH3)3, 3 × CH2CH2CHNH, 24H); 1.41 (s, C(CH3)3, 9H) 1.40 (s, C(CH3)3, 9H); 
1.25 (app s, 18 × alkylCH2, 36H); 0.87 (t, 2 × alkylCH3, 
3
J = 7.0 Hz, 6H). 
13
C NMR (100 MHz, CDCl3) δ: 173.41 (2 × C=O, ester); 171.02 (3 × C=O, amide); 
156.12, 156.05 (2 × C=O, carbamate); 80.69, 79.81 (2 × C(CH3)3); 66.08, 65.33 
(CH2O); 54.42, 54.02 (CH2NHBoc); 53.91, 53.86 (CHNHBoc); 48.41 (AspCHNHLys); 
40.33, 40.09, 40.03 (LysCH2CHNH); 36.18 (AspCH2CHNH); 31.88 (2 × 
CH2CH2NHBoc, CH2CH2NHLys); 29.64, 29.61, 29.52, 29.41, 29.33, 29.26, 29.28, 
28.49 (alkylCH2); 28.43, 28.36 (2 × C(CH3)3); 25.86, 25.79 (alkylCH2); 22.66 (2 × 






 (C66H123N7NaO15) m/z = 1276.8969, found [M+Na]
+
 = 
1276.8930 (error 3.0 ppm). 
IR ν [cm-1]: 3301m (N–H), 2925s (C–H), 2855m (C–H), 1739m (C=O, esters), 1688s 
(CONH, amide I), 1644s (CONH, carbamates I), 1520s (CONH, amide II), 1456m, 
1391m, 1365s, 1272w, 1247s (C–N), 1168s (C–N), 1091w, 1046w, 1017w, 867w, 782w. 
LαD: + 18.4 (c. 1.0, CHCl3). 
DαD: − 22.2 (c. 1.0, CHCl3). 
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(C12)2-L-Asp-L-Lys(L-Lys)2.4TFA (L: 6.19, D: 6.20) 
 
Chemical Formula: C54H95F12N7O15 
Molecular Weight: 1310.37 
(C12)2-L-Asp-L-Lys(L-Lys(Boc)2)2 (28 mg, 22 µmol) was dissolved in a mixture of 
trifluoroacetic acid, triisopropylsilane and deionised water (500 µL, 95 : 2.5 : 2.5 v/v) 
before being shaken until TLC indicated reaction to be complete (2 h). Following 
careful addition of deionised water (1.5 mL), the reaction mixture was washed with 
chloroform (3 × 4 mL). The combined organic layers were dried over MgSO4 and the 
resulting filtrate concentrated in vacuo to afford the product as a white powdery solid 
(25 mg, 19 µmol, 87%). D-yield: 90%. 
Rf = 0.00 (9 : 1 DCM : methanol, ninhydrin). 
1
H  NMR (400 MHz, CD3OD) δ: 4.82 (exp dd, app t, AspCHNH, 
3
J = 6.4 Hz, 1H); 4.38 
(exp dd, app t, LysCHNH, 
3









J = 6.0 Hz, 1H); 3.29 – 3.18 (m, CH2NH, 
2H); 3.00 – 2.92 (m, 2 × CH2NH3
+
, 4H); 2.87 (d, AspCH2CHNH, 
3
J = 6.4 Hz, 2H); 1.94 
– 1.82 (m, 2 × CH2CHNH3
+
, CH2CHNH, 6H); 1.74 – 1.69 (m, 2 × CH2CH2NH3
+
, 
CH2CH2NH, 6H); 1.64 (exp m, app s, 2 × CH2CH2O, 4H); 1.52 – 1.43 (m, 2 × 
CH2CH2CHNH3
+
, CH2CH2CHNH, 6H); 1.30 (s, 18 × alkylCH2, 36H); 0.90 (t, 2 × 
alkylCH3, 
3
J = 6.8 Hz, 6H). 
13
C NMR (100 MHz, CD3OD) δ: 173.87, 172.12 (C=O, esters); 172.05, 170.09, 170.00 
(C=O, amide); 77.66 (2 × CH2NH3
+
); 66.95, 66.42 (CH2O); 54.87 (CH2NH, 
LysCHNHLys); 54.31, 53.93 (CHNH3
+
); 49.05 (AspCHNH); 40.48, 40.30, 40.26 
(LysCH2CHN); 37.03 (AspCH2CHNH); 33.14, 32.73, 32.17 (CH2CH2N); 30.82, 30.78, 
30.55, 30.50, 30.47, 29.96, 29.74, 29.71, 27.12, 27.09 (alkylCH2); 23.80, 23.02, 22.41 
(CH2CH2CHN); 14.50 (2 × alkylCH3).  
ESI-MS: 427.85 [M+2H]
2+
 (100%), 854.71 [M+H]
+
 (13%). 




 (C46H93N7NaO7) m/z = 427.8563, found [M+H]
+
 = 427.8545 
(error 4.4 ppm).   
IR ν [cm-1]: 3305m (N–H), 2930s (C–H), 2855m (C–H), 1739m (C=O, esters), 1689s 
(CONH, amide I), 1524s (CONH, amide II), 1455m, 1390m, 1364s, 1248s (C–N), 
1168s (C–N), 1091w, 1046w, 1017w, 868w.   
LαD: + 8.0 (c. 1.0, CHCl3). 
DαD: – 6.5 (c. 1.0, CHCl3). 
7.2 Assay Materials and Methods 
Assay Materials 
All materials, except novel compounds, employed in spectroscopic assays were 
obtained from commercial sources and used without further purification unless stated. 
Sodium salt heparin from porcine intestinal mucosa with a molecular weight between 
15,000 ± 2,000 Da (1 KU = 1000 units) was obtained from Calbiochem®. Ammonium 
carbonate, deoxyribonucleic acid sodium salt from calf thymus (DNA), 
ethylenediaminetetraacetic acid trisodium salt hydrate (EDTA), ethidium bromide 
(EthBr), Gly-Ala, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)  (HEPES), 
human serum (from human male AB plasma), Nile red, PAMAM dendrimers, 
phosphate buffered saline (PBS), protamine sulfate salt from salmon (Grade X, 
amorphous powder) and Trizma® hydrochloride (Tris HCl) were obtained from Sigma 
Aldrich.  
UV/Vis absorbance was measured on a Shimadzu UV-2401PC spectrophotometer and 
fluorescence on a Hitachi F-4500 spectrofluorimeter. All MalB solutions were 
incubated at 50°C for 24 hours prior to use and stored in the dark. Unless stated, all 
experiments were performed in triplicate and data is reported as a mean value plus or 
minus one standard deviation.  
Binding of Heparin (or other GAGs) to MalB 
A cuvette was charged with 2 mL of a stock solution of MalB (25 μM) in NaCl (150 
mM) and Tris HCl (10 mM). This solution was titrated with a stock solution of heparin 
(or other GAG) (811 μM) in MalB (25 μM), NaCl (150 mM) and Tris HCl (10 mM) to a 
final cuvette volume of 3 mL. The absorbance at 615 nm was recorded after each 
addition. 
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Interference to the MalB-Heparin Interaction By Electrolyte/Buffer 
A cuvette was charged with 2 mL of a stock solution of MalB (30 μM MalB) and 
heparin (27 μM) in Tris HCl (1 mM). For the electrolyte titration, the cuvette was 
titrated with aliquots of the same stock solution additionally containing a concentration 
of a NaCl (3 M) to a final cuvette volume of 3 mL. For the buffer titration, stock 
solutions containing MalB (30 μM), heparin (27 μM) and NaCl (150 mM) were 
prepared in clean water and Tris HCl (1 M). Titrating different amounts of each stock 
solution into the other effected the buffer concentration in the cuvette. The absorbance 
at 615 nm was recorded after each addition. 
Determination of Heparin Concentration with MalB 
A range of heparin stock solutions (0 U mL
-1 – 10 U mL-1) were made up in 100% 
Human Serum. 0.5 mL of each heparin-in-serum stock was titrated into a cuvette 
containing 1.5 mL MalB (25 μM) in Tris HCl (20 mM). The absorbance at 615 nm was 
recorded.  
Heparin Displacement Assay In Buffer 
A cuvette containing 2 mL of MalB (25 μM), heparin (27 μM) and NaCl (150 mM) in 
Tris HCl (10 mM) was titrated with binder stock solution to give the cuvette a suitable 
binder-heparin charge ratio. The binder stock solution was composed of the original 
MalB/heparin/NaCl/Tris HCl stock solution endowed additionally with a concentration 
of binder such that, after addition of 10 μL binder stock, the cuvette charge ratio (+ : –) 
is 0.037. After each addition, the cuvette was inverted to ensure good mixing and the 
absorbance at 615 nm was recorded against a Tris HCl (10 mM) baseline. Absorbance 
was normalised between a solution of MalB (25 μM), NaCl (150 mM) in Tris HCl (10 
mM) and one containing MalB (25 μM), heparin (27 μM), NaCl (150 mM) in Tris HCl 
(10 mM).   
Heparin Displacement Assay In Serum 
Fourteen cuvettes were charged with 1.75 mL of MalB (28.53 μM) in Tris HCl (10 
mM) and a volume of binder stock solution to give the cuvette a suitable binder-heparin 
charge ratio. The binder stock solution was additionally endowed with its own MalB 
(25 μM), heparin (27 μM) and Tris HCl (10 mM) concentrations. The concentration of 
binder in the binder stock was determined in the same manner described for the heparin 
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displacement assay in buffer.  Separately, a heparin (216 μM) solution was made in 
100% human serum.  Sequentially, each cuvette was titrated with 0.25 mL of the 
heparin-in-serum solution and inverted to ensure thorough mixing.  The absorbance was 
recorded at 615 nm against a baseline of (1.75 mL 10 mM Tris HCl, 0.25 mL 100% 
Human Serum) and normalised between a solution containing exclusively MalB (25 
μM) and one containing MalB (25 μM) and heparin (27 μM).   
Transgeden Heparin Binding Fluorescence Study 
A cuvette was charged with 1 mL TGD-dendrimer (1 µM) in NaCl (150 mM) and Tris 
HCl (10 mM) before being titrated with the same solution additionally endowed with 
heparin (24 µM) up to a total cuvette volume of 2 mL. Following each addition, a 
fluorescence spectrum was recorded following irradiation at 318 nm. All data obtained 
from a single run only. 
Dynamic Light Scattering (DLS) 
Aggregate characteristics were determined using a Zetasizer Nano (Malvern 
Instruments Ltd., Worcestershire, UK). The principle is based on the measurement of 
the backscattered light fluctuations at an angle of 173° and the calculation of an 
autocorrelation function. Data were recorded from 15–20 runs per single measurement, 
each of which was carried out at 25°C using folded capillary cells (DTS 1060). 
Monomer solutions were freshly prepared by dissolving an appropriate amount of dry 
compound in filtered aqueous media (e.g. Tris HCl). All samples were agitated and 
incubated at 25°C for 10 minutes prior to measurement. These studies were carried out 
in the laboratory of Dr Marcelo Calderon at Freie Universität Berlin, Germany with 
assistance from Dr Shashwat Malhotra.  
Plasma Clotting Assays 
Clotting studies employed an Axis Shield Thrombotrack coagulation analyser in 
conjunction with Behnk Elektronik cuvettes and ball bearings. Technoclone normal 
citrated plasma (re-suspended in HPLC grade water), Acros Organics calcium chloride 
(50 mM in HPLC grade water), Celsus porcine mucosal heparin (201 IU mg-1), Siemens 
Thromborel® S (re-suspended in HPLC grade water at double the manufacturers 
recommended concentration) and Siemens Pathromtin SL (inverted 8 times prior to 
use). 
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Prothrombin (PT) Assay 
A cylindrical cuvette, pre-warmed to 37°C on a heating block, was placed in the 
coagulation analyser and charged with a ball bearing and normal citrated plasma (50 
μL). Following incubation for at least 1 minute, pre-warmed (37°C) test sample (50 μL) 
was added along with Thromborel® S reagent (50 μL). Upon addition of the final 
reagent, the coagulation analyser was initiated. Clotting times are reported as the time at 
which the coagulometer was no longer able to stir the sample. Samples remaining 
unclotted after 120 seconds were recorded as ‘no clot.’ All measurements were carried 
out in triplicate with error values reported as one standard deviation. 
Activated Partial Thromboplastin (aPTT) Assay 
A cylindrical cuvette, pre-warmed to 37°C on a heating block, was placed in the 
coagulation analyser and charged with a ball bearing, normal citrated plasma (50 μL), 
Pathromtin SL (50 μL) and test sample (25 μL). Following incubation for at least 2 
minutes, pre-warmed (37°C) calcium chloride (25 μL) was added and the coagulation 
analyser was initiated. Clotting times are reported as the time at which the coagulometer 
was no longer able to stir the sample. Samples remaining unclotted after 120 seconds 
were recorded as ‘no clot.’ All measurements were carried out in triplicate with error 
values reported as one standard deviation. 
These studies were carried out in the laboratory of Professor Jeremy Turnbull at 
University of Liverpool, UK. 
Nile Red Release Assay 
The binder (25 µM) was dissolved in phosphate buffered saline (PBS, 0.01 M, endowed 
with NaCl (138 µM) and KCl (2.7 µM)). In a cuvette, an aliquot (1 mL) of this solution 
was mixed with a small amount of Nile red (1 µL, 2.5 mM in ethanol). Following 
inversion to ensure mixing, fluorescence intensity at 635 nm was recorded using a 550 
nm excitation wavelength. The binder stock solution was incubated at 37°C for 24 hours 
before another aliquot (1 mL) was taken for fluorescence measurement as before. In the 
time-resolved study, the initial solution was left in the fluorimeter and the emission was 
monitored at regular time periods. For the degradation experiment in the presence of 
heparin, the binder stock solution was additionally endowed with a heparin 
concentration corresponding to a dosage of 0.79 mg / 100IU.   
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Mass Spectrometric Degradation Assay 
The binder was dissolved (200 µM) in ammonium carbonate (10 mM, pH 7.5). 250 µL 
of this binder solution was combined with 250 µL of a Gly-Ala standard (1 mM, in 10 
mM ammonium carbonate) for mass spectrometric analysis. Following incubation of the 
binder solution for 24 hours at 37°C, the same analysis was repeated.  
Nile Red Encapsulation Assay
326
 
A dendron stock solution was prepared at a suitable concentration in PBS buffer (0.01 
M, endowed with NaCl (138 μM) and KCl (2.7 μM)). In a cuvette, the dendron stock 
solution was diluted to 1 mL final volume with PBS buffer to afford the required 
concentration. To the cuvette was added 1 μL Nile Red (2.5 mM, prepared in ethanol). 
Following inversion to ensure mixing, fluorescence intensity at 635 nm was recorded 
using a 550 nm excitation wavelength.  
TEM Imaging 
Monomer solutions were prepared in clean water at concentrations above previously-
calculated CAC values to ensure compounds were present in their assembled form. For 
samples imaged in the presence of heparin, the polysaccharide was introduced at a 
charge ratio (+ : –) under which the binder had previously exhibited significant 
interaction with it. Once prepared, aliquots of each solution were loaded on a formvar 
grid, negatively stained with uranyl acetate and allowed to dry before imaging. 
 DNA Binding Assay
356,373
  
A cuvette containing 2 mL of EthBr (5.07 μM) and DNA (4 μM with respect to each 
base (assumed RMM: 330 g mol
-1
)) in SHE Buffer (HEPES (2 mM), EDTA (0.05 mM) 
and NaCl (150 mM)) was titrated with binder stock solution to give the cuvette a 
suitable binder-heparin charge ratio. The binder stock solution was composed of the 
original EthBr/DNA/SHE Buffer stock solution endowed additionally with a 
concentration of binder such that, after addition of 10 μL binder stock, the cuvette 
charge ratio (+ : –) is 0.1. After each addition, the cuvette was inverted to ensure good 
mixing and the fluorescence at 595 nm was recorded using a 540 nm excitation 
wavelength. Fluorescence was normalised between a solution of EthBr (5.07 μM) and 
DNA (4 μM) in SHE Buffer and one containing EthBr (5.07 μM) alone in SHE Buffer 
(0.01 M).   
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Abbreviations 
AA  Azure A 
AB  Alcian Blue 
ACQ  Aggregation-caused quenching  
AIE  Aggregation-induced emission 
app  Apparent (NMR) 
aPTT  Activated partial thromboplastin time 
ATIII  Antithrombin III 
bis-MPA 2,2-bis(hydroxymethyl)propionic acid 
Boc  tert-butyloxycarbonyl 
CAC  Critical Aggregation Concentration 
CD  Circular dichroism or Cyclodextrin 
CE50  Charge excess or charge efficiency at 50% binding 
Ceff  Effective concentration 
CMC  Critical Micelle Concentration 
CNT  Carbon nanotubes 
Con A  Concanavalin A 
CS  Chondroitin sulfate 
d  doublet (NMR) 
DAPMA N,N-di-(3-aminopropyl)-N-methylamine 
DCC  N,N’-dicyclohexylcarbodiimide 
DCM  Dichloromethane 
Deg  Degradation peak (Mass Spectrometry)  
DLS  Dynamic light scattering 
DMF  Dimethylformamide 
DNA  Deoxyribose nucleic acid 
DOFLA Diversity-oriented fluorescent library approach 
DPD  Dissipative particle dynamics 
EC50  Effective concentration at 50% binding 
EDTA  Ethylenediaminetetraacetic acid  
EM  Effective molarity 
EthBr  Ethidium bromide 
FRET  Fluorescence resonance electron transfer 
GAG  Glycosaminoglycan  
GO  Graphene oxide 
Gx  Generation x 
HA  Hyaluronic acid 
HEPES N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) 
HS  Heparan sulfate 
IC50  Concentration at 50% inhibition 
IDA  Indicator displacement assay 
IHS  International heparin standard 
ITC  Isothermal titration calorimetry  
LMWH Low molecular weight heparin 
LMWP Low molecular weight protamine 
m  medium (IR) 
m  multiplet (NMR) 
MalB  Mallard blue 
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MB  Methylene blue 
MD  Molecular dynamics 
MG  Methyl green 
Mr  Relative molecular mass 
MRI  Magnetic resonance imaging 
NIR  Near infrared 
NMR  Nuclear magnetic resonance 
NP  Nanoparticles 
NR  Nile red 
PAH  Poly(allylaminehydrochloride) 
PAMAM Poly(amidoamine) 
PBS  Phosphate buffered saline   
PCPE  Phosphorescent conjugated polyelectrolyte 
PDI  Polydispersity index (DLS) 
PEG  Poly(ethyleneglycol) 
PEI  Poly(ethyleneimine) 
PNA  Peptide nucleic acid  
PPB  Plasma-protein binding 
PPV  Poly(phenylenevinylidene) 
PT  Prothrombin 
PVC  Polyvinyl chloride 
q  quartet (NMR) 
RGD  Arginine-glycine-aspartic acid tripeptide 
RNA  Ribose nucleic acid 
s  strong (IR) 
s  singlet (NMR) 
SAMul Self-assembled multivalency  
siRNA  Small interfering RNA 
Std  Standard peak (MS) 
t  triplet (NMR) 
TA  Thionine acetate 
TBTU  O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate 
TEM  Transmission electron microscopy 
TGD  Transgeden  
THF  Tetrahydrofuran 
TPE  Tetraphenylethene 
UFH  Unfractionated heparin 
UV  Ultra-violet 
w  weak (IR) 
 268 
References 
1. J. Huskens, Curr. Opin. Chem. Biol., 2006, 10, 537-543. 
2. R. W. Saalfrank, H. Maid and A. Scheurer, Angew. Chem. Int. Edit., 2008, 47, 
8794-8824. 
3. K. Bowman-James, Accounts Chem. Res., 2005, 38, 671-678. 
4. M. Mammen, S. K. Choi and G. M. Whitesides, Angew. Chem. Int. Edit., 1998, 
37, 2755-2794. 
5. G. Ercolani, J. Am. Chem. Soc., 2003, 125, 16097-16103. 
6. S. W. Benson, J. Am. Chem. Soc., 1958, 80, 5151-5154. 
7. A. Mulder, J. Huskens and D. N. Reinhoudt, Org. Biomol. Chem., 2004, 2, 
3409-3424. 
8. B. Perlmutter-Hayman, Accounts Chem. Res., 1986, 19, 90-96. 
9. G. Ercolani and L. Schiaffino, Angew. Chem. Int. Edit., 2011, 50, 1762-1768. 
10. A. Whitty, Nat. Chem. Biol., 2008, 4, 435-439. 
11. C. A. Hunter and H. L. Anderson, Angew. Chem. Int. Edit., 2009, 48, 7488-
7499. 
12. W. A. Eaton, E. R. Henry, J. Hofrichter and A. Mozzarelli, Nat. Struct. Biol., 
1999, 6, 351-358. 
13. M. F. Perutz, Q. Rev. Biophys., 1989, 22, 139-236. 
14. M. Takeuchi, M. Ikeda, A. Sugasaki and S. Shinkai, Accounts Chem. Res., 2001, 
34, 865-873. 
15. J. J. Lundquist and E. J. Toone, Chem. Rev., 2002, 102, 555-578. 
16. M. I. Page and W. P. Jencks, P. Natl. Acad. Sci. USA, 1971, 68, 1678-&. 
17. M. Mammen, E. I. Shakhnovich and G. M. Whitesides, J. Org. Chem., 1998, 63, 
3168-3175. 
18. G. Ercolani, J. Org. Chem., 1999, 64, 3350-3353. 
19. C. Galli and L. Mandolini, Eur. J. Org. Chem., 2000, 3117-3125. 
20. H. L. Anderson, S. Anderson and J. K. M. Sanders, J. Chem. Soc. Perk. T. 1, 
1995, 2231-2245. 
21. F. Felluga, P. Tecilla, L. Hillier, C. A. Hunter, G. Licini and P. Scrimin, Chem. 
Commun., 2000, 1087-1088. 
22. J. H. Rao, I. J. Colton and G. M. Whitesides, J. Am. Chem. Soc., 1997, 119, 
9336-9340. 
23. J. H. Rao and G. M. Whitesides, J. Am. Chem. Soc., 1997, 119, 10286-10290. 
 269 
24. J. H. Rao, L. Yan, J. Lahiri, G. M. Whitesides, R. M. Weis and H. S. Warren, 
Chem. Biol., 1999, 6, 353-359. 
25. J. H. Rao, J. Lahiri, L. Isaacs, R. M. Weis and G. M. Whitesides, Science, 1998, 
280, 708-711. 
26. J. H. Rao, J. Lahiri, R. M. Weis and G. M. Whitesides, J. Am. Chem. Soc., 2000, 
122, 2698-2710. 
27. P. R. Ashton, P. J. Campbell, E. J. T. Chrystal, P. T. Glink, S. Menzer, D. Philp, 
N. Spencer, J. F. Stoddart, P. A. Tasker and D. J. Williams, Angew. Chem. Int. 
Edit., 1995, 34, 1865-1869. 
28. T. Chang, A. M. Heiss, S. J. Cantrill, M. C. T. Fyfe, A. R. Pease, S. J. Rowan, J. 
F. Stoddart and D. J. Williams, Org. Lett., 2000, 2, 2943-2946. 
29. H. W. Gibson, N. Yamaguchi, L. Hamilton and J. W. Jones, J. Am. Chem. Soc., 
2002, 124, 4653-4665. 
30. V. Balzani, M. Clemente-Leon, A. Credi, J. N. Lowe, J. D. Badjić, J. F. Stoddart 
and D. J. Williams, Chem-Eur. J., 2003, 9, 5348-5360. 
31. A. H. Flood, R. J. A. Ramirez, W. Q. Deng, R. P. Muller, W. A. Goddard and J. 
F. Stoddart, Aust. J. Chem., 2004, 57, 301-322. 
32. J. D. Badjić, A. Nelson, S. J. Cantrill, W. B. Turnbull and J. F. Stoddart, 
Accounts Chem. Res., 2005, 38, 723-732. 
33. M. C. Misuraca, T. Grecu, Z. Freixa, V. Garavini, C. A. Hunter, P. van 
Leeuwen, M. D. Segarra-Maset and S. M. Turegat, J. Org. Chem., 2011, 76, 
2723-2732. 
34. W. Jiang, K. Nowosinski, N. L. Low, E. V. Dzyuba, F. Klautzsch, A. Schäfer, J. 
Huuskonen, K. Rissanen and C. A. Schalley, J. Am. Chem. Soc., 2012, 134, 
1860-1868. 
35. C. A. Hunter, M. C. Misuraca and S. M. Turega, J. Am. Chem. Soc., 2011, 133, 
582-594. 
36. H. J. Hogben, J. K. Sprafke, M. Hoffmann, M. Pawlicki and H. L. Anderson, J. 
Am. Chem. Soc., 2011, 133, 20962-20969. 
37. C. Fasting, C. A. Schalley, M. Weber, O. Seitz, S. Hecht, B. Koksch, J. 
Dernedde, C. Graf, E. W. Knapp and R. Haag, Angew. Chem. Int. Edit., 2012, 
51, 10472-10498. 
38. G. M. Whitesides, J. P. Mathias and C. T. Seto, Science, 1991, 254, 1312-1319. 
39. A. Klug, Angew. Chem. Int. Edit., 1983, 22, 565-582. 
40. D. Philp and J. F. Stoddart, Angew. Chem. Int. Edit., 1996, 35, 1155-1196. 
41. J. M. Lehn, Science, 1993, 260, 1762-1763. 
42. J. P. Mathias and J. F. Stoddart, Chem. Soc. Rev., 1992, 21, 215-225. 
43. D. Chandler, Nature, 2005, 437, 640-647. 
 270 
44. X. L. Chi, A. J. Guerin, R. A. Haycock, C. A. Hunter and L. D. Sarson, J. Chem. 
Soc. Chem. Comm., 1995, 2563-2565. 
45. J. N. Israelachvili, D. J. Mitchell and B. W. Ninham, J. Chem. Soc. Farad. T. 1, 
1976, 72, 1525-1568. 
46. A. Barnard and D. K. Smith, Angew. Chem. Int. Edit., 2012, 51, 6572-6581. 
47. J. E. Kingery-Wood, K. W. Williams, G. B. Sigal and G. M. Whitesides, J. Am. 
Chem. Soc., 1992, 114, 7303-7305. 
48. J. Voskuhl, M. C. A. Stuart and B. J. Ravoo, Chem-Eur. J., 2010, 16, 2790-
2796. 
49. R. V. Vico, J. Voskuhl and B. J. Ravoo, Langmuir, 2011, 27, 1391-1397. 
50. H. K. Lee, K. M. Park, Y. J. Jeon, D. Kim, D. H. Oh, H. S. Kim, C. K. Park and 
K. Kim, J. Am. Chem. Soc., 2005, 127, 5006-5007. 
51. X. Chen, U. C. Tam, J. L. Czlapinski, G. S. Lee, D. Rabuka, A. Zettl and C. R. 
Bertozzi, J. Am. Chem. Soc., 2006, 128, 6292-6293. 
52. K. Petkau-Milroy and L. Brunsveld, Eur. J. Org. Chem., 2013, 3470-3476. 
53. S. Laschat, A. Baro, N. Steinke, F. Giesselmann, C. Haegele, G. Scalia, R. 
Judele, E. Kapatsina, S. Sauer, A. Schreivogel and M. Tosoni, Angew. Chem. 
Int. Edit., 2007, 46, 4832-4887. 
54. A. R. A. Palmans, J. Vekemans, H. Fischer, R. A. Hikmet and E. W. Meijer, 
Chem-Eur. J., 1997, 3, 300-307. 
55. K. Petkau-Milroy, M. H. Sonntag, A. Colditz and L. Brunsveld, Int. J. Mol. Sci., 
2013, 14, 21189-21201. 
56. D. J. Welsh and D. K. Smith, Org. Biomol. Chem., 2011, 9, 4795-4801. 
57. D. Deniaud, K. Julienne and S. G. Gouin, Org. Biomol. Chem., 2011, 9, 966-
979. 
58. J. J. Reczek, A. A. Kennedy, B. T. Halbert and A. R. Urbach, J. Am. Chem. Soc., 
2009, 131, 2408-2415. 
59. S. W. A. Reulen, P. Y. W. Dankers, P. H. H. Bomans, E. W. Meijer and M. 
Merkx, J. Am. Chem. Soc., 2009, 131, 7304-7312. 
60. E. L. Doyle, C. A. Hunter, H. C. Phillips, S. J. Webb and N. H. Williams, J. Am. 
Chem. Soc., 2003, 125, 4593-4599. 
61. D. J. Welsh, P. Posocco, S. Pricl and D. K. Smith, Org. Biomol. Chem., 2013, 
11, 3177-3186. 
62. U. Griesenbach, D. M. Geddes, E. Alton and U. K. C. F. G. T. Co, Gene Ther., 
2006, 13, 1061-1067. 
63. B. L. Fang and J. A. Roth, Cancer Biol. Ther., 2003, 2, S115-S121. 
64. N. P. Gabrielson and J. Cheng, Biomaterials, 2010, 31, 9117-9127. 
 271 
65. S. P. Jones, N. P. Gabrielson, D. W. Pack and D. K. Smith, Chem. Commun., 
2008, 4700-4702. 
66. S. K. M. Nalluri, J. Voskuhl, J. B. Bultema, E. J. Boekema and B. J. Ravoo, 
Angew. Chem. Int. Edit., 2011, 50, 9747-9751. 
67. S. P. Jones, G. M. Pavan, A. Danani, S. Pricl and D. K. Smith, Chem-Eur. J., 
2010, 16, 4519-4532. 
68. D. J. Welsh, S. P. Jones and D. K. Smith, Angew. Chem. Int. Edit., 2009, 48, 
4047-4051. 
69. A. Barnard, P. Posocco, S. Pricl, M. Calderon, R. Haag, M. E. Hwang, V. W. T. 
Shum, D. W. Pack and D. K. Smith, J. Am. Chem. Soc., 2011, 133, 20288-
20300. 
70. A. Barnard, P. Posocco, M. Fermeglia, A. Tschiche, M. Calderon, S. Pricl and 
D. K. Smith, Org. Biomol. Chem., 2014, 12, 446-455. 
71. A. Barnard, M. Calderon, A. Tschiche, R. Haag and D. K. Smith, Org. Biomol. 
Chem., 2012, 10, 8403-8409. 
72. A. Tschiche, A. M. Staedtler, S. Malhotra, H. Bauer, C. Bottcher, S. Sharbati, 
M. Calderon, M. Koch, T. M. Zollner, A. Barnard, D. K. Smith, R. Einspanier, 
N. Schmidt and R. Haag, J. Mater. Chem. B, 2014, 2, 2153-2167. 
73. Y. Zhang, J. Chen, C. S. Xiao, M. Q. Li, H. Y. Tian and X. S. Chen, 
Biomacromolecules, 2013, 14, 4289-4300. 
74. P. M. Levine, T. P. Carberry, J. M. Holub and K. Kirshenbaum, Med. Chem., 
2013, 4, 493-509. 
75. S. Middeldorp, Thromb. Res., 2008, 122, 753-762. 
76. J. McLean, Am. J. Physiol., 1916, 41, 250-257. 
77. J. McLean, Circulation, 1959, 19, 75-78. 
78. W. H. Howell, Am. J. Physiol., 1925, 71, 553-562. 
79. R. D. Rosenberg and P. S. Damus, J. Biol. Chem., 1973, 248, 6490-6505. 
80. D. L. Rabenstein, Nat. Prod. Rep., 2002, 19, 312-331. 
81. T. R. Rudd, M. A. Skidmore, M. Guerrini, M. Hricovini, A. K. Powell, G. 
Siligardi and E. A. Yates, Curr. Opin. Struc. Biol., 2010, 20, 567-574. 
82. I. Capila and R. J. Linhardt, Angew. Chem. Int. Edit., 2002, 41, 390-412. 
83. R. Sasisekharan and G. Venkataraman, Curr. Opin. Chem. Biol., 2000, 4, 626-
631. 
84. R. Raman, V. Sasisekharan and R. Sasisekharan, Chem. Biol., 2005, 12, 267-
277. 
85. J. Hirsh and R. Raschke, Chest, 2004, 126, 188S-203S. 
 272 
86. J. Hirsh, R. Raschke, T. E. Warkentin, J. E. Dalen, D. Deykin and L. Poller, 
Chest, 1995, 108, S258-S275. 
87. R. J. Kandrotas, Clin. Pharmacokinet., 1992, 22, 359-374. 
88. P. Brunet, N. Simon, A. Opris, V. Faure, A. M. Lorec-Penet, H. Portugal, B. 
Dussol and Y. Berland, Am. J. Kidney Dis., 2008, 51, 789-795. 
89. E. W. Davie and O. D. Ratnoff, Science, 1964, 145, 1310-1312. 
90. R. G. Macfarlane, Nature, 1964, 202, 498-&. 
91. E. W. Davie, K. Fujikawa and W. Kisiel, Biochemistry, 1991, 30, 10363-10370. 
92. J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. 
Raschke, C. Granger, E. M. Ohman and J. E. Dalen, Chest, 2001, 119, 64S-94S. 
93. M. Petitou, B. Casu and U. Lindahl, Biochimie, 2003, 85, 83-89. 
94. H. C. Hemker and S. Beguin, Thromb. Haemostasis, 1993, 70, 724-728. 
95. W. H. Howell, Am. J. Physiol., 1923, 63, 434. 
96. S. Wessler and S. N. Gitel, Blood, 1979, 53, 525-544. 
97. D. R. Bangham and M. V. Mussett, B. World Health Organ., 1959, 20, 1201-
1208. 
98. D. Basu, J. Cade, A. Gallus and J. Hirsh, New Engl. J. Med., 1972, 287, 324-
327. 
99. V. Ignjatovic, R. Summerhayes, A. Gan, J. Than, A. Chan, A. Cochrane, M. 
Bennett, S. Horton, F. Shann, G. Lane, M. Ross-Smith and P. Monagle, Thromb. 
Res., 2007, 120, 347-351. 
100. R. Balhorn, Genome Biol., 2007, 8, 227. 
101. F. P. Ottensmeyer, R. F. Whiting and A. P. Korn, P. Natl. Acad. Sci. USA, 1975, 
72, 4953-4955. 
102. S. M. Bromfield, P. Posocco, M. Fermeglia, S. Pricl, J. Rodríguez-López and D. 
K. Smith, Chem. Commun., 2013, 49, 4830-4832. 
103. J. Butterworth, Y. A. Lin, R. C. Prielipp, J. Bennett, J. W. Hammon and R. L. 
James, Ann. Thorac. Surg., 2002, 74, 1589-1595. 
104. J. Butterworth, Y. A. Lin, R. Prielipp, J. Bennett and R. James, Anesth. Analg., 
2002, 94, 514-522. 
105. K. H. Teoh, E. Young, C. A. Bradley and J. Hirsh, Circulation, 1993, 88, Ii420-
425. 
106. A. Galeone, C. Rotunno, P. Guida, B. Assunta, G. Rubino, L. d. L. T. Schinosa 
and D. Paparella, J. Cardiothor. Vasc. An., 2013, 27, 853-858. 
107. C. Hermans and D. Claeys, Curr. Med. Res. Opin., 2006, 22, 471-481. 
 273 
108. P. Martin, F. Horkay, N. K. Gupta, C. Gebitekin and D. R. Walker, Blood 
Coagul. Fibrin., 1992, 3, 187-191. 
109. K. H. T. Teoh, E. Young, M. H. Blackall, R. S. Roberts and J. Hirsh, J. Thorac. 
Cardiovasc. Surg., 2004, 128, 211-219. 
110. M. Stafford-Smith, E. A. Lefrak, A. G. Qazi, I. J. Welsby, L. Barber, A. Hoeft, 
A. Dorenbaum, J. Mathias, J. J. Rochon and M. F. Newman, Anesthesiology, 
2005, 103, 229-240. 
111. R. Porsche and Z. R. Brenner, Heart Lung, 1999, 28, 418-428. 
112. Y. Q. Chu, L. J. Cai, D. C. Jiang, D. Jia, S. Y. Yan and Y. Q. Wang, Clin. Ther., 
2010, 32, 1729-1732. 
113. M. Nybo and J. S. Madsen, Basic & Clinical Pharmacology & Toxicology, 
2008, 103, 192-196. 
114. S. E. Kimmel, M. A. Sekeres, J. A. Berlin, L. R. Goldberg and B. L. Strom, J. 
Clin. Epidemiol., 1998, 51, 1-10. 
115. J. J. van Veen, R. M. Maclean, K. K. Hampton, S. Laidlaw, S. Kitchen, P. Toth 
and M. Makris, Blood Coagul. Fibrin., 2011, 22, 565-570. 
116. M. A. Crowther, L. R. Berry, P. T. Monagle and A. K. C. Chan, Br. J. 
Haematol., 2002, 116, 178-186. 
117. G. J. Despotis, G. Gravlee, K. Filos and J. Levy, Anesthesiology, 1999, 91, 
1122-1151. 
118. P. D. Raymond, M. J. Ray, S. N. Callen and N. A. Marsh, Perfusion-UK, 2003, 
18, 269-276. 
119. D. J. Murray, W. J. Brosnahan, B. Pennell, D. Kapalanski, J. M. Weiler and J. 
Olson, J. Cardiothor. Vasc. An., 1997, 11, 24-28. 
120. D. P. Prisco, R, Thromb. J., 2003, 1, 1 - 10  
121. A. F. Rosenberg, M. Zumberg, L. Taylor, A. LeClaire and N. Harris, J. Pharm. 
Pract., 2010, 23, 210-216. 
122. P. D. Raymond, M. J. Ray, S. N. Callen and N. A. Marsh, Perfusion-UK, 2003, 
18, 277-281. 
123. J. C. Horrow, Anesth. Analg., 1985, 64, 348-361. 
124. N. Sadeghi, D. Hoppensteadt, O. Iqbal, W. Jeske, J. M. Walenga and J. Fareed, 
Faseb J., 2010, 24, 1. 
125. T. D. James and S. Shinkai, in Host-Guest Chemistry: Mimetic Approaches to 
Study Carbohydrate Recognition, ed. S. Penades, Springer-Verlag Berlin, 
Berlin, 2002, vol. 218, pp. 159-200. 
126. K. Sandanayake and S. Shinkai, J. Chem. Soc. Chem. Comm., 1994, 1083-1084. 
127. R. Nishiyabu, Y. Kubo, T. D. James and J. S. Fossey, Chem. Commun., 2011, 
47, 1106-1123. 
 274 
128. S. D. Bull, M. G. Davidson, J. M. H. Van den Elsen, J. S. Fossey, A. T. A. 
Jenkins, Y. B. Jiang, Y. Kubo, F. Marken, K. Sakurai, J. Z. Zhao and T. D. 
James, Accounts Chem. Res., 2013, 46, 312-326. 
129. Y. J. Huang, W. J. Ouyang, X. Wu, Z. Li, J. S. Fossey, T. D. James and Y. B. 
Jiang, J. Am. Chem. Soc., 2013, 135, 1700-1703. 
130. J. P. Lorand and J. O. Edwards, J. Org. Chem., 1959, 24, 769-774. 
131. J. Yoon and A. W. Czarnik, J. Am. Chem. Soc., 1992, 114, 5874-5875. 
132. J. Yan, G. Springsteen, S. Deeter and B. H. Wang, Tetrahedron, 2004, 60, 
11205-11209. 
133. S. C. Ma, V. C. Yang and M. E. Meyerhoff, Anal. Chem., 1992, 64, 694-697. 
134. J. A. Wahr, J. H. Yun, V. C. Yang, L. M. Lee and M. E. Meyerhoff, J. 
Cardiothor. Vasc. An., 1996, 10, 447-450. 
135. S. C. Ma, V. C. Yang, B. Fu and M. E. Meyerhoff, Anal. Chem., 1993, 65, 2078-
2084. 
136. S. Amemiya, Y. Kim, R. Ishimatsu and B. Kabagambe, Anal. Bioanal. Chem., 
2011, 399, 571-579. 
137. H. Qi, L. Zhang, L. Yang, P. Yu and L. Mao, Anal. Chem., 2013, 85, 3439-3445. 
138. Y. Chen, R. N. Liang and W. Qin, Chinese Chem. Lett., 2012, 23, 233-236. 
139. J. Umlas, R. H. Taff, G. Gauvin and P. Swierk, Anesth. Analg., 1983, 62, 1095-
1099. 
140. G. Gauvin, J. Umlas and N. Chin, Med. Instrum., 1983, 17, 165-168. 
141. M. D. Klein, R. A. Drongowski, R. J. Linhardt and R. S. Langer, Anal. 
Biochem., 1982, 124, 59-64. 
142. Q. C. Jiao, Q. Liu, C. Sun and H. He, Talanta, 1999, 48, 1095-1101. 
143. Q. C. Jiao and Q. Liu, Anal. Lett., 1998, 31, 1311-1323. 
144. Z. L. Zhong and E. V. Anslyn, J. Am. Chem. Soc., 2002, 124, 9014-9015. 
145. A. T. Wright, Z. L. Zhong and E. V. Anslyn, Angew. Chem. Int. Edit., 2005, 44, 
5679-5682. 
146. Y. Egawa, R. Hayashida, T. Seki and J.-i. Anzai, Talanta, 2008, 76, 736-741. 
147. Q. Chen, Y. Cui, J. Cao and B.-H. Han, Polymer, 2011, 52, 383-390. 
148. S. V. Nalage, S. V. Bhosale and S. K. Bhargava, Tetrahedron Lett., 2012, 53, 
2864-2867. 
149. W. Sun, H. Bandmann and T. Schrader, Chem-Eur. J., 2007, 13, 7701-7707. 
150. M. Wang, D. Q. Zhang, G. X. Zhang and D. B. Zhu, Chem. Commun., 2008, 
4469-4471. 
 275 
151. L. T. Zeng, P. F. Wang, H. Y. Zhang, X. Q. Zhuang, Q. Dai and W. M. Liu, 
Org. Lett., 2009, 11, 4294-4297. 
152. K. Y. Pu and B. Liu, Macromolecules, 2008, 41, 6636-6640. 
153. K.-Y. Pu and B. Liu, Adv. Funct. Mater., 2009, 19, 277-284. 
154. K. Pu, R. Zhan, J. Liang and B. Liu, Science China-Chemistry, 2011, 54, 567-
574. 
155. B. Xu, X. Wu, H. Li, H. Tong and L. Wang, Polymer, 2012, 53, 490-494. 
156. T. Bříza, Z. Kejík, I. Císařová, J. Králová, P. Martásek and V. Král, Chem. 
Commun., 2008, 1901-1903. 
157. J. C. Sauceda, R. M. Duke and M. Nitz, ChemBioChem, 2007, 8, 391-394. 
158. H. Szelke, S. Schübel, J. Harenberg and R. Krämer, Chem. Commun., 2010, 46, 
1667-1669. 
159. M. C.-L. Yeung and V. W.-W. Yam, Chem-Eur. J., 2011, 17, 11987-11990. 
160. S. L. Wang and Y. T. Chang, Chem. Commun., 2008, 1173-1175. 
161. X. Gu, G. Zhang and D. Zhang, Analyst, 2012, 137, 365-369. 
162. J. D. Luo, Z. L. Xie, J. W. Y. Lam, L. Cheng, H. Y. Chen, C. F. Qiu, H. S. 
Kwok, X. W. Zhan, Y. Q. Liu, D. B. Zhu and B. Z. Tang, Chem. Commun., 
2001, 1740-1741. 
163. N. B. Shustova, T. C. Ong, A. F. Cozzolino, V. K. Michaelis, R. G. Griffin and 
M. Dinca, J. Am. Chem. Soc., 2012, 134, 15061-15070. 
164. R. T. K. Kwok, J. L. Geng, J. W. Y. Lam, E. G. Zhao, G. Wang, R. Y. Zhan, B. 
Liu and B. Tang, J. Mater. Chem. B, 2014, 2, 4134-4141. 
165. H. L. Liu, P. S. Song, R. R. Wei, K. Li and A. J. Tong, Talanta, 2014, 118, 348-
352. 
166. H. Szelke, J. Harenberg and R. Krämer, Thromb. Haemostasis, 2009, 102, 859-
864. 
167. H. F. Shi, H. B. Sun, H. R. Yang, S. J. Liu, G. Jenkins, W. Feng, F. Y. Li, Q. 
Zhao, B. Liu and W. Huang, Adv. Funct. Mater., 2013, 23, 3268-3276. 
168. D. H. Kim, Y. J. Park, K. H. Jung and K. H. Lee, Anal. Chem., 2014, 86, 6580-
6586. 
169. E. Climent, P. Calero, M. D. Marcos, R. Martínez-Máňez, F. Sancenon and J. 
Soto, Chem-Eur. J., 2009, 15, 1816-1820. 
170. B. K. Jena and C. R. Raj, Biosens. Bioelectron., 2008, 23, 1285-1290. 
171. R. Cao and B. X. Li, Chem. Commun., 2011, 47, 2865-2867. 
172. X. L. Fu, L. X. Chen and J. H. Li, Analyst, 2012, 137, 3653-3658. 
 276 
173. X. L. Fu, L. X. Chen, J. H. Li, M. Lin, H. Y. You and W. H. Wang, Biosens. 
Bioelectron., 2012, 34, 227-231. 
174. R. Godavarti and R. Sasisekharan, J. Biol. Chem., 1998, 273, 248-255. 
175. T. Ammar and C. F. Fisher, Anesthesiology, 1997, 86, 1382-1386. 
176. H. F. Wu, R. L. Lundblad and F. C. Church, Blood, 1995, 85, 421-428. 
177. A. K. Udit, C. Everett, A. J. Gale, J. R. Kyle, M. Ozkan and M. G. Finn, 
ChemBioChem, 2009, 10, 503-510. 
178. A. Luganini, A. Giuliani, G. Pirri, L. Pizzuto, S. Landolfo and G. Gribaudo, 
Antivir. Res., 2010, 85, 532-540. 
179. Y. Byun, V. K. Singh and V. C. Yang, Thromb. Res., 1999, 94, 53-61. 
180. L. C. Chang, H. F. Lee, Z. Q. Yang and V. C. Yang, AAPS Pharmsci, 2001, 3, 
art. no.-17. 
181. L. C. Chang, J. F. Liang, H. F. Lee, L. M. Lee and V. C. Yang, AAPS Pharmsci, 
2001, 3, art. no.-18. 
182. L. M. Lee, L. C. Chang, S. Wrobleski, T. W. Wakefield and V. C. Yang, AAPS 
Pharmsci, 2001, 3, art. no.-19. 
183. T. W. Wakefield, P. C. Andrews, S. K. Wrobleski, A. M. Kadell, A. Fazzalari, 
B. J. Nichol, T. Vanderkooi and J. C. Stanley, J. Surg. Res., 1994, 56, 586-593. 
184. M. J. Hernaiz, L. A. LeBrun, Y. Wu, J. W. Sen, R. J. Linhardt and N. H. H. 
Heegaard, Eur. J. Biochem., 2002, 269, 2860-2867. 
185. W. A. Weiss, J. S. Gilman, A. J. Catenacci and A. E. Osterberg, JAMA-J. Am. 
Med. Assoc., 1958, 166, 603-607. 
186. M. Kikura, M. K. Lee and J. H. Levy, Anesth. Analg., 1996, 83, 223-227. 
187. G. Montalescot, W. M. Zapol, A. Carvalho, D. R. Robinson, A. Torres and E. 
Lowenstein, Circulation, 1990, 82, 1754-1764. 
188. C. W. Lillehei, L. P. Sterns, D. M. Long and D. Lepley, Ann. Surg., 1960, 151, 
11-16. 
189. K. Kamiński, M. Płonka, J. Ciejka, K. Szczubiałka, M. Nowakowska, B. 
Lorkowska, R. Korbut and R. Lach, J. Med. Chem., 2011, 54, 6586-6596. 
190. B. Kalaska, E. Sokolowska, K. Kaminski, K. Szczubialka, K. Kramkowski, A. 
Mogielnicki, M. Nowakowska and W. Buczko, Eur. J. Pharmacol., 2012, 686, 
81-89. 
191. K. Kamiński, B. Kałaska, P. Koczurkiewicz, M. Michalik, K. Szczubiałka, A. 
Mogielnicki, W. Buczko and M. Nowakowska, Med. Chem., 2014, 5, 489-495. 
192. S. H. Bai, C. Thomas and F. Ahsan, J. Pharm. Sci., 2007, 96, 2090-2106. 
193. X. Y. Feng, Y. Y. Cheng, K. Yang, J. H. Zhang, Q. L. Wu and T. W. Xu, J. 
Phys. Chem. B, 2010, 114, 11017-11026. 
 277 
194. S. Bai and F. Ahsan, Pharm. Res., 2009, 26, 539-548. 
195. S. Metz, J. C. Horrow, I. P. Goel, M. L. R. Kuretu and C. Bellwoar, J. 
Cardiothor. Vasc. An., 1996, 10, 474-476. 
196. R. E. McAllister, Circulation, 2010, 122. 
197. J. Kuziej, E. Litinas, D. A. Hoppensteadt, D. H. Liu, J. M. Walenga, J. Fareed 
and W. Jeske, Clin. Appl. Thromb.-Hem., 2010, 16, 377-386. 
198. C. E. Mahan, J. Thromb. Thrombolys., 2014, 37, 271-278. 
199. F. Cunsolo, G. M. L. Consoli, C. Geraci and T. Mecca, Abiotic Heparin 
Antagonists, 2005, WO/2005/028422. 
200. T. Mecca, G. M. L. Consoli, C. Geraci, R. La Spina and F. Cunsolo, Org. 
Biomol. Chem., 2006, 4, 3763-3768. 
201. T. Mecca and F. Cunsolo, Polym. Advan. Technol., 2010, 21, 752-757. 
202. S. Choi, D. J. Clements, V. Pophristic, I. Ivanov, S. Vemparala, J. S. Bennett, M. 
L. Klein, J. D. Winkler and W. E. DeGrado, Angew. Chem. Int. Edit., 2005, 44, 
6685-6689. 
203. C. Kelly, S. Khaja, A. Vena, A. Yu and J. M. Esson, Anal. Chim. Acta, 2010, 
681, 1-7. 
204. G. L. Montalvo, Y. Zhang, T. M. Young, M. J. Costanzo, K. B. Freeman, J. 
Wang, D. J. Clements, E. Magavern, R. W. Kavash, R. W. Scott, D. H. Liu and 
W. F. DeGrado, ACS Chem. Biol., 2014, 9, 967-975. 
205. M. Schuksz, M. M. Fuster, J. R. Brown, B. E. Crawford, D. P. Ditto, R. 
Lawrence, C. A. Glass, L. C. Wang, Y. Tor and J. D. Esko, P. Natl. Acad. Sci. 
USA, 2008, 105, 13075-13080. 
206. D. T. Hunter and J. M. Hill, Nature, 1961, 191, 1378-1379. 
207. K. Rajangam, H. A. Behanna, M. J. Hui, X. Q. Han, J. F. Hulvat, J. W. 
Lomasney and S. I. Stupp, Nano Lett., 2006, 6, 2086-2090. 
208. H. A. Behanna, K. Rajangam and S. I. Stupp, J. Am. Chem. Soc., 2007, 129, 
321-327. 
209. K. Rajangam, M. S. Arnold, M. A. Rocco and S. I. Stupp, Biomaterials, 2008, 
29, 3298-3305. 
210. A. D. Cardin and H. J. R. Weintraub, Arteriosclerosis, 1989, 9, 21-32. 
211. A. C. Rodrigo, A. Barnard, J. Cooper and D. K. Smith, Angew. Chem. Int. Edit., 
2011, 50, 4675-4679. 
212. S. M. Bromfield, E. Wilde and D. K. Smith, Chem. Soc. Rev., 2013, 42, 9184-
9195. 
213. G. R. Jones, R. Hashim and D. M. Power, Biochim. Biophys. Acta., 1986, 883, 
69-76. 
 278 
214. J. H. Stebbins, J. Am. Chem. Soc., 1884, 6, 304-305. 
215. P. N. Marshall, Histochem. J., 1979, 11, 489-493. 
216. P. N. Marshall and S. M. Lewis, Stain Technol., 1975, 50, 375-381. 
217. R. W. Mowry and F. H. Kasten, Biotech. Histochem., 1975, 50, 65-81. 
218. W. Löhr, I. Sohmer and D. Wittekind, Stain Technol., 1974, 49, 359-366. 
219. E. Tuite and J. M. Kelly, Biopolymers, 1995, 35, 419-433. 
220. E. M. Sloand, C. M. Kessler, C. L. McIntosh and H. G. Klein, Thromb. Res., 
1989, 54, 677-686. 
221. E. H. Flewellen, Tex. Med., 1980, 76, 49-51. 
222. J. G. Whitwam, A. R. Taylor and J. M. White, Anaesthesia, 1979, 34, 181-182. 
223. N. Blass and D. Fung, Anesthesiology, 1976, 45, 458-459. 
224. V. C. Yang, Y. Y. Fu, C. L. C. Teng, S. C. Ma and J. N. Shanberge, Thromb. 
Res., 1994, 74, 427-434. 
225. V. E. Nicotra, M. F. Mora, R. A. Iglesias and A. M. Baruzzi, Dyes Pigments, 
2008, 76, 315-318. 
226. M. Havelcová, P. Kubát and I. Nĕmcová, Dyes Pigments, 1999, 44, 49-54. 
227. K. Ahmed, R. Azmat, F. Uddin and M. Q. Fatmi, Chinese J. Chem., 2011, 29, 
643-649. 
228. R. Nothelfer, J. Ruprecht, Heyl and H. Baumgärtel, Biopolymers, 1986, 25, 
1273-1281. 
229. W. C. Lai, N. S. Dixit and R. A. Mackay, J. Phys. Chem., 1984, 88, 5364-5368. 
230. R. A. Rhoades and D. R. Bell, Medical Physiology: Principles for Clinical 
Medicine, Lippincott, Williams and Wilkins, Philadelphia, PA, 2008. 
231. A. K. Krey and F. E. Hahn, Biochemistry, 1975, 14, 5061-5067. 
232. J. E. Scott, Histochemistry, 1967, 9, 30-47. 
233. J. E. Scott, G. Quintarelli and M. C. Dellovo, Histochemistry, 1964, 4, 73-85. 
234. J. E. Scott, Eur. J. Oral Sci., 1996, 104, 2-9. 
235. P. Whiteman, Biochem. J., 1973, 131, 343-350. 
236. J. E. Scott and I. H. Willett, Nature, 1966, 209, 985-&. 
237. S. Bjornsson, Anal. Biochem., 1993, 210, 282-291. 
238. T. T. Williams, C. Dohno, E. D. A. Stemp and J. K. Barton, J. Am. Chem. Soc., 
2004, 126, 8148-8158. 
239. R. E. Hileman, J. R. Fromm, J. M. Weiler and R. J. Linhardt, Bioessays, 1998, 
20, 156-167. 
 279 
240. A. Isidro-Llobet, M. Álvarez and F. Albericio, Chem. Rev., 2009, 109, 2455-
2504. 
241. P. A. Wender, T. C. Jessop, K. Pattabiraman, E. T. Pelkey and C. L. VanDeusen, 
Org. Lett., 2001, 3, 3229-3232. 
242. S. M. Bromfield, A. Barnard, P. Posocco, M. Fermeglia, S. Pricl and D. K. 
Smith, J. Am. Chem. Soc., 2013, 135, 2911-2914. 
243. J. C. van Kerkhof, P. Bergveld and R. B. M. Schasfoort, Biosens. Bioelectron., 
1995, 10, 269-282. 
244. K. Gaus and E. A. H. Hall, Biosens. Bioelectron., 1998, 13, 1307-1315. 
245. J. F. Callan, A. P. de Silva and D. C. Magri, Tetrahedron, 2005, 61, 8551-8588. 
246. Z. Shriver and R. Sasisekharan, Nat. Chem., 2013, 5, 644-646. 
247. L. Zhang and G. Q. Tang, J. Fluoresc., 2013, 23, 303-310. 
248. B. S. Fujimoto, J. B. Clendenning, J. J. Delrow, P. J. Heath and M. Schurr, J. 
Phys. Chem., 1994, 98, 6633-6643. 
249. G. Somer and A. Temizer, Photochem. Photobiol., 1984, 40, 575-580. 
250. A. Mills and J. Wang, J. Photoch. Photobio. A, 1999, 127, 123-134. 
251. A. H. Gemeay, I. A. Mansour, R. G. El-Sharkawy and A. B. Zaki, J. Chem. 
Technol. Biot., 2004, 79, 85-96. 
252. Y. Usui and M. Koizumi, B. Chem. Soc. Jpn., 1961, 34, 1651-1658. 
253. A. Chakraborty, M. Ali and S. K. Saha, Spectrochim. Acta A, 2010, 75, 1577-
1583. 
254. A. Czímerová, J. Bujdák and A. Gáplovský, Colloid Surface A, 2004, 243, 89-
96. 
255. D. K. Smith, Chem. Commun., 1999, 1685-1686. 
256. G. M. Dykes, L. J. Brierley, D. K. Smith, P. T. McGrail and G. J. Seeley, Chem-
Eur. J., 2001, 7, 4730-4739. 
257. G. J. Despotis, J. H. Joist, C. W. Hogue, A. Alsoufiev, D. JoinerMaier, S. A. 
Santoro, E. Spitznagel, J. I. Weitz and L. T. Goodnough, Thromb. Haemostasis, 
1996, 76, 902-908. 
258. B. P. Schick, D. Maslow, A. Moshinski and J. D. San Antonio, Blood, 2004, 
103, 1356-1363. 
259. J. D. Zhang, G. Rivers, Y. Y. Zhu, A. Jacobsen, J. Peyers, G. Grundstrom, P. 
Burch, S. Hussein, A. Marolewski, W. Herlihy and J. Rusche, Bioorg. Med. 
Chem., 2001, 9, 825-836. 
260. A. Sekiya, S. Oishi, N. Fujii and T. Koide, Chem. Pharm. Bull., 2012, 60, 371-
376. 
 280 
261. S. L. Wiskur, H. Ait-Haddou, J. J. Lavigne and E. V. Anslyn, Accounts Chem. 
Res., 2001, 34, 963-972. 
262. B. T. Nguyen and E. V. Anslyn, Coordin. Chem. Rev., 2006, 250, 3118-3127. 
263. N. Y. Kang, H. H. Ha, S. W. Yun, Y. H. Yu and Y. T. Chang, Chem. Soc. Rev., 
2011, 40, 3613-3626. 
264. P. Rossmann, K. Matoušovic and V. Horáček, Virchows Arch. B, 1982, 40, 81-
98. 
265. J. Maurer, S. Haselbach, O. Klein, D. Baykut, V. Vogel and W. Mäntele, J. Am. 
Chem. Soc., 2011, 133, 1134-1140. 
266. D. A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. 
Ryder and P. Smith, Polym. J., 1985, 17, 117-132. 
267. D. A. Tomalia, A. M. Naylor and W. A. Goddard, Angew. Chem. Int. Edit., 
1990, 29, 138-175. 
268. D. K. Smith and F. Diederich, Chem-Eur. J., 1998, 4, 1353-1361. 
269. C. Liang and J. M. J. Frechet, Prog. Polym. Sci., 2005, 30, 385-402. 
270. R. Esfand and D. A. Tomalia, Drug Discov. Today, 2001, 6, 427-436. 
271. W. D. Jang, K. M. K. Selim, C. H. Lee and I. K. Kang, Prog. Polym. Sci., 2009, 
34, 1-23. 
272. N. T. Pourianazar, P. Mutlu and U. Gunduz, J. Nanopart. Res., 2014, 16, 38. 
273. A. E. Beezer, A. S. H. King, I. K. Martin, J. C. Mitchell, L. J. Twyman and C. F. 
Wain, Tetrahedron, 2003, 59, 3873-3880. 
274. R. Z. Xu, Y. L. Wang, X. L. Wang, E. K. Jeong, D. L. Parker and Z. R. Lu, Exp. 
Biol. Med., 2007, 232, 1081-1089. 
275. B. Klajnert, M. Cangiotti, S. Calici, M. Ionov, J. P. Majoral, A. M. Caminade, J. 
Cladera, M. Bryszewska and M. F. Ottaviani, New J. Chem., 2009, 33, 1087-
1093. 
276. R. Duncan and L. Izzo, Adv. Drug Deliv. Rev., 2005, 57, 2215-2237. 
277. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J. W. Weener, 
E. W. Meijer, W. Paulus and R. Duncan, J. Control. Release, 2000, 65, 133-148. 
278. P. K. Maiti, T. Cagin, S. T. Lin and W. A. Goddard, Macromolecules, 2005, 38, 
979-991. 
279. Y. Liu, V. S. Bryantsev, M. S. Diallo and W. A. Goddard, J. Am. Chem. Soc., 
2009, 131, 2798-2799. 
280. H. Szelke, S. Schübel, J. Harenberg and R. Krämer, Bioorg. Med. Chem. Lett., 
2010, 20, 1445-1447. 
281. P. Posocco, S. Pricl, S. Jones, A. Barnard and D. K. Smith, Chem. Sci., 2010, 1, 
393-404. 
 281 
282. E. Díez-Barra, J. C. García-Martínez and J. Rodríguez-López, J. Org. Chem., 
2003, 68, 832-838. 
283. A. R. Cano-Marín, E. Díez-Barra and J. Rodríguez-López, Tetrahedron, 2005, 
61, 395-400. 
284. C. Hadad, J. C. García-Martínez and J. Rodríguez-López, J. Org. Chem., 2012, 
77, 6223-6230. 
285. E. Díez-Barra, J. C. Garcia-Martínez, R. del Rey, J. Rodríguez-López, F. 
Giacalone, J. L. Segura and N. Martín, J. Org. Chem., 2003, 68, 3178-3183. 
286. J. C. García-Martínez, E. Díez-Barra and J. Rodríguez-López, Curr. Org. Synth., 
2008, 5, 267-290. 
287. J. C. Garcia-Martínez, C. Atienza, M. de la Peña, A. C. Rodrigo, J. Tejeda and J. 
Rodríguez-López, J. Mass Spectrom., 2009, 44, 613-620. 
288. J. Tolosa, C. Romero-Nieto, E. Díez-Barra, P. Sánchez-Verdú and J. Rodríguez-
López, J. Org. Chem., 2007, 72, 3847-3852. 
289. E. Díez-Barra, J. C. García-Martínez, S. Merino, R. del Rey, J. Rodríguez-
López, P. Sánchez-Verdú and J. Tejeda, J. Org. Chem., 2001, 66, 5664-5670. 
290. M. Martin-Zarco, S. Toribio, J. C. Garcia-Martinez and J. Rodriguez-Lopez, J. 
Polym. Sci. A1, 2009, 47, 6409-6419. 
291. A. C. Rodrigo, I. Rivilla, F. C. Pérez-Martínez, S. Monteagudo, V. Ocaña, J. 
Guerra, J. C. García-Martínez, S. Merino, P. Sánchez-Verdú, V. Ceña and J. 
Rodríguez-López, Biomacromolecules, 2011, 12, 1205-1213. 
292. G. M. Pavan, S. Monteagudo, J. Guerra, B. Carrion, V. Ocana, J. Rodríguez-
López, A. Danani, F. C. Perez-Martínez and V. Cena, Curr. Med. Chem., 2012, 
19, 4929-4941. 
293. J. Guerra, A. C. Rodrigo, S. Merino, J. Tejeda, J. C. García-Martínez, P. 
Sánchez-Verdú, V. Ceña and J. Rodríguez-López, Macromolecules, 2013, 46, 
7316-7324. 
294. S. M. Bromfield, P. Posocco, M. Fermeglia, J. Tolosa, A. Herreros-López, S. 
Pricl, J. Rodríguez-López and D. K. Smith, Chem-Eur. J., 2014, 20, 9666-9674. 
295. G. M. Pavan, A. Danani, S. Pricl and D. K. Smith, J. Am. Chem. Soc., 2009, 
131, 9686-9694. 
296. G. M. Pavan, L. Albertazzi and A. Danani, J. Phys. Chem. B, 2010, 114, 2667-
2675. 
297. C. B. Sun, T. Tang and H. Uludag, J. Phys. Chem. B, 2012, 116, 2405-2413. 
298. E. Chargaff and K. B. Olson, J. Biol. Chem., 1937, 122, 153-167. 
299. M. Schapira and B. W. Christman, Circulation, 1990, 82, 1877-1879. 
300. C. A. Palma, M. Cecchini and P. Samori, Chem. Soc. Rev., 2012, 41, 3713-3730. 
 282 
301. L. Brunsveld, B. G. G. Lohmeijer, J. A. J. M. Vekemans and E. W. Meijer, 
Chem. Commun., 2000, 2305-2306. 
302. M. K. Müller and L. Brunsveld, Angew. Chem. Int. Edit., 2009, 48, 2921-2924. 
303. D. K. Smith, Chem. Commun., 2006, 34-44. 
304. M. A. Kostiainen, C. Pietsch, R. Hoogenboom, R. J. M. Nolte and J. 
Cornelissen, Adv. Funct. Mater., 2011, 21, 2012-2019. 
305. J. Mikkilä, H. Rosilo, S. Nummelin, J. Seitsonen, J. Ruokolainen and M. A. 
Kostiainen, ACS Macro Lett., 2013, 2, 720-724. 
306. J. M. Chen, T. M. Su and C. Y. Mou, J. Phys. Chem., 1986, 90, 2418-2421. 
307. V. K. Aswal and P. S. Goyal, Chem. Phys. Lett., 2002, 364, 44-50. 
308. J. Lu, S. C. Owen and M. S. Shoichet, Macromolecules, 2011, 44, 6002-6008. 
309. T. Miller, A. Hill, S. Uezguen, M. Weigandt and A. Goepferich, 
Biomacromolecules, 2012, 13, 1707-1718. 
310. S. Kim, Y. Z. Shi, J. Y. Kim, K. Park and J. X. Cheng, Expert Opin. Drug Del., 
2010, 7, 49-62. 
311. J. K. Choi, J. Ho, S. Curry, D. H. Qin, R. Bittman and J. A. Hamilton, J. Lipid 
Res., 2002, 43, 1000-1010. 
312. S. M. Bates and J. I. Weitz, Circulation, 2005, 112, E53-E60. 
313. E. R. Gillies and J. M. J. Fréchet, J. Am. Chem. Soc., 2002, 124, 14137-14146. 
314. E. R. Gillies, E. Dy, J. M. J. Fréchet and F. C. Szoka, Mol. Pharm., 2005, 2, 
129-138. 
315. C. C. Lee, E. R. Gillies, M. E. Fox, S. J. Guillaudeu, J. M. J. Fréchet, E. E. Dy 
and F. C. Szoka, P. Natl. Acad. Sci. USA, 2006, 103, 16649-16654. 
316. G. Stehle, A. Wunder, H. Sinn, H. H. Schrenk, E. A. Friedrich, C. E. Dempfle, 
W. Maierborst and D. L. Heene, J. Surg. Res., 1995, 58, 197-204. 
317. R. J. Linhardt, J. Med. Chem., 2003, 46, 2551-2564. 
318. R. M. C. Sutton, K. L. Sutton and A. M. Stalcup, Electrophoresis, 1997, 18, 
2297-2304. 
319. H. Nishi and Y. Kuwahara, J. Biochem. Bioph. Meth., 2001, 48, 89-102. 
320. A. M. Stalcup and N. M. Agyei, Anal. Chem., 1994, 66, 3054-3059. 
321. J. Wang and D. L. Rabenstein, Biochemistry, 2006, 45, 15740-15747. 
322. J. Wang and D. L. Rabenstein, Biochim. Biophys. Acta., 2009, 1790, 1689-1697. 
323. K. S. Partridge, D. K. Smith, G. M. Dykes and P. T. McGrail, Chem. Commun., 
2001, 319-320. 
324. W. Edwards and D. K. Smith, J. Am. Chem. Soc., 2013, 135, 5911-5920. 
 283 
325. P. Wu, M. Malkoch, J. N. Hunt, R. Vestberg, E. Kaltgrad, M. G. Finn, V. V. 
Fokin, K. B. Sharpless and C. J. Hawker, Chem. Commun., 2005, 5775-5777. 
326. M. C. A. Stuart, J. C. van de Pas and J. Engberts, J. Phys. Org. Chem., 2005, 18, 
929-934. 
327. Y. B. Lim, E. Lee and M. Lee, Angew. Chem. Int. Edit., 2007, 46, 9011-9014. 
328. S. M. Bromfield, P. Posocco, C. W. Chan, M. Calderon, S. E. Guimond, J. E. 
Turnbull, S. Pricl and D. K. Smith, Chem. Sci., 2014, 5, 1484-1492. 
329. M. Friedman, J. Agr. Food Chem., 1999, 47, 3457-3479. 
330. M. Friedman and C. E. Levin, Amino Acids, 2012, 42, 1553-1582. 
331. J. D. Watson and F. H. C. Crick, Nature, 1953, 171, 737-738. 
332. R. Srinivas, S. Samanta and A. Chaudhuri, Chem. Soc. Rev., 2009, 38, 3326-
3338. 
333. X. Guo and L. Huang, Accounts Chem. Res., 2012, 45, 971-979. 
334. M. A. Mintzer and E. E. Simanek, Chem. Rev., 2009, 109, 259-302. 
335. S. Y. Wong, J. M. Pelet and D. Putnam, Prog. Polym. Sci., 2007, 32, 799-837. 
336. P. P. Karmali and A. Chaudhuri, Med. Res. Rev., 2007, 27, 696-722. 
337. S. C. De Smedt, J. Demeester and W. E. Hennink, Pharm. Res., 2000, 17, 113-
126. 
338. D. K. Smith, Curr. Top. Med. Chem., 2008, 8, 1187-1203. 
339. J. G. Hardy, M. A. Kostiainen, D. K. Smith, N. P. Gabrielson and D. W. Pack, 
Bioconjugate Chem., 2006, 17, 172-178. 
340. S. P. Jones, N. P. Gabrielson, C. H. Wong, H. F. Chow, D. W. Pack, P. Posocco, 
M. Fermeglia, S. Pricl and D. K. Smith, Mol. Pharm., 2011, 8, 416-429. 
341. M. Michaud, E. Jourdan, A. Villet, A. Ravel, C. Grosset and E. Peyrin, J. Am. 
Chem. Soc., 2003, 125, 8672-8679. 
342. M. A. Rehder-Silinski and L. B. McGown, J. Chromatogr. A, 2003, 1008, 233-
245. 
343. X. G. Qu, J. O. Trent, I. Fokt, W. Priebe and J. B. Chaires, P. Natl. Acad. Sci. 
USA, 2000, 97, 12032-12037. 
344. S. Sforza, G. Haaima, R. Marchelli and P. E. Nielsen, Eur. J. Org. Chem., 1999, 
197-204. 
345. S. Sforza, T. Tedeschi, R. Corradini and R. Marchelli, Eur. J. Org. Chem., 2007, 
5879-5885. 
346. S. Sforza, R. Corradini, S. Ghirardi, A. Dossena and R. Marchelli, Eur. J. Org. 
Chem., 2000, 2905-2913. 
 284 
347. A. Calabretta, T. Tedeschi, R. Corradini, R. Marchelli and S. Sforza, 
Tetrahedron Lett., 2011, 52, 300-304. 
348. V. Menchise, G. De Simone, T. Tedeschi, R. Corradini, S. Sforza, R. Marchelli, 
D. Capasso, M. Saviano and C. Pedone, P. Natl. Acad. Sci. USA, 2003, 100, 
12021-12026. 
349. G. Roelfes, Mol. Biosyst., 2007, 3, 126-135. 
350. A. J. Boersma, R. P. Megens, B. L. Feringa and G. Roelfes, Chem. Soc. Rev., 
2010, 39, 2083-2092. 
351. G. Roelfes, A. J. Boersma and B. L. Feringa, Chem. Commun., 2006, 635-637. 
352. S. Park and H. Sugiyama, Molecules, 2012, 17, 12792-12803. 
353. A. J. Boersma, B. L. Feringa and G. Roelfes, Org. Lett., 2007, 9, 3647-3650. 
354. D. Coquière, B. L. Feringa and G. Roelfes, Angew. Chem. Int. Edit., 2007, 46, 
9308-9311. 
355. A. J. Boersma, B. L. Feringa and G. Roelfes, Angew. Chem. Int. Edit., 2009, 48, 
3346-3348. 
356. B. F. Cain, B. C. Baguley and W. A. Denny, J. Med. Chem., 1978, 21, 658-668. 
357. H. Ihre, A. Hult, J. M. J. Fréchet and I. Gitsov, Macromolecules, 1998, 31, 
4061-4068. 
358. B. Trappmann, K. Ludwig, M. R. Radowski, A. Shukla, A. Mohr, H. Rehage, C. 
Böttcher and R. Haag, J. Am. Chem. Soc., 2010, 132, 11119-11124. 
359. B. J. Boyd, L. M. Kaminskas, P. Karellas, G. Krippner, R. Lessene and C. J. H. 
Porter, Mol. Pharm., 2006, 3, 614-627. 
360. S. E. Stiriba, H. Frey and R. Haag, Angew. Chem. Int. Edit., 2002, 41, 1329-
1334. 
361. K. T. Al-Jamal, W. T. Al-Jamal, S. Akerman, J. E. Podesta, A. Yilmazer, J. A. 
Turton, A. Bianco, N. Vargesson, C. Kanthou, A. T. Florence, G. M. Tozer and 
K. Kostarelos, P. Natl. Acad. Sci. USA, 2010, 107, 3966-3971. 
362. K. T. Al-Jamal, W. T. Al-Jamal, J. T. W. Wang, N. Rubio, J. Buddle, D. 
Gathercole, M. Zloh and K. Kostarelos, ACS Nano, 2013, 7, 1905-1917. 
363. M. Ohsaki, T. Okuda, A. Wada, T. Hirayama, T. Niidome and H. Aoyagi, 
Bioconjugate Chem., 2002, 13, 510-517. 
364. C. S. Love, A. R. Hirst, V. Chechik, D. K. Smith, I. Ashworth and C. Brennan, 
Langmuir, 2004, 20, 6580-6585. 
365. A. R. Hirst, J. E. Miravet, B. Escuder, L. Noirez, V. Castelletto, I. W. Hamley 
and D. K. Smith, Chem-Eur. J., 2009, 15, 372-379. 
366. J. G. Hardy, A. R. Hirst and D. K. Smith, Soft Matter, 2012, 8, 3399-3406. 
 285 
367. E. Durán-Lara, L. Guzmán, A. John, E. Fuentes, M. Alarcón, I. Palomo and L. 
S. Santos, Eur. J. Med. Chem., 2013, 69, 601-608. 
368. S. Boye, D. Appelhans, V. Boyko, S. Zschoche, H. Komber, P. Friedel, P. 
Formanek, A. Janke, B. I. Voit and A. Lederer, Biomacromolecules, 2012, 13, 
4222-4235. 
369. T. Okuda, S. Kawakami, N. Akimoto, T. Niidome, F. Yamashita and M. 
Hashida, J. Control. Release, 2006, 116, 330-336. 
370. M. Driffield, D. M. Goodall and D. K. Smith, Org. Biomol. Chem., 2003, 1, 
2612-2620. 
371. O. Freund, J. Amédee, D. Roux and R. Laversanne, Life Sci., 2000, 67, 411-419. 
372. M. Pittelkow, R. Lewinsky and J. B. Christensen, Synthesis-Stuttgart, 2002, 
2195-2202. 
373. H. Gershon, R. Ghirlando, S. B. Guttman and A. Minsky, Biochemistry, 1993, 
32, 7143-7151. 
 
